HK1068506A - Compositions and methods for the therapy and diagnosis of ovarian cancer - Google Patents
Compositions and methods for the therapy and diagnosis of ovarian cancer Download PDFInfo
- Publication number
- HK1068506A HK1068506A HK05102191.8A HK05102191A HK1068506A HK 1068506 A HK1068506 A HK 1068506A HK 05102191 A HK05102191 A HK 05102191A HK 1068506 A HK1068506 A HK 1068506A
- Authority
- HK
- Hong Kong
- Prior art keywords
- seq
- polypeptide
- sequence
- polynucleotide
- cells
- Prior art date
Links
Description
no marking
Technical Field
The present invention relates generally to the treatment of ovarian cancer. More specifically, the invention relates to polypeptides comprising at least a portion of an ovarian carcinoma protein, polynucleotides encoding the polypeptides, and antibodies and immune system cells that specifically recognize the polypeptides. Such polypeptides, polynucleotides, antibodies and cells may be used in vaccines and pharmaceutical compositions for the treatment of ovarian cancer.
Background
Ovarian cancer is a serious health problem for women in the united states and throughout the world. Despite advances in the detection and treatment of such cancers, no prophylactic or therapeutic vaccine or other generally successful methods are currently available. Current treatments for this disease rely on a combination of early diagnosis and invasive treatment, which may include one or more of a variety of treatments, such as surgery, radiation therapy, chemotherapy and hormonal therapy. The course of treatment for a particular cancer is often selected based on various prognostic parameters, including analysis of specific tumor markers. However, the use of established markers often leads to difficult to interpret results and high mortality rates continue to be observed in many cancer patients.
Immunotherapy has the potential to significantly improve cancer treatment and survival. Such therapy may involve the generation and enhancement of an immune response to ovarian cancer antigens. However, to date, few ovarian cancer antigens are known, and the generation of an immune response against such antigens has not proven therapeutically beneficial.
Accordingly, there is a need in the art for improved methods of identifying ovarian tumor antigens and using such antigens in the treatment of ovarian cancer. The present invention fulfills these needs and further provides other related advantages.
Summary of The Invention
Briefly, the present invention provides compositions and methods for treating cancer, such as ovarian cancer. In one aspect, the invention provides a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof, the variant differing in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished. In some embodiments, the ovarian carcinoma protein comprises a sequence selected from SEQ ID NOs: 456-457, 460-477, and 512-570 and the complementary sequences of these polynucleotide sequences.
The invention further provides polynucleotides encoding the above polypeptides or portions thereof, expression vectors comprising such polynucleotides, and host cells transformed or transfected with such expression vectors.
The invention further provides polypeptide compositions comprising a polypeptide selected from the group consisting of SEQ id nos: 394-455, 458-459, 478-511 and 571-596.
In another aspect, the invention provides pharmaceutical compositions and vaccines. The pharmaceutical composition may include a physiologically acceptable carrier or excipient in combination with one or more of the following: (i) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof, said variant differing in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence encoded by a polynucleotide comprising the amino acid sequence set forth in SEQ id nos: 456-457, 460-477, and 512-570; or (ii) a polynucleotide encoding such a polypeptide; (iii) antibodies that specifically bind such polypeptides; (iv) (iv) antigen presenting cells expressing such a polypeptide, and/or (v) T cells specifically reactive with such a polypeptide. The vaccine may include a non-specific immune response enhancer in combination with one or more of the following: (i) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof, said variant differing in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises the amino acid sequence of SEQ ID Nos: 394-455, 458-459, 478-511 and 571-596 or an amino acid sequence encoded by a polynucleotide comprising the amino acid sequence of SEQ ID NO: 456-457, 460-477 and 512-570, or (ii) a polynucleotide encoding such a polypeptide; (iii) an anti-idiotype antibody specifically binding to an antibody that specifically binds to such a polypeptide; (iv) (iv) antigen presenting cells expressing such a polypeptide, and/or (v) T cells specifically reactive with such a polypeptide.
In another aspect, the invention further provides fusion proteins comprising at least one of the above polypeptides, and polynucleotides encoding such fusion proteins.
In a related aspect, a pharmaceutical composition comprising a fusion protein or a polynucleotide encoding a fusion protein and a physiologically acceptable carrier is provided.
In another aspect, there is further provided a vaccine comprising a fusion protein or a polynucleotide encoding a fusion protein and a non-specific immunopotentiator.
In another aspect, the present invention provides a method of inhibiting the development of cancer in a patient comprising administering to the patient a pharmaceutical composition or vaccine as described above.
In another aspect, the invention further provides a method of stimulating and/or expanding T cells comprising administering to a subject in need thereof an effective amount of a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof, said variant differing in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with an ovarian carcinoma protein-specific antiserum is not substantially diminished, wherein the ovarian carcinoma protein comprises the amino acid sequence set forth in SEQ ID Nos: 394-455, 458-459, 478-511 and 571-596 or an amino acid sequence encoded by a polynucleotide comprising the amino acid sequence of SEQ ID NO: 456-457, 460-477, and 512-570; (b) a polynucleotide encoding such a polypeptide, and/or (c) an antigen presenting cell expressing such a polypeptide, under conditions and for a time sufficient to allow stimulation and/or expansion of the T cell. Such polypeptides, polynucleotides and/or antigen presenting cells may be present in a pharmaceutical composition or vaccine for stimulating and/or expanding T cells of a mammal.
In another aspect, the invention provides a method of inhibiting the development of ovarian cancer in a patient, comprising administering to the patient T cells prepared as described above.
In another aspect, the invention provides a method of inhibiting the development of ovarian cancer in a patient, comprising the steps of: (a) incubation of CD4 isolated from patients+And/or CD8+T cells and one or more of the following: (i) polypeptides comprising immunogenic portions of ovarian carcinoma proteins, or thereofA variant which differs by one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian oncoprotein-specific antisera is not significantly diminished, wherein the ovarian oncoprotein comprises an amino acid sequence encoded by a polynucleotide comprising the amino acid sequence of SEQ ID NO: 456-457, 460-477, and 512-570; (ii) polynucleotides encoding such polypeptides; (iii) antigen presenting cells expressing such polypeptides; to proliferate T cells; and (b) administering to the patient an effective amount of the proliferated T cells, thereby inhibiting the development of ovarian cancer in the patient. The proliferating cells may be cloned prior to administration to a patient.
In another aspect, the invention also provides methods for identifying secreted tumor antigens. This method comprises the steps of: (a) implanting tumor cells in an immunodeficient mammal; (b) obtaining serum from the immunodeficient mammal after a time sufficient to allow secretion of the tumor antigen into the serum; (c) immunizing an immunocompetent mammal with serum; (d) obtaining antisera from an immunocompetent mammal; and (e) screening the tumor expression library with antisera, and thereby identifying a secreted tumor antigen. A preferred method of identifying a secreted ovarian cancer antigen comprises the steps of: (a) implanting ovarian cancer cells in SCID mice; (b) obtaining serum from the SCID mouse after a time sufficient to allow secretion of ovarian cancer antigens into the serum; (c) immunizing a mouse with the serum; (d) obtaining antisera from said immunocompetent mouse; and (e) screening the ovarian cancer expression library with antisera, and thereby identifying a secreted ovarian cancer antigen.
The invention also discloses an antibody epitope recognized by the O8E polyclonal antiserum, wherein the antibody epitope is shown as SEQ ID NO: 394-415.
The invention further discloses 10-mer and 9-mer peptides predicted to bind to HLA-0201, which are SEQ ID NO: 416-435 and SEQ ID NO: 436-455.
These and other aspects of the invention will be apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are incorporated by reference in their entirety as if each were individually incorporated.
In another aspect of the invention, applicants have unexpectedly identified a series of novel repeat elements encoding the 5' -end of the O772P gene. Accordingly, the present invention provides a compound having Xn-O772P polypeptide of the structure represented by Y, wherein X comprises a sequence identical to SEQ ID NO: 596, O772P repeat sequences having at least 50% identity, preferably at least 70% identity, more preferably at least 90% identity. Typically Y comprises a sequence identical to SEQ ID NO: 594, and preferably at least 90%, and more preferably at least 95%. According to this embodiment, n is generally an integer from 1 to 35, preferably an integer from 15 to 25, and X may be the same or different.
In a preferred embodiment, X comprises a sequence selected from SEQ ID NOs: 574-593, Y comprises the sequence of SEQ ID NO: 594 to seq id no.
In another preferred embodiment, the exemplary O772P polypeptide comprises SEQ ID NO: 595, containing 20 repetitive sequence elements (i.e., X)20) Wherein the X elements are arranged in the following order (moving from N-terminus to C-terminus in the O772P repeat region): SEQ ID NO: 574-SEQ ID NO: 575-SEQ ID NO: 576-SEQ ID NO: 577-SEQ ID NO: 578-SEQ ID NO: 579-SEQ ID NO: 580-SEQ ID NO: 581-SEQ ID NO: 582-SEQ ID NO: 583-SEQ ID NO: 584-SEQ ID NO: 585-SEQ ID NO: 586-SEQ ID NO: 587-SEQ ID NO: 588-SEQ ID NO: 589-SEQ ID NO: 590-SEQ ID NO: 591-SEQ ID NO: 592-SEQ ID NO: 593.
according to another aspect of the present invention, there is provided a compound having Xn-an O772P polynucleotide of the Y structure, wherein X comprises a sequence selected from the group consisting of SEQ ID NOs: 512-540, 542-546 and 548-567. Typically Y comprises a sequence identical to SEQ ID NO: 586 to O772P constant region sequence, is at least 80% identical, preferably at least 90% identical, more preferably at least 95% identical. In this embodiment, typically n is from 1 to 35,preferably from 15 to 25, and X may be the same or different.
In another embodiment, the exemplary O772P polynucleotide comprises the nucleotide sequence of SEQ ID NO: 569 said sequence, contains 20 repetitive sequence elements (i.e., X)20)。
According to another aspect of the invention, there is provided an O772 polypeptide comprising at least the amino acid sequence of SEQ id no: 490-511 or any of the antibody epitope (antibody epitope) sequences shown in FIGS.
According to another aspect of the present invention, there is provided an O8E polypeptide comprising at least SEQ id nos: 394-415 of any one of the antibody epitope sequences.
Brief description of sequence identifiers and figures
SEQ ID NO: 1-71 are the ovarian cancer antigen polynucleotides shown in FIGS. 1A-1S.
SEQ ID NO: 72-74 are the ovarian cancer antigen polynucleotides shown in FIGS. 2A-2C.
SEQ ID NO: and 75 is ovarian cancer polynucleotide 3g (FIG. 4).
SEQ ID NO: 76 is ovarian cancer polynucleotide 3f (FIG. 5).
SEQ ID NO: 77 is ovarian cancer polynucleotide 6b (FIG. 6).
SEQ ID NO: 78 is ovarian cancer polynucleotide 8e (FIG. 7A).
SEQ ID NO: 79 is ovarian cancer polynucleotide 8h (FIG. 7B).
SEQ ID NO: 80 is ovarian cancer polynucleotide 12e (FIG. 8).
SEQ ID NO: 81 is ovarian cancer polynucleotide 12h (FIG. 9).
SEQ ID NO: 82-310 are the ovarian cancer antigen polynucleotides shown in FIGS. 15A-15 EEE.
SEQ ID NO: 311 is the full length sequence of ovarian cancer polynucleotide O772P.
SEQ ID NO: 312 is O772P amino acid sequence.
SEQ ID NO: 313-384 is an ovarian cancer antigen polynucleotide.
SEQ ID NO: 385 represents a form of the cDNA sequence of clone O772P, designated 21013.
SEQ ID NO: 386 represents the cDNA sequence of clone O772P in one form, and is named 21003.
SEQ ID NO: 387 represents the cDNA sequence of clone O772P in one form, designated 21008.
SEQ ID NO: 388 is a sequence identical to SEQ ID NO: 385.
SEQ ID NO: 389 is a nucleotide sequence identical to SEQ ID NO: 386. SEQ ID NO: 390 is a peptide corresponding to SEQ ID NO: 387 corresponding amino acid sequence.
SEQ ID NO: 391 is the full length sequence of ovarian cancer polynucleotide O8E.
SEQ ID NO: 392-393 is the protein sequence encoded by O8E.
SEQ ID NO: 394-415 are peptide sequences corresponding to the epitope of the OE8 antibody.
SEQ ID NO: 416-435 is a potential HLA-A210 mer binding peptide predicted by the full-length open reading frame of OE 8.
SEQ ID NO: 436-455 is a potential HLA-A29 mer binding peptide predicted by the full-length open reading frame of OE 8.
SEQ ID NO: 456 is a truncated nucleotide sequence of the full-length Genbank sequence showing homology to O772P.
SEQ ID NO: 457 is a full-length Genbank sequence showing significant homology to O772P.
SEQ ID NO: 458 is a protein encoding a truncated form of the full-length Genbank sequence showing homology to O772P.
SEQ ID NO: 459 is the full-length protein sequence of Genbank showing significant homology to the O772P protein sequence.
SEQ ID NO: 460 encodes the unique N-terminal portion of O772P contained in residues 1-70.
SEQ ID NO: 461 comprises a single sequence and encodes SEQ ID NO: 456 residues 1-313.
SEQ ID NO: 462 is the hypothetical sequence of clone O772P.
SEQ ID NO: 463 is the cDNA sequence of clone FLJ 14303.
SEQ ID NO: 464 is a partial cDNA sequence of clone O772P.
SEQ ID NO: 465 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 466 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 467 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 468 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 469 is a partial cDNA sequence of clone O772P.
SEQ ID NO: 470 is a partial cDNA sequence of clone O772P.
SEQ ID NO: 471 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 472 is a partial cDNA sequence of clone O772P.
SEQ ID NO: 473 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 474 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 475 is the partial cDNA sequence of clone O772P.
SEQ ID NO: 476 is a partial cDNA sequence of clone O772P.
SEQ ID NO: 477 represent the new 5' -terminus of the ovarian tumor antigen O772P.
SEQ ID NO: 478 is SEQ ID NO: 462, or a pharmaceutically acceptable salt thereof.
SEQ ID NO: 479 is SEQ ID NO: 463.
SEQ ID NO: 480 is SEQ ID NO: 472, or a partial amino acid sequence.
SEQ ID NO: 481 is SEQ ID NO: 471 possible open reading frames.
SEQ ID NO: 482 is SEQ ID NO: 471, a second possible open reading frame.
SEQ ID NO: 483 is SEQ ID NO: 467 in the sequence listing.
SEQ ID NO: 484 is SEQ ID NO: 466 possible open reading frame.
SEQ ID NO: 485 is SEQ ID NO: 466A partial amino acid sequence encoded by the second possible open reading frame.
SEQ ID NO: 486 is SEQ ID NO: 465, or a partial amino acid sequence encoded by the polynucleotide.
SEQ ID NO: 487 is SEQ ID NO: 464 of a partial amino acid sequence encoded by (a).
SEQ ID NO: 488 represents the extracellular, transmembrane and cytoplasmic domain of O772P.
SEQ ID NO: 489 represents the predicted extracellular domain of O772P.
SEQ ID NO: 490 represents the amino acid sequence of peptide #2 corresponding to the epitope of an O772P-specific antibody.
SEQ ID NO: 491 represents the amino acid sequence of peptide #6 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 492 represents the amino acid sequence of peptide #7 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 493 represents the amino acid sequence of peptide #8 corresponding to an epitope of an O772P-specific antibody.
SEQ ID NO: 494 represents the amino acid sequence of peptide #9 corresponding to the epitope of the O772P specific antibody.
SEQ ID NO: 495 represents the amino acid sequence of peptide #11 corresponding to the epitope of the O772P specific antibody.
SEQ ID NO: 496 represents the amino acid sequence of peptide #13 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 497 represents the amino acid sequence of peptide #22 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 498 represents the amino acid sequence of peptide #24 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 499 represents the amino acid sequence of peptide #27 corresponding to the epitope of an antibody specific for O772P.
SEQ ID NO: 500 represents the amino acid sequence of peptide #40 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 501 represents the amino acid sequence of peptide #41 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 502 represents the amino acid sequence of peptide #47 corresponding to the epitope of an O772P-specific antibody.
SEQ ID NO: 503 represents the amino acid sequence of peptide #50 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 504 represents the amino acid sequence of peptide #51 corresponding to the epitope of an O772P-specific antibody.
SEQ ID NO: 505 represents the amino acid sequence of peptide #52 corresponding to the epitope of an O772P-specific antibody.
SEQ ID NO: 506 represents the amino acid sequence of peptide #53 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 507 represents the amino acid sequence of peptide #58 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 508 represents the amino acid sequence of peptide #59 corresponding to the epitope of an O772P-specific antibody.
SEQ ID NO: 509 represents the amino acid sequence of peptide #60 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 510 represents the amino acid sequence of peptide #61 corresponding to the epitope of an O772P specific antibody.
SEQ ID NO: 511 represents the amino acid sequence of peptide #71 corresponding to the epitope of the O772P specific antibody.
SEQ ID NO: 512(O772P repeat 1) represents an example of cDNA sequence corresponding to O772P 5' variable region repeat number 21.
SEQ ID NO: 513(O772P repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 20.
SEQ ID NO: 514(O772P repeat 3) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 19.
SEQ ID NO: 515(O772P repeat 4) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 18.
SEQ ID NO: 516(O772P repeat 5) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 17.
SEQ ID NO: 517(HB repeat 1) represents an example of a cDNA sequence corresponding to the variable region repeat number 21 of O772P 5'.
SEQ ID NO: 518(HB repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 20.
SEQ ID NO: 519(HB repeat 3) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 19.
SEQ ID NO: 520(HB repeat 4) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 18.
SEQ ID NO: 521(HB repeat 5) represents an example of a cDNA sequence corresponding to the variable region repeat number 17 of O772P 5'.
SEQ ID NO: 522(HB repeat 65 '-end) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 16.
SEQ ID NO: 523(1043400.1 repeat 1) represents an example of a cDNA sequence corresponding to the variable region repeat number 9 of O772P 5'.
SEQ ID NO: 524(1043400.1 repeat 2) represents an example of a cDNA sequence corresponding to variable region repeat number 10 of O772P 5'.
SEQ ID NO: 525(1043400.1 repeat 3) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 10/11.
SEQ ID NO: 526(1043400.1 repeat 4) represents an example of a cDNA sequence corresponding to the O772P 5' variable region repeat number 11.
SEQ ID NO: 527(1043400.1 repeat 5) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 14.
SEQ ID NO: 528(1043400.1 repeat 6) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 17.
SEQ ID NO: 529(1043400.3 repeat 1) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 20.
SEQ ID NO: 530(1043400.3 repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 21.
SEQ ID NO: 531(1043400.5 repeat 1) represents an example of a cDNA sequence corresponding to repeat number 8 of the 5' variable region of O772P 5.
SEQ ID NO: 532(1043400.5 repeat 2) represents an example of a cDNA sequence corresponding to the repeat number 9 of the 5' variable region of O772P 5 and additionally contains intron sequences.
SEQ ID NO: 533(1043400.5 repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 9.
SEQ ID NO: 534(1043400.8 repeat 1) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 17.
SEQ ID NO: 535(1043400.8 repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 18.
SEQ ID NO: 536(1043400.8 repeat 3) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 19.
SEQ ID NO: 537(1043400.9 repeat 1) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 4.
SEQ ID NO: 538(1043400.9 repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 5.
SEQ ID NO: 539(1043400.9 repeat 3) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 7.
SEQ ID NO: 540(1043400.9 repeat 4) represents an example of a cDNA sequence corresponding to the O772P 5' variable region repeat number 8.
SEQ ID NO: 541(1043400.11 repeat 1) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 1.
SEQ ID NO: 542(1043400.11 repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 2.
SEQ ID NO: 543(1043400.11 repeat 3) represents an example of a cDNA sequence corresponding to the variable region repeat No. 3 of O772P 5'.
SEQ ID NO: 544(1043400.11 repeat 4) represents an example of a cDNA sequence corresponding to repeat number 11 of the 5' variable region of O772P 5.
SEQ ID NO: 545(1043400.11 repeat 5) represents an example of a cDNA sequence corresponding to the O772P 5' variable region repeat number 12.
SEQ ID NO: 546(1043400.12 repeat 1) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 20.
SEQ ID NO: 547(PB repeat A) represents an example of a cDNA sequence corresponding to variable region repeat number 1 of O772P 5'.
SEQ ID NO: 548(PB repeat B) represents an example of a cDNA sequence corresponding to variable region repeat number 2 of O772P 5'.
SEQ ID NO: 549(PB repeat E) represents an example of a cDNA sequence corresponding to variable region repeat No. 3 of O772P 5'.
SEQ ID NO: 550(PB repeat G) represents an example of a cDNA sequence corresponding to variable region repeat number 4 of O772P 5'.
SEQ ID NO: 551(PB repeat C) represents an example of cDNA sequence corresponding to the variable region repeat number 4 of O772P 5'.
SEQ ID NO: 552(PB repeats H) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 6.
SEQ ID NO: 553(PB repeat J) represents an example of a cDNA sequence corresponding to variable region repeat No. 7 of O772P 5'.
SEQ ID NO: 554(PB repeat K) represents an example of a cDNA sequence corresponding to variable region repeat number 8 of O772P 5'.
SEQ ID NO: 555(PB repeat D) represents an example of a cDNA sequence corresponding to variable region repeat No. 9 of O772P 5'.
SEQ ID NO: 556(PB repeat I) represents an example of a cDNA sequence corresponding to variable region repeat number 10 of O772P 5'.
SEQ ID NO: 557(PB repeat M) represents an example of a cDNA sequence corresponding to the variable region repeat number 11 of O772P 5'.
SEQ ID NO: 558(PB repeat 9) represents an example of a cDNA sequence corresponding to variable region repeat No. 12 of O772P 5'.
SEQ ID NO: 559(PB repeat 8.5) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 13.
SEQ ID NO: 560(PB repeat 8) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 14.
SEQ ID NO: 561(PB repeat 7) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 15.
SEQ ID NO: 562(PB repeat 6) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat No. 16.
SEQ ID NO: 563(PB repeat 5) represents an example of a cDNA sequence corresponding to the variable region repeat number 17 of O772P 5'.
SEQ ID NO: 564(PB repeat 4) represents an example of a cDNA sequence corresponding to variable region repeat No. 18 of O772P 5'.
SEQ ID NO: 565(PB repeat 3) represents an example of a cDNA sequence corresponding to the variable region repeat No. 19 of O772P 5'.
SEQ ID NO: 566(PB repeat 2) represents an example of a cDNA sequence corresponding to O772P 5' variable region repeat number 20.
SEQ ID NO: 567(PB repeat 1) represents an example of a cDNA sequence corresponding to variable region repeat number 21 of O772P 5'.
SEQ ID NO: 568 represents the 3' constant region cDNA sequence.
SEQ ID NO: 569 represents the cDNA sequence containing the 21 repeats of the consensus sequence, the 3 'constant region and the 3' untranslated region.
SEQ ID NO: 570 represents the cDNA sequence of the consensus repeat sequence.
SEQ ID NO: 571 represents the consensus amino acid sequence of one possible open reading frame of variable region repeat No. 1 of O772P 5'.
SEQ ID NO: 572 represents the consensus amino acid sequence of the second possible open reading frame of variable region repeat No. 1 of O772P 5'.
SEQ ID NO: 573 represents the consensus amino acid sequence of the third possible open reading frame of variable region repeat No. 1 of O772P 5'.
SEQ ID NO: 574 represents the consensus amino acid sequence of O772P 5 variable region repeat No. 2.
SEQ ID NO: 575 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 3.
SEQ ID NO: 576 represents the consensus amino acid sequence of variable region repeat No. 4 of O772P 5'.
SEQ ID NO: 577 represents the consensus amino acid sequence of O772P 5' variable region repeat number 5.
SEQ ID NO: 578 represents the consensus amino acid sequence of O772P 5' variable region repeat number 6.
SEQ ID NO: 579 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 7.
SEQ ID NO: 580 represents the consensus amino acid sequence of O772P 5 variable region repeat number 8.
SEQ ID NO: 581 represents the consensus amino acid sequence of O772P 5' variable region repeat number 9.
SEQ ID NO: 582 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 10.
SEQ ID NO: 583 represents the consensus amino acid sequence of O772P 5' variable region repeat number 11.
SEQ ID NO: 584 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 12.
SEQ ID NO: 585 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 13.
SEQ ID NO: 586 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 14.
SEQ ID NO: 587 represents the consensus amino acid sequence of O772P 5' variable region repeat number 15.
SEQ ID NO: 588 represents the consensus amino acid sequence of O772P 5' variable region repeat number 16.
SEQ ID NO: 589 represents the consensus amino acid sequence of O772P 5' variable region repeat number 17.
SEQ ID NO: 590 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 18.
SEQ ID NO: 591 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 19.
SEQ ID NO: 592 represents the consensus amino acid sequence of O772P 5' variable region repeat No. 20.
SEQ ID NO: 593 represents the consensus amino acid sequence of O772P 5' variable region repeat number 21.
SEQ ID NO: 594 represents the amino acid sequence of the 3' constant region.
SEQ ID NO: 595 represents an amino acid sequence comprising a 21-repeat consensus sequence and a 3' constant region.
SEQ ID NO: 596 represents the amino acid sequence of the consensus repeat.
FIGS. 1A-1S (SEQ ID NOS: 1-71) depict partial sequences of polynucleotides encoding representative secreted ovarian cancer antigens.
FIGS. 2A-2C depict the entire insert sequence of the 3 clones of FIG. 1. FIG. 2 shows the sequence designated O7E (11731; SEQ ID NO: 72), FIG. 2B shows the sequence designated O9E (11785; SEQ ID NO: 73), and FIG. 2C shows the sequence designated O8E (13695; SEQ ID NO: 74).
FIG. 3 shows the results of microarray expression analysis of ovarian cancer sequence designated O8E.
FIG. 4 shows a partial sequence (designated 3 g; SEQ ID NO: 75) of a polynucleotide encoding an ovarian cancer sequence that is a splice fusion of the human T-cell leukemia virus type I oncoprotein TAX and osteonectin.
FIG. 5 shows an ovarian cancer polynucleotide designated 3f (SEQ ID NO: 76).
FIG. 6 shows the ovarian cancer polynucleotide designated 6b (SEQ ID NO: 77).
FIGS. 7A and 7B show ovarian cancer polynucleotides designated 8e (SEQ ID NO: 78) and 8h (SEQ ID NO: 79).
FIG. 8 shows an ovarian cancer polynucleotide designated 12c (SEQ ID NO: 80).
FIG. 9 shows the ovarian cancer polynucleotide designated 12h (SEQ ID NO: 81).
FIG. 10 depicts the results of the ovarian cancer sequence microarray expression analysis designated 3 f.
FIG. 11 depicts the results of the ovarian cancer sequence microarray expression analysis designated 6 b.
FIG. 12 depicts the results of the ovarian cancer sequence microarray expression analysis designated 8 e.
FIG. 13 depicts the results of the ovarian cancer sequence microarray expression analysis designated 12 c.
FIG. 14 depicts the results of the ovarian cancer sequence microarray expression analysis designated 12 h.
FIGS. 15A-15EEE depict partial sequences of additional polynucleotides encoding representative secreted ovarian cancer antigens (SEQ ID NOS: 82-310).
Fig. 16 is a diagram illustrating the positions of various partial O8E sequences in the full-length sequence.
FIG. 17 is a graph illustrating the results of a study on epitope mapping of the O8E protein.
FIG. 18 is a photograph of Fluorescence Activated Cell Sorting (FACS) analysis of O8E cell surface expression.
FIG. 19 is a photograph of Fluorescence Activated Cell Sorting (FACS) analysis of O8E cell surface expression.
FIG. 20 shows fluorescence-activated cell sorting (FACS) analysis of O8E transfected HEK293 cells demonstrating cell surface expression of O8E.
FIG. 21 shows Fluorescence Activated Cell Sorting (FACS) analysis of SKBR3 breast tumor cells demonstrating cell surface expression of O8E.
FIG. 22 shows O8E expression in HEK293 cells. Cells were probed with anti-O8E rabbit polyclonal antiserum # 233L.
FIG. 23 shows ELISA analysis of anti-O8E rabbit serum.
FIG. 24 shows ELISA analysis of affinity purified rabbit anti-O8E polyclonal antibody.
FIG. 25 is a graph depicting the determination of antibody internalization against O8E mAb (monoclonal antibody), indicating that mAbs directed against amino acids 61-80 induced ligand internalization.
Detailed Description
As indicated above, the present invention relates generally to compositions and methods for the treatment of cancer, such as ovarian cancer. The compositions of the invention can include immunogenic polypeptides, polynucleotides encoding such polypeptides, binding agents that bind the polypeptides, such as antibodies, Antigen Presenting Cells (APCs), and/or immune system cells (e.g., T cells).
The polypeptides of the invention will typically comprise at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof. Some ovarian cancer proteins have been identified using immunoassay techniques and are referred to herein as ovarian cancer antigens. An "ovarian cancer antigen" is a protein that is expressed by ovarian tumor cells (preferably human cells) at a level that is at least 2-fold higher than that of normal ovarian cells. Certain ovarian cancer antigens react detectably (in an immunoassay such as ELISA or Western blot) with antisera raised against the sera of immunodeficient animals implanted with human ovarian tumors. Such ovarian cancer antigens are shed or secreted from ovarian tumors into the serum of immunodeficient animals. Thus, some ovarian cancer antigens provided by the present invention are secreted antigens. Some nucleic acid sequences of the invention will typically comprise a DNA or RNA sequence encoding all or a portion of such a polypeptide, or a sequence complementary to such a sequence.
The invention further provides ovarian cancer sequences identified using techniques for assessing changes in expression in ovarian tumors. Such sequences may be polynucleotide or protein sequences. Ovarian cancer sequences are typically expressed in ovarian tumors at a level at least 2-fold, preferably at least 5-fold, higher than the level expressed in normal ovarian tissue, as determined by the representative assays provided herein. The invention provides some partial ovarian cancer polynucleotide sequences. Proteins encoded by genes comprising such polynucleotide sequences (or their complements) are also considered ovarian carcinoma proteins.
Antibodies are typically immune system proteins, or antigen-binding fragments thereof, that bind to at least a portion of an ovarian cancer polypeptide described herein. The T cells that can be used in the compositions provided herein are typically T cells specific for such polypeptides (e.g., CD4+And/or CD8+). Some of the methods described herein further utilize antigen presenting cells (e.g., dendritic cells or macrophages) that express ovarian cancer polypeptides provided herein.
Ovarian cancer polynucleotides
Any polynucleotide encoding an ovarian carcinoma protein described herein, or a portion or other variant thereof, is included in the present invention. Preferred polynucleotides comprise at least 15 contiguous nucleotides, preferably at least 30 contiguous nucleotides, more preferably at least 45 contiguous nucleotides encoding a portion of an ovarian carcinoma protein. More preferably, the polynucleotide encodes an ovarian carcinoma protein, such as an immunogenic portion of an ovarian carcinoma antigen. Polynucleotides complementary to any such sequence are also encompassed by the invention. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA, or synthetic) or RNA molecules. Additional coding or non-coding sequences may, but need not, be present in the polynucleotides of the invention, and the polynucleotides may, but need not, be linked to other molecules and/or support materials.
The polynucleotide may comprise the native sequence (i.e., the endogenous sequence encoding the ovarian carcinoma protein or portions thereof) or may comprise variants of such a sequence. A polynucleotide variant may comprise one or more substitutions, additions, deletions and/or insertions such that the encoded polypeptide is not reduced in immunogenicity as compared to the native ovarian carcinoma protein. The effect on the immunogenicity of the encoded polypeptide can generally be assessed as described herein. Preferably, the variant exhibits at least about 70% identity, more preferably at least about 80% identity, and most preferably at least about 90% identity to the polynucleotide encoding the native ovarian carcinoma protein or portion thereof.
The percent identity of two polynucleotide or polypeptide sequences can be readily detected by comparing the sequences using computer algorithms well known to those skilled in the art, such as Megalign, using default parameters. Two sequence comparisons are typically performed by comparing sequences over a "comparison window" to identify and compare local regions of sequence similarity. As used herein, a "comparison window" refers to at least about 20 contiguous positions, typically 30 to about 75, or 40 to about 50, where after optimal alignment (aligned) of two sequences, the sequences can be compared to a reference sequence of the same number of contiguous positions. The best alignment of the compared sequences can be performed using default parameters, for example, using the Megalign program of the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.). Preferably, the percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the window may comprise additions or deletions (i.e., gaps) of 20% or less, typically 5-15%, or 10-12% compared to the reference sequence (which does not comprise additions or deletions). Percent identity can be calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size), and multiplying the result by 100 to yield the percent sequence identity.
Variants may also, or alternatively, be substantially homologous to the native gene, or a portion or complement thereof. Such polynucleotide variants hybridize to a naturally occurring DNA sequence encoding a native ovarian carcinoma protein (or a complementary sequence) under moderately stringent conditions. Suitable moderately stringent conditions include prewashing in a solution of 5 XSSC, 0.5% SDS, 1.0mM EDTA (pH 8.0); hybridization overnight in 5 XSSC at 50 ℃ to 65 ℃; subsequently, the cells were washed 2 times for 20 minutes each with 2X, 0.5X and 0.2 XSSC containing 0.1% SDS at 65 ℃.
One skilled in the art will appreciate that as a result of the degeneracy of the genetic code, there are many nucleotide sequences encoding the polypeptides of the invention. Some of these polynucleotides have minimal homology to the nucleotide sequence of any native gene. Thus, polynucleotides that vary due to different codon usage are specifically contemplated by the present invention. Moreover, alleles of genes comprising the polynucleotide sequences provided herein are within the scope of the invention. An allele is an endogenous gene that is altered by one or more mutations, such as nucleotide deletions, additions and/or substitutions. The resulting mRNA and protein may, but need not, have altered structure or function. Alleles can be identified using standard techniques (e.g., hybridization, amplification, and/or database sequence comparison).
Polynucleotides can be prepared by any of a variety of techniques. For example, as will be described in detail below, ovarian cancer polynucleotides can be identified by screening late-passaged ovarian tumor expression libraries with antisera produced from immunocompetent mice injected with SCID mouse sera implanted with late-passaged ovarian tumors. Ovarian cancer polynucleotides may also be identified using any of a variety of techniques for the purpose of assessing differential gene expression. Alternatively, the polynucleotide may be amplified from cDNA prepared from ovarian tumor cells. Such polynucleotides may be amplified by Polymerase Chain Reaction (PCR). For this method, sequence-specific primers can be designed, purchased or synthesized based on the sequences provided by the present invention.
The amplified portions can be used to isolate full-length genes from a suitable library (e.g., an ovarian cancer cDNA library) using well-known techniques. In such techniques, libraries (cDNA or genomic) are screened with one or more polynucleotide probes or primers suitable for amplification. Preferably, the library is screened by size to include larger molecules. Random primer libraries may also be preferred to identify the 5' and upstream regions of the gene. Genomic libraries are preferred to obtain introns and to extend 5' sequences.
For hybridization techniques, labeling can be accomplished by known techniques (e.g., by using a label prepared from a compound of formula I and formula II)32P-nick translation or end-labeling) partial sequence. Followed by labeling with a probe (see Sambrook et al, Molecular Clo)ning: a Laboratory Manual, Cold Spring Harbor laboratories, Cold Spring Harbor, NY, 1989) filters containing denatured bacterial colonies (or plaques containing) were screened for bacteria or bacteriophage libraries. The hybrid colonies or plaques are screened and expanded and the DNA isolated for further analysis. The amount of additional sequence can be detected, for example, by PCR analysis of the cDNA clone with primers on the partial sequence and the vector primer. Restriction maps and partial sequences can be generated to identify one or more overlapping clones. The complete sequence can then be determined using standard techniques, which include generating a series of deletion clones. The resulting overlapping sequences are then assembled into a single contiguous sequence. Full-length cDNA molecules can be generated by ligating appropriate fragments using well-known techniques.
Alternatively, there are a number of amplification techniques that obtain the full-length coding sequence from a partial cDNA sequence. In these techniques, amplification is usually performed by PCR. The amplification step can be performed using any of a variety of commercially available kits. Primers can be designed, for example, using software known in the art. Preferably 22-30 nucleotides in length, having a GC content of at least 50% and a primer that anneals to the target sequence at a temperature of about 68-72 ℃. The amplified regions can be sequenced as described above, and overlapping sequences can be assembled as contiguous sequences.
One such amplification technique is reverse PCR (see Triglia et al, Nucl. acids SRes.16: 8186, 1988) which uses restriction endonucleases to generate fragments in known regions of the gene. This fragment is then circularized by intramolecular ligation, and PCR is performed using primers from different orientations derived from the known region, using this fragment as a template. In an alternative method, the sequence of the contiguous part sequence may be obtained by amplification with primers for the adaptor sequence and primers specific for the known region. The amplified sequences are typically subjected to a second round of amplification using the same adapter primer and a second primer specific for the known region. A variation of this method is to use two primers which start to extend in opposite directions of a known sequence, as described in WO 96/38591. Additional techniques include capture PCR (capture PCR) (Lagrstrom et al, PCR methods application.1: 111-19, 1991) and walk PCR (walking PCR) (Parker et al, nucleic acids. Res.19: 3055-60, 1991). Other methods of amplification may also be used to obtain the full-length cDNA sequence.
In some cases, the full-length cDNA sequence may be obtained by analysis of sequences provided in an Expressed Sequence Tag (EST) database, which is available from GenBank. Searches for overlapping ESTs can generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs can be used to generate contiguous full-length sequences.
FIGS. 1A-1S (SEQ ID NOS: 1-71) and FIGS. 15A-15EEE (SEQ ID NOS: 82-310) provide some nucleic acid sequences of cDNA molecules encoding portions of ovarian cancer antigens. The sequences provided in FIGS. 1A-1S appear to be novel. For the sequences of FIGS. 15A-15EEE, database searches indicated pairs with significant identity. These polynucleotides are isolated by serological screening of ovarian tumor cDNA expression libraries using techniques aimed at identifying secreted tumor antigens. Briefly, late passage ovarian tumor expression libraries were prepared from SCID-derived human ovarian tumors (OV9334) in the vector λ -screen (novagen). Sera for screening were obtained by injecting immunocompetent mice with sera from SCID mice implanted with advanced passage ovarian tumors. This technique allows the identification of cDNA molecules encoding immunogenic portions of secreted tumor antigens.
In particular, the invention includes the polynucleotides described herein, as well as full-length polynucleotides comprising such sequences, other portions of such full-length polynucleotides, and sequences complementary to all or part of such full-length molecules. This technique can also be used to identify antigens secreted by other types of tumors, as will be apparent to those skilled in the art.
FIGS. 4-9(SEQ ID NOS: 75-81) and SEQ ID NOS: 313-384 provides additional nucleic acid sequences encoding a portion of the cDNA molecule of the ovarian carcinoma protein. These sequences were identified by screening microarray cdnas for tumor-associated expression (i.e., ovarian tumors express at least 5-fold more than normal ovarian tissue as determined by representative assays herein). Such screening was carried out using the Synteni microarray (Palo Alto CA) according to the manufacturer's instructions (and essentially as described by Schena et al, Proc. Natl. Acad. Sci. USA 93: 10614-10619, 1996 and Heller et al, Proc. Natl. Acad. Sci. USA 94: 2150-2155). SEQ ID NO: 311 and 319 provide full-length sequences comprising some of these nucleic acid sequences.
Any of a variety of well-known techniques can be used to assess tumor-associated expression of the cDNA. For example, hybridization techniques using labeled polynucleotide probes can be applied. Alternatively, or in addition, amplification techniques such as real-time PCR (see Gibson et al, Genome Research 6: 995-. Real-time PCR is a technique to assess the level of accumulation of PCR products during amplification. This technique allows for quantitative assessment of mRNA levels in multiple samples. Briefly, mRNA is extracted from tumor and normal tissues, and cDNA is prepared using standard techniques. For example, real-time PCR can be performed using a Perkinelmer/Applied biosystems (Foster City, Calif.) 7700Prism instrument. The paired primers and fluorescent probes can be designed for the gene of interest using, for example, the Primer expression program supplied by Perkin Elmer/Applied biosystems (Foster City, Calif.). Optimal concentrations of primers and probes can be initially determined by one skilled in the art, and control (e.g., β -actin) primers and probes are available, for example, from Perkin Elmer/Applied biosystems (Foster City, Calif.). To determine the amount of a particular RNA in a sample, a standard curve is generated simultaneously with the plasmid containing the gene of interest. The Ct value determined by real-time PCR can be used to generate a standard curve, which value is related to the starting cDNA concentration used in the assay. Typically in the range of 10-106Standard dilutions of the gene copy of interest are sufficient. In addition, a standard curve of the control sequence was generated. This allows for normalization of the starting RNA content of the tissue sample relative to the control amount for comparison.
Polynucleotide variants can generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis. Modifications can also be introduced into the nucleotide sequence using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (see Adelman et al, DNA 2: 183, 1983). Alternatively, if the DNA is introduced into the vector together with a suitable RNA polymerase promoter (e.g., T7 or SP6), then RNA molecules may be produced by in vitro or in vivo transcription of the DNA sequence encoding the ovarian cancer antigen or portion thereof. As described herein, some of the moieties may be used to prepare encoded polypeptides. In addition, or as an alternative, a moiety may be administered to a patient for in vivo production of the encoded polypeptide.
A portion of the sequence complementary to the coding sequence (i.e., an antisense polynucleotide) may also be used as a probe or to modulate gene expression. cDNA constructs that can be transcribed into antisense RNA can be introduced into cells or tissues to facilitate antisense RNA production. The antisense polynucleotides of the invention may also be used to inhibit the expression of ovarian carcinoma proteins. Gene expression can be controlled by the formation of triple helices using antisense technology, which impairs the ability of the double helix to open sufficiently to bind polymerases, transcription factors or regulatory molecules (see Gee et al, description in Huber and Carr, Molecular and immunological applications, Futura Publishing Co., Mt. Kisco, NY; 1994). Alternatively, antisense molecules can be designed to hybridize to a gene control region (e.g., a promoter, enhancer, or transcription initiation site) and prevent transcription of the gene; or by inhibiting the binding of the transcript to ribosomes.
Any polynucleotide may be further modified to enhance in vivo stability. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5 'and/or 3' ends; bonded in the backbone with phosphorothioate or 2' O-methyl, rather than phosphodiesterase; and/or include unconventional bases such as inosine, queosine, wybutosine, and acetyl-, methyl-, thio-and other modified forms of adenine, cytosine, guanine, thymine and uracil nucleosides.
The nucleotide sequences of the present invention may be joined to various other nucleotide sequences using established recombinant DNA techniques. For example, polynucleotides can be cloned into a variety of cloning vectors, including plasmids, phagemids, lambda-phage derivatives, and cosmids. Particularly useful vectors include expression vectors, replication vectors, probe generation vectors and sequencing vectors. Generally, the vector will comprise an origin of replication functional in at least one organism, a convenient restriction enzyme site and one or more selectable markers. Other elements depend on the desired use and are apparent to those skilled in the art.
In some embodiments, the polynucleotide may be formulated to allow entry into, and expression in, mammalian cells. Such formulations are particularly useful for therapeutic purposes, as described below. One skilled in the art will appreciate that there are many ways to express a polynucleotide in a target cell and that any suitable method may be utilized. For example, the polynucleotide may be introduced into a viral vector such as, but not limited to, an adenovirus, an adeno-associated virus, a retrovirus, or a vaccinia or other poxvirus (e.g., avipoxvirus). Techniques for introducing DNA into such vectors are well known to those skilled in the art. The retrovirus may additionally transfer or introduce a selectable marker gene (to aid in the identification or screening of transduced cells) and/or a target component, such as a gene encoding a ligand for a receptor for a particular target cell, to render the vector target specific. Targeting can also be accomplished with antibodies by methods well known to those skilled in the art.
Other formulations for therapeutic purposes include colloidally dispersed systems such as macromolecular complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles and liposomes. The preferred colloidal systems for use as delivery vehicles in vitro and in vivo are liposomes (i.e., artificial membrane vesicles). The preparation and use of such systems are well known in the art.
Ovarian cancer polypeptides
In the context of the present invention, the polypeptide may comprise at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof, as described herein. As described above, some ovarian carcinoma proteins are ovarian carcinoma antigens expressed by ovarian tumor cells and react detectably in an immunoassay (e.g., ELISA) with antisera raised against the serum of an immunodeficient animal implanted with an ovarian tumor. The ovarian cancer polynucleotides described herein encode other ovarian cancer proteins. The polypeptides of the invention may be of any length. Additional sequences derived from the native protein and/or heterologous sequences may be present, and such sequences may (but need not) be further immunogenic or antigenic.
As used herein, an "immunogenic moiety" is an antigenic moiety that is recognized (i.e., specifically binds) by a B cell and/or T cell surface antigen receptor. Such immunogenic portions typically comprise at least 5 amino acid residues, more preferably at least 10, and more preferably at least 20 amino acid residues of the ovarian carcinoma protein or a variant thereof. Preferred immunogenic portions are encoded by cDNA molecules isolated as described herein. Further immunogenic portions can generally be identified using well known techniques, as outlined in Paul, Fundamental Immunology, third edition, 243-247(ravenPress, 1993) and references cited therein. Such techniques include screening for polypeptides reactive with antibodies specific for ovarian carcinoma proteins, anti-serum and/or T cell lines or clones. Antisera and antibodies as used herein are "ovarian carcinoma protein-specific" if they specifically bind to ovarian carcinoma protein (i.e., they react with ovarian carcinoma protein but not detectably with other unrelated proteins in an ELISA or other immunoassay). Such antisera, antibodies, and T cells can be prepared as described herein using well-known techniques. An immunogenic portion of a native ovarian carcinoma protein is one that reacts with such antisera, antibodies, and/or T cells at a level that is not significantly less reactive than the full-length polypeptide (i.e., in an ELISA and/or T cell reactivity assay). In such assays, such immunogenic portions may react at a level similar to or greater than the reactivity of the full-length protein. Such screening can generally be carried out using methods well known to those skilled in the art, such as those described in Harlow and Lane, Antibodies: a Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, the polypeptide can be immobilized on a solid support and contacted with patient serum to allow binding of antibodies in the serum to the immobilized polypeptide. Unbound serum is then removed and used, for example125I labeled protein a detects bound antibody.
As described above, the composition may include a variant of the native ovarian carcinoma protein. A polypeptide "variant", as described herein, is a polypeptide that differs from the native ovarian carcinoma protein by one or more substitutions, deletions, and/or insertions such that the immunogenicity of the polypeptide is not significantly diminished. In other words, the ability of a variant to react with an ovarian carcinoma protein-specific antiserum may be enhanced or unchanged compared to the native ovarian carcinoma protein, or may be attenuated by less than 50%, preferably by less than 20%, compared to the native ovarian carcinoma protein. Such variants are generally identified by modifying one of the above polypeptide sequences and assessing the reactivity of the modified polypeptide with an antibody or antisera specific for an ovarian carcinoma protein according to the present invention. Preferred variants include those in which one or more portions, such as the N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include those in which a small portion (e.g., 1-30 amino acids, preferably 5-15 amino acids) is removed from the N-terminus and/or C-terminus of the mature protein.
Preferably, the polypeptide variant exhibits at least about 70%, more preferably at least about 90%, and most preferably at least about 95% identity with the native polypeptide. Preferably, the variant comprises conservative substitutions. A "conservative substitution" is one that has similar properties as one amino acid to another, so one skilled in the art of peptide chemistry would expect no significant change in the secondary structure and hydrophilicity of the polypeptide. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids with similar hydrophilicity values without charged polar head groups include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine, and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) alanine, proline, glycine, glutamic acid, aspartic acid, glutamine, asparagine, serine, threonine; (2) cysteine, serine, tyrosine, threonine; (3) valine, isoleucine, leucine, methionine, alanine, phenylalanine; (4) lysine, arginine, histidine; and (5) phenylalanine, tyrosine, tryptophan, histidine. Variants may also, or alternatively, comprise non-conservative changes. Variants may also (or alternatively) be modified, for example by deletion or addition of amino acids that have a minor effect on the immunogenicity, secondary structure and hydrophilicity of the polypeptide.
As described above, the polypeptide may comprise a signal (or leader) sequence at the protein terminal N-terminus that co-translationally or post-translationally directs protein transfer. The polypeptide may also be conjugated to a linker or other sequence that facilitates synthesis, purification or identification of the polypeptide, or enhances binding of the polypeptide to a solid support (conjugated). For example, the polypeptide may be conjugated to an immunoglobulin Fc region.
The polypeptide may be prepared by any of various known methods. The recombinant polypeptides encoded by the DNA sequences of the present invention may be readily prepared from the DNA sequences using any of a variety of expression vectors well known to those skilled in the art. Expression may be accomplished in a suitable host cell transformed or transfected with an expression vector comprising a recombinant polypeptide-encoding DNA molecule. Suitable host cells include prokaryotes, yeast, higher eukaryotic cells. Preferably, the host cell used is e.coli (e.coli), yeast or a mammalian cell line, such as COS or CHO. The supernatant from a suitable host/vector system secreting the recombinant protein or polypeptide into the culture medium may be first concentrated using commercially available filters. After concentration, the concentrate may be applied to a suitable purification matrix, such as an affinity matrix or an ion exchange resin. Finally, the recombinant polypeptide is further purified using one or more reverse phase HPLC steps.
Portions and other variants having less than about 100 amino acids, and often less than about 50 amino acids, can also be produced by synthetic methods using techniques well known to those skilled in the art. For example, such polypeptides may be synthesized using any commercially available solid phase technique, such as Merrifield solid phase synthesis, in which amino acids are added sequentially to a growing amino acid chain. See Merrifield, j.am.chem.soc.85: 2149-2146, 1963. Polypeptide automated synthesis equipment is commercially available from suppliers, such as Applied biosystems, inc. (Foster City, CA), and may be operated according to the manufacturer's instructions.
In some particular embodiments, the polypeptide may be a fusion protein comprising a plurality of polypeptides of the invention, or a fusion protein comprising one polypeptide of the invention and a known tumor antigen, such as an ovarian carcinoma protein or a variant of such a protein. The fusion partner may, for example, contribute to the provision of T helper epitopes (immunological fusion partners), preferably human-recognized T helper epitopes, or may contribute to the expression of the protein in higher yields than the native recombinant protein (expression enhancers). Some preferred fusion partners are both immunological and expression-enhanced fusion partners. Other fusion partners may be selected to increase protein solubility or to target the protein to a desired intracellular compartment. Further fusion partners include affinity tags that facilitate protein purification.
Fusion proteins can generally be prepared using standard techniques, including chemical conjugation. Preferably, in the expression system, the fusion protein is expressed as a recombinant protein, allowing for increased levels of production compared to non-fusion proteins. In short, DNA sequences encoding the polypeptide components may be assembled separately and incorporated into a suitable expression vector. With or without a peptide linker, the 3 '-end of the DNA sequence encoding one polypeptide component is linked to the 5' -end of the DNA sequence encoding the second polypeptide component such that the open reading frame is in phase. This translates into a single fusion protein that retains the biological activity of the two constituent polypeptides.
The peptide linker sequence may be used to separate the first and second polypeptide components at a sufficient distance to ensure that each polypeptide folds into its secondary and tertiary structures. Such peptide linker sequences are introduced into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be selected based on the following factors: (1) they are capable of forming bendable extended conformations; (2) they are incapable of forming a secondary structure capable of interacting with a functional epitope of the first and second polypeptides; and (3) lack of hydrophobic or charged residues that may react with a functional epitope of a polypeptide. Preferred polypeptide linker sequences comprise glycine, asparagine and serine residues. Other near neutral amino acids, such as threonine and alanine, can also be used in the linker sequence. Amino acid sequences that may be usefully employed as linkers are included in Maratea et al, Gene 40: 39-46, 1985; murphy et al, proc.natl.acid.sci.usa 83: 8258-8262, 1986; those described in U.S. patent No. 4,935,233 and U.S. patent No. 4,751,180. Linker sequences can typically be from 1 to about 50 amino acids in length. If the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate functional domains and prevent steric interference, no linker sequence is required.
The linked DNA sequence is operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for the expression of the DNA are located only 5' to the DNA sequence encoding the first polypeptide. Similarly, the stop codon and the transcription termination signal required for termination of translation are only present in the DNA sequence 3' encoding the second polypeptide.
Fusion proteins comprising a polypeptide of the invention and an unrelated immunogenic protein are also provided. Preferably, the immunogenic protein is capable of eliciting a memory response. Examples of such proteins include tetanus, tuberculosis, and hepatitis proteins (see, e.g., Stoute et al, New Engl. J. Med. 336: 86-91, 1997).
In a preferred embodiment, the immunological fusion partner is derived from protein D, the surface protein of the gram-negative bacterium Haemophilus influenzae (Haemophilus influenza) B (WO 91/18926). Preferably, the protein D derivative comprises approximately the first 1/3 (e.g., the first N-terminal 100-110 amino acids) of the protein, and the protein D derivative may be lipidated. In some preferred embodiments, the first 109 residues of the lipoprotein D fusion partner are included at the N-terminus to provide additional foreign T cell epitopes to the polypeptide and to increase expression levels in e. The lipid tail ensures optimal presentation of antigen to antigen presenting cells. Other fusion partners include the non-structural protein of influenza virus, NS1 (hemagglutinin). The N-terminal 81 amino acids are typically used, although different portions including T helper epitopes may be used.
In another embodiment, the immunological fusion partner is a protein known as LYTA, or a portion thereof (preferably the C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase, known as the amidase LYTA (encoded by the LytA Gene; Gene 43: 265-292, 1986). LYTA is an autolysin that specifically cleaves certain bonds of the peptidoglycan backbone. The C-terminal domain of the LYTA protein is associated with the affinity of choline or some choline analogs, such as DEAE. This property has been exploited to develop E.coli (E.coli) C-LYTA expression plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing a fragment of C-LYTA at the amino terminus has been described (see Biotechnology 10: 795-798, 1992). In preferred embodiments, a LYTA repeat moiety may be introduced into the fusion protein. In the C-terminal region, repeats were found starting from 178 residues. Particularly preferred repeat portions comprise residues 188-305.
Generally, polypeptides (including fusion proteins) and polynucleotides according to the invention are isolated. An "isolated" polypeptide or polynucleotide is one that has been removed from its original environment. For example, a naturally occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure, and most preferably at least about 99% pure. A polynucleotide is considered isolated if, for example, it is cloned into a vector that is not part of its natural environment.
Binding agents
The invention further provides agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to ovarian carcinoma proteins. Is used inAn antibody, or antigen-binding fragment thereof, herein "specifically binds" to an ovarian carcinoma protein if it reacts at a detectable level with the ovarian carcinoma protein (e.g., in an ELISA) but does not detectably react with an unrelated protein under similar conditions. As used herein, "association" refers to the non-covalent association between two separate molecules such that a "complex" is formed. For example, binding capacity can be assessed by determining the binding constant of complex formation. The binding constant is the value obtained when the complex concentration is divided by the component product concentration. Generally, when the complex is formed with a binding constant in excess of about 103L/mol, two compounds are referred to as "combined" in the context of the present invention. Binding constants can be determined by methods known in the art.
Using the representative assays provided herein, the binding agent is further capable of distinguishing between patients with cancer (e.g., ovarian cancer) and patients without cancer. In other words, an antibody or other binding agent that binds to an ovarian cancer antigen will produce a signal indicating the presence of cancer in at least about 20% of patients with the disease, and will produce a negative signal indicating the absence of the disease in at least about 90% of individuals without cancer. To detect whether a binding agent meets this requirement, the presence of a polypeptide that binds to the binding agent in a biological sample (e.g., blood, serum, leukaphoresis, urine, and/or tumor biopsy) from a patient with cancer (as determined by standard diagnostic methods) and a patient without cancer can be determined as described herein. Obviously, statistically significant numbers of diseased and non-diseased samples should be determined. Each binder should meet the above criteria; however, one skilled in the art will recognize that binding agents may be used in combination to improve sensitivity.
Any agent that meets the above requirements may be a binding agent. For example, the binding agent can be a ribosome, RNA molecule or polypeptide with or without a peptide component. In a preferred embodiment, the binding agent is an antibody or antigen-binding fragment thereof. Antibodies can be prepared by any of a variety of techniques well known to those skilled in the art. See, e.g., Harlow and Lane, Antibodies: ALABORT Manual, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the production of monoclonal antibodies as described herein, or by gene transfection of antibodies into suitable bacterial or mammalian cell hosts to allow for the production of recombinant antibodies. In one technique, an immunogen comprising a polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep, and goats). In this step, the polypeptide of the present invention can be used as an immunogen without modification. Alternatively, especially for relatively short peptides, it may be possible to elicit a strong immune response if the peptide is linked to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The animal host is injected with an immunogen, preferably according to a predetermined protocol comprising one or more booster immunizations. Blood was taken from the animals periodically. Polypeptide-specific polyclonal antibodies are subsequently purified from such antisera, for example, by affinity chromatography using the polypeptide attached to a suitable solid support.
For example, the reaction is carried out using a mixture of Kohler and Milstein, Eur.J. Immunol.6: 511-519, 1976 and the improved techniques thereof allow the preparation of monoclonal antibodies specific for the antigenic polypeptide of interest. Briefly, these methods involve the preparation of immortalized cell lines capable of producing antibodies of the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines can be produced, for example, from spleen cells obtained from the above-described immunized animals. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably a myeloma cell fusion partner that is syngeneic with the immunized animal. Various fusion techniques may be utilized. For example, spleen cells and myeloma cells can be mixed with a non-ionic detergent for several minutes and then placed at low density on a selective medium that supports hybrid cell growth but not myeloma cell growth. The preferred screening technique is HAT (hypoxanthine, aminopterin, thymidine) screening. After a sufficient time, typically about 1 to 2 weeks, hybrid colonies are observed. The single colonies were screened and their culture supernatants were assayed for binding activity to the polypeptide. Hybridomas with high reactivity and specificity are preferred.
Monoclonal antibodies were isolated from the supernatant of growing hybridoma colonies. In addition, various techniques can be used to increase production, such as injecting hybridoma cell lines into the abdominal cavity of a suitable vertebrate host, such as a mouse. The monoclonal antibodies are then collected from the ascites fluid or blood. Contaminants are removed from the antibody by conventional techniques such as chromatography, gel filtration, precipitation and extraction. The polypeptides of the invention may also be used in purification processes, such as affinity chromatography steps.
In some embodiments, it is preferred to use antigen binding fragments of antibodies. Such fragments include Fab fragments, which can be prepared using standard techniques. Briefly, immunoglobulins can be purified from rabbit serum by affinity chromatography on protein A bead columns (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988) and digested with papain to produce Fab and Fc fragments. Fab and Fc fragments can be separated by protein A bead column affinity chromatography.
The monoclonal antibodies of the invention may be conjugated to one or more therapeutic agents. Suitable therapeutic agents in this regard include radionuclides, differentiation inducers, drugs, toxins and derivatives thereof. Preferred radionuclides include90Y,123I,125I,131I,186Re,188Re,211At and212and (4) Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol ester and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, pseudomonas exotoxin, shiga toxin, and pokeweed antiviral protein.
The therapeutic agent can be coupled (e.g., covalently bonded) directly or indirectly (e.g., via a linker group) to a suitable monoclonal antibody. When the therapeutic agent and the antibody each have a substituent capable of reacting with each other, a direct reaction between the two is possible. For example, a nucleophilic group on one, such as an amino or thiol group, can react with a group containing a carbonyl group on the other, such as an anhydride or acid halide, or with an alkyl group containing a readily leaving group (e.g., halide).
Alternatively, it may be desirable to couple the therapeutic agent and the antibody via a linker group. The linker group acts as a spacer to space the antibody and therapeutic agent from interfering with the binding capacity. The linker group also serves to increase the chemical reactivity of the substituents on the therapeutic agent or antibody, thus increasing the coupling efficiency. The increase in chemical reactivity may also facilitate the use of the therapeutic agent, or a functional group on the therapeutic agent, or vice versa may not be possible.
It will be apparent to those skilled in the art that a variety of bifunctional or multifunctional agents, including homobifunctional or heterobifunctional (as described in Pierce Chemical co., Rockford, IL catalogue) may be used as linker groups. Coupling can be achieved, for example, by amino, carboxyl, sulfhydryl or oxidized carbohydrate residues. There are numerous references describing such methodologies, for example, U.S. Pat. No. 4,671,958, Rodwell et al.
When a therapeutic agent is more effective without an immunoconjugate antibody portion of the invention, it may be desirable to use a linker group that is cleavable upon or during internalization into a cell. A large number of different cleavable linker groups have been described. Mechanisms for intracellular release of therapeutic agents from these linker groups include cleavage by disulfide bond reduction (e.g., U.S. Pat. No.: 4,489,710, Spitler), by irradiation of photolabile bonds (e.g., U.S. Pat. No.: 4,625,014, Senter et al), by hydrolysis of the side chains of the derivatized amino acids (e.g., U.S. Pat. No.: 4,638,045, Kohn et al), by serum complement mediated hydrolysis (e.g., U.S. Pat. No.: 4,671,958, Rodwell et al), and by acid catalyzed hydrolysis (e.g., U.S. Pat. No.: 4,569,789, Blattler et al).
It may be desirable to couple more than one therapeutic agent to the antibody. In one embodiment, a plurality of therapeutic agent molecules are coupled to one antibody molecule. In another embodiment, more than one type of therapeutic agent may be coupled to an antibody. Regardless of the particular embodiment, immunoconjugates having more than one therapeutic agent can be prepared by various methods. For example, more than one therapeutic agent may be directly coupled to the antibody molecule, or a linker providing multiple sites for binding may be used.
The carrier may carry the therapeutic agent by a variety of methods, including covalent attachment directly or through a linker group. Suitable carriers include proteins such as albumin (e.g., U.S. Pat. No. 4,507,234, Kato, etc.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat. No. 4,699,784, Shih, etc.). The carrier may also carry the therapeutic agent by non-covalent association or by encapsulation, e.g., in a liposome vesicle (e.g., U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. Radionuclide chelates can be formed from chelating compounds, including those containing a nitrogen atom and a sulfur atom as the binding metal, or an oxidizing metal, the donor atom of the radionuclide. For example, U.S. Pat. No. 4,673,562, Davison et al, discloses representative chelating compounds and their synthesis.
Various routes of administration of antibodies and immunoconjugates are available. Typically, administration will be intravenous, intramuscular, subcutaneous or on the basal bed where the tumor is resected. It is clear that the precise dosage of antibody/immunoconjugate will vary with the antibody used, the antigen density on the tumor, and the rate of antibody clearance.
The invention also provides anti-idiotype antibodies that mimic the immunogenic portion of an ovarian carcinoma protein. Such antibodies can be raised against antibodies or antigen-binding fragments thereof that specifically bind to the immunogenic portion of the ovarian carcinoma protein using well-known techniques. Anti-idiotype antibodies that mimic the immunogenic portion of an ovarian carcinoma protein, as described herein, are those antibodies that bind to an antibody or antigen-binding fragment thereof that specifically binds to the immunogenic portion of an ovarian carcinoma protein.
T cells
Immunotherapeutic compositions may also, or alternatively, include ovarian carcinoma protein-specific T cells. Can be generally in vivoSuch cells are prepared ex vivo or using standard techniques. For example, using commercially available cell separation systems, such as CEPRATE available from CellPro Inc., Bothell WATMSystems (see also U.S. Pat. No. 5,240,856; U.S. Pat. No. 5,215,926; WO 89/06280; WO 91/16116; WO 92/07243) T cells can be present in (or isolated from) bone marrow, peripheral blood or a portion of bone marrow or peripheral blood of a mammal, such as a patient. Alternatively, the T cells may be obtained from related or unrelated human, non-human animals, cell lines or cultures.
T cells can be stimulated with ovarian cancer polypeptides, polynucleotides encoding ovarian cancer polypeptides, and/or Antigen Presenting Cells (APCs) expressing such polypeptides. Such stimulation is performed under conditions and for a time sufficient to allow production of polypeptide-specific T cells. Preferably, the ovarian cancer polypeptide or polynucleotide is present in a delivery vehicle, such as a microsphere, to facilitate the production of specific T cells.
A T cell is considered specific for an ovarian cancer polypeptide if it kills a target cell coated with the ovarian cancer polypeptide or that expresses a gene encoding such a polypeptide. T cell specificity can be assessed using any of a variety of standard techniques. For example, in a chromium release assay or proliferation assay, a stimulation index of greater than 2-fold increase in lysis and/or proliferation compared to a negative control indicates T cell specificity. For example, the method may be as described by Chen et al, Cancer Res.54: 1065, 1070, 1994, for carrying out such a measurement method. Alternatively, T cell proliferation assays can be accomplished by various well-known techniques. For example, T cell proliferation can be detected by measuring the rate of increased DNA synthesis (e.g., by pulsing T cell cultures with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into the DNA). Contact with ovarian cancer polypeptide (200 ng/ml-100. mu.g/ml, preferably 100 ng/ml-25. mu.g/ml) for 3-7 days should result in at least a 2-fold increase in T cell proliferation and/or contact for 2-3 hours as described above should result in T cell activation as measured by standard cytokine assays, where a 2-fold increase in the level of cytokine release (e.g., TNF or IFN-. gamma.) is indicative of T cell activation (see Coligan et al, Current protocols in ImmNeurology, Vol.1, Wiley Interscience (Greene 1998)). The T cell activated by the APC in response to the ovarian cancer polypeptide, polynucleotide or expressing the ovarian cancer polypeptide may be CD4+And/or CD8+. Ovarian cancer polypeptide-specific T cells can be expanded using standard techniques. In a preferred embodiment, the T cells are obtained from the patient or a related or unrelated donor and are administered to the patient after stimulation and expansion (expansion).
For therapeutic purposes, CD4 that proliferates in response to an ovarian cancer polypeptide, polynucleotide or APC can be amplified in large amounts in vitro or in vivo+Or CD8+T cells. In vitro proliferation of such T cells can be accomplished by a variety of methods. For example, the T cells can be re-exposed to the ovarian cancer polypeptide, with or without additional T cell growth factors, such as interleukin-2, and/or stimulating cells that synthesize the ovarian cancer polypeptide. Alternatively, one or more T cells that proliferate in the presence of an ovarian cancer polypeptide can be expanded in large numbers by cloning. Methods for cloning cells are well known in the art and include limiting dilution. After expansion, the patient may be returned cells, e.g., as taught by Chang et al, crit. 213, 1996.
Pharmaceutical composition and vaccine
In some aspects, a pharmaceutical composition or vaccine may comprise a polypeptide, polynucleotide, binding agent and/or immune system cell of the invention. Pharmaceutical compositions comprise one or more such compounds or cells and a physiologically acceptable carrier. A vaccine may comprise one or more such compounds or cells and a non-specific immune response enhancer. The non-specific immune response enhancer may be any substance that enhances an immune response to a foreign antigen. Examples of non-specific immune response enhancers include adjuvants, biodegradable microspheres (e.g., polylactic acid), and liposomes (including compounds; see, e.g., Fullerton, U.S. Pat. No. 4,235,877). Typically, vaccines are prepared as described, for example, in M.F.Powell and M.J.Newman, eds, "Vaccine Design (the subbunit and adjuvant Vaccine)," Plenum Press (NY 1995). The pharmaceutical compositions and vaccines within the scope of the present invention may also comprise other compounds that are biologically active or biologically inert. For example, one or more immunogenic portions of other tumor antigens may be present in the composition or vaccine, either incorporated into the fusion protein or as a separate compound.
The pharmaceutical composition or vaccine may comprise DNA encoding one or more of the polypeptides described above, whereby the polypeptide is produced in situ. As noted above, DNA may be present in any of a variety of delivery systems known to those skilled in the art, including nucleic acid expression systems, bacterial and viral expression systems. Suitable nucleic acid expression systems comprise DNA sequences necessary for expression in a patient (e.g., suitable promoters and termination signals). Bacterial delivery systems include the administration of bacteria (e.g., bcg) that express an immunogenic portion of a polypeptide on their cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression vector system (e.g., vaccinia or other poxvirus, retrovirus, or adenovirus), which may include the use of a non-pathogenic (defective), replication competent virus. Many documents disclose suitable systems, such as Fisher-Hoch et al, PNAS 86: 317 and 321, 1989; flexner et al, ann.n.y.acad.sci.569: 86-103, 1989; flexner et al, Vaccines 8: 17-21, 1990; U.S. Pat. nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. patent nos. 4,777,127; GB2,200,651; EP 0,345,242; WO 91/02805; berkner, Biotechniques 6: 616-627, 1988; rosenfeld et al, Science 252: 431-434, 1991; kolls et al, PANS 91: 215-; Kass-Eisler et al, PANS 90: 11498. 11502, 1993; guzman et al, Circulation 88: 2838 2848, 1993; and Guzman et al, cir. Res.73: 1202-1207, 1993. Techniques for introducing DNA into such expression systems are well known to those skilled in the art. DNA may also be "naked", e.g., as described in Ulmer et al, Science 259: 1745. cndot. 1749, 1993 and Cohen, Science 259: 1691 1692, 1993. By coating the DNA on the biodegradable beads, uptake of naked DNA can be increased, effectively transporting the naked DNA into the cell.
Although the pharmaceutical compositions of the present invention may utilize any suitable carrier known to those skilled in the art, the type of carrier will vary depending upon the mode of administration. The compositions of the invention may be formulated for any suitable mode of administration, including, for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous, and intramuscular administration. For parenteral administration, e.g., subcutaneous injection, preferred carriers include water, saline, ethanol, fats, waxes or buffers. For oral administration, any of the above carriers or solid carriers can be employed, such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, and magnesium carbonate. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be used as carriers for the pharmaceutical compositions of the invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. nos. 4,897,268 and 5,075,109.
Such compositions may also include buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextran), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelators such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and/or preservatives. Alternatively, the compositions of the present invention may form a lyophilized powder. The compounds may also be encapsulated in liposomes using well known techniques.
Any of a variety of non-specific immune response enhancers may be used in the vaccines of the present invention. For example, an adjuvant may be included. Most adjuvants contain substances aimed at protecting the antigen from rapid catabolism, such as aluminium hydroxide or mineral oil, and immune response stimulators, such as lipid a, proteins obtained in Bortadella Pertussis or mycobacterium tuberculosis. Suitable adjuvants are commercially available, for example Freund's incomplete and complete adjuvants (Difco laboratories, Detroit, MI), Merck Adjuvant 65(Merck and Company, Inc., Rahway, NJ), alum, biodegradable microspheres, monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or-12, may also be used as adjuvants.
Among the vaccines provided by the present invention, adjuvant compositions designed to induce predominantly a Th1 type immune response are preferred. High levels of Th1 type cytokines (e.g., IFN-. gamma., IL-2 and IL-12) tend to promote cell-mediated induction of immune responses to administered antigens. In contrast, high levels of Th 2-type cytokines (e.g., IL-4, IL-5, IL-6, IL-10, and TNF-. beta.) tend to promote the induction of humoral immune responses. After application of the vaccines provided by the present invention, patients will support an immune response that induces a Th 1-and Th 2-type response. In a preferred embodiment, the response is predominantly of the Th1 type, with Th1 type cytokine levels increasing to a greater extent than Th2 type cytokine levels. These cytokine levels can be readily assessed using standard assays. For a review of the cytokine family see Mosmann and Coffman, ann.rev.immunol.7: 145-173, 1989.
Preferred adjuvants for eliciting a predominantly Th 1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), and an aluminum salt. MPL adjuvant is available from Ribi ImmunoChem Research Inc. (Hamilton, MT; see U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). Also preferred is AS-2(Smithkline Beecham). CpG-containing oligonucleotides, in which the CpG dinucleotide is unmethylated, also induce a predominantly Th1 response. Such oligonucleotides are well known and described, for example, in WO 96/02555. Another preferred adjuvant is a saponin, preferably QS21, which may be used alone or in combination with other adjuvants. For example, boosting systems include combinations of monophosphoryl lipid A and saponin derivatives, such as QS21 and 3D-MPL in combination, as described in WO 94/00153, or weakly reactive compositions in which QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations include oil-in-water emulsions and tocopherols. WO 95/17210 describes a particularly effective adjuvant formulation comprising QS21, 3D-MPL and tocopherol in an oil-in-water emulsion. Any of the vaccines described herein can be prepared using known methods of combining an antigen, an immune response enhancer and a suitable carrier or excipient.
The compositions described herein may be administered as part of a sustained release formulation (i.e., a formulation that causes the compound to be slowly released after administration, such as a capsule or sponge). Such formulations may generally be prepared by known techniques, for example by oral, rectal or subcutaneous implantation, or by administration of such formulations by implantation at the desired target site. Sustained release formulations may comprise a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. The carriers used in such formulations are biocompatible and may also be biodegradable; formulations that provide a relatively constant level of active ingredient release are preferred. The amount of active compound included in a sustained release formulation depends on the site of implantation, the rate of release and the desired duration of release and the nature of the disease to be treated and prevented.
Any of a variety of delivery vehicles may be utilized in pharmaceutical compositions and vaccines to facilitate the generation of antigen-specific immune responses that target tumor cells. Delivery vehicles include Antigen Presenting Cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells genetically engineered to be potent APCs. These cells may, but need not, be genetically modified to increase the ability to present antigens, to improve the activation and/or maintenance of T cell responses, to have an anti-tumor effect on their own and/or to be immunologically compatible with the recipient (i.e. matched HLA haplotypes). APCsAPCs can also be autologous, allogeneic, syngeneic or xenogeneic cells.
Some preferred embodiments of the invention use dendritic cells or progenitors thereof as antigen presenting cells. Dendritic cells are highly potent presenting cells (Banchereau and Steinman, Nature 392: 245-. In general, dendritic cells can be identified based on their general shape (star-shaped in situ, with obvious cytoplasmic processes (dendrites) visible in vitro) and the lack of differentiation markers of dendritic cells as determined by standard assays for B cells (CD19 and CD20), T cells (CD3), monocytes (CD14) and natural killer cells (CD 56). Dendritic cells can of course also be genetically engineered to express specific surface cell receptors or ligands not normally found on dendritic cells in vivo or in vitro, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secretory vesicles loaded dendritic cells (called exosomes) may also be used in vaccines (see Zitvogel et al, Nature Med.4: 594-600, 1998).
Dendritic cells and progenitor cells can be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, tumor-peripheral tissue-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood, or any other suitable tissue or liquid. For example, dendritic cells can be differentiated ex vivo by adding cytokine combinations, such as GM-CSF, IL-4, IL-13, and/or TNF α, to monocyte cultures collected from peripheral blood. Alternatively, CD34 positive cells collected from peripheral blood, umbilical cord blood or bone marrow can be differentiated into dendritic cells by adding GM-CSF, IL-3, TNF α, CD40 ligand, LPS, flt3 ligand and/or other compounds that induce maturation and proliferation of dendritic cells in combination to the culture medium.
For convenience, dendritic cells are classified as "immature" and "mature" cells, which allows simple methods to distinguish between the two well-characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APCs, with high capacity for antigen uptake and processing, which correlates with Fc γ receptor, mannose receptor and DEC-205 labeling. The mature phenotype is generally characterized by low expression of these markers, while cell surface molecules associated with T cell activation, such as class I MHC and class II MHC, adhesion molecules (e.g., CD54 and CD11), and costimulatory molecules (e.g., CD40, CD80, and CD86) are highly expressed.
APCs can generally be transfected with a polynucleotide encoding an ovarian cancer antigen (or portion or other variant thereof), thereby expressing the antigen, or immunogenic portion thereof, on the cell surface. Such transfection may be performed ex vivo, and compositions or vaccines comprising such transfected cells may subsequently be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vector targeting a dendritic or other antigen presenting cell can be administered to the patient, resulting in transfection occurring in vivo. For example, in vivo and ex vivo transfection of dendritic cells can generally be performed by any method known in the art, such as the method described in WO 92/24447, or by Mahvi et al, Immunology and cell biology 75: 456-460, 1997. By incubation of dendritic cells or progenitor cells with polypeptides, DNA (in naked or plasmid vectors) or RNA; or incubation with antigen-expressing recombinant bacteria or viruses (e.g., vaccinia, avipox, adenovirus, or lentiviral vectors) can result in antigen-loaded dendritic cells. Prior to loading, the polypeptide may be covalently conjugated to provide a T cell-assisted immune partner. Alternatively, dendritic cells can be pulsed with a non-conjugated immune partner alone or in the presence of a polypeptide.
Cancer treatment
In a further aspect of the invention, the compositions described herein may be used in the immunotherapy of cancer, such as ovarian cancer. In such methods, pharmaceutical compositions and vaccines are typically administered to the patient. As used herein, "patient" refers to any warm-blooded animal, preferably a human. The patient may or may not have cancer. Thus, the pharmaceutical compositions and vaccines described above may be used to prevent the development of cancer or to treat patients suffering from cancer. In some preferred embodiments, the patient has ovarian cancer. Such cancers, including the appearance of malignant tumors, can be diagnosed using criteria generally accepted in the art. The pharmaceutical compositions and vaccines can be administered prior to or after surgical removal of the primary tumor and/or treatment, such as administration of a radioactive or conventional chemotherapeutic agent.
In some embodiments, the immunotherapy may be an active immunotherapy, in which an immune response modifier (such as a tumor vaccine, bacterial adjuvant and/or cytokine) is administered, and the treatment depends on in vivo stimulation of the endogenous host immune system to generate an anti-tumor response.
In other embodiments, the immunotherapy may be passive immunotherapy, wherein the therapy involves an agent with defined tumor immunoreactivity (e.g., an effect)Cells or antibodies) that directly or indirectly mediate an anti-tumor effect without having to rely on the intact host immune system. Examples of effector cells include T lymphocytes (e.g., CD 8)+Cytotoxic T lymphocytes and CD4+T-helper tumor infiltrating lymphocytes), killer cells (e.g., natural killer cells and lymphokine-activated killer cells), B cells, and antigen presenting cells (e.g., dendritic cells and macrophages) expressing a polypeptide provided by the present invention. For adoptive immunotherapy, T cell receptors and antibody receptors specific for the polypeptides of the invention can be cloned, expressed and transferred into other vectors or effector cells. The polypeptides of the invention may also be used to generate antibodies or anti-idiotype antibodies (as described above and in U.S. Pat. No. 4,918,164) for passive immunotherapy.
As described herein, by growing in vitro, a sufficient number of effector cells for adoptive immunotherapy are typically available. Culture conditions that expand a single antigen-specific effector cell to billions while retaining in vivo antigen recognition are well known in the art. Such in vitro culture conditions are usually stimulated intermittently with antigen, often in the presence of cytokines (e.g., IL-2) and non-dividing feeder cells. As described above, the immunoreactive polypeptides provided by the invention can be used to rapidly expand antigen-specific T cell cultures to produce sufficient immunotherapeutic quantities of cells. In particular, antigen presenting cells, such as dendritic cells, macrophages or B cells, may be transfected with one or more polynucleotides or pulsed with an immunoreactive polypeptide using standard techniques well known in the art. For example, antigen presenting cells may be transfected with a polynucleotide having a promoter suitable for increasing expression in a recombinant virus or other expression system. The cultured effector cells used in therapy must be able to grow and distribute widely in vivo and survive for long periods. Studies have shown that cultured effector cells can be induced to grow in vivo and survive for long periods in considerable numbers by repeated stimulation with IL-2-supplemented antigens (see, e.g., Cheever et al, Immunological Reviews 157: 177, 1997).
Alternatively, a vector expressing a polypeptide of the present invention may be introduced into stem cells, which are derived from a patient and clonally propagated in vitro for autologous transplantation back to the same patient.
The route and frequency of administration and the dosage will vary from individual to individual and can be readily determined by standard techniques. In general, the pharmaceutical compositions and vaccines can be administered by injection (e.g., intradermal, intramuscular, intravenous and subcutaneous), intranasally (inhalation), orally or by tumor resection in the bed. Preferably, 1 to 10 doses may be administered over a period of 52 weeks. Preferably, 6 doses are administered at 1 month intervals, and booster inoculations may be given periodically thereafter. Alternatives may be applicable for each patient. Suitable doses are those amounts of the compound which, when administered as described above, increase the anti-tumor immune response and are at least 10-50% above the baseline level (i.e., untreated). Such a response can be detected by assaying the patient for anti-tumor antibodies or by the production of vaccine-dependent cytolytic effector cells that kill tumor cells in the patient in vitro. Such vaccines should also elicit an immune response that produces improved clinical outcomes in vaccinated patients (e.g., more frequent remission, complete or partial or longer disease-free survival) compared to non-vaccinated patients. Generally, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in the dose ranges from about 100 μ g to 5mg per kg of subject. Suitable dosage volumes vary with patient volume, but typically range from about 0.1mL to about 5 mL.
In general, suitable dosages and treatment regimens provide an amount of the active compound sufficient to provide a therapeutic and/or prophylactic benefit. Such a response can be determined by determining an improved clinical outcome (e.g., more frequent remission, complete or partial or longer disease-free survival) in the treated patient compared to the untreated patient. An increase in the pre-existing ovarian cancer antigen immune response is often associated with improved clinical outcomes. Such immune responses can generally be assessed using standard proliferation, cytotoxicity or cytokine assays, which can be performed using samples obtained from patients before and after treatment.
Screening to identify secreted ovarian cancer antigens
The present invention provides methods for identifying secreted tumor antigens. In this method, an immunodeficient animal, such as a SCID mouse, is implanted with a tumor while maintaining the tumor for a period of time sufficient to allow secretion of tumor antigens into the serum. Generally, the tumor will be implanted, usually subcutaneously or in the gonadal lipid pad of immunodeficient animals, and will last for 1-9 months, preferably 1-4 months. Implantation is generally carried out as described in WO 97/18300. Antisera were then prepared from the sera containing the secreted antigen in immunocompetent mice using standard and described techniques. Briefly, 50-100 μ L of serum (pooled from three groups of immunodeficient animals, each with a different SCID-derived human ovarian carcinoma tumor) can be mixed with a suitable adjuvant, such as RIBI-MPL or MPT + TDM (Sigachemical Co., St. Louis, Mo.) 1: 1 (vol: vol), injected intraperitoneally into syngeneic immunocompetent animals at monthly intervals for a total of 5 months. After the third, fourth and fifth immunizations, antisera were obtained from animals immunized in this way by drawing blood. The resulting antisera are typically pre-cleared of E.coli (E.coli) and phage antigens and used (typically after dilution, e.g., 1: 200) for serological expression screening.
The library is typically an expression library containing cDNAs of one or more tumors of the type implanted in SCID mice. The expression library may be prepared in any suitable vector, such as in lambda-Screen (Novagen). cDNAs encoding polypeptides reactive with antisera can be identified and sequenced using standard techniques. Such cDNA molecules can be further characterized to assess expression in tumor and normal tissues, and to assess antigen secretion in patients.
The method provided by the invention has the advantages over other tumor antigen discovery methods. In particular, all antigens identified by this method should be secreted and released by tumor cell necrosis. This antigen may be present on the surface of the tumor cells for a sufficient period of time to allow targeting and killing by the immune system after vaccination.
Method for detecting cancer
In general, a patient may be detected for cancer based on the presence of one or more ovarian cancer proteins and/or polynucleotides encoding such proteins in a biological sample (e.g., blood, serum, urine, and/or tumor biopsy) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of cancer, such as ovarian cancer. In addition, such proteins may be used in the detection of other cancers. The binding agents provided by the present invention generally allow for the detection of the level of protein in a biological sample that binds to the binding agent. Polynucleotide primers and probes can be used to detect mRNA levels encoding tumor proteins, which mRNA levels also indicate the presence or absence of cancer. In general, ovarian cancer-associated sequences should be present at a level at least 3-fold higher in tumor tissue than in normal tissue.
There are various assay formats known to those skilled in the art for detecting polypeptide tags in a sample with a binding agent. See, e.g., Harlow and Lane, Antibodies: a Laboratory Manual, Cold Spring Harbor Laboratory, 1988. Generally, the presence or absence of cancer in a patient can be determined by: (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting the level of polypeptide bound to the binding agent in the sample; and (c) comparing the level of the polypeptide to a predetermined cutoff value.
In a preferred embodiment, the assay comprises binding and isolating the polypeptide in the remainder of the sample with a binding agent immobilized on a solid support. The bound polypeptide can then be detected with a detection reagent containing a reporter group, which can specifically bind to the binding agent/polypeptide complex. Such detection reagents may include, for example, a binding agent that specifically binds the polypeptide, or other reagents that specifically bind or antibody the binding agent, such as an anti-immunoglobulin, protein G, protein a, or lectin. Alternatively, a competition assay may be utilized in which the polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which the sample component inhibits the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use in such an assay include full length ovarian carcinoma proteins and portions thereof to which a binding agent binds, as described above.
The solid support can be any substance known to those skilled in the art that can bind to tumor proteins. For example, the solid support may be a detection well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or a disc, such as glass, glass fibre, latex or a plastics material, such as polystyrene or polyvinyl chloride. The carrier may also be a magnetic particle or fiber optic sensor as disclosed, for example, in U.S. Pat. No. 5,359,681. The binding agents can be immobilized on solid supports using a variety of techniques well known to those skilled in the art, which are well described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to non-covalent attachment, such as adsorption, and covalent bonding (where it may be the direct attachment of the agent to the functional group on the support, or it may be attached by means of a cross-linking agent). Immobilization by adsorption to the wells or membranes of a titer plate is preferred. In this case, adsorption is accomplished by contacting the binding agent with the solid support in a suitable buffer for a suitable time. The contact time varies with temperature, but is generally from about 1 hour to about 1 day. Generally, contacting the wells of a plastic microtiter plate (e.g., polystyrene or polyvinyl chloride) with an amount of binding agent ranging from about 10ng to about 10 μ g, preferably from about 100ng to about 1 μ g, is sufficient to immobilize a sufficient amount of binding agent.
Covalent attachment of the binding agent to the solid support is generally achieved by first reacting the support with a bifunctional agent which will react with the support and functional groups, such as hydroxyl or amino groups, on the binding agent. The binding agent may be covalently bound to a carrier with a suitable polymer coating, for example with benzoquinone, or by condensation of aldehyde groups on the carrier with amines and active hydrogens on the binding partner (see, for example, Pierce immunology Catalog and Handbook, 1991, at a 12-13).
In some embodiments, the assay is a double antibody sandwich assay. Such an assay is performed by first contacting the antibody immobilized on a solid support, typically a well of a microtiter plate, with the sample such that the polypeptide in the sample is allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complex and a detection reagent containing a reporter group (preferably a second antibody that binds to a different site on the polypeptide) is added. The amount of detection reagent that remains bound to the solid support is then determined by a method suitable for the specific reporter group.
More specifically, as described above, once the antibody is immobilized on the carrier, the remaining protein binding sites on the carrier are typically blocked. Any suitable blocking reagent known to those skilled in the art may be used, such as bovine serum albumin or Tween20TM(Sigma Chemical Co., St. Louis, Mo.). The immobilized antibody is then incubated with the sample and the polypeptide allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as Phosphate Buffered Saline (PBS), prior to incubation. Generally, a suitable contact time (i.e., incubation time) is a time sufficient to detect a polypeptide in a sample obtained from an individual having ovarian cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of the level of binding achieved at equilibrium between bound and unbound polypeptide. One skilled in the art will appreciate that the time required to reach equilibrium can be readily determined by determining the level of binding that occurs over a period of time. An incubation time of typically about 30 minutes at room temperature is sufficient.
Then, by using a suitable buffer, such as containing 0.1% Tween20TMThe solid phase carrier was washed with PBS to remove unbound sample. Subsequently, a second antibody containing a reporter group is added to the solid support. Preferred reporter groups include those described above.
The detection reagent is then incubated with the immobilized antibody-polypeptide complex for a period of time sufficient to detect the bound polypeptide. By measuring the level of binding that occurs over a period of time, the appropriate time can generally be determined. Subsequently, unbound detection reagent is removed and bound detection reagent is detected with the reporter group. The method used to detect the reporter group depends on the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally suitable. Dyes, fluorophores, and fluorophores can be detected spectrophotometrically. Biotin can be detected with avidin coupled to a different reporter group, usually a radioactive or fluorescent group or an enzyme. The enzyme reporter group is typically detected by addition of a substrate (usually for a specified time) followed by spectrophotometric or other analysis of the reaction product.
To detect the presence or absence of a cancer, such as ovarian cancer, the detection signal of the reporter group that remains bound to the solid support is typically compared to a signal corresponding to a predetermined cutoff value. In a preferred embodiment, the cancer detection cut-off is the mean median signal obtained when the immobilized antibody is incubated with a sample derived from a patient not suffering from cancer. Generally, samples that produce a signal of 3 standard deviations above a predetermined cutoff value are considered positive for cancer. In an alternative preferred embodiment, a Receiver Operator curve is used, according to Sackett et al, Clinical epidemic: the cut-off was determined by the method of A Basic Science for Clinical medicine, Little Brown and Co., 1985, pages 106-7. Briefly, in this embodiment, cutoff values may be determined from a plot of true positive rate (i.e., sensitivity) and false positive rate (100% specificity) pairs corresponding to each possible cutoff value for a diagnostic test result. The cut-off value closest to the top left corner in the graph (i.e., the value encompassing the largest area) is the most accurate cut-off value, and samples that produce a higher signal than the cut-off value determined by this method can be considered positive. Alternatively, the cutoff value may be moved along the graph to the left to minimize the false positive rate, or to the right to minimize the false negative rate. Generally, samples that produce a signal higher than the cutoff value determined by this method are considered to be cancer positive.
In a related embodiment, the assay is performed as a flow-through or tape assay, wherein a binding agent is immobilized on a membrane, such as nitrocellulose. In a flow-through assay, polypeptides in a sample bind to an immobilized binding agent as the sample passes through the membrane. Then, a second labeled binding agent binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. Detection of the bound second binding agent may then be performed as described above. In the tape test format, one end of the binding agent-bound membrane is immersed into a solution containing the sample. The sample moves along the membrane through the zone containing the second binding agent and reaches the zone of immobilized binding agent. Concentration of the second binding agent in the immobilized antibody region indicates the presence of cancer. Typically, the second binding agent is concentrated at this site to produce a macroscopic pattern, such as a line. The absence of such a pattern indicates a negative result. Generally, the amount of binding agent immobilized on the membrane is selected so that a visually discernible pattern is produced when the biological sample contains a sufficient level of polypeptide to produce a positive signal in the double antibody sandwich assay in the manner described above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25ng to about 1 μ g, more preferably from about 50ng to about 500 ng. Such tests can generally be performed with very small amounts of biological samples.
Of course, there are a number of other assay protocols that are suitable for use with the tumor proteins or binding agents of the present invention. The above description is merely exemplary. For example, the above protocol can be readily modified to detect antibodies binding to ovarian cancer polypeptides in a biological sample using such polypeptides, as will be apparent to those skilled in the art. Detection of such ovarian carcinoma protein-specific antibodies may be correlated with the presence of cancer.
Cancer may also, or alternatively, be detected based on the presence of T cells in the biological sample that specifically react with ovarian cancer proteins. In some methods, the isolated from the patient comprises CD4+And/or CD8+A biological sample of T cells is incubated with an ovarian carcinoma protein, a polynucleotide encoding such a polypeptide and/or an Antigen Presenting Cell (APC) expressing at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells can be isolated from a patient by conventional techniques (e.g., by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells can be cultured in vitro at 37 ℃ and in ovaryOncoproteins (e.g., 5-25. mu.g/ml) are incubated for 2-9 days (usually 4 days). It may be desirable to incubate another aliquot of the T cell sample as a control in the absence of ovarian carcinoma protein. For CD4+T cells, activation is preferably detected by assessing T cell proliferation. For CD8+T cells, preferably by assessing cytolytic activity. A level of proliferation that is at least two times greater than that of disease-free patients and/or a level of cytolytic activity that is at least 20% greater than that of disease-free patients indicates that the patients have cancer.
As described above, cancer may also, or alternatively, be detected based on the level of mRNA encoding ovarian cancer protein in the biological sample. For example, to amplify ovarian carcinoma protein cDNA derived from a biological sample, at least two oligonucleotide primers may be utilized in a Polymerase Chain Reaction (PCR) -based assay, wherein at least one oligonucleotide primer is specific for (i.e., hybridizes to) a polynucleotide encoding an ovarian carcinoma protein. The amplified cDNA is then isolated and detected by techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to polynucleotides encoding ovarian carcinoma proteins can also be used in hybridization assays to detect the presence of polynucleotides encoding tumor proteins in biological samples.
To allow hybridization under assay conditions, the oligonucleotide primers and probes should comprise oligonucleotide sequences that are at least about 60%, preferably at least about 75%, more preferably at least about 90% identical to the ovarian carcinoma protein-encoding polynucleotide portion, which is at least 10 nucleotides, preferably at least 20 nucleotides in length. Preferably, the oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide of the present invention under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes that may be usefully employed in the diagnostic methods of the present invention are preferably at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primer comprises at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides of a DNA molecule having a sequence provided herein. PCR-based assays and hybridization assay techniques are well known in the art (see, e.g., Mullis et al, Cold Spring Harbor Symp. Quant. biol., 51: 263, 1987; Erlich eds., PCR Technology, StocktonPress, NY, 1989).
One preferred assay utilizes RT-PCR, where PCR is used in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and reverse transcribed to produce cDNA molecules. The cDNA molecules are PCR amplified using at least one specific primer, and can be isolated and visualized, for example, by gel electrophoresis. Biological samples taken from test patients and individuals not suffering from cancer may be amplified. Amplification reactions can be performed on several dilutions of cDNA spanning 2 orders of magnitude. It is generally considered positive that several dilutions of the test patient sample have a 2-fold or greater increase in expression over the same dilution in the non-cancerous sample.
In another embodiment, ovarian carcinoma proteins and polynucleotides encoding such proteins can be used as markers for detecting a trend toward cancer progression. In this embodiment, the cancer diagnostic assay described above can be performed over time, and changes in the level of reactive polypeptide assessed. For example, the measurement is performed every 24 to 72 hours over a period of 6 months to 1 year, and thereafter, the measurement is performed as necessary. Generally, the level of polypeptide detected by the binding agent increases over time in patients in whom the cancer is progressing. In contrast, when the level of reactive polypeptide remains constant or decreases over time, the cancer does not progress.
Several in vivo diagnostic assays can be performed directly on cancer. One such assay involves contacting tumor cells with a binding agent. The bound binding agent can then be detected directly or indirectly via the reporter group. Such binders may also be utilized in histological applications. Alternatively, polynucleotide probes may be used for such applications.
As described above, to improve sensitivity, multiple ovarian carcinoma protein markers can be determined in known samples. It is clear that binding agents specific for the different proteins provided by the invention can be combined in a single assay. Furthermore, a plurality of primers and probes may be used at the same time. Tumor protein marker screening can be performed based on routine assays to detect the combination that gives rise to the best sensitivity. In addition, or alternatively, assays for tumor proteins provided herein can be combined with other well-known tumor antigen assays.
Diagnostic kit
The invention further provides a kit for use in any of the above diagnostic methods. Typically such kits comprise two or more components necessary to perform a diagnostic assay. The component may be a compound, a reagent, a container and/or a device. For example, one container of the kit may contain a monoclonal antibody or fragment thereof that specifically binds to ovarian carcinoma protein. As mentioned above, such antibodies or fragments may be provided attached to a support material. One or more other containers may contain components for detection, such as reagents or buffers. Such kits may also, or alternatively, comprise a detection reagent as described above, the detection reagent comprising a reporter group suitable for direct or indirect detection of antibody binding.
Alternatively, kits can be designed to detect the level of mRNA encoding ovarian carcinoma protein in a biological sample. Such kits typically include at least one oligonucleotide probe or primer that hybridizes to a polynucleotide encoding an ovarian carcinoma protein, as described above. Such oligonucleotide primers may be utilized, for example, in PCR or hybridization assays. Other components that may be present in such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate detection of the polynucleotide encoding the ovarian carcinoma protein.
The following examples are provided by way of illustration and not by way of limitation.
Examples
Example 1: identification of representative ovarian carcinoma protein cDNAs
This example illustrates the identification of a cDNA molecule encoding an ovarian carcinoma protein.
Coli (e.coli) and phage antigens were previously cleared from anti-SCID mouse serum (generated against the serum of SCID mice bearing late passage ovarian cancer (latex ovarian carcinoma)) and used at a dilution of 1: 200 in serum expression screens. Screening libraries were prepared from human ovarian tumors (OV9334) derived from SCID using a directional RH oligo (dT) primed cDNA library construction kit and lambda Screen vector (Novagen). Screening with bacteriophage lambda. An amplified OV9334 library of approximately 400,000pfu (plaque forming units) was screened.
196 positive clones were isolated. In FIGS. 1A-1S and SEQ ID NO: 1 to 71, some seemingly new sequences are provided. FIGS. 2A-2C (SEQ ID NOS: 72 to 74) show three complete inserts. Other clones with known sequences are shown in FIGS. 15A-15EEE (SEQ ID NOs: 82 to 310). Database searches identified the following sequences that are significantly identical to the sequences shown in FIGS. 15A-15 EEE.
These clones were further characterized by microarray technology to detect mRNA expression levels in various tumor and normal tissues. This analysis was performed using Synteni (Palo Alto, Calif.) microarrays, according to the manufacturer's instructions. The PCR amplification products are arranged on a slide, and each product occupies a unique position in the array. mRNA to be tested is extracted from the tissue sample, reverse transcribed and a fluorescently labeled cDNA probe is generated. The microarray was probed with a labeled cDNA probe and the slide was scanned to detect the fluorescence intensity. Data were analyzed using GEMtools software supplied by Syntei's. The results of one clone (13695, also known as O8E) are shown in FIG. 3.
EXAMPLE 2 identification of ovarian cancer cDNA Using microarray technology
This example illustrates the identification of ovarian cancer polynucleotides by PCR subtraction and microarray analysis. The ovarian tumor-specific expression of cDNAs was analyzed using Synteni (Palo Alto, CA) microarrays according to the manufacturer's instructions (and essentially as described by Schena et al, Proc. Natl. Acad. Sci. USA 93: 10614-10619, 1996 and Heller et al, Proc. Natl. Acad. Sci. USA 94: 2150-2155, 1997).
PCR subtraction was performed with a tester (tester) containing four ovarian tumor (3 of them are metastatic tumors) cdnas and a driver (driver) of 5 normal tissue (adrenal, lung, pancreas, spleen and brain) cdnas. The cDNA fragments recovered from this subtraction were used for DNA array analysis, where the fragments were PCR amplified, attached to a chip, and hybridized with fluorescently labeled probes derived from human ovarian tumors and various normal human tissue mRNAs. In this analysis, slides were scanned and fluorescence intensity was measured and the data analyzed using GEMtools software from Syntei. In general, sequences that show at least a 5-fold increase in expression in tumor cells (relative to normal cells) are considered ovarian tumor antigens. The fluorescence results were analyzed and those clones showing increased expression in ovarian tumors were further characterized by DNA sequencing and database search to determine sequence novelty.
Using such an assay, an ovarian cancer tumor antigen was identified which is a spliced fusion of the human T-Cell leukemia virus type I oncoprotein TAX (see Jin et al, Cell 93: 81-91, 1998) and an extracellular matrix protein known as osteonectin. Splice linker sequences are present at the fusion site. The sequence of this clone is shown in FIG. 4 and SEQ ID NO: shown at 75. From this assay, bone adhesion proteins without splicing and without alteration were also identified separately.
Further clones identified by this method are referred to herein as 3f, 6b, 8e, 8h, 12c and 12 h. The sequences of these clones are shown in fig. 5 to 9 and SEQ ID NO: shown at 76 to 81. Microarray analysis was performed as described above and shown in FIGS. 10 to 14. The full-length sequences comprising clones 3f, 6b, 8e and 12h were obtained by screening an ovarian tumor (SCID-derived) cDNA library. This 2996 base pair sequence (designated O772P) is set forth in SEQ ID NO: 311, and the sequence of the encoded 914 amino acid protein is shown in SEQ ID NO: 312, shown in the figure. PSORT analysis indicated type 1a transmembrane proteins localized to the plasma membrane.
In addition to some of the sequences described above, the screen identified the following sequences detailed in table 1:
TABLE 1
| Sequence of | Note |
| OV4vG11(SEQ ID NO:313) | Clone 1119D9 on human chromosome 20p12 |
| OV4vB11(SEQ ID NO:314) | uWGC of human chromosome 6p 21: y14c094 |
| OV4vD9(SEQ ID NO:315) | Clone 1049G16 of human chromosome 20q12-13.2 |
| OV4vD5(SEQ ID NO:316) | Human KIAA0014 gene |
| OV4vC2(SEQ ID NO:317) | Human KIAA0084 gene |
| OV4vF3(SEQ ID NO:318) | Human chromosome 19 cosmid R31167 |
| OV4VC1(SEQ ID NO:319) | Novel |
| OV4vH3(SEQ ID NO:320) | Novel |
| OV4vD2(SEQ ID NO:321) | Novel |
| O815P(SEQ ID NO:322) | Novel |
| OV4vC12(SEQ ID NO:323) | Novel |
| OV4vA4(SEQ ID NO:324) | Novel |
| OV4vA3(SEQ ID NO:325) | Novel |
| OV4v2A5(SEQ ID NO:326) | Novel |
| O819P(SEQ ID NO:327) | Novel |
| O818P(SEQ ID NO:328) | Novel |
| O817P(SEQ ID NO:329) | Novel |
| O816P(SEQ ID NO:330) | Novel |
| Ov4vC5(SEQ ID NO:331) | Novel |
| 21721(SEQ ID NO:332) | Human lumican |
| 21719(SEQ ID NO:333) | Human retinoic acid binding protein II |
| 21717(SEQ ID NO:334) | Human 26S proteasome ATPase subunit |
| 21654(SEQ ID NO:335) | Human copine I |
| 21627(SEQ ID NO:336) | Human neuron specific gamma-2 enolase |
| 21623(SEQ ID NO:337) | Human geranylgeranyl transferase II |
| 21621(SEQ ID NO:338) | Human cyclin-dependent protein kinases |
| 21616(SEQ ID NO:339) | Human promegakaryocyte potentiator |
| 21612(SEQ ID NO:340) | Human UPH1 |
| 21558(SEQ ID NO:341) | Human RalGDS 2(RGL-2) |
| 21555(SEQ ID NO:342) | Human autoantigen P542 |
| 21548(SEQ ID NO:343) | Human actin related protein (ARP2) |
| 21462(SEQ ID NO:344) | Human Huntingtin interacting proteins |
| 21441(SEQ ID NO:345) | Human 90K products (tumor associated antigens) |
| 21439(SEQ ID NO:346) | Human guanine nucleotide regulatory protein (TIML) |
| 21438(SEQ ID NO:347) | Human Ku autoimmune (p70/p80) antigen |
| 21237(SEQ ID NO:348) | Human S-laminin |
| 21436(SEQ ID NO:349) | Human ribosome binding protein I |
| 21435(SEQ ID NO:350) | Human cytoplasmic chaperone protein hTRIC5 |
| 21425(SEQ ID NO:351) | Human EMX2 |
| 21423(SEQ ID NO:352) | Human p87/p89 gene |
| 21419(SEQ ID NO:353) | Human HPBRII-7 |
| 21252(SEQ ID NO:354) | Human T1-227H |
| 21251(SEQ ID NO:355) | Human cullinn I |
| 21247(SEQ ID NO:356) | Kunitz type protease inhibitor (KOP) |
| 21244-1(SEQ ID NO:357) | Human Protein Tyrosine Phosphate Receptor F (PTPRF) |
| 21718(SEQ ID NO:358) | Human LTR repeats |
| OV2-90(SEQ ID NO:359) | Novel |
| Human zinc finger (SEQ ID NO: 360) | |
| Human poly (A) binding protein (SEQ ID NO: 361) | |
| Human pleitrophin (SEQ ID NO: 362) | |
| Human PAC clone 278C19(SEQ ID NO: 363) | |
| Human LLRep3(SEQ ID NO: 364) | |
| Human Kunitz-type protease inhibitors(SEQ ID NO:365) | |
| Human KIAA0106 gene (SEQ ID NO: 366) | |
| Human keratin (SEQ ID NO: 367) | |
| Human HIV-1TAR (SEQ ID NO: 368) | |
| Human glial-derived microtubule associated protein (SEQ ID NO: 369) | |
| Human fibronectin (SEQ ID NO: 370) | |
| Human ECM Pro BM40(SEQ ID NO: 371) | |
| Human collagen (SEQ ID NO: 372) | |
| Human alpha-enolase (SEQ ID NO: 373) | |
| Human aldolase (SEQ ID NO: 374) | |
| Human transfer growth factor BIG H3(SEQ ID NO: 375) | |
| Human SPARC bone adhesion protein (SEQ ID NO: 376) | |
| Human SLP1 leukocyte protease (SEQ ID NO: 377) | |
| Human mitochondrial ATP synthase (SEQ ID NO: 378) | |
| Human DNA sequence gLongton 461P17(SEQ ID NO: 379) | |
| Human dbpB Pro Y box (SEQ ID NO: 380) | |
| Human 40kDa keratin (SEQ ID NO: 381) | |
| Human argininosuccinate synthase (SEQ ID NO: 382) | |
| Human acidic ribosomal phosphoprotein (SEQ ID NO: 383) | |
| Human colon cancer laminin binding protein (SEQ ID NO: 384) | |
This screen further identified various forms of clone O772P, designated 21013, 21003 and 21008 herein. PSORT analysis showed that 21003(SEQ ID NO: 386; translated to SEQ ID NO: 389) and 21008(SEQ ID NO: 387; translated to SEQ ID NO: 390) represented the type 1a transmembrane protein form of O772P. 21013(SEQ ID NO: 385; translated to SEQ ID NO: 388) looks like a truncated form of the protein and is predicted to be a secreted protein by PRORT analysis.
Additional sequence analysis yielded a full-length clone of O8E (2627bp, consistent with the informative size observed by Northern analysis; SEQ ID NO: 391). This nucleotide sequence was obtained as follows: the original O8E sequence (OrigO8E cons) was found to have an overlap of 33 nucleotides with the EST clone (IMAGE #1987589) sequence. This clone provided 1042 additional nucleotides upstream of the original O8E sequence. The linkage between the EST and O8E was confirmed by sequencing multiple PCR fragments generated from an ovarian primary tumor library using a single EST and O8E sequence primer (ESTXO8 EPCR). The full-length state is further indicated when the ovarian tumor library anchored PCR gave several clones that all terminated upstream of the putative initiating methionine without producing any additional sequence information (anchored PCR cons). Fig. 16 shows a diagram illustrating the position of each partial sequence in the full-length O8E sequence.
From the full-length O8E sequence, two protein sequences can be translated. For "a" (SEQ ID NO: 393) the putative initiating methionine is initiated. Second form "b" SEQ ID NO: 392) 27 additional upstream residues were included at the 5' end of the nucleotide sequence.
Example 3
This example discloses the identification and characterization of the epitope of antibodies (antibodypipipes) recognized by the O8E polyclonal antiserum.
Rabbit antisera was generated against the O8E recombinant protein from e.coli (e.coli) and antibody epitope recognition was detected for the 20 or 21mer peptide corresponding to the O8E amino acid sequence. The acid and/or salt elution peaks from the affinity purified anti-O8E serum identified peptides spanning amino acid regions 31 to 65, 76 to 110, 136 to 200 and 226 to 245 of the full-length O8E protein. The amino acid sequence corresponding to the above peptide thus constitutes an epitope of the antibody recognized by the affinity purified anti-O8E antibody.
ELISA analysis of anti-O8E rabbit serum is shown in FIG. 23, and ELISA analysis of affinity purified rabbit anti-O8E polyclonal antibody is shown in FIG. 24.
For epitope mapping, 20 or 21mer peptides corresponding to O8E protein were synthesized. For antibody affinity purification, rabbit anti-O8E serum was passed through an O8E sepharose column containing 0.5M NaCl and 20mM PO4The antibody was eluted in salt buffer followed by an acid wash step with 0.2M glycine, pH 2.3. The purified antibody was neutralized by the addition of 1M Tris, pH8, and the buffer was switched to Phosphate Buffered Saline (PBS). For enzyme-linked immunosorbent assay (ELISA) analysis, the O8E peptide and O8E recombinant protein were coated at 2. mu.g/ml on a 96-well flat bottom plate for 2 hours at Room Temperature (RT). The plates were then washed 5 times with PBS + 0.1% Tween20 and blocked with PBS + 1% Bovine Serum Albumin (BSA) for 1 hour. The anti-O8E antibody was then affinity purified at 1. mu.g/ml of the acid or salt eluted fraction into the wells and incubated for 1 hour at Room Temperature (RT). Washing the plate again, adding donkey anti-rabbit Ig horseradish peroxidase (HRP) antibody,room temperature for 1 hour. The plate is washed and then washed by adding the chromogenic substrate 3 ', 3', 5 ', 5' -Tetramethylbenzidine (TMB) (Bos et al, J2: 187-204 (1981); available from Sigma (st. louis, MO). The reaction was incubated at room temperature for 15 minutes by adding 1N H2SO4The reaction was stopped. The plates were read at a visible density 450(OD450) on an automated plate reader. Peptide sequences corresponding to the OE8 antibody epitope are disclosed herein in SEQ ID NO: 394-415. Fig. 17 discloses the epitope of antibodies recognized by O8E polyclonal antisera.
Example 4
This example discloses an IHC analysis of O8E expression in ovarian cancer tissue samples.
For immunohistochemical studies, paraffin-embedded formaldehyde-fixed ovarian cancer tissues were sectioned at 8 microns. Epitope Recovery (SHIER) was induced by Steam heating in 0.1M sodium citrate buffer (pH6.0) as the optimal staining condition. Sections were incubated with 10% serum/PBS for 5 minutes. Primary antibody (anti-O8E rabbit affinity purified polyclonal antibody) was added to each section for 25 minutes followed by incubation with anti-rabbit biotin labelled antibody for 25 minutes. Endogenous peroxidase activity was blocked by three 1.5 min incubations with hydrogen peroxide. The avidin-biotin complex/horseradish peroxide system was used with DAB chromogen to visualize antigen expression. Slides were counterstained with hematoxylin. One of the six ovarian cancer tissue sections (papillary serous carcinoma) showed O8E immunoreactivity. When staining conditions were optimized, the O8E polyclonal antibody, 4/5 ovarian cancer samples stained positive. O8E expression mapped to the plasma membrane.
Six ovarian cancer tissues were analyzed with anti-O8E rabbit polyclonal antibody. One of the six ovarian cancer tissue samples (papillary serous carcinoma) stained positive for O8E expression. O8E expression localized to the surface film.
Example 5
This example discloses O8E peptides predicted to bind to HLA-a2 while being immunogenic to human CD8T cell responses.
By using the O8E full-length Open Reading Frame (ORF) and by running it with "Episeek" (a program for predicting MHC binding peptides), the O8E likely HLA-a2 binding peptides were predicted. The procedure used was Parker, k.c. et al, j.immunol.152(1):163- & 175(1994), which is incorporated herein by reference in its entirety. The 10mer and 9mer peptides predicted to bind to HLA-0201 are disclosed herein as SEQ ID NO: 416-435 and SEQ ID NO: 436-455.
Example 6
This example discloses the detection of O8E surface expression by Fluorescence Activated Cell Sorting (FACS).
For FACS analysis, cells were washed with ice cold staining buffer (PBS/1% BSA/azide). Next, the cells were incubated with 10. mu.g/ml affinity purified rabbit anti-B305D polyclonal antibody for 30 minutes on ice. Cells were washed 3 times with staining buffer and then incubated on ice for 30 minutes with goat anti-rabbit Ig (H + L) -FITC reagent (Southern Biotechnolyg) diluted 1: 100. After 3 washes, the cells were resuspended in staining buffer containing propidium iodide (sodium iodide), which vital stain allows the identification of permeable cells, after which the cells were analyzed by FACS. O8E surface expression was confirmed on SKBR3 breast cancer cells and HEK293 cells stably expressing the O8E cDNA. Neither MB415 cells nor HEK293 cells stably transfected with control unrelated plasmid DNA showed O8E surface expression (fig. 18 and 19).
Example 7
This example further evaluated the expression and surface localization of O8E.
For expression and purification of antigens for immunization, O8E expressed in an e.coli (e.coli) recombinant expression system was grown overnight in LB broth with the appropriate antibiotics at 37 ℃ in a shaking incubator. The following morning, 10ml of overnight culture was added to 500ml of 2 XYT supplemented with the appropriate antibiotic in a 2L baffled Erlenmeyer flask. When the culture optical density (at 560nm) reached 0.4-0.6, the cells were induced with IPTG (1 mM). Cells were harvested by centrifugation 4 hours after incubation with IPTG. The cells were then washed with phosphate buffered saline and centrifuged again. The supernatant is discarded, or the cells are frozen for use or immediately processed. Add lysis buffer to 20ml of the cell pellet and vortex. To crush the E.coli cells, the mixture was then passed through a French press under 16,000psi pressure. The cells were then centrifuged again and the distribution of the recombinant protein in the supernatant and pellet was examined by SDS-PAGE. For proteins localized to the cell pellet, the pellet was resuspended in 10mM Tris pH8.0, 1% CHAPS, and the inclusion body pellet was washed and centrifuged again. This process was repeated 2 more times. The washed inclusion body pellet was solubilized with 8M urea or 6M guanidine hydrochloride containing pH8.010mM Tris added with 10mM imidazole. The solubilized protein was added to 5ml of nickel chelate resin (Qiagen) and incubated at room temperature for 45 minutes to 1 hour with constant stirring. After incubation, the resin and protein mixture was poured through a disposable column and the flow-through was collected. The column was then washed with 10-20 column volumes of lysis buffer. Subsequently, the antigen was eluted from the column with 8M urea, 10mM tris pH8.0 and 300mM imidazole, collected in 3ml fractions. SDS-PAGE gels were performed to determine which fractions were pooled for further purification. As a final purification step, a strong anion exchange resin, such as Hi-PrepQ (Biorad), is equilibrated with a suitable buffer and the above-combined fractions are applied to the column. The antigen on the column was eluted with a stepwise increasing salt gradient. When the column was run, fractions were collected and another SDS-PAGE gel was run to detect which fractions on the column were pooled. Pooled fractions were dialyzed against 10mM Tris pH 8.0. This material is then assessed for acceptable purity as determined by SDS-PAGE or HPLC, for concentration as determined by Lowry assay or amino acid analysis, for identity as determined by amino acid terminal protein sequencing, and for endotoxin levels as determined by limulus (LAL) assay. Then, after filtration through a 0.22 μm filter, the proteins were bottled and the antigens were frozen before immunization was required.
To generate polyclonal antisera, 400. mu.g of each prostate antigen was mixed with 100. mu.g of Muramyl Dipeptide (MDP). Equal volumes of Incomplete Freund's Adjuvant (IFA) were added and then mixed. Every 4 weeks, the immunization was boosted with 100. mu.g of antigen mixed with an equal volume of IFA. 7 days after each booster immunization, animal blood was taken. Blood was incubated at 4 ℃ for 12-24 hours and centrifuged to generate serum.
To characterize the polyclonal antisera, 96-well plates were coated by incubation with 50. mu.l (typically 1. mu.g) of antigen for 20 hours at 4 ℃. 250 μ l BSA blocking buffer was added to the wells and incubated for 2 hours at room temperature. The plate was washed 6 times with PBS/0.01% Tween. anti-O8E rabbit serum or affinity purified anti-O8 e antibody was diluted in PBS. 50 μ l of diluted antibody was added to each well and incubated at room temperature for 30 minutes. The plate was washed as above, after which 50. mu.l goat anti-rabbit horseradish peroxidase (HRP) was added at 1: 10000 dilution and incubated at room temperature for 30 minutes. The plate was washed as above and 100. mu.l of TMB microwell peroxidase substrate was added to each well. After incubation for 15 min at room temperature in the dark, 100. mu.l of 1N H was used2SO4The colorimetric reaction was terminated and read immediately at 450 nm. All polyclonal antibodies showed immunoreactivity to the O8E antigen.
For recombinant expression in mammalian HEK293 cells, the full-length O8E cDNA was subcloned into mammalian expression vectors pcdna3.1+ and pCEP4(Invitrogen), which were modified to contain histidine and FLAG epitope tags, respectively. These constructs were transfected into HEK293 cells (ATCC, american type culture collection) with Fugene6 reagent (Roche). Briefly, HEK293 cells were seeded at 100,000 cells/ml in dmem (gibco) containing 10% fbs (hyclone) and cultured overnight. The next day, 2. mu.l Fugene6 was added to 100. mu.l DMEM without FBS, and incubated for 15 minutes at room temperature. To 1. mu.g of O8E/pCEP4 or O8E/pcDNA3.1 plasmid DNA was added a Fugene6/DMEM mixture. Then add Fugene/DNA mixture to HEK293 cells at 37 ℃ with 7% CO2Incubated for 48-72 hours. Cells were rinsed with PBS, then collected by centrifugation and pelleted. For Western blot analysis, whole cell lysates were generated by incubating the cells on ice in lysis buffer containing Triton-X100. Lysates were clarified by centrifugation at 10,000rpm for 5 minutes at 4 ℃. Samples were diluted with SDS-PAGE loading buffer containing beta-mercaptoethanol and then boiled for 10 min before loading onto the SDS-PAGE gel. Transfer protein to Nitrocellulose and anti-O8E Rabbit polyclonal dilution 1: 750Serum #2333L probe. Blots were developed with goat anti-rabbit Ig conjugated with HRP and subsequent incubation in ECL substrate.
For FACS analysis, cells were further washed with ice-cold staining buffer (PBS + 1% BSA + azide). Next, the cells were incubated with 10. mu.g/ml protein A purified anti-O8E polyclonal serum for 30 minutes on ice. Cells were washed 3 times with staining buffer and then incubated on ice for 30 minutes with goat anti-rabbit Ig (H + L) -FITC reagent (Southern Biotechnology) diluted 1: 100. After 3 washes, the cells were resuspended in staining buffer containing Propidium Iodide (PI), which vital stain allows identification of permeable cells, before the cells were analyzed by FACS.
From these experiments (results are illustrated in FIGS. 20-21), expression of O8E on the surface of transfected HEK293 and SKBR3 cells was detected by FACS analysis using rabbit anti-O8E serum. Expression was also detected in transfected HEK293 cell lysates by Western blot analysis (figure 22).
Example 8 production and characterization of anti-O8E MABS (monoclonal antibody)
A mouse monoclonal antibody was generated against O8E protein derived from escherichia coli (e. A/J mice were immunized Intraperitoneally (IP) with Complete Freund's Adjuvant (CFA) containing 50. mu.g of recombinant O8E, followed by booster immunization with Incomplete Freund's Adjuvant (IFA) containing 10. mu.g of recombinant O8E protein. Mice were immunized intravenously with approximately 50 μ g of solubilized O8E recombinant protein 3 days prior to removal of the spleen. Spleens from mice with positive titers to O8E were removed and single cell suspensions were prepared for fusion with SP2/0 myeloma cells to produce B cell hybridomas. The hybrid clone supernatants were tested for specificity for recombinant O8E by ELIAS and epitope-mapped with peptides spanning the entire O8E sequence. mAbs were also tested by flow cytometry for the ability to stably transfect O8E on the cell surface and O8E on the surface of breast tumor cell lines.
For ELISA assays, 96-well plates were coated with recombinant O8E protein or overlapping 20mer peptides spanning the entire O8E molecule at 1-2. mu.g/ml or 10. mu.g/ml concentrations, respectively. After coating, plates were washed 5 times with wash buffer (PBS + 0.1% Tween20) and blocked with PBS containing 0.5% BSA, 0.4% Tween 20. Hybrid supernatants or purified mAbs were then added and the plates incubated for 60 minutes at room temperature. The plates were washed 5 times with wash buffer and secondary antibody conjugated to horseradish peroxidase (HRP), donkey anti-mouse ig (jackson immunoresearch), 60 min. The plate was washed once more 5 times in the wash buffer, followed by addition of horseradish peroxidase substrate. Among the hybridoma clones produced, 15 secreted mAbs recognizing the entire O8E protein were identified. Epitope mapping showed that of these 15 clones, 14 secreted mAbs recognized amino acid residues 61-80 of O8E, and one clone secreted mAb that recognized amino acid residue 151-170.
For flow cytometry analysis, HEK293 cells stably transfected with O8E and SKBR3 cells expressing O8E mRNA were collected and washed in flow staining buffer (PBS + 1% BSA + azide). Cells were incubated with mAb hybrid supernatant for 30 minutes on ice, followed by 3 washes with staining buffer. Cells were incubated with goat anti-mouse Ig-FITC for 30 minutes on ice, followed by 3 washes with staining buffer before resuspension in wash buffer containing propidium iodide. Flow cytometry analysis showed 15/15mAbs were able to detect O8E protein expressed on the surface of O8E transfected HEK293 cells. 6/6mAbs tested on SKBR3 cells recognized surface expressed O8E.
Example 9 extended DNA and protein sequence analysis of sequence O772P
The full-length sequences comprising clones 3f, 6b, 8e and 12 were obtained by screening an ovarian tumor (SCID-derived) cDNA library, as detailed in example 2. This 2996 base pair sequence, designated O722P, is shown as sequence SEQ ID NO: 311, and the sequence of the encoded 914 amino acid protein is shown in SEQ ID NO: 312, shown in the figure. The DNA sequence O772P was retrieved using a public database, including Genbank, and showed a significant hit with Genbank accession number AK024365(SEQ ID NO: 457). This Genbank sequence was found to be 3557 base pairs in length, encoding a protein of 1156 amino acids in length (SEQ ID NO: 459). A truncated form of this sequence, residues 25-3471(SEQ ID NO: 456), encodes a protein of 1148 amino acids in length (SEQ ID NO: 458), where residue 25 corresponds to the first ATG start codon in the Genbank sequence. The disclosed DNA sequence (SEQ ID NO: 457) differs from O772P in that it has a sequence identical to the sequence set forth in SEQ ID NO: the 5 base pair insertion corresponding to base 958-962 of 457. This insertion causes a reading frame shift such that, compared to O772P (SEQ ID NO: 312), the reading frame of SEQ ID NO: 457 encodes an additional N-terminal protein sequence. Furthermore, O772P encoded a single N-terminal portion contained in residues 1-79(SEQ ID NO: 460). SEQ ID NO: 456 also contains a single sequence (unique sequence) from residues 1-313 of the N-terminal portion, as shown in SEQ ID NO: 461.
Example 10 production of polyclonal antibodies for immunochemical and flow cytometric analysis of cell-associated expression patterns of O772P molecules
The O772P molecule was identified in examples 2 and 9 of the present application. To assess the subcellular localization and specificity of antigen expression in various tissues, polyclonal antibodies against O772P were generated. To produce these antibodies, O772P-1 (amino acids 44-772 of sequence SEQ ID NO: 312) and O772P-2 (amino acid 477-914 of sequence SEQ ID NO: 312) were expressed in an E.coli (E.coli) recombinant expression system and grown overnight in LB broth at 37 ℃. The next day, 10ml of overnight culture was added to 500ml of 2 XYT containing the appropriate antibiotic. When the culture optical density (at 560nm) reached 0.4-0.6, the cells were induced with IPTG (1 mM). After incubation, cells were collected, washed, lysed, and passed through a French press under 16,000psi pressure. The cells were then centrifuged and the distribution of the recombinant protein was checked by SDS-PAGE. For proteins localized to the cell pellet, the pellet was resuspended in 10mM Tris pH8.0, 1% CHAPS, and the inclusion body pellet was washed and centrifuged. The washed inclusion body precipitate was dissolved with 8M urea or 6M guanidine HCl pH8.010mM Tris containing the addition of 10mM imidazole. The solubilized protein was added to 5ml of nickel chelate resin (Qiagen) and incubated for 45 minutes at room temperature.
After incubation, the resin and protein mixture was poured through the column and the flow through was collected. The column is then washed with 10-20 column volumes of buffer. Subsequently, the antigen was eluted from the column with 8M urea, 10mM TrispH8.0 and 300mM imidazole, and collected in 3ml fractions. SDS-PAGE gels were performed to determine which fractions were pooled for further purification. As a final purification step, the strong anion exchange resin is equilibrated with a suitable buffer and the above-incorporated fractions are loaded onto the column. The antigen on the column was eluted with a stepwise increasing salt gradient. Fractions were collected and analyzed on SDS-PAGE gels to determine which fractions on the column were pooled. The pooled fractions were dialyzed against 10mM Tris pH8.0, presenting the protein thus produced for quality control of final release. The release criteria were: (a) purity as determined by SDS-PAGE or HPLC, (b) concentration as determined by Lowry assay or amino acid analysis, (c) identity as determined by amino acid terminal protein sequencing, and (d) endotoxin level as determined by limulus (LAL) assay. Then, after filtering the protein through a 0.22 μm filter, the antigen was frozen before immunization was required.
To generate polyclonal antisera, 400. mu. g O772P-1 or O772P-2 was mixed with 100. mu.g Muramyl Dipeptide (MDP). Every 4 weeks, rabbits were immunized with 100 μ g of antigen mixed with an equal volume of Incomplete Freund's Adjuvant (IFA). 7 days after each booster immunization, animal blood was taken. Blood was incubated at 4 ℃ for 12-24 hours and centrifuged to generate serum.
To characterize the polyclonal antisera, 96-well plates were coated with antigen and subsequently blocked with BSA. Anti-rabbit serum was diluted in PBS and added to each well. The plates were then washed and goat anti-rabbit horseradish peroxidase (HRP) was added. The plate was washed again and each well was added TMB microwell peroxidase substrate. After incubation, the colorimetric reaction was terminated and the plate was read immediately at 450 nm. All polyclonal antibodies showed immunoreactivity to the appropriate antigen.
Immunohistochemical analysis of O772P expression was performed on paraffin-embedded formaldehyde-fixed tissues. O772P was found to be expressed in normal ovarian and ovarian cancers, but not in heart, kidney, colon, lung or liver. In addition, immunohistochemistry and flow cytometry analysis indicated that O772P was a plasma membrane-associated molecule. O772P1 contained transmembrane plasma membrane domain 1 predicted to be encoded by amino acids 859-880. The N-terminus of O772P is extracellular and is encoded by amino acids 1-859, while the C-terminus is intracellular. Sequence analysis indicated that there were 17 possible N-linked glycosylation sites.
Example 11O 772P expression on the surface of Primary ovarian tumor cells
For recombinant expression in mammalian cells, the full-length cDNAs O772P-21008(SEQ ID NO: 387) and O772P (SEQ ID NO: 311, encoding the protein SEQ ID NO: 312) were subcloned into the mammalian expression vector pBIB or pCEP4, respectively. These constructs were transfected into HEK293 cells with Fugene6 (Roche). Then, HEK293 cells were seeded at 100,000 cells/ml in DMEM containing Fetal Bovine Serum (FBS) and grown overnight. On day 2, 2. mu.l Fugene6 was added to 100. mu.l DMEM without FBS and incubated for 15 minutes at room temperature. To 1 u g O772P/pBIB or O772P/pCEP4 plasmid DNA was added Fugene6/DMEM mixture and incubated at room temperature for another 15 minutes. Then, the Fugene6/DNA mixture was added to HEK293 cells at 37 ℃ with 7% CO2Culturing for 48-72 hr. Cells were washed and then pelleted by centrifugation.
For Western blot analysis, whole cell lysates were generated by incubating the cells in lysis buffer, followed by centrifugation for clarification. The samples were diluted and subjected to SDS-PAGE. The gel was then transferred to nitrocellulose and probed with purified anti-O772P-2 rabbit polyclonal antibody. Blots were developed after incubation in ECL substrate with HRP-conjugated goat anti-rabbit Ig. Western blot analysis showed that O772P-21008 could be detected in HEK293 cells transfected with O772P.
To examine the cell expression profile of O772P in cells, primary ovarian cancer tumor cells were grown in SCID mice. Cells were retrieved from mice and analyzed by flow cytometry. Briefly, cells were washed in a cool staining buffer containing PBS, 1% BSA, and sodium azide. Cells were incubated with 10. mu.g/ml purified anti-O772P-1 and O772P-2 polyclonal serum for 30 minutes. After incubation, cells were washed 3 times in staining buffer and incubated with FITC conjugated goat anti-rabbit Ig (H + L) (Southern Biotechnology). Cells were washed and resuspended in staining buffer containing Propidium Iodide (PI), a vital stain that identifies non-viable cells. Cells were then analyzed by Fluorescence Activated Cell Sorting (FACS). FACS analysis indicated that O772P was present on the cell surface. Surface expression of O772P on tumor cells allowed for immune targeting by therapeutic antibodies.
Example 12 functional characterization of anti-O8E monoclonal antibody
A mouse monoclonal antibody (mAb) was generated against O8E derived from e.coli (e.coli) and tested for its ability to promote internalization of the O8E antigen as described in example 8. Antibody internalization was determined in vitro by a cytotoxicity assay. Briefly, HEK293 and O8E/HEK transfected cells were seeded in 96-well plates containing DME supplemented with 10% heat-inactivated FBS in the presence of 50 ng/well purified anti-O8E or control antibody. Isoforms of anti-O8E mAb are as follows: 11A6-IgG 1/kappa, 15C6-IgG2 b/kappa, 18A8-IgG2 b/kappa, and 14F1-IgG2 a/kappa. W6/32 was a chimpanzee (pan) anti-human MHC class I mouse monoclonal antibody used as a positive control, and also included two unrelated mAbs, Ir-Pharm and Ir-Crxa, as negative controls. After incubation with O8E-specific antibody or related control antibody, mAb-zap (a goat anti-mouse Ig-saporin conjugated secondary antibody) (Advanced Targeting Systems) was added to half the wells at a concentration of 100ng/ml, 37 ℃ in 7% CO2Plates were incubated in the incubator for 48 to 72 hours. This assay takes advantage of the toxic properties of saporin (a ribozyme-inactivating protein) which has a cytotoxic effect when internalized. Following incubation with mAb-zap, internalization was quantified by adding MTS reagent followed by plate OD490 reading on a microplate ELISA reader. The results obtained from these assays are depicted in fig. 25. The top panel represents HEK cells that were not transfected with O8E, and therefore the O8E antibody should not bind and be internalized. Whether or not the samples were incubated with mAb-zap, the level of proliferation was the same for all samples except for the positive control Ab, W6/32. The lower panel represents HEK cells transfected with O8E and should therefore bind to O8E specific antibodies. Antibodies from hybridomas 11H6, 14F1, and 15C6 recognizing amino acids 61-80 of O8E promote internalization of O8E surface proteins, as detected by a decrease in proliferation levels due to mAb-zap toxicity.
Example 13 characterization of ovarian tumor antigen O772P
Various forms of cDNA and protein sequences for ovarian tumor antigen O772P have been described above (e.g., examples 2 and 9). Genbank searches showed that O772P shares high similarity with FLJ14303 (accession No. AKO 24365; SEQ ID NOS: 457 and 463). In the sequence SEQ ID NO: 478 and 479, respectively, discloses protein sequences corresponding to O772P and FLJ 14303. FLJ14303 is largely identical to O772P, a large sequence at the 3' -end, showing 100% homology. However, the FLJ143035 '-end was extended 5' further than O772P. Furthermore, FLJ14303 contains a 5bp insertion (SEQ ID NO: 457) which causes a reading frame shift of the amino terminal protein sequence, so that FLJ14303 utilizes a different initiating methionine amino acid, compared to O772P, and thus encodes a different protein. The presence of this insertion in the genomic sequence, and visible in all EST clones showing identity to this region, indicates that FLJ14303(SEQ ID NO: 457) represents a splice variant of O772P, together with an ORF containing an extension and a different amino terminus. The additional 5' nucleotide sequence includes the repeat sequence identified during O772P genome mapping. The 5' end of O772P and the corresponding region of FLJ14303 showed 90-100% homology. Taken together, this indicates that O772P and FLJ14303 are differently spliced variants of the same gene, with different single repeats spliced into the 5' -end of the gene.
The identification of another 10 or more repeats in the same region of chromosome 19 indicates that there may be many forms of O772P, each with a different 5' -end, due to the different splicing of the different repeats. Northern blot analysis of O772P demonstrated that several transcripts hybridizing to O772P of different sizes, some exceeding 10kb, were present.
Further analysis identified 13 additional O772P related sequences, whose cDNA and amino acid sequences are described in table 2.
TABLE 2
| SEQ ID NO: | Description of the invention | Transmembrane domain |
| 464 | LS#1043400.1(cDNA) | nd |
| 465 | LS#1043400.10(cDNA) | 0 |
| 466 | LS#1043400.11(cDNA) | 2 |
| 467 | LS#1043400.12(cDNA) | 2 |
| 468 | LS#1043400.2(cDNA) | nd |
| 469 | LS#1043400.3(cDNA) | |
| 470 | LS#1043400.5(cDNA) | nd |
| 471 | LS#1043400.8(cDNA) | 1 |
| 472 | LS#1043400.9(cDNA) | 0 |
| 473 | LS#1043400.6(cDNA) | nd |
| 474 | LS#1043400.7(cDNA) | nd |
| 475 | LS#1043400.4(cDNA) | nd |
| 476 | LS#1397610.1(cDNA) | 0 |
| 477 | 1043400.10 New 5' (cDNA) | - |
| 480 | LS #1043400.9 (amino acid) | - |
| 481 | LS #1043400.8B (amino acid) contains a transmembrane domain | - |
| 482 | LS #1043400.8A (amino acid) | - |
| 483 | LS #1043400.12 (amino acid) contains a transmembrane domain | - |
| 484 | LS #1043400.11B (amino acid) contains a transmembrane domain | - |
| 485 | LS #1043400.11A (amino acid) | - |
| 486 | LS #1043400.10 (amino acid) | - |
| 487 | LS #1043400.1 (amino acid) | - |
nd is not detected
Initially, these sequences were thought to represent overlapping and/or discontiguous sequences of the spliced form of O772P that encode polypeptides unique to the particular spliced form of O772P. However, the nucleotide alignment (alignment) of these sequences failed to identify identical regions within the repeat elements. This indicates that these sequences may represent different specific regions of a single O772P gene, which contains 16 or more repeat domains, all of which form a single linear transcript. The 5 '-end of sequence LS #104300.10 (Table 2; SEQ ID NO: 465) was unique to both O772P and FLJ14303 and contained no repetitive elements, indicating that this sequence might represent the 5' -end of O772P.
Previously, transmembrane prediction analysis indicated that O772P contained 1 to 3 transmembrane spanning domains. This was confirmed by immunohistochemistry and flow cytometry, and the presence of plasma membrane associated molecules representing O772P was also confirmed. Immunohistochemistry, however, also indicated the presence of a secreted form of O772P, which may arise from an alternatively spliced form of O772P or from a post-translational cleavage event. Analysis of several sequences shown in table 2 indicated that sequences 1043400b.12, 1043400.8B, and 1043400.11B all contained a transmembrane region, while 1043400.8a, 1043400.10, 1043400.1, 1043400.11a, and 1043400.9 all lacked a transmembrane region, indicating that these proteins may be secreted.
The analysis showed that the fraction O772P was expressed and/or retained on the plasma membrane, making O772P an attractive target for targeting specific immunotherapies against this protein, such as therapeutic antibodies. In the sequence SEQ ID NO: 489 discloses a predicted extracellular domain of O772P, and secretion of O772P may occur due to cleavage events in the following sequence:
SLVEQVFLD KTLNASFHWLGSTYQLVDIHVTEMESSVYQP.
in SEQ ID NO: protease cleavage is most likely to occur at lysine (K) at position 10 of 489. The extracellular, transmembrane and cytoplasmic regions of O772P were all within the sequence SEQ ID NO: 488 discloses that:
extracellular:
SLVEQVFLDKTLNASFHWLGSTYQLVDIHVTEMESSVYQPTSSSSTQHFYLNFTITNLPYSQDKAQPGTTNYQRNKRNIEDALNQLFRNSSIKSYFSDCQVSTFRSVPNRHHTGVDSLCNFSPLARRVDRVAIYEEFLRMTRNGTQLQNFTLDRSSVLVDGYFPNRNEPLTGNSDLPF
transmembrane:
WAVILIGLAGLLGLITCLICGVLVTT
cytoplasmic:
RRRKKEGEYNVQQQCPGYYQSHLDLEDLQ
example 14 Immunohistochemical (IHC) analysis of O8E expression in ovarian cancer and Normal tissues
To detect which tissues express ovarian cancer antigen O8E, IHC analysis was performed on various tissue sections using polyclonal and monoclonal antibodies specific for O8E. The production of O8E-specific monoclonal antibodies was described in detail in example 8. The monoclonal antibodies used for staining were 11A6 and 14F1, which are specific for amino acids 61-80 of O8E, and 18A8, which recognizes amino acids 151-170 of OE8 (see example 12 for details of their production).
For staining, tissue samples were fixed in formaldehyde solution for 12-24 hours and embedded in paraffin before cutting into 8 μm sections. Epitope retrieval (SHEIR) was induced by steam heating in 0.1M sodium citrate buffer as the optimal staining condition. Sections were incubated with 10% serum/PBS for 5 minutes. The primary antibody was then added to each section for 25 minutes, followed by 25 minutes of incubation with anti-rabbit or anti-mouse biotin-labeled antibody. Endogenous peroxidase activity was blocked by three 1.5 min incubations with hydrogen peroxide. The avidin-biotin complex/horseradish peroxidase (ABC/HRP) system was used with DAB chromogen to observe antigen expression. Slides were counterstained with hematoxylin to visualize nuclei.
The results obtained by rabbit affinity purification of the polyclonal antibody (amino acids 29-283; see example 3 for details of the production of this antibody) using O8E are shown in Table 3. The results obtained with 3 monoclonal antibodies are shown in table 4.
TABLE 3
O8E immunohistochemical analysis with polyclonal antibodies
| Tissue of | Expression of O8E |
| Ovarian cancer | Positive for |
| Breast cancer | Positive for |
| Normal ovary | Positive for |
| Normal mammary gland | Positive for |
| Blood vessel | Positive for |
| Kidney (Kidney) | Negative of |
| Lung (lung) | Negative of |
| Colon | Negative of |
| Liver disease | Negative of |
| Heart and heart | Negative of |
TABLE 4
O8E immunohistochemical analysis with monoclonal antibodies
| Normal tissue | 11A6 | 18A8 | 14F1 | |||
| Inner skin | Epithelium (epithelial cell) | Inner skin | Epithelium (epithelial cell) | Inner skin | Epithelium (epithelial cell) | |
| Skin(s) | 2 | 2 | 0 | 0 | 1 | 1 |
| Skin(s) | 1 | 1 | 0 | 0 | 1 | 1 |
| Mammary gland | 0 | 1 | n/a | n/a | 1 | 1 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 |
| Jejunum | 0 | 0 | 0 | 0 | 0 | 0 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 |
| Colon | 0 | 0 | 0 | 0 | 0 | 0 |
| Ovary (LU) of human | 0 | 0 | 0 | 0 | 1 | 0 |
| Colon | 0 | 0 | 0 | 0 | 0 | 1 |
| Liver disease | 0 | 0 | 0 | 0 | 1 | 2 |
| Skin(s) | 0 | 0 | 0 | 0 | 1 | 0 |
| Duodenum and pancreas | 0 | 0 | 0 | 0 | 0 | 0 |
| Appendix with appendix | 0 | 0 | 0 | 0 | 0 | 0 |
| Ileum | 0 | 0 | 0 | 0 | 0 | 0 |
0-no staining, 1-light staining, 2-medium staining, n/a-no staining was obtained
Example 15 epitope mapping of the polyclonal antibody O772P
For epitope mapping of O772P, peptides were generated, the sequences of which were derived from the O772P sequence. These peptides are 15mers, with 5 amino acid overlaps, and were generated by chemical synthesis on a membrane support. The peptide was covalently bound to Whatman50 cellulose carrier via its C-terminus, while the N-terminus was not bound. To determine epitope specificity, membranes were wetted with 100% ethanol for 1 minute, then blocked in TBS/Tween/Triton buffer (50mM Tris, 137mM NaCl, 2.7mM KCl, 0.5% BSA, 0.05% Tween20, 0.05% Triton X-100, pH7.5) for 16 hours. Two O772P-specific antibodies, O772P-1 (amino acids 44-772 of SEQ ID NO: 312) and O772P-2 (477-914 of SEQ ID NO: 312; see details of antibody production in example 10) and an irrelevant rabbit antibody were then used as control probe peptides. The diluted antibody was 1. mu.g/ml and incubated with the membrane for 2 hours at room temperature. The membranes were then washed in TBS/Tween/Triton buffer for 30 minutes before incubation with HRP-linked anti-rabbit secondary antibody at a 1: 10,000 dilution for 2 hours. The membranes were washed once more in TBS/Tween/Triton for 30 minutes. Anti-peptide reactivity was observed with ECL. The binding specificity of a particular epitope for each O772P polyclonal antibody is described in table 5.
TABLE 5
| SEQ ID NO: | Peptide # | anti-O772P 1 | anti-O772P2 | Peptide sequences |
| 490 | 2 | *** | - | TCGMRRTCSTLAPGS |
| 491 | 6 | * | */- | CRLTLLRPEKDGTAT |
| 492 | 7 | - | - | DGTATGVDAICTHHP |
| 493 | 8 | - | - | CTHHPDPKSPRLDRE |
| 494 | 9 | *** | *** | RLDREQLYWELSQLT |
| 495 | 11 | */- | - | LGPYALDNDSLFVNG |
| 496 | 13 | **** | - | SVSTTSTPGTPTYVL |
| 497 | 22 | - | - | LRPEKDGEATGVDAI |
| 498 | 24 | ** | */- | DPTGPGLDREQLYLE |
| 499 | 27 | */- | - | LDRDSLYVNGFTHRS |
| 500 | 40 | */- | - | GPYSLDKDSLYLNGY |
| 501 | 41 | - | - | YLNGYNEPGPDEPPT |
| 502 | 47 | *** | *** | ATFNSTEGVLQHLLR |
| 503 | 50 | - | *** | QLISLRPEKDGAATG |
| 504 | 51 | - | ** | GAATGVDTTCTYHPD |
| 505 | 52 | - | */- | TYHPDPVGPGLDIQQ |
| 506 | 53 | - | * | LDIQQLYWELSQLTH |
| 507 | 58 | - | * | HIVNWNLSNPDPTSS |
| 508 | 59 | - | * | DPTSSEYITLLRDIQ |
| 509 | 60 | - | * | LRDIQDKVTTLYKGS |
| 510 | 61 | - | *** | LYKGSQLHDTFRFCL |
| 511 | 71 | - | ** | DKAQPGTTNYQRNKR |
Relative reaction level, -unbound, -maximal bound
Example 16 identification of novel N-terminal repeat structures related to O772P
As described above, various O772P cDNA and protein forms have been identified and characterized (e.g., examples 1, 2, 9, and 14). Importantly, O772P RNA and protein demonstrated overexpression in ovarian cancer tissues relative to normal tissues and is therefore an attractive target for ovarian cancer diagnostic and therapeutic applications.
Multiple nucleotide repeats were identified in the 5' region of the gene encoding O772P protein using bioinformatic analysis of Open Reading Frames (ORFs) of genomic nucleotide sequences previously identified as having homology to O772P. Many of these repeat sequences were confirmed by RT-PCR with primers specific for each repeat. Fragments containing multiple repeats are amplified from the cDNA, thus confirming the presence of specific repeats and allowing the order of these repeats to be determined.
Surprisingly, when analyzing various sets of O772P sequences from different databases and laboratory sources, at least 20 different repeat structures were identified in the 5' -region of the O772P gene and the corresponding N-terminal region of the O772P protein, each having a substantial level of identity to each other (see table 6). Each repeat comprises a contiguous open reading frame encoding a polypeptide unit that is capable of being spliced to one or more other repeats, thus forming a different number and order of repeat strings. Interestingly, other molecules with repeat domains similar to those of O772P described in the present invention were described in the scientific literature. For example, the family of protein mucins, which are the major glycoprotein components of mucus that coats the cell surfaces of the respiratory, digestive and genitourinary tracts. Different mucins have been shown to consist of tandem repeats of varying numbers, lengths and amino acid sequences (Perez-villa and Hill, J.biol.chem.274 (45): 31751-31754, 1999).
It is expected that the various identified repeat structures described herein are likely to produce multiple forms of O772P by alternative splicing. The identified repetitive cDNA sequence is set forth in SEQ id no: 513, 540, 542, 546 and 548, respectively. The repeated coding amino acid sequence is shown as SEQ ID NOs: 574 and 593. In many cases, these amino acid sequences represent consensus sequences derived from the alignment of more than one experimentally derived sequence.
Each of these splice forms can encode a unique O772P protein with multiple repeat domains linked to the O772P constant carboxy-terminal protein portion containing the transmembrane region. The cDNA sequence of the O772P constant region is set forth in SEQ ID NO: 568 and the encoded amino acid sequence is as set forth in SEQ ID NO: 594 to (b).
All resulting available O772P sequences were resolved into identifiable repeats. These sequences were compared using a Weighted residue Weight table (Weighted residue Weight table) and the Cluster method (MegAlign software in DNASTAR sequence analysis package) to identify relationships between repeated sequences. Using this information, an exemplary consensus full-length O772P contig comprising 20 distinctly different repeat units was identified by the sequencing data provided by RT-PCR and sequence alignment (both automated and manual) with seqman (dnastar). The cDNA of this O772P cDNA contig is set forth in SEQ ID NO: 569 and encodes an amino acid sequence as set forth in SEQ ID NO: 595. This form of O772P protein includes the following consensus repeat structure in the following order:
SEQ ID NO:572-SEQ ID NO:574-SEQ ID NO:575-SEQ ID NO:576-SEQ ID NO:577-SEQ ID NO:578-SEQ ID NO:579-SEQ ID NO:580-SEQ ID NO:581-SEQ ID NO:582-SEQ ID NO:583-SEQ ID NO:584-SEQ ID NO:585-SEQ ID NO:586-SEQ ID NO:587-SEQ ID NO:588-SEQ ID NO:589-SEQ ID NO:590-SEQ ID NO:591-SEQ ID NO:592-SEQ ID NO:593。
thus, SEQ ID NO: 595 represents an exemplary full-length consensus sequence for the O772P protein. However, as mentioned above, based on the current knowledge of this protein and on the scientific literature describing proteins containing similar repetitive structures, it is expected that there are many other forms of O772P that are more or less repetitive. In addition, many forms of O772P are contemplated having different arrangements, such as different sequences of these N-terminal repeats. Northern analysis by O772P supported the presence of multiple forms of O772P with varying numbers of repeats. In this study, Northern hybridization of O772P-specific probes produced multiple fragmented bands, some over 10kb, of the O772P hybridizing transcript.
Thus, the variable repeat region of the O772P protein can be exemplarily represented by the Xn-Y structure, wherein X comprises a sequence identical to SEQ ID NO: 596, and a repeat structure having at least 50% identity to the consensus repeat sequence; n is the number of repeats present in the protein, and is expected to be typically an integer from 1 to about 35; y comprises SEQ ID NO: 594, or to SEQ ID NO: 594 has at least 80% identity. Each X present in the Xn repeat region of the O772P molecule is different.
To determine the consensus sequence for each of the 20 repeats, the sequences of the experimentally determined discrete repeats are aligned and the consensus sequence is determined. In addition to determining the consensus sequence for each repeat region, consensus repeats are also determined. This sequence was obtained by aligning 20 consensus sequences. Variability of the repeats was examined by aligning the consensus amino acid sequence derived from each of the individual repeat regions with the total repeat consensus sequence. The identity data are shown in table 6.
TABLE 6
Percentage identity of repeat sequences compared to common repeat sequences
| Repetition number (amino acid) | SEQ ID NO: | Percent identity to consensus repeats |
| 2 | 574 | 88 |
| 3 | 575 | 84 |
| 4 | 576 | 88 |
| 5 | 577 | 89 |
| 6 | 578 | 93 |
| 7 | 579 | 90 |
| 8 | 580 | 91 |
| 9 | 581 | 88 |
| 10 | 582 | 85 |
| 11 | 583 | 86 |
| 12 | 584 | 87 |
| 13 | 585 | 87 |
| 14 | 586 | 89 |
| 15 | 587 | 89 |
| 16 | 588 | 89 |
| 17 | 589 | 83 |
| 18 | 590 | 84 |
| 19 | 591 | 83 |
| 20 | 592 | 57 |
| 21 | 593 | 68 |
From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not to be restricted except in light of the attached claims.
Sequence listing
<110>Corixa Corporation
Mitcham,Jennifer L.
King,Gordon E.
Algate,Paul A.
Fling,Steven P.
Retter,Marc W.
Fanger,Gary Richard
Reed,Steven G.
Vedvick,Thomas S.
Carter,Darrick
Hill,Paul
Albone,Earl
<120> compositions and methods for treating and diagnosing ovarian cancer
<130>210121.46201PC
<140>PCT
<141>2001-07-17
<160>596
<170>FastSEQ for Windows Version 4.0
<210>1
<211>461
<212>DNA
<213> human (Homo sapiens)
<400>1
ttagagaggc acagaaggaa gaagagttaa aagcagcaaa gccgggtttt tttgttttgt 60
tttgttttgt tttgttttga gatggagtct cactctgttg cccaagctgg agtacaacgg 120
catgatctca gctcgctgca acctccgcct cccacgttca agtgattctc ctgcctcagc 180
ctcccaagta gctgggatta caggcgcccg ccaccacgct cagctaattt tttttgtatt 240
tttagtagag acagggtttc accaggttgg ccaggctgct cttgaactcc tgacctcagg 300
tgatccaccc gcctcggcct cccaaagtgc tgggattaca ggcgtgagcc accacgcccg 360
gcccccaaag ctgtttcttt tgtctttagc gtaaagctct cctgccatgc agtatctaca 420
taactgacgt gactgccagc aagctcagtc actccgtggt c 461
<210>2
<211>540
<212>DNA
<213> human
<400>2
taggatgtgt tggaccctct gtgtcaaaaa aaacctcaca aagaatcccc tgctcattac 60
agaagaagat gcatttaaaa tatgggttat tttcaacttt ttatctgagg acaagtatcc 120
attaattatt gtgtcagaag agattgaata cctgcttaag aagcttacag aagctatggg 180
aggaggttgg cagcaagaac aatttgaaca ttataaaatc aactttgatg acagtaaaaa 240
tggcctttct gcatgggaac ttattgagct tattggaaat ggacagttta gcaaaggcat 300
ggaccggcag actgtgtcta tggcaattaa tgaagtcttt aatgaactta tattagatgt 360
gttaaagcag ggttacatga tgaaaaaggg ccacagacgg aaaaactgga ctgaaagatg 420
gtttgtacta aaacccaaca taatttctta ctatgtgagt gaggatctga aggataagaa 480
aggagacatt ctcttggatg aaaattgctg tgtagagtcc ttgcctgaca aagatggaaa 540
<210>3
<211>461
<212>DNA
<213> human
<400>3
ttagagaggc acagaaggaa gaagagttaa aagcagcaaa gccgggtttt tttgttttgt 60
tttgttttgt tttgttttga gatggagtct cactctgttg cccaagctgg agtacaacgg 120
catgatctca gctcgctgca acctccgcct cccacgttca agtgattctc ctgcctcagc 180
ctcccaagta gctgggatta caggcgcccg ccaccacgct cagctaattt tttttgtatt 240
tttagtagag acagggtttc accaggttgg ccaggctgct cttgaactcc tgacctcagg 300
tgatccaccc gcctcggcct cccaaagtgc tgggattaca ggcgtgagcc accacgcccg 360
gcccccaaag ctgtttcttt tgtctttagc gtaaagctct cctgccatgc agtatctaca 420
taactgacgt gactgccagc aagctcagtc actccgtggt c 461
<210>4
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>454,492,526
<223> n ═ A, T, C or G
<400>4
tctttttctt tcgatttcct tcaatttgtc acgtttgatt ttatgaagtt gttcaagggc 60
taactgctgt gtattatagc tttctctgag ttccttcagc tgattgttaa atgaatccat 120
ttctgagagc ttagatgcag tttctttttc aagagcatct aattgttctt taagtctttg 180
gcataattct tccttttctg atgacttttt atgaagtaaa ctgatccctg aatcaggtgt 240
gttactgagc tgcatgtttt taattctttc gtttaatagc tgcttctcag ggaccagata 300
gataagctta ttttgatatt ccttaagctc ttgttgaagt tgtttgattt ccataatttc 360
caggtcacac tgtttatcca aaacttctag ctcagtcttt tgtgtttgct ttctgatttg 420
gacatcttgt agtctgcctg agatctgctg atgntttcca ttcactgctt ccagttccag 480
gtggagactt tnctttctgg agctcagcct gacaatgcct tcttgntccc t 531
<210>5
<211>531
<212>DNA
<213> human
<400>5
agccagatgg ctgagagctg caagaagaag tcaggatcat gatggctcag tttcccacag 60
cgatgaatgg agggccaaat atgtgggcta ttacatctga agaacgtact aagcatgata 120
aacagtttga taacctcaaa ccttcaggag gttacataac aggtgatcaa gcccgtactt 180
ttttcctaca gtcaggtctg ccggccccgg ttttagctga aatatgggcc ttatcagatc 240
tgaacaagga tgggaagatg gaccagcaag agttctctat agctatgaaa ctcatcaagt 300
taaagttgca gggccaacag ctgcctgtag tcctccctcc tatcatgaaa caacccccta 360
tgttctctcc actaatctct gctcgttttg ggatgggaag catgcccaat ctgtccattc 420
atcagccatt gcctccagtt gcacctatag caacaccctt gtcttctgct acttcaggga 480
ccagtattcc tcccctaatg atgcctgctc ccctagtgcc ttctgttagt a 531
<210>6
<211>531
<212>DNA
<213> human
<400>6
aatagattta atgcagagtg tcaacttcaa ttgattgata gtggctgcct agagtgctgt 60
gttgagtagg tttctgagga tgcaccctgg cttgaagaga aagactggca ggattaacaa 120
tatctaaaat ctcacttgta ggagaaacca caggcaccag agctgccact ggtgctggca 180
ccagctccac caaggccagc gaagagccca aatgtgagag tggcggtcag gctggcacca 240
gcactgaagc caccactggt gctggcactg gcactggcac tgttattggt actggtactg 300
gcaccagtgc tggcactgcc actctcttgg gctttggctt tagcttctgc tcccgcctgg 360
atccgggctt tggcccaggg tccgatatca gcttcgtccc agttgcaggg cccggcagca 420
ttctccgagc cgagcccaat gcccattcga gctctaatct cggccctagc cttggcttca 480
gctgcagcct cagctgcagc cttcaaatcc gcttccatcg cctctcggta c 531
<210>7
<211>531
<212>DNA
<213> human
<400>7
gccaagaaag cccgaaaggt gaagcatctg gatggggaag aggatggcag cagtgatcag 60
agtcaggctt ctggaaccac aggtggccga agggtctcaa aggccctaat ggcctcaatg 120
gcccgcaggg cttcaagggg tcccatagcc ttttgggccc gcagggcatc aaggactcgg 180
ttggctgctt gggcccggag agccttgctc tccctgagat cacctaaagc ccgtaggggc 240
aaggctcgcc gtagagctgc caagctccag tcatcccaag agcctgaagc accaccacct 300
cgggatgtgg cccttttgca agggagggca aatgatttgg tgaagtacct tttggctaaa 360
gaccagacga agattcccat caagcgctcg gacatgctga aggacatcat caaagaatac 420
actgatgtgt accccgaaat cattgaacga gcaggctatt ccttggagaa ggtatttggg 480
attcaattga aggaaattga taagaatgac cacttgtaca ttcttctcag c 531
<210>8
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>481
<223> n ═ A, T, C or G
<400>8
gaggtctcac tatgttgccc aggctgttct tgaactcctg ggatcaagca atccacccat 60
gttggtctcc aaaagtgctg ggatcatagg cgtgagccac ctcacccagc caccaatttt 120
caatcaggaa gactttttcc ttcttcaaga agtgaagggt ttccagagta tagctacact 180
attgcttgcc tgagggtgac tacaaaattg cttgctaaaa ggttaggatg ggtaaagaat 240
tagattttct gaatgcaaaa ataaaatgtg aactaatgaa ctttaggtaa tacatattca 300
taaaataatt attcacatat ttcctgattt atcacagaaa taatgtatga aatgctttga 360
gtttcttgga gtaaactcca ttactcatcc caagaaacca tattataagt atcactgata 420
ataagaacaa caggaccttg tcataaattc tggataagag aaatagtctc tgggtgtttg 480
ntcttaattg ataaaattta cttgtccatc ttttagttca gaatcacaaa a 531
<210>9
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>528
<223> n ═ A, T, C or G
<400>9
aagcggaaat gagaaaggag ggaaaatcat gtggtattga gcggaaaact gctggatgac 60
agggctcagt cctgttggag aactctgggt ggtgctgtag aacagggcca ctcacagtgg 120
ggtgcacaga ccagcacggc tctgtgacct gtttgttaca ggtccatgat gaggtaaaca 180
atacactgag tataagggtt ggtttagaaa ctcttacagc aatttgacaa agtaatcttc 240
tgtgcagtga atctaagaaa aaaattgggg ctgtatttgt atgttccttt ttttcatttc 300
atgttctgag ttacctattt ttattgcatt ttacaaaagc atccttccat gaaggaccgg 360
aagttaaaaa caaagcaggt cctttatcac agcactgtcg tagaacacag ttcagagtta 420
tccacccaag gagccaggga gctgggctaa accaaagaat tttgcttttg gttaatcatc 480
aggtacttga gttggaattg ttttaatccc atcattacca ggctggangt g 531
<210>10
<211>861
<212>DNA
<213> human
<400>10
ccgcggctcc tgtccagacc ctgaccctcc ctcccaaggc tcaaccgtcc cccaacaacc 60
gccagccttg tactgatgtc ggctgcgaga gcctgtgctt aagtaagaat caggccttat 120
tggagacatt caagcaaagg ttggacaact acttttccag aacagaaagg aaactcatgc 180
atcagaaaag gtgactaata aaggtaccag aagaatatgg ctgcacaaat accagaatct 240
gatcagataa aacagtttaa ggaatttctg gggacctaca ataaacttac agagacctgc 300
tttttggact gtgttagaga cttcacaaca agagaagtaa aacctgaaga gaccacctgt 360
tcagaacatt gcttacagaa atatttaaaa atgacacaaa gaatatccat gagatttcag 420
gaatatcata ttcagcagaa tgaagccctg gcagccaaag caggactcct tggccaacca 480
cgatagagaa gtcctgatgg atgaactttt gatgaaagat tgccaacagc tgctttattg 540
gaaatgagga ctcatctgat agaatcccct gaaagcagta gccaccatgt tcaaccatct 600
gtcatgactg tttggcaaat ggaaaccgct ggagaaacaa aattgctatt taccaggaat 660
aatcacaata gaaggtctta ttgttcagtg aaataataag atgcaacatt tgttgaggcc 720
ttatgattca gcagcttggt cacttgatta gaaaaataaa ccattgtttc ttcaattgtg 780
actgttaatt ttaaagcaac ttatgtgttc gatcatgtat gagatagaaa aatttttatt 840
actcaaagta aaataaatgg a 861
<210>11
<211>541
<212>DNA
<213> human
<400>11
gaaaaaaaat ataaaacaca cttttgcgaa aacggtggcc ctaaaagagg aaaagaattt 60
caccaatata aatccaattt tatgaaaact gacaatttaa tccaagaatc acttttgtaa 120
atgaagctag caagtgatga tatgataaaa taaacgtgga ggaaataaaa acacaagact 180
tggcataaga tatatccact tttgatatta aacttgtgaa gcatattctt cgacaaattg 240
tgaaagcgtt cctgatcttg cttgttctcc atttcaaata aggaggcata tcacatccca 300
agagtaacag aaaaagaaaa aagacatttt tgcattttga gatgaaccaa agacacaaaa 360
caaaacgaac aaagtgtcat gtctaattct agcctctgaa ataaaccttg aacatctcct 420
acaaggcacc gtgatttttg taattctaac ctgaagaaat gtgatgactt ttgtggacat 480
gaaaatcaga tgagaaaact gtggtctttc caaagcctga actcccctga aaacctttgc 540
a 541
<210>12
<211>541
<212>DNA
<213> human
<400>12
ctgggatcat ttctcttgat gtcataaaag actcttcttc ttcctcttca tcctcttctt 60
catcctcttc tgtacagtgc tgccgggtac aacggctatc tttgtcttta tcctgagatg 120
aagatgatgc ttctgtttct cctaccataa ctgaagaaat ttcgctggaa gtcgtttgac 180
tggctgtttc tctgacttca ccttctttgt caaacctgag tctttttacc tcatgcccct 240
cagcttccac agcatcttca tctggatgtt tatttttcaa agggctcact gaggaaactt 300
ctgattcaga ggtcgaagag tcactgtgat ttttctcctc attttgctgc aaatttgcct 360
ctttgctgtc tgtgctctca ggcaacccat ttgttgtcat gggggctgac aaagaaacct 420
ttggtcgatt aagtggcctg ggtgtcccag gcccatttat attagacctc tcagtatagc 480
ttggtgaatt tccaggaaac ataacaccat tcattcgatt taaactattg gaattggttt 540
t 541
<210>13
<211>441
<212>DNA
<213> human
<400>13
gagggttggt ggtagcggct tggggaggtg ctcgctctgt cggtcttgct ctctcgcacg 60
cttcccccgg ctcccttcgt ttcccccccc cggtcgcctg cgtgccggag tgtgtgcgag 120
ggagggggag ggcgtcgggg gggtgggggg aggcgttccg gtccccaaga gacccgcgga 180
gggaggcgga ggctgtgagg gactccggga agccatggac gtcgagaggc tccaggaggc 240
gctgaaagat tttgagaaga gggggaaaaa ggaagtttgt cctgtcctgg atcagtttct 300
ttgtcatgta gccaagactg gagaaacaat gattcagtgg tcccaattta aaggctattt 360
tattttcaaa ctggagaaag tgatggatga tttcagaact tcagctcctg agccaagagg 420
tcctcccaac cctaatgtcg a 441
<210>14
<211>131
<212>DNA
<213> human
<220>
<221>misc_feature
<222>126
<223> n ═ A, T, C or G
<400>14
aagcaggcgg ctcccgcgct cgcagggccg tgccacctgc ccgcccgccc gctcgctcgc 60
tcgcccgccg cgccgcgctg ccgaccgcca gcatgctgcc gagagtgggc tgccccgcgc 120
tgccgntgcc g 131
<210>15
<211>692
<212>DNA
<213> human
<400>15
atctcttgta tgccaaatat ttaatataaa tctttgaaac aagttcagat gaaataaaaa 60
tcaaagtttg caaaaacgtg aagattaact taattgtcaa atattcctca ttgccccaaa 120
tcagtatttt ttttatttct atgcaaaagt atgccttcaa actgcttaaa tgatatatga 180
tatgatacac aaaccagttt tcaaatagta aagccagtca tcttgcaatt gtaagaaata 240
ggtaaaagat tataagacac cttacacaca cacacacaca cacacacgtg tgcacgccaa 300
tgacaaaaaa caatttggcc tctcctaaaa taagaacatg aagaccctta attgctgcca 360
ggagggaaca ctgtgtcacc cctccctaca atccaggtag tttcctttaa tccaatagca 420
aatctgggca tatttgagag gagtgattct gacagccacg ttgaaatcct gtggggaacc 480
attcatgtcc acccactggt gccctgaaaa aatgccaata atttttcgct cccacttctg 540
ctgctgtctc ttccacatcc tcacatagac cccagacccg ctggcccctg gctgggcatc 600
gcattgctgg tagagcaagt cataggtctc gtctttgacg tcacagaagc gatacaccaa 660
attgcctggt cggtcattgt cataaccaga ga 692
<210>16
<211>728
<212>DNA
<213> human
<400>16
cagacggggt ttcactatgt tggctaggct ggtcttgaac tcctgacttc aggtgatctg 60
cctgccttgg cctcccaaag tgctgggatt acaggcataa gccactgcgc ccggctgatc 120
tgatggtttc ataaggcttt tccccctttt gctcagcact tctccttcct gccgccatgt 180
gaagaaggac atgtttgctt ccccttccac cacgattgta agttgtttcc tgaggcctcc 240
ccggccatgc tgaactgtga gtcaattaaa cctctttcct ttataaatta tccagttttg 300
ggtatgtctt tattagtaga atgagaacag actaatacaa cccttaaagg agactgacgg 360
agaggattct tcctggatcc cagcacttcc tctgaatgct actgacattc ttcttgagga 420
ctttaaactg ggagatagaa aacagattcc atggctcagc agcctgagag cagggaggga 480
gccaagctat agatgacatg ggcagcctcc cctgaggcca ggtgtggccg aacctgggca 540
gtgctgccac ccaccccacc agggccaagt cctgtccttg gagagccaag cctcaatcac 600
tgctagcctc aagtgtcccc aagccacagt ggctaggggg actcagggaa cagttcccag 660
tctgccctac ttctcttacc tttacccctc atacctccaa agtagaccat gttcatgagg 720
tccaaagg 728
<210>17
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>518,528
<223> n ═ A, T, C or G
<400>17
aagcgaggaa gccactgcgg ctcctggctg aaaagcggcg ccaggctcgg gaacagaggg 60
aacgcgaaga acaggagcgg aagctgcagg ctgaaaggga caagcgaatg cgagaggagc 120
agctggcccg ggaggctgaa gcccgggctg aacgtgaggc cgaggcgcgg agacgggagg 180
agcaggaggc tcgagagaag gcgcaggctg agcaggagga gcaggagcga ctgcagaagc 240
agaaagagga agccgaagcc cggtcccggg aagaagctga gcgccagcgc caggagcggg 300
aaaagcactt tcagaaggag gaacaggaga gacaagagcg aagaaagcgg ctggaggaga 360
taatgaagag gactcggaaa tcagaagccg ccgaaaccaa gaagcaggat gcaaaggaga 420
ccgcagctaa caattccggc ccagaccctt gtgaaagctg tagagactcg gccctctggg 480
cttccagaaa ggattctatt gcagaaagga aggagctngg ccccccangg a 531
<210>18
<211>1041
<212>DNA
<213> human
<220>
<221>misc_feature
<222>544
<223> n ═ A, T, C or G
<400>18
ctctgtggaa aactgatgag gaatgaattt accattaccc atgttctcat ccccaagcaa 60
agtgctgggt ctgattactg caacacagag aacgaagaag aacttttcct catacaggat 120
cagcagggcc tcatcacact gggctggatt catactcacc ccacacagac cgcgtttctc 180
tccagtgtcg acctacacac tcactgctct taccagatga tgttgccaga gtcagtagcc 240
attgtttgct cccccaagtt ccaggaaact ggattcttta aactaactga ccatggacta 300
gaggagattt cttcctgtcg ccagaaagga tttcatccac acagcaagga tccacctctg 360
ttctgtagct gcagccacgt gactgttgtg gacagagcag tgaccatcac agaccttcga 420
tgagcgtttg agtccaacac cttccaagaa caacaaaacc atatcagtgt actgtagccc 480
cttaatttaa gctttctaga aagctttgga agtttttgta gatagtagaa aggggggcat 540
cacntgagaa agagctgatt ttgtatttca ggtttgaaaa gaaataactg aacatatttt 600
ttaggcaagt cagaaagaga acatggtcac ccaaaagcaa ctgtaactca gaaattaagt 660
tactcagaaa ttaagtagct cagaaattaa gaaagaatgg tataatgaac ccccatatac 720
ccttccttct ggattcacca attgttaaca tttttttcct ctcagctatc cttctaattt 780
ctctctaatt tcaatttgtt tatatttacc tctgggctca ataagggcat ctgtgcagaa 840
atttggaagc catttagaaa atcttttgga ttttcctgtg gtttatggca atatgaatgg 900
agcttattac tggggtgagg gacagcttac tccatttgac cagattgttt ggctaacaca 960
tcccgaagaa tgattttgtc aggaattatt gttatttaat aaatatttca ggatattttt 1020
cctctacaat aaagtaacaa t 1041
<210>19
<211>1043
<212>DNA
<213> human
<400>19
ctctgtggaa aactgatgag gaatgaattt accattaccc atgttctcat ccccaagcaa 60
agtgctgggt ctgattactg caacacagag aacgaagaag aacttttcct catacaggat 120
cagcagggcc tcatcacact gggctggatt catactcacc ccacacagac cgcgtttctc 180
tccagtgtcg acctacacac tcactgctct taccagatga tgttgccaga gtcagtagcc 240
attgtttgct cccccaagtt ccaggaaact ggattcttta aactaactga ccatggacta 300
gaggagattt cttcctgtcg ccagaaagga tttcatccac acagcaagga tccacctctg 360
ttctgtagct gcagccacgt gactgttgtg gacagagcag tgaccatcac agaccttcga 420
tgagcgtttg agtccaacac cttccaagaa caacaaaacc atatcagtgt actgtagccc 480
cttaatttaa gctttctaga aagctttgga agtttttgta gatagtagaa aggggggcat 540
cacctgagaa agagctgatt ttgtatttca ggtttgaaaa gaaataactg aacatatttt 600
ttaggcaagt cagaaagaga acatggtcac ccaaaagcaa ctgtaactca gaaattaagt 660
tactcagaaa ttaagtagct cagaaattaa gaaagaatgg tataatgaac ccccatatac 720
ccttccttct ggattcacca attgttaaca tttttttcct ctcagctatc cttctaattt 780
ctctctaatt tcaatttgtt tatatttacc tctgggctca ataagggcat ctgtgcagaa 840
atttggaagc catttagaaa atcttttgga ttttcctgtg gtttatggca atatgaatgg 900
agcttattac tggggtgagg gacagcttac tccatttgac cagattgttt ggctaacaca 960
tcccgaagaa tgattttgtc aggaattatt gttatttaat aaatatttca ggatattttt 1020
cctctacaat aaagtaacaa tta 1043
<210>20
<211>448
<212>DNA
<213> human
<400>20
ggacgacaag gccatggcga tatcggatcc gaattcaagc ctttggaatt aaataaacct 60
ggaacaggga aggtgaaagt tggagtgaga tgtcttccat atctatacct ttgtgcacag 120
ttgaatggga actgtttggg tttagggcat cttagagttg attgatggaa aaagcagaca 180
ggaactggtg ggaggtcaag tggggaagtt ggtgaatgtg gaataactta cctttgtgct 240
ccacttaaac cagatgtgtt gcagctttcc tgacatgcaa ggatctactt taattccaca 300
ctctcattaa taaattgaat aaaagggaat gttttggcac ctgatataat ctgccaggct 360
atgtgacagt aggaaggaat ggtttcccct aacaagccca atgcactggt ctgactttat 420
aaattattta ataaaatgaa ctattatc 448
<210>21
<211>411
<212>DNA
<213> human
<400>21
ggcagtgaca ttcaccatca tgggaaccac cttccctttt cttcaggatt ctctgtagtg 60
gaagagagca cccagtgttg ggctgaaaac atctgaaagt agggagaaga acctaaaata 120
atcagtatct cagagggctc taaggtgcca agaagtctca ctggacattt aagtgccaac 180
aaaggcatac tttcggaatc gccaagtcaa aactttctaa cttctgtctc tctcagagac 240
aagtgagact caagagtcta ctgctttagt ggcaactaca gaaaactggt gttacccaga 300
aaaacaggag caattagaaa tggttccaat atttcaaagc tccgcaaaca ggatgtgctt 360
tcctttgccc atttagggtt tcttctcttt cctttctctt tattaaccac t 411
<210>22
<211>896
<212>DNA
<213> human
<220>
<221>misc_feature
<222>230,320
<223> n ═ A, T, C or G
<400>22
tgcgctgaaa acaacggcct cctttactgt taaaatgcag ccacaggtgc ttagccgtgg 60
gcatctcaac caccagcctc tgtggggggc aggtgggcgt ccctgtgggc ctctgggccc 120
acgtccagcc tctgtcctct gccttccgtt cttcgacagt gttcccggca tccctggtca 180
cttggtactt ggcgtgggcc tcctgtgctg ctccagcagc tcctccaggn ggtcggcccg 240
cttcaccgca gcctcatgtt gtgtccggag gctgctcacg gcctcctcct tcctcgcgag 300
ggctgtcttc accctccggn gcacctcctc cagctccagc tgctggcggg cctgcagcgt 360
ggccagctcg gccttggcct gccgcgtctc ctcctcarag gctgccagcc ggtcctcgaa 420
ctcctggcgg atcacctggg ccaggttgct gcgctcgcta gaaagctgct cgttcaccgc 480
ctgcgcatcc tccagcgccc gctccttctg ccgcacaagg ccctgcagac gcagattctc 540
gccctcggcc tccccaagct ggcccttcag ctccgagcac cgctcctgaa gcttccgctc 600
cgactgctcc agctcggaga gctcggcctc gtacttgtcc cgtaagcgct tgatgcggct 660
ctcggcagcc ttctcactct cctccttggc cagcgccatg tcggcctcca gccggtgaat 720
gaccagctca atctccttgt cccggccttt ccggatttct tccctcagct cctgttcccg 780
gttcagcagc cacgcctcct ccttcctggt gcggccggcc tcccacgcct gcctctccag 840
ctccagctgc tgcttcaggg tattcagctc catctggcgg gcctgcagcg tggcca 896
<210>23
<211>111
<212>DNA
<213> human
<400>23
caacttatta cttgaaatta taatatagcc tgtccgtttg ctgtttccag gctgtgatat 60
attttcctag tggtttgact ttaaaaataa ataaggttta attttctccc c 111
<210>24
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>472,494
<223> n ═ A, T, C or G
<400>24
tgcaagtcac gggagtttat ttatttaatt tttttcccca gatggagact ctgtcgccca 60
ggctggagtg caatggtgtg atcttggctc actgcaacct ccacctcctg ggttcaagcg 120
attctcctgc cacagcctcc cgagtagctg ggattacagg tgcccgccac cacacccagc 180
taatttttat atttttagta aagacagggt ttccccatgt tggccaggct ggtcttgaac 240
ttctgacctc aggtgatcca cctgcctcgg cctcccaaag tgttgggatt acaggcgtga 300
gctacccgtg cctggccagc cactggagtt taaaggacag tcatgttggc tccagcctaa 360
ggcggcattt tcccccatca gaaagcccgc ggctcctgta cctcaaaata gggcacctgt 420
aaagtcagtc agtgaagtct ctgctctaac tggccacccg gggccattgg cntctgacac 480
agccttgcca ggangcctgc atctgcaaaa gaaaagttca cttcctttcc g 531
<210>25
<211>471
<212>DNA
<213> human
<220>
<221>misc_feature
<222>377
<223> n ═ A, T, C or G
<400>25
cagagaatct kagaaagatg tcgcgttttc ttttaatgaa tgagagaagc ccatttgtat 60
ccctgaatca ttgagaaaag gcggcggtgg cgacagcggc gacctaggga tcgatctgga 120
gggacttggg gagcgtgcag agacctctag ctcgagcgcg agggacctcc cgccgggatg 180
cctggggagc agatggaccc tactggaagt cagttggatt cagatttctc tcagcaagat 240
actccttgcc tgataattga agattctcag cctgaaagcc aggttctaga ggatgattct 300
ggttctcact tcagtatgct atctcgacac cttcctaatc tccagacgca caaagaaaat 360
cctgtgttgg atgttgngtc caatccttga acaaacagct ggagaagaac gaggagaccg 420
gtaatagtgg gttcaatgaa catttgaaag aaaaccaggt tgcagaccct g 471
<210>26
<211>541
<212>DMA
<213> human
<400>26
gactgtcctg aacaagggac ctctgaccag agagctgcag gagatgcaga gtggtggcag 60
gagtggaagc caaagaacac ccaccttcct cccttgaagg agtagagcaa ccatcagaag 120
atactgtttt attgctctgg tcaaacaagt cttcctgagt tgacaaaacc tcaggctctg 180
gtgacttctg aatctgcagt ccactttcca taagttcttg tgcagacaac tgttcttttg 240
cttccatagc agcaacagat gctttggggc taaaaggcat gtcctctgac cttgcaggtg 300
gtggattttg ctcttttaca acatgtacat ccttactggg ctgtgctgtc acagggatgt 360
ccttgctgga ctgttctgct atggggatat cttcgttgga ctgttcttca tgcttaattg 420
cagtattagc atccacatca gacagcctgg tataaccaga gttggtggtt actgattgta 480
gctgctcttt gtccacttca tatggcacaa gtattttcct caacatcctg gctctgggaa 540
g 541
<210>27
<211>461
<212>DNA
<213> human
<220>
<221>misc_feature
<222>367
<223> n ═ A, T, C or G
<400>27
gaaatgtata tttaatcatt ctcttgaacg atcagaactc traaatcagt tttctataac 60
arcatgtaat acagtcaccg tggctccaag gtccaggaag gcagtggtta acacatgaag 120
agtgtgggaa gggggctgga aacaaagtat tcttttcctt caaagcttca ttcctcaagg 180
cctcaattca agcagtcatt gtccttgctt tcaaaagtct gtgtgtgctt catggaaggt 240
atatgtttgt tgccttaatt tgaattgtgg ccaggaaggg tctggagatc taaattcaga 300
gtaagaaaac ctgagctaga actcaggcat ttctcttaca gaacttggct tgcagggtag 360
aatgaangga aagaaactta gaagctcaac aagctgaaga taatcccatc aggcatttcc 420
cataggcctt gcaactctgt tcactgagag atgttatcct g 461
<210>28
<211>541
<212>DNA
<213> human
<400>28
agtctggagt gagcaaacaa gagcaagaaa caarragaag ccaaaagcag aaggctccaa 60
tatgaacaag ataaatctat cttcaaagac atattagaag ttgggaaaat aattcatgtg 120
aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag tgcatcccca 180
gatctcaggg acctccccct gcctgtcacc tggggagtga gaggacagga tagtgcatgt 240
tctttgtctc tgaattttta gttatatgtg ctgtaatgtt gctctgagga agcccctgga 300
aagtctatcc caacatatcc acatcttata ttccacaaat taagctgtag tatgtaccct 360
aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt tagtaatggg 420
tcaaatgatt cactttttat gatgcttccc aaggtgcctt ggcttctctt cccaactgac 480
aaatgcccaa gttgagaaaa atgatcataa ttttagcata aaccgagcaa tcggcgaccc 540
c 541
<210>29
<211>411
<212>DNA
<213> human
<400>29
tagctgtctt cctcactctt atggcaatga ccccatatct taatggatta agataatgaa 60
agtgtatttc ttacactctg tatctatcac cagaagctga ggtgatagcc cgcttgtcat 120
tgtcatccat attctgggac tcaggcggga actttctgga atattgccag ggagcatggc 180
agaggggcac agtgcattct gggggaatgc acattggctc agcctgggta atgagtgata 240
tacattacct ctgttcacaa ctcattgccc agcaccagtc acaaggcccc accaaatacc 300
agagcccaag aaatgtagtc ctgttgatat ggttttgctg tgtcccaacc caaatctcat 360
cttgaattgt aagctcccat aattcccatg tgttgtggga gggacctggt g 411
<210>30
<211>511
<212>DNA
<213> human
<400>30
atcatgagga tgttaccaaa gggatggtac taaaccattt gtattcgtct gttttcacac 60
tgctttgaag atactacctg agactgggta atttataaac aaaagagatt taattgactc 120
acagttctgc atggctgaag aggcctcagg aaacttacag tcatggtgga aggcaaagga 180
ggagcaaggc atgtcttaca tgtcagtagg agagagagcg agagcaggag aacctgccac 240
ttataaacca ttcagatctc ataactccct atcatgagaa aaacatggag gaaaccaccc 300
tcatgatcca atcacctccc gccaggtccc tccctcgaca cgtggggatt ataattcagg 360
attagaggga cacagagaca aaccatatca tcattcatga gaaatccacc ctcatagtcc 420
aatcagctcc taccaggccc cacctccaac actggggatt gcaattcaac atgagatttg 480
gatggggaca cagattcaaa ccatatcata c 511
<210>31
<211>827
<212>DNA
<213> human
<400>31
catggccttt ctccttagag gccagaggtg ctgccctggc tgggagtgaa gctccaggca 60
ctaccagctt tcctgatttt cccgtttggt ccatgtgaag agctaccacg agccccagcc 120
tcacagtgtc cactcaaggg cagcttggtc ctcttgtcct gcagaggcag gctggtgtga 180
ccctgggaac ttgacccggg aacaacaggt ggcccagagt gagtgtggcc tggcccctca 240
acctagtgtc cgtcctcctc tctcctggag ccagtcttga gtttaaaggc attaagtgtt 300
agatacaagc tccttgtggc tggaaaaaca cccctctgct gataaagctc agggggcact 360
gaggaagcag aggccccttg ggggtgccct cctgaagaga gcgtcaggcc atcagctctg 420
tccctctggt gctcccacgt ctgttcctca ccctccatct ctgggagcag ctgcacctga 480
ctggccacgc gggggcagtg gaggcacagg ctcagggtgg ccgggctacc tggcacccta 540
tggcttacaa agtagagttg gcccagtttc cttccacctg aggggagcac tctgactcct 600
aacagtcttc cttgccctgc catcatctgg ggtggctggc tgtcaagaaa ggccgggcat 660
gctttctaaa cacagccaca ggaggcttgt agggcatctt ccaggtgggg aaacagtctt 720
agataagtaa ggtgacttgc ctaaggcctc ccagcaccct tgatcttgga gtctcacagc 780
agactgcatg tsaacaactg gaaccgaaaa catgcctcag tataaaa 827
<210>32
<211>291
<212>DNA
<213> human
<400>32
ccagaacctc cttctctttg gagaatgggg aggcctcttg gagacacaga gggtttcacc 60
ttggatgacc tctagagaaa ttgcccaaga agcccacctt ctggtcccaa cctgcagacc 120
ccacagcagt cagttggtca ggccctgctg tagaaggtca cttggctcca ttgcctgctt 180
ccaaccaatg ggcaggagag aaggccttta tttctcgccc acccattctc ctgtaccagc 240
acctccgttt tcagtcagyg ttgtccagca acggtaccgt ttacacagtc a 291
<210>33
<211>491
<212>DNA
<213> human
<400>33
tgcatgtagt tttatttatg tgttttsgtc tggaaaacca agtgtcccag cagcatgact 60
gaacatcact cacttcccct acttgatcta caaggccaac gccgagagcc cagaccagga 120
ttccaaacac actgcacgag aatattgtgg atccgctgtc aggtaagtgt ccgtcactga 180
cccaracgct gttacgtggc acatgactgt acagtgccac gtaacagcac tgtacttttc 240
tcccatgaac agttacctgc catgtatcta catgattcag aacattttga acagttaatt 300
ctgacacttg aataatccca tcaaaaaccg taaaatcact ttgatgtttg taacgacaac 360
atagcatcac tttacgacag aatcatctgg aaaaacagaa caacgaatac atacatctta 420
aaaaatgctg gggtgggcca ggcacagctt cacgcctgta atcccagcac tttgggaggc 480
ttaagcgggt g 491
<210>34
<211>521
<212>DNA
<213> human
<220>
<221>misc_feature
<222>453,476,487
<223> n ═ A, T, C or G
<400>34
tggggcggaa agaagccaag gccaaggagc tggtgcggca gctgcagctg gaggccgagg 60
agcagaggaa gcagaagaag cggcagagtg tgtcgggcct gcacagatac cttcacttgc 120
tggatggaaa tgaaaattac ccgtgtcttg tggatgcaga cggtgatgtg atttccttcc 180
caccaataac caacagtgag aagacaaagg ttaagaaaac gacttctgat ttgtttttgg 240
aagtaacaag tgccaccagt ctgcagattt gcaaggatgt catggatgcc ctcattctga 300
aaatggcaag aaatgaaaaa gtacacttta gaaaataaag aggaaggatc actctcagat 360
actgaagccg atgcagtctc tggacaactt ccagatccca caacgaatcc cagtgctgga 420
aaggacgggc ccttccttct ggtggtggaa cangtcccgg tggtggatct tggaanggaa 480
cctgaangtg gtgtaccccg tccaaggccg accttggcca c 521
<210>35
<211>161
<212>DNA
<213> human
<220>
<221>misc_feature
<222>18
<223> n ═ A, T, C or G
<400>35
tcccgcgctc gcagggcncg tgccacctgc cygtccgccc gctcgctcgc tcgcccgccg 60
cgccgcgctg ccgaccgyca gcatgctgcc gagagtgggc tgccccgcgc tgccgctgcc 120
gccgccgccg ctgctgccgc tgctgccgct gctgctgctg c 161
<210>36
<211>341
<212>DNA
<213> human
<400>36
ggcgggtagg catggaactg agaagaacga agaagctttc agactacgtg gggaagaatg 60
aaaaaaccaa aattatcgcc aagattcagc aaaggggaca gggagctcca gcccgagagc 120
ctattattag cagtgaggag cagaagcagc tgatgctgta ctatcacaga agacaagagg 180
agctcaagag attggaagaa aatgatgatg atgcctattt aaactcacca tgggcggata 240
acactgcttt gaaaagacat tttcatggag tgaaagacat aaagtggaga ccaagatgaa 300
gttcaccagc tgatgacact tccaaagaga ttagctcacc t 341
<210>37
<211>521
<212>DNA
<213> human
<220>
<221>misc_feature
<222>516
<223> n ═ A, T, C or G
<400>37
tctgaaggtt aaatgtttca tctaaatagg gataatgrta aacacctata gcatagagtt 60
gtttgagatt aaatgagata atacatgtaa aattatgtgc ctggcataca gcaagattgt 120
tgttgttgtt gatgatgatg atgatgatga taatattttt ctatccccag tgcacaactg 180
cttgaaccta ttagataatc aatacatgtt tcttgaactg agatcaattt ccccatgttg 240
tctgactgat gaagccctac attttcttct agaggagatg acatttgagc aagatcttaa 300
agaaaatcag atgccttcac ctgaccactg cttggtgatc ccatggcact ttgtacatct 360
ctccattagc tctcatctca ccagcccatc attattgtat gtgctgcctt ctgaagcttg 420
cagctggcta ccatcmggta gaataaaaat catcctttca taaaatagtg accctccttt 480
tttatttgca tttcccaaag ccaagcaccg tggganggta g 521
<210>38
<211>461
<212>DNA
<213> human
<400>38
tatgaagaag ggaaaagaag ataatttgtg aaagaaatgg gtccagttac tagtctttga 60
aaagggtcag tctgtagctc ttcttaatga gaataggcag ctttcagttg ctcagggtca 120
gatttcctta gtggtgtatc taatcacagg aaacatctgt ggttccctcc agtctctttc 180
tgggggactt gggcccactt ctcatttcat ttaattagag gaaatagaac tcaaagtaca 240
atttactgtt gtttaacaat gccacaaaga catggttggg agctatttct tgatttgtgt 300
aaaatgctgt ttttgtgtgc tcataatggt tccaaaaatt gggtgctggc caaagagaga 360
tactgttaca gaagccagca agaagacctc tgttcattca cacccccggg gatatcagga 420
attgactcca gtgtgtgcaa atccagtttg gcctatcttc t 461
<210>39
<211>769
<212>DNA
<213> human
<400>39
tgagggactg attggtttgc tctctgctat tcaattcccc aagcccactt gttcctgcag 60
cgtcctcctt ctcattccct ttagttgtac cctctctttc atctgagacc tttccttctt 120
gatgtcgcct tttcttcttc ttgctttttc tgatgttctg ctcagcatgt tctgggtgct 180
tctcatctgc atcattcctt tcagatgctg tagcttcttc ctcctctttc tgcctccttt 240
tctttttctt ttttttgggg ggcttgctct ctgactgcag ttgaggggcc ccagggtcct 300
ggcctttgag acgagccagg aaggcctgct cctgggcctc taggcgagca agcttggcct 360
tcattgtgat cccaagacgg gcagccttgt gtgctgttcg cccctcacag gcttggagca 420
gcatctcatc agtcagaatc tttggggact tggacccctg gttgtcgtca tcactgcagc 480
tctccaagtc tttgtttggc ttctctccac ctgaagtcaa tgtagccatc ttcacaaact 540
tctgatacag caagttgggc ttgggatgat tataacgggt ggtctcctta gaaaggctcc 600
ttatctgtac tccatcctgc ccagtttcca ctaccaagtt ggccgcagtc ttgttgaaga 660
gctcattcca ccagtggttt gtgaactcct tggcagggtc atgtcctacc ccatgagtgt 720
cttgcttcag ygtcaccctg agagcctgag tgataccatt ctccttccg 769
<210>40
<211>292
<212>DNA
<213> human
<400>40
gacaacatga aataaatcct agaggacaaa attaaactca atagagtgta gtctagttaa 60
aaactcgaaa aatgagcaag tctggtggga gtggaggaag ggctatacta taaatccaag 120
tgggcctcct gatcttaaca agccatgctc attatacaca tctctgaact ggacatacca 180
cctttacgca ggaaacaggg cttggaactt ctaagggaaa ttaacatgca ccacccacat 240
ctaacctacc tgccgggtag gtaccatccc tgcttcgctg aaatcagtgc tc 292
<210>41
<211>406
<212>DNA
<213> human
<400>41
ttggaattaa ataaacctgg aacagggaag gtgaaagttg gagtgagatg tcttccatat 60
ctataccttt gtgcacagtt gaatgggaac tgtttgggtt tagggcatct tagagttgat 120
tgatggaaaa agcagacagg aactggtggg aggtcaagtg gggaagttgg tgaatgtgga 180
ataacttacc tttgtgctcc acttaaacca gatgtgttgc agctttcctg acatgcaagg 240
atctacttta attccacact ctcattaata aattgaataa aagggaatgt tttggcacct 300
gatataatct gccaggctat gtgacagtag gaaggaatgg tttcccctaa caagcccaat 360
gcactggtct gactttataa attatttaat aaaatgaact attatc 406
<210>42
<211>381
<212>DNA
<213> human
<400>42
aaactggacc tgcaacaggg acatgaattt actgcarggt ctgagcaagc tcagcccctc 60
tacctcaggg ccccacagcc atgactacct cccccaggag cgggagggtg aagggggcct 120
gtctctgcaa gtggagccag agtggaggaa tgagctctga agacacagca cccagccttc 180
tcgcaccagc caagccttaa ctgcctgcct gaccctgaac cagaacccag ctgaactgcc 240
cctccaaggg acaggaaggc tgggggaggg agtttacaac ccaagccatt ccaccccctc 300
ccctgctggg gagaatgaca catcaagctg ctaacaattg ggggaagggg aaggaagaaa 360
actctgaaaa caaaatcttg t 381
<210>43
<211>451
<212>DNA
<213> human
<400>43
catgcgtttc accactgttg gccaggctgg tctcgaactc ctggcctcaa gcaatccacc 60
cgcctcagcc tccaaaagtg ctgggattac agatgtgagc catggcacca tgccaaaagg 120
ctatattcct ggctctgtgt ttccgagact gcttttaatc ccaacttctc tacatttaga 180
ttaaaaaata ttttattcat ggtcaatctg gaacataatt actgcatctt aagtttccac 240
tgatgtatat agaaggctaa aggcacaatt tttatcaaat ctagtagagt aaccaaacat 300
aaaatcatta attactttca acttaataac taattgacat tcctcaaaag agctgttttc 360
aatcctgata ggttctttat tttttcaaaa tatatttgcc atgggatgct aatttgcaat 420
aaggcgcata atgagaatac cccaaactgg a 451
<210>44
<211>521
<212>DNA
<213> human
<400>44
gttggacccc cagggactgg aaagacactt cttgcccgag ctgtggcggg agaagctgat 60
gttccttttt attatgcttc tggatccgaa tttgatgaga tgtttgtggg tgtgggagcc 120
agccgtatca gaaatctttt tagggaagca aaggcgaatg ctccttgtgt tatatttatt 180
gatgaattag attctgttgg tgggaagaga attgaatctc caatgcatcc atattcaagg 240
cagaccataa atcaacttct tgctgaaatg gatggtttta aacccaatga aggagttatc 300
ataataggag ccacaaactt cccagaggca ttagataatg ccttaatacc gtcctggtcg 360
ttttgacatg caagttacag ttccaaggcc agatgtaaaa ggtcgaacag aaattttgaa 420
atggtatctc aataaaataa agtttgatca atcccgttga tccagaaatt atagcctcga 480
ggtactggtg gcttttccgg aagcagagtt gggagaatct t 521
<210>45
<211>585
<212>DNA
<213> human
<400>45
gcctacaaca tccagaaaga gtctaccctg cacctggtgc tscgtctcag aggtgggatg 60
cagatcttcg tgaagaccct gactggtaag accatcactc tcgaagtgga gccgagtgac 120
accatygaga acgtcaaagc aaagatccar gacaaggaag gcrtycctcc tgaccagcag 180
aggttgatct ttgccggaaa gcagctggaa gatggdcgca ccctgtctga ctacaacatc 240
cagaaagagt cyaccctgca cctggtgctc cgtctcagag gtgggatgca ratcttcgtg 300
aagaccctga ctggtaagac catcaccctc gaggtggagc ccagtgacac catcgagaat 360
gtcaaggcaa agatccaaga taaggaaggc atccctcctg atcagcagag gttgatcttt 420
gctgggaaac agctggaaga tggacgcacc ctgtctgact acaacatcca gaaagagtcc 480
actctgcact tggtcctgcg cttgaggggg ggtgtctaag tttccccttt taaggtttcm 540
acaaatttca ttgcactttc ctttcaataa agttgttgca ttccc 585
<210>46
<211>481
<212>DNA
<213> human
<400>46
gaactgggcc ctgagcccaa gtcatgcctt gtgtccgcat ctgccgtgtc acctctgtkc 60
ctgcccctca cccctccctc ctggtcttct gagccagcac catctccaaa tagcctattc 120
cttcctgcaa atcacacaca catgcgggcc acacatacct gctgccctgg agatggggaa 180
gtaggagaga tgaatagagg cccatacatt gtacagaagg aggggcaggt gcagataaaa 240
gcagcagacc cagcggcagc tgaggtgcat ggagcacggt tggggccggc attgggctga 300
gcacctgatg ggcctcatct cgtgaatcct cgaggcagcg ccacagcaga ggagttaagt 360
ggcacctggg ccgagcagag caggagactg agggtcagag tggaggctaa gctgccctgg 420
aactcctcaa tcttgcctgc cccctagtat gaagccccct tcctgcccct acaattcctg 480
a 481
<210>47
<211>461
<212>DNA
<213> human
<220>
<221>misc_feature
<222>128
<223> n ═ A, T, C or G
<400>47
atggatctta ctttgccacc caggttggag tgcagtgctg caatcttggc tcactgcagc 60
cttaacctcc caggctcaag ctatcctcct gccaaagcct tccacatagc tgggactaca 120
ggtacacngc caccacaccc agctaaaatt tttgtatttt ttgtagagac gggatctcgc 180
cacgttgccc aggctggtcc catcctgacc tcaagcagat ctgcccacct cagcccccca 240
acgtgctagg attacaggcg tgagccaccg cacccagcct ttgttttgct tttaatggaa 300
tcaccagttc ccctccgtgt ctcagcagca gctgtgagaa atgctttgca tctgtgacct 360
ttatgaaggg gaacttccat gctgaatgag ggtaggatta catgctcctg tttcccgggg 420
gtcaagaaag cctcagactc cagcatgata agcagggtga g 461
<210>48
<211>571
<212>DNA
<213> human
<400>48
ataggggctt taaggaggga attcaggttc aatgaggtcg taaggccagg gctcttatcc 60
agtaagactg gggtccttag atgagaaaga gacacccgag gtccttctct ctgccgtgtg 120
aggatgcatc aagaaggcgg ccgtctgcaa gcgaaggaga ggccgcacca gaaaccgaca 180
ccttcatctt ggacttgcag cctctagaac tgagaaaata actgtctgtt ggttaagcca 240
cccagtttgt agtattctct tatggcttcc taagcagact aacaaacaaa cacccaaaat 300
taactgatgg cttcgctgtc ttctgtaaaa attgctatga gagaactttt cactcactgt 360
tttgcagttt ctccctcagt ccctggttct ttcttctcac ataatcccaa tttcaattta 420
tagttcatgg cccaggcaga gtcattcatc acggcatctc ctgagctaaa ccagcacctg 480
ctctgctcac ttcttgactg gctgctcatc atcagccctc ttgcagagat ttcatttcct 540
cccgtgccag gtacttcacg caccaagctc a 571
<210>49
<211>511
<212>DNA
<213> human
<400>49
ggataatgaa gttgttttat ttagcttgga caaaaaggca tattcctcta ttttcttata 60
caacaaatat ccccaaaata aagcaagcat atatatcttg aatgtgtaat aatccagtga 120
taaacaagag cagtacttta aaagaaaaaa aaatatgtat ttctgtcagg ttaaaatgag 180
aatcaaaacc atttactctg ctaactcatt attttttgct ttctttttgg ttaagagagg 240
caatgcaata cactgaaaaa ggtttttatc ttatctggca ttggaattag acatattcaa 300
accccagccc ccatttccaa actttaagac cacaaacaag taatttactt ttctgaacat 360
tggttttttc tggaaaatgg gaattataaa atagactttg cagactctta tgagattaaa 420
taagataatg tatgaaattc tttcttcttt tttacttctt tttccttttt gagatggagt 480
ctcaccccgt cacccaggct ggagtacagt g 511
<210>50
<211>561
<212>DNA
<213> human
<400>50
ccactgcact ccagcctggg tgacggagtg agactctgtc tcaaaaaaac aaacaaacaa 60
acaaacaaaa aactgaaaag gaaatagagt tcctctttcc tcatatatga atatattatt 120
tcaacagatt gttgatcacc taccatatgc ttggtattgt tctaattgct ggggatacag 180
caagaggttc tgcagaactt catggagcat gaaagtaaat aaacaaagtt aatttcaagg 240
ccaggcatgg ttgctcacac ctttagtccc agcactttgg gaggctgagg caggtggatc 300
acttgggccc aggagttcaa ggctgcagtg agccaagatt gtgccactac tctccaggct 360
gggcaacaga gcaagaccct gtctcagggg gaacaaaaag ttaatttcag attttgttaa 420
gtgctgtaaa ggaagtaaat aggttgatat tcaagagagc acctgaaggc caggcgtggt 480
ggctcacgcc tgtggtctaa cgctttggga agcccgagcg ggcggatcac aaggtcagga 540
gaattttggc caggcatggt g 561
<210>51
<211>451
<212>DNA
<213> human
<400>51
agaatccatt tattgggttt taaactagtt acacaactga aatcagtttg gcactacttt 60
atacagggat tacgcctgtg tatgccgaca cttaaatact gtaccaggac cactgctgtg 120
cttaggtctg tattcagtca ttcagcatgt agatactaaa aatatactgt agtgttcctt 180
taaggaagac tgtacagggt gtgttgcaag atgacattca ccaatttgtg aattatttca 240
acccagaaga tacctttcac tctataaact tgtcataggc aaacatgtgg tgttagcatt 300
gagagatgca cacaaaaatg ttacataaaa gttcagacat tctaatgata agtgaactga 360
aaaaaaaaaa aaccccacat ctcaattttt gtaacaagat aaagaaaata atttaaaaac 420
acaaaaaatg gcattcagtg ggtacaaagc c 451
<210>52
<211>682
<212>DNA
<213> human
<400>52
caaatattta atataaatct ttgaaacaag ttcagakgaa ataaaaatca aagtttgcaa 60
aaacgtgaag attaacttaa ttgtcaaata ttcctcattg ccccaaatca gtattttttt 120
tatttctatg caaaagtatg ccttcaaact gcttaaatga tatatgatat gatacacaaa 180
ccagttttca aatagtaaag ccagtcatct tgcaattgta agaaataggt aaaagattat 240
aagacacctt acacacacac acacacacac acacacacgt gtgcaccgcc aatgacaaaa 300
aacaatttgg cctctcctaa aataagaaca tgaagaccct taattgctgc caggagggaa 360
cactgtgtca cccctcccta caatccaggt agtttccttt aatccaatag caaatctggg 420
catatttgag aggagtgatt ctgacagcca csgttgaaat cctgtgggga accattcatg 480
tccacccact ggtgccctga aaaaatgcca ataatttttc gctcccactt ctgctgctgt 540
ctcttccaca tcctcacata gaccccagac ccgctggccc ctggctgggc atcgcattgc 600
tggtagagca agtcataggt ctcgtctttg acgtcacaga agcgatacac caaattgcct 660
ggtcggtcat tgtcataacc ag 682
<210>53
<211>311
<212>DNA
<213> human
<220>
<221>misc_feature
<222>208
<223> n ═ A, T, C or G
<400>53
tttgacttta gtaggggtct gaactattta ttttactttg ccmgtaatat ttaraccyta 60
tatatctttc attatgccat cttatcttct aatgbcaagg gaacagwtgc taamctggct 120
tctgcattwa tcacattaaa aatggctttc ttggaaaatc ttcttgatat gaataaagga 180
tcttttavag ccatcattta aagcmggntt ctctccaaca cgagtctgct sasggggggk 240
gagctgtgaa ctctggctga aggctttccc atacacactg caatgacmtg gtttctgacc 300
agbgtgagtt a 311
<210>54
<211>561
<212>DNA
<213> human
<400>54
agagaagccc cataaatgca atcagtgtgg gaaggccttc agtcagagct caagcctttt 60
cctccatcat cgggttcata ctggagagaa accctatgta tgtaatgaat gcggcagagc 120
ctttggtttt aactctcatc ttactgaaca cgtaaggatt cacacaggag aaaaacccta 180
tgtttgtaat gagtgcggca aagcctttcg tcggagttcc actcttgttc agcatcgaag 240
agttcacact ggggagaagc cctaccagtg cgttgaatgt gggaaagctt tcagccagag 300
ctcccagctc accctacatc agccgagttc acactggaga gaagccctat gactgtggtg 360
actgtgggaa ggccttcagc cggaggtcaa ccctcattca gcatcagaaa gttcacagcg 420
gagagactcg taagtgcaga aaacatggtc cagcctttgt tcatggctcc agcctcacag 480
cagatggaca gattcccact ggagagaagc acggcagaac ctttaaccat ggtgcaaatc 540
tcattctgcg ctggacagtt c 561
<210>55
<211>811
<212>DNA
<213> human
<400>55
gagacagggt ctcactttgt cacccaggct ggaatgcagt ggtgcgatct tacgtagctc 60
actgcagccc tgacctcctg gactcaaaca attctcctgc ctcagccctg caagtagctg 120
ggactgtggg tgcatgccac catgcctggc taacttttgt agtttttgta aagatggggt 180
tttgccatgt tgcacatgct ggtcttgaac tcctgagctc aaacgatctg cccacctcgg 240
cctcccagaa tgttgggatt acaggggtaa accaccacgc ctggccccat tagggtattc 300
ttagcatcca cttgctcact gagattaatc ataagagatg ataagcactg gaagaaaaaa 360
atttttacta ggctttggat atttttttcc tttttcagct ttatacagag gattggatct 420
ttagttttcc tttaactgat aataaaacat tgaaaggaaa taagtttacc tgagattcac 480
agagataacc ggcatcactc ccttgctcaa ttccagtctt taccacatca attattttca 540
gaggtgcagg ataaaggcct ttagtctgct ttcgcacttt ttcttccact tttttgtaaa 600
cctgttgcct gacaaatgga attgacagcg tatgccatga ctattccatt tgtcaggcat 660
acgctgtcaa tttttccacc aatcccttgt ctctctttgg agagatcttc ttatcagcta 720
gtcctttggc aaaagtaatt gcaacttctt ctaggtattc tattgtccgt tccactggtg 780
gaacccctgg gaccaggact aaaacctcca g 811
<210>56
<211>591
<212>DNA
<213> human
<220>
<221>misc_feature
<222>45,477,490,561
<223> n ═ A, T, C or G
<400>56
atctcatata tatatttctt cctgacttta tttgcttgct tctgncacgc atttaaaata 60
tcacagagac caaaatagag cggctttctg gtggaacgca tggcagtcac aggacaaaat 120
acaaaactag ggggctctgt cttctcatac atcatacaat tttcaagtat tttttttatg 180
tacaaagagc tactctatct gaaaaaaaat taaaaaataa atgagacaag atagtttatg 240
catcctagga agaaagaatg ggaagaaaga acggggcagt tgggtacaga ttcctgtccc 300
ctgttcccag ggaccactac cttcctgcca ctgagttccc ccacagcctc acccatcatg 360
tcacagggca agtgccaggg taggtgggga ccagtggaga caggaaccag caacatactt 420
tggcctggaa gataaggaga aagtctcaga aacacactgg tgggaagcaa tcccacnggc 480
cgtgccccan gagcttccca cctgctgctg gctccctggg tggctttggg aacagcttgg 540
gcaggccctt ttgggtgggg nccaactggg cctttgggcc cgtgtggaaa g 591
<210>57
<211>481
<212>DNA
<213> human
<400>57
aaacattgag atggaatgat agggtttccc agaatcaggt ccatatttta actaaatgaa 60
aattatgatt tatagccttc tcaaatacct gccatacttg atatctcaac cagagctaat 120
tttacctctt tacaaattaa ataagcaagt aactggatcc acaatttata atacctgtca 180
attttttctg tattaaacct ctatcatagt ttaagcctat tagggtactt aatccttaca 240
aataaacagg tttaaaatca cctcaatagg caactgccct tctggttttc ttctttgact 300
aaacaatctg aatgcttaag attttccact ttgggtgcta gcagtacaca gtgttacact 360
ctgtattcca gacttcttaa attatagaaa aaggaatgta cactttttgt attctttctg 420
agcagggccg ggaggcaaca tcatctacca tggtagggac ttgtatgcat ggactacttt 480
a 481
<210>58
<211>141
<212>DNA
<213> human
<400>58
actctgtcgc ccaggctgga gcccabtggm gcgatctcga ctccctgcaa gctmcgcctc 60
acaggwtcat gccattctcc tgcctcagca tctggagtag ctgggactac aggcgccagc 120
caccatgccc agctaatttt t 141
<210>59
<211>191
<212>DNA
<213> human
<400>59
accttaaaga cataggagaa tttatactgg gagagaaagc ttacaaatgt aaggtttctg 60
acaagacttg ggagtgattc acacctggaa caacatactg gacttcacac tggabagaaa 120
ccttacaagt gtaatgagtg tggcaaagcc tttggcaagc agtcaacact tattcaccat 180
caggcaattc a 191
<210>60
<211>480
<212>DNA
<213> human
<400>60
agtcaggatc atgatggctc agtttcccac agcgatgaat ggagggccaa atatgtgggc 60
tattacatct gaagaacgta ctaagcatga taaacagttt gataacctca aaccttcagg 120
aggttacata acaggtgatc aagcccgtac ttttttccta cagtcaggtc tgccggcccc 180
ggttttagct gaaatatggg ccttatcaga tctgaacaag gatgggaaga tggaccagca 240
agagttctct atagctatga aactcatcaa gttaaagttg cagggccaac agctgcctgt 300
agtcctccct cctatcatga aacaaccccc tatgttctct ccactaatct ctgctcgttt 360
tgggatggga agcatgccca atctgtccat tcatcagcca ttgcctccag ttgcacctat 420
agcaacaccc ttgtcttctg ctacttcagg gaccagtatt cctccctaat gatgcctgct 480
<210>61
<211>381
<212>DNA
<213> human
<400>61
ctttcgattt ccttcaattt gtcacgtttg attttatgaa gttgttcaag ggctaactgc 60
tgtgtattat agctttctct gagttccttc agctgattgt taaatgaatc catttctgag 120
agcttagatg cagtttcttt ttcaagagca tctaattgtt ctttaagtct ttggcataat 180
tcttcctttt ctgatgactt tctatgaagt aaactgatcc ctgaatcagg tgtgttactg 240
agctgcatgt ttttaattct ttcgtttaat agctgcttct cagggaccag atagataagc 300
ttattttgat attccttaag ctcttggtga agttgttcga tttccataat ttccaggtca 360
cactggttat cccaaacttc t 381
<210>62
<211>906
<212>DNA
<213> human
<400>62
gtggaggtga aacggaggca agaaaggggg ctacctcagg agcgagggac aaagggggcg 60
tgaggcacct aggccgcggc accccggcga caggaagccg tcctgaaccg ggctaccggg 120
taggggaagg gcccgcgtag tcctcgcagg gccccagagc tggagtcggc tccacagccc 180
cgggccgtcg gcttctcact tcctggacct ccccggcgcc cgggcctgag gactggctcg 240
gcggagggag aagaggaaac agacttgagc agctccccgt tgtctcgcaa ctccactgcc 300
gaggaactct catttcttcc ctcgctcctt caccccccac ctcatgtaga aaggtgctga 360
agcgtccgga gggaagaaga acctgggcta ccgtcctggc cttcccmccc ccttcccggg 420
gcgctttggt gggcgtggag ttggggttgg gggggtgggt gggggttctt ttttggagtg 480
ctggggaact tttttccctt cttcaggtca ggggaaaggg aatgcccaat tcagagagac 540
atgggggcaa gaaggacggg agtggaggag cttctggaac tttgcagccg tcatcgggag 600
gcggcagctc taacagcaga gagcgtcacc gcttggtatc gaagcacaag cggcataagt 660
ccaaacactc caaagacatg gggttggtga cccccgaagc agcatccctg ggcacagtta 720
tcaaaccttt ggtggagtat gatgatatca gctctgattc cgacaccttc tccgatgaca 780
tggccttcaa actagaccga agggagaacg acgaacgtcg tggatcagat cggagcgacc 840
gcctgcacaa acatcgtcac caccagcaca ggcgttcccg ggacttacta aaagctaaac 900
agaccg 906
<210>63
<211>491
<212>DNA
<213> human
<400>63
gacatgtttg cctgcagggg accagagaca atgggattag ccagtgctca ctgttcttta 60
tgcttccaga gaggatgggg acagctctca ggtcagaatc caggctgaga aggccatgct 120
ggttgggggc ccccggaagc acggtccgga tcctccctgg catcagcgta gacccgctgc 180
tcaggcttgg ggtaccaaac tcatgctctg tactgttttg gccccatgcg gtgagaggaa 240
aacctagaaa aagattggtc gtgctaagga atcagctgcc ccctcatcct ccgcatccaa 300
tgctggtgac aacatattcc ctctcccagg acacagactc ggtgactcca cactgggctg 360
agtggcctct ggaggctcgt ggcctaaggc agggctccgt aaggctgatc ggctgaactg 420
ggtggggtga gggtttctga cccttcgctt cccatcccat aaccgctgtc aatgagctca 480
cactgtggtc a 491
<210>64
<211>511
<212>DNA
<213> human
<400>64
gatggcatgg tcgttgctaa tgtgcctgct gggatggagc acttcctcct gtgagcccag 60
gggacccgcc tgtccctgga gcttggggca aggagggaag agtgatacca ggaaggtggg 120
gctgcagcca ggggccagag tcagttcagg gagtggtcct cggccctcaa agctcctccg 180
gggactgctc aggagtgatg gtgccctgga gtttgcccca acttccctgg ccaccctgga 240
aggtgcctgg ctgctccagg cctctaggct gggctgatgg gtttctccag gacacaagta 300
tcattaaagc caccctctcc tcagcttgtc aggccgcaca tgtgggacag gctgtgctca 360
caaccccctc gcctgccctg ccctccatca ggaggagcca gtggaacctt cggaaagctc 420
ccagcatctc agcagccctc aaaagtcgtc ctggggcaag ctctggttct cctgactgga 480
ggtcatctgg gcttggcctg ctctctctcg c 511
<210>65
<211>394
<212>DNA
<213> human
<400>65
taaaaaagtg taacaaaggt ttatttagac tttcttcatg cccccagatc caggatgtct 60
atgtaaaccg ttatcttaca aagaaagcac aatatttggt ataaactaag tcagtgactt 120
gcttaactga aatagcgtcc atccaaaagt gggtttaagg taaaactacc tgacgatatt 180
ggcggggatc ctgcagtttg gactgcttgc cgggtttgtc cagggttccg ggtctgttct 240
tggcactcat ggggacaggc atcctgctcg tctgtggggc cccgctggag cccttacgtg 300
aagctgaagg tatcgaccst agggggctct agggcagtgg gaccttcatc cggaactaac 360
aagggtcggg gagaggcctc ttgggctatg tggg 394
<210>66
<211>359
<212>DNA
<213> human
<400>66
caagcgttcc tttatggatg taaattcaaa cagtcatgct gagccatccc gggctgacag 60
tcacgttwaa gacactaggt cgggcgccac agtgccaccc aaggagaaga agaatttgga 120
atttttccat gaagatgtac ggaaatctga tgttgaatat gaaaatggcc cccaaatgga 180
attccaaaag gttaccacag gggctgtaag acctagtgac cctcctaagt gggaaagagg 240
aatggagaat agtatttctg atgcatcaag aacatcagaa tataaaactg agatcataat 300
gaaggaaaat tccatatcca atatgagttt actcagagac agtagaaact attcccagg 359
<210>67
<211>450
<212>DNA
<213> human
<220>
<221>misc_feature
<222>425
<223> n ═ A, T, C or G
<400>67
taggaataac aaatgtttat tcagaaatgg ataagtaata cataatcacc cttcatctct 60
taatgcccct tcctctcctt ctgcacagga gacacagatg ggtaacatag aggcatggga 120
agtggaggag gacacaggac tagcccacca ccttctcttc ccggtctccc aagatgactg 180
cttatagagt ggaggaggca aacaggtccc ctcaatgtac cagatggtca cctatagcac 240
cagctccaga tggccacgtg gttgcagctg gactcaatga aactctgtga caaccagaag 300
atacctgctt tgggatgaga gggaggataa agccatgcag ggaggatatt taccatccct 360
accctaagca cagtgcaagc agtgagcccc cggctcccag tacctgaaaa accaaggcct 420
actgnctttt ggatgctctc ttgggccacg 450
<210>68
<211>511
<212>DNA
<213> human
<400>68
aagcctcctg ccctggaaat ctggagcccc ttggagctga gctggacggg gcagggaggg 60
gctgagaggc aagaccgtct ccctcctgct gcagctgctt ccccagcagc cactgctggg 120
cacagcagaa acgccagcag agaaaatggg agccgagagt ccttagccct ggagctgagg 180
ctgcctctgg gctgacccgc tggctgtacg tggccagaac tggggttggc atctggcatc 240
catttgaggc cagggtggag gaaagggagg ccaacagagg aaaacctatt cctgctgtga 300
caacacagcc cttgtcccac gcagcctaag tgcagggagc gtgatgaagt caggcagcca 360
gtcggggagg acgaggtaac tcagcagcaa tgtcaccttg tagcctatgc gctcaatggc 420
ccggaggggc agcaaccccc cgcacacgtc agccaacagc agtgcctctg caggcaccaa 480
gagagcgatg atggacttga gcgccgtgtt c 511
<210>69
<211>511
<212>DNA
<213> human
<400>69
gtttggcaga agacatgttt aataacattt tcatatttaa aaaatacagc aacaattctc 60
tatctgtcca ccatcttgcc ttgcccttcc tggggctgag gcagacaaag gaaaggtaat 120
gaggttaggg cccccaggcg ggctaagtgc tattggcctg ctcctgctca aagagagcca 180
tagccagctg ggcacggccc cctagcccct ccaggttgct gaggcggcag cggtggtaga 240
gttcttcact gagccgtggg ctgcagtctc gcagggagaa cttctgcacc agccctggct 300
ctacggcccg aaagaggtgg agccctgaga accggaggaa aacatccatc acctccagcc 360
cctccagggc ttcctcctct tcctggcctg ccagttcacc tgccagccgg gctcgggccg 420
ccaggtagtc agcgttgtag aagcagccct ccgcagaagc ctgccggtca aatctccccg 480
ctataggagc cccccgggag gggtcagcac c 511
<210>70
<211>511
<212>DNA
<213> human
<400>70
caagttgaac gtcaggcttg gcagaggtgg agtgtagatg aaaacaaagg tgtgattatg 60
aagaggatgt gagtcctttg ggtgtaggag agaaaggctg ttgagcttct atttcaagat 120
acttttacct gtgcaaaaag cacattttcc acctccttct catggcattt gtgtaaggtg 180
agtatgattc ctattccatc tgcattttag aggtgaagaa taacgtacaa gggattcagt 240
gattagcaag ggacccctca ctaagtgttg atggagttag gacagagctc agctgtttga 300
atctcagagc ccaggcagct ggagctgggt aggatcctgg agctggcact aatgtgaggt 360
gcattccctc caacccaggc tcagatccgg aacctgaccg tgctgacccc cgaaggggag 420
gcagggctga gctggcccgt tgggctccct gctcctttca caccacactc tcgctttgag 480
gtgctgggct gggactactt cacagagcag c 511
<210>71
<211>511
<212>DNA
<213> human
<400>71
tggcctgggc aggattggga gagaggtagc tacccggatg cagtcctttg ggatgaagac 60
tatagggtat gaccccatca tttccccaga ggtctcggcc tcctttggtg ttcagcagct 120
gcccctggag gagatctggc ctctctgtga tttcatcact gtgcacactc ctctcctgcc 180
ctccacgaca ggcttgctga atgacaacac ctttgcccag tgcaagaagg gggtgcgtgt 240
ggtgaactgt gcccgtggag ggatcgtgga cgaaggcgcc ctgctccggg ccctgcagtc 300
tggccagtgt gccggggctg cactggacgt gtttacggaa gagccgccac gggaccgggc 360
cttggtggac catgagaatg tcatcagctg tccccacctg ggtgccagca ccaaggaggc 420
tcagagccgc tgtggggagg aaattgctgt tcagttcgtg gacatggtga aggggaaatc 480
tctcacgggg gttgtgaatg cccaggccct t 511
<210>72
<211>2017
<212>DNA
<213> human
<400>72
agccagatgg ctgagagctg caagaagaag tcaggatcat gatggctcag tttcccacag 60
cgatgaatgg agggccaaat atgtgggcta ttacatctga agaacgtact aagcatgata 120
aacagtttga taacctcaaa ccttcaggag gttacataac aggtgatcaa gcccgtactt 180
ttttcctaca gtcaggtctg ccggccccgg ttttagctga aatatgggcc ttatcagatc 240
tgaacaagga tgggaagatg gaccagcaag agttctctat agctatgaaa ctcatcaagt 300
taaagttgca gggccaacag ctgcctgtag tcctccctcc tatcatgaaa caacccccta 360
tgttctctcc actaatctct gctcgttttg ggatgggaag catgcccaat ctgtccattc 420
atcagccatt gcctccagtt gcacctatag caacaccctt gtcttctgct acttcaggga 480
ccagtattcc tcccctaatg atgcctgctc ccctagtgcc ttctgttagt acatcctcat 540
taccaaatgg aactgccagt ctcattcagc ctttatccat tccttattct tcttcaacat 600
tgcctcatgc atcatcttac agcctgatga tgggaggatt tggtggtgct agtatccaga 660
aggcccagtc tctgattgat ttaggatcta gtagctcaac ttcctcaact gcttccctct 720
cagggaactc acctaagaca gggacctcag agtgggcagt tcctcagcct tcaagattaa 780
agtatcggca aaaatttaat agtctagaca aaggcatgag cggatacctc tcaggttttc 840
aagctagaaa tgcccttctt cagtcaaatc tctctcaaac tcagctagct actatttgga 900
ctctggctga catcgatggt gacggacagt tgaaagctga agaatttatt ctggcgatgc 960
acctcactga catggccaaa gctggacagc cactaccact gacgttgcct cccgagcttg 1020
tccctccatc tttcagaggg ggaaagcaag ttgattctgt taatggaact ctgccttcat 1080
atcagaaaac acaagaagaa gagcctcaga agaaactgcc agttactttt gaggacaaac 1140
ggaaagccaa ctatgaacga ggaaacatgg agctggagaa gcgacgccaa gtgttgatgg 1200
agcagcagca gagggaggct gaacgcaaag cccagaaaga gaaggaagag tgggagcgga 1260
aacagagaga actgcaagag caagaatgga agaagcagct ggagttggag aaacgcttgg 1320
agaaacagag agagctggag agacagcggg aggaagagag gagaaaggag atagaaagac 1380
gagaggcagc aaaacaggag cttgagagac aacgccgttt agaatgggaa agactccgtc 1440
ggcaggagct gctcagtcag aagaccaggg aacaagaaga cattgtcagg ctgagctcca 1500
gaaagaaaag tctccacctg gaactggaag cagtgaatgg aaaacatcag cagatctcag 1560
gcagactaca agatgtccaa atcagaaagc aaacacaaaa gactgagcta gaagttttgg 1620
ataaacagtg tgacctggaa attatggaaa tcaaacaact tcaacaagag cttaaggaat 1680
atcaaaataa gcttatctat ctggtccctg agaagcagct attaaacgaa agaattaaaa 1740
acatgcagct cagtaacaca cctgattcag ggatcagttt acttcataaa aagtcatcag 1800
aaaaggaaga attatgccaa agacttaaag aacaattaga tgctcttgaa aaagaaactg 1860
catctaagct ctcagaaatg gattcattta acaatcagct gaaggaactc agagaaagct 1920
ataatacaca gcagttagcc cttgaacaac ttcataaaat caaacgtgac aaattgaagg 1980
aaatcgaaag aaaaagatta gagcaaaaaa aaaaaaa 2017
<210>73
<211>414
<212>DNA
<213> human
<400>73
atggcagtga cattcaccat catgggaacc accttccctt ttcttcagga ttctctgtag 60
tggaagagag cacccagtgt tgggctgaaa acatctgaaa gtagggagaa gaacctaaaa 120
taatcagtat ctcagagggc tctaaggtgc caagaagtct cactggacat ttaagtgcca 180
acaaaggcat actttcggaa tcgccaagtc aaaactttct aacttctgtc tctctcagag 240
acaagtgaga ctcaagagtc tactgcttta gtggcaacta cagaaaactg gtgttaccca 300
gaaaaacagg agcaattaga aatggttcca atatttcaaa gctccgcaaa caggatgtgc 360
tttcctttgc ccatttaggg tttcttctct ttcctttctc tttattaacc acta 414
<210>74
<211>1567
<212>DNA
<213> human
<400>74
atatctagaa gtctggagtg agcaaacaag agcaagaaac aaaaagaagc caaaagcaga 60
aggctccaat atgaacaaga taaatctatc ttcaaagaca tattagaagt tgggaaaata 120
attcatgtga actagacaag tgtgttaaga gtgataagta aaatgcacgt ggagacaagt 180
gcatccccag atctcaggga cctccccctg cctgtcacct ggggagtgag aggacaggat 240
agtgcatgtt ctttgtctct gaatttttag ttatatgtgc tgtaatgttg ctctgaggaa 300
gcccctggaa agtctatccc aacatatcca catcttatat tccacaaatt aagctgtagt 360
atgtacccta agacgctgct aattgactgc cacttcgcaa ctcaggggcg gctgcatttt 420
agtaatgggt caaatgattc actttttatg atgcttccaa aggtgccttg gcttctcttc 480
ccaactgaca aatgccaaag ttgagaaaaa tgatcataat tttagcataa acagagcagt 540
cggcgacacc gattttataa ataaactgag caccttcttt ttaaacaaac aaatgcgggt 600
ttatttctca gatgatgttc atccgtgaat ggtccaggga aggacctttc accttgacta 660
tatggcatta tgtcatcaca agctctgagg cttctccttt ccatcctgcg tggacagcta 720
agacctcagt tttcaatagc atctagagca gtgggactca gctggggtga tttcgccccc 780
catctccggg ggaatgtctg aagacaattt tgttacctca atgagggagt ggaggaggat 840
acagtgctac taccaactag tggataaagg ccagggatgc tgctcaacct cctaccatgt 900
acaggacgtc tccccattac aactacccaa tccgaagtgt caactgtgtc aggactaaga 960
aaccctggtt ttgagtagaa aagggcctgg aaagagggga gccaacaaat ctgtctgctt 1020
cctcacatta gtcattggca aataagcatt ctgtctcttt ggctgctgcc tcagcacaga 1080
gagccagaac tctatcgggc accaggataa catctctcag tgaacagagt tgacaaggcc 1140
tatgggaaat gcctgatggg attatcttca gcttgttgag cttctaagtt tctttccctt 1200
cattctaccc tgcaagccaa gttctgtaag agaaatgcct gagttctagc tcaggttttc 1260
ttactctgaa tttagatctc cagacccttc ctggccacaa ttcaaattaa ggcaacaaac 1320
atataccttc catgaagcac acacagactt ttgaaagcaa ggacaatgac tgcttgaatt 1380
gaggccttga ggaatgaagc tttgaaggaa aagaatactt tgtttccagc ccccttccca 1440
cactcttcat gtgttaacca ctgccttcct ggaccttgga gccacggtga ctgtattaca 1500
tgttgttata gaaaactgat tttagagttc tgatcgttca agagaatgat taaatataca 1560
tttccta 1567
<210>75
<211>240
<212>DNA
<213> human
<400>75
tcgagcggcc gcccgggcag gtccttcaga cttggactgt gtcacactgc caggcttcca 60
gggctccaac ttgcagacgg cctgttgtgg gacagtctct gtaatcgcga aagcaaccat 120
ggaagacctg ggggaaaaca ccatggtttt atccaccctg agatctttga acaacttcat 180
ctctcagcgt gcggagggag gctctggact ggatatttct acctcggccg cgaccacgct 240
<210>76
<211>330
<212>DNA
<213> human
<220>
<221>misc_feature
<222>288
<223> n ═ A, T, C or G
<400>76
tagcgyggtc gcggccgagg yctgcttytc tgtccagccc agggcctgtg gggtcagggc 60
ggtgggtgca gatggcatcc actccggtgg cttccccatc tttctctggc ctgagcaagg 120
tcagcctgca gccagagtac agagggccaa cactggtgtt cttgaacaag ggccttagca 180
ggccctgaag grccctctct gtagtgttga acttcctgga gccaggccac atgttctcct 240
cataccgcag gytagygatg gtgaagttga gggtgaaata gtattmangr agatggctgg 300
caracctgcc cgggcggccg ctcsaaatcc 330
<210>77
<211>361
<212>DNA
<213> human
<400>77
agcgtggtcg cggccgaggt gtccttcagg gtctgcttat gcccttgttc aagaacacca 60
gtgtcagctc tctgtactct ggttgcagac tgaccttgct caggcctgag aaggatgggg 120
cagccaccag agtggatgct gtctgcaccc atcgtcctga ccccaaaagc cctggactgg 180
acagagagcg gctgtactgg aagctgagcc agctgaccca cggcatcact gagctgggcc 240
cctacaccct ggacagggac agtctctatg tcaatggttt cacccatcgg agctctgtac 300
ccaccaccag caccggggtg gtcagcgagg agccattcaa cctgcccggg cggccgctcg 360
a 361
<210>78
<211>356
<212>DNA
<213> human
<220>
<221>misc_feature
<222>7,346,350,353
<223> n ═ A, T, C or G
<400>78
ttggggnttt mgagcggccg cccgggcagg taccggggtg gtcagcgagg agccattcac 60
actgaacttc accatcaaca acctgcggta tgaggagaac atgcagcacc ctggctccag 120
gaagttcaac accacggaga gggtccttca gggcctgctc aggtccctgt tcaagagcac 180
cagtgttggc cctctgtact ctggctgcag actgactttg ctcagacttg agaaacatgg 240
ggcagccact ggagtggacg ccatctgcac cctccgcctt gatcccactg gtcctggact 300
ggacagagag cggctatact gggagctgag ccagtcctct ggcggngacn ccnctt 356
<210>79
<211>226
<212>DNA
<213> human
<400>79
agcgtggtcg cggccgaggt ccagtcgcag catgctcttt ctcctgccca ctggcacagt 60
gaggaagatc tctgctgtca gtgagaaggc tgtcatccac tgagatggca gtcaaaagtg 120
catttaatac acctaacgta tcgaacatca tagcttggcc caggttatct catatgtgct 180
cagaacactt acaatagcct gcagacctgc ccgggcggcc gctcga 226
<210>80
<211>444
<212>DNA
<213> human
<220>
<221>misc_feature
<222>23
<223> n ═ A, T, C or G
<400>80
tgtggtgttg aacttcctgg agncagggtg acccatgtcc tccccatact gcaggttggt 60
gatggtgaag ttgagggtga atggtaccag gagagggcca gcagccataa ttgtsgrgck 120
gsmgmssgag gmwggwgtyy cwgaggttcy rarrtccact gtggaggtcc caggagtgct 180
ggtggtgggc acagagstcy gatgggtgaa accattgaca tagagactgt tcctgtccag 240
ggtgtagggg cccagctctt yratgycatt ggycagttkg ctyagctccc agtacagccr 300
ctctckgyyg mgwccagsgc ttttggggtc aagatgatgg atgcagatgg catccactcc 360
agtggctgct ccatccttct cggacctgag agaggtcagt ctgcagccag agtacagagg 420
gccaacactg gtgttctttg aata 444
<210>81
<211>310
<212>DNA
<213> human
<400>81
tcgagcggcc gcccgggcag gtcaggaagc acattggtct tagagccact gcctcctgga 60
ttccacctgt gctgcggaca tctccaggga gtgcagaagg gaagcaggtc aaactgctca 120
gatcagtcag actggctgtt ctcagttctc acctgagcaa ggtcagtctg cagccagagt 180
acagagggcc aacactggtg ttcttgaaca agggcttgag cagaccctgc agaaccctct 240
tccgtggtgt tgaacttcct ggaaaccagg gtgttgcatg tttttcctca taatgcaagg 300
ttggtgatgg 310
<210>82
<211>571
<212>DNA
<213> human
<220>
<221>misc_feature
<222>202
<223> n ═ A, T, C or G
<400>82
acggtttcaa tggacacttt tattgtttac ttaatggatc atcaattttg tctcactacc 60
tacaaatgga atttcatctt gtttccatgc tgagtagtga aacagtgaca aagctaatca 120
taataaccta catcaaaaga gaactaagct aacactgctc actttctttt taacaggcaa 180
aatataaata tatgcactct anaatgcaca atggtttagt cactaaaaaa ttcaaatggg 240
atcttgaaga atgtatgcaa atccagggtg cagtgaagat gagctgagat gctgtgcaac 300
tgtttaaggg ttcctggcac tgcatctctt ggccactagc tgaatcttga catggaaggt 360
tttagctaat gccaagtgga gatgcagaaa atgctaagtt gacttagggg ctgtgcacag 420
gaactaaaag gcaggaaagt actaaatatt gctgagagca tccaccccag gaaggacttt 480
accttccagg agctccaaac tggcaccacc cccagtgctc acatggctga ctttatcctc 540
cgtgttccat ttggcacagc aagtggcagt g 571
<210>83
<211>551
<212>DNA
<213> human
<400>83
aaggctggtg ggtttttgat cctgctggag aacctccgct ttcatgtgga ggaagaaggg 60
aagggaaaag atgcttctgg gaacaaggtt aaagccgagc cagccaaaat agaagctttc 120
cgagcttcac tttccaagct aggggatgtc tatgtcaatg atgcttttgg cactgctcac 180
agagcccaca gctccatggt aggagtcaat ctgccacaga aggctggtgg gtttttgatg 240
aagaaggagc tgaactactt tgcaaaggcc ttggagagcc cagagcgacc cttcctggcc 300
atcctgggcg gagctaaagt tgcagacaag atccagctca tcaataatat gctggacaaa 360
gtcaatgaga tgattattgg tggtggaatg gcttttacct tccttaaggt gctcaacaac 420
atggagattg gcacttctct gtttgatgaa gagggagcca agattgtcaa agacctaatg 480
tccaaagctg agaagaatgg tgtgaagatt accttgcctg ttgactttgt cactgctgac 540
aagtttgatg a 551
<210>84
<211>571
<212>DNA
<213> human
<400>84
tttgttcctt acatttttct aaagagttac ttaaatcagt caactggtct ttgagactct 60
taagttctga ttccaactta gctaattcat tctgagaact gtggtatagg tggcgtgtct 120
cttctagctg ggacaaaagt tctttgtttt ccccctgtag agtatcacag accttctgct 180
gaagctggac ctctgtctgg gccttggact cccaaatctg cttgtcatgt tcaagcctgg 240
aaatgttaat ctttaattct tccatatgga tggacatctg tctaagttga tcctttagaa 300
cactgcaatt atcttctttg agtctaattt cttcttcttt gctttgaatc gcatcactaa 360
acttcctctc ccatttctta gcttcatcta tcaccctgtc acgatcatcc tggagggaag 420
acatgctctt agtaaaggct gcaagctggg tcacagtact gtccaagttt tcctgaagtt 480
gctgaacttc cttgtctttc ttgttcaaag taacctgaat ctctccaatt gtctcttcca 540
agtggacttt ttctctgcgc aaagcatcca g 571
<210>85
<211>561
<212>DNA
<213> human
<400>85
tcattgcctg tgatggcatc tggaatgtga tgagcagcca ggaagttgta gatttcattc 60
aatcaaagga ttcagcatgt ggtggaagct gtgaggcaag agaaacaaga actgtatggc 120
aagttaagaa gcacagaggc aaacaagaag gagacagaaa agcagttgca ggaagctgag 180
caagaaatgg aggaaatgaa agaaaagatg agaaagtttg ctaaatctaa acagcagaaa 240
atcctagagc tggaagaaga gaatgaccgg cttagggcag aggtgcaccc tgcaggagat 300
acagctaaag agtgtatgga aacacttctt tcttccaatg ccagcatgaa ggaagaactt 360
gaaagggtca aaatggagta tgaaaccctt tctaagaagt ttcagtcttt aatgtctgag 420
aaagactctc taagtgaaga ggttcaagat ttaaagcatc agatagaagg taatgtatct 480
aaacaagcta acctagaggc caccgagaaa catgataacc aaacgaatgt cactgaagag 540
ggaacacagt ctataccagg t 561
<210>86
<211>795
<212>DNA
<213> human
<400>86
aagccaataa tcaccattta ttacttaata tatgccaacc actgtacttg gcagttcaca 60
aattctcacc gttacaacaa ccccatgagg tatttattcc cattctatag atagggaaac 120
cacagctcaa gtaagttagg aaactgagcc aagtatacac agaatacgaa gtggcaaaac 180
tagaaggaaa gactgacact gctatctgct ggcctccagt gtcctggctc ttttcacacg 240
ggttcaatgt ctccagcgct gctgctgctg ctgcattacc atgccctcat tgtttttctt 300
cctctggtgt tcaactgcat ccttcaaaga atctaactca ttccagagac cacttatttc 360
tttctctctt tctgaaatta cttttaataa ttcttcatga gggggaaaag aagatgcctg 420
ttggtagttt tgttgtttaa gctgctcaat ttgggactta aacaatttgt tttcatcttg 480
tacatcctgt aacagctgtg ttttgctaga aagatcactc tccctctctt ttagcatggc 540
ttctaacctc ttcaattcat tttccttttc tttcaacaca atctcaagtt cttcaaactg 600
tgatgcagaa gaggcctctt tcaagttatg ttgtgctact tcctgaacat gtgcttttaa 660
agattcattt tcttcttgaa gatcctgtaa ccacttccct gtattggcta ggtctttctc 720
tttctcttcc aaaacagcct tcatggtatt catctgttcc tcttttcctt ttaataagtt 780
caggagcttc agaac 795
<210>87
<211>594
<212>DNA
<213> human
<400>87
caagcttttt tttttttttt aaaaagtgtt agcattaatg ttttattgtc acgcagatgg 60
caactgggtt tatgtcttca tattttatat ttttgtaaat taaaaaaatt acaagtttta 120
aatagccaat ggctggttat attttcagaa aacatgatta gactaattca ttaatggtgg 180
cttcaagctt ttccttattg gctccagaaa attcacccac cttttgtccc ttcttaaaaa 240
actggaatgt tggcatgcat ttgacttcac actctgaagc aacatcctga cagtcatcca 300
catctacttc aaggaatatc acgttggaat acttttcaga gagggaatga aagaaaggct 360
tgatcatttt gcaaggccca caccacgtgg ctgagaagtc aactactaca agtttatcac 420
ctgcagcgtc caaggcttcc tgaaaagcag tcttgctctc gatctgcttc accatcttgg 480
ctgctggagt ctgacgagcg gctgtaagga ccgatggaaa tggatccaaa gcaccaaaca 540
gagcttcaag actcgctgct tggcttgaat tcggatccga tatcgccatg gcct 594
<210>88
<211>557
<212>DNA
<213> human
<400>88
aagtgttagc attaatgttt tattgtcacg cagatggcaa ctgggtttat gtcttcatat 60
tttatatttt tgtaaattaa aaaaattmca agttttaaat agccaatggc tggttatatt 120
ttcagaaaac atgattagac taattcatta atggtggctt caagcttttc cttattggct 180
ccagaaaatt cacccacctt ttgtcccttc ttaaaaaact ggaatgttgg catgcatttg 240
acttcacact ctgaagcaac atcctgacag tcatccacat ctacttcaag gaatatcacg 300
ttggaatact tttcagagag ggaatgaaag aaaggcttga tcattttgca aggcccacac 360
cacgtggctg agaagtcaac tactacaagt ttatcacctg cagcgtccaa ggcttcctga 420
aaagcagtct tgctctcgat ctgcttcacc atcttggctg ctggagtctg acgagcggct 480
gtaaggaccg atggaaatgg atccaaagca ccaaacagag cttcaagact cgctgcttgg 540
catgaattcg gatccga 557
<210>89
<211>561
<212>DNA
<213> human
<220>
<221>misc_feature
<222>544,551
<223> n ═ A, T, C or G
<400>89
tacaaacttt attgaaacgc acacgcgcac acacacaaac acccctgtgg atagggaaaa 60
gcacctggcc acagggtcca ctgaaacggg gaggggatgg cagcttgtaa tgtggctttt 120
gccacaaccc ccttctgaca gggaaggcct tagattgagg ccccacctcc catggtgatg 180
gggagctcag aatggggtcc agggagaatt tggttagggg gaggtgctag ggaggcatga 240
gGagagggca ccctccgagt ggggtcccga gggctgcaga gtcttcagta ctgtccctca 300
cagcagctgt ctcaaggctg ggtccctcaa aggggcgtcc cagcgcgggg cctccctgcg 360
caaacacttg gtacccctgg ctgcgcagcg gaagccagca ggacagcagt ggcgccgatc 420
agcacaacag acgccctggc ggtagggaca gcaggcccag ccctgtcggt tgtctcggca 480
gcaggtctgg ttatcatggc agaagtgtcc ttcccacact tcacgtcctt cacacccacg 540
tganggctac nggccaggaa g 561
<210>90
<211>561
<212>DNA
<213> human
<400>90
cccgtgggtg ccatccacgg agttgttacc tgatctttgg aagcaggatc gcccgtctgc 60
actgcagtgg aagccccgtg ggcagcagtg atggccatcc ccgcatgcca cggcctctgg 120
gaaggggcag caactggaag tccctgagac ggtaaagatg caggagtggc cggcagagca 180
gtgggcatca acctggcagg ggccacccag atgcctgctc agtgttgtgg gccatttgtc 240
cagaagggga cggcagcagc tgtagctggc tcctccgggg tccaggcagc aggccacagg 300
gcagaactga ccatctgggc accgcgttcc agccaccagc cctgctgtta aggccaccca 360
gctcaccagg gtccacatgg tctgcctgcg tccgactccg cggtccttgg gccctgatgg 420
ttctacctgc tgtgagctgc ccagtgggaa gtatggctgc tgccaatgcc caacgccacc 480
tgctgctccg atcacctgca ctgctgcccc aagacactgt gtgtgacctg atccagagta 540
agtgcctctc caaggagaac g 561
<210>91
<211>541
<212>DNA
<213> human
<220>
<221>misc_feature
<222>480,491
<223> n ═ A, T, C or G
<400>91
gaatcacctt tctggtttag ctagtacttt gtacagaaca atgaggtttc ccacagcgga 60
gtctccctgg gctctgtttg gctctcggta aggcaggcct acaccttttc ctctcctcta 120
tggagagggg aatatgcatt aaggtgaaaa gtcaccttcc aaaagtgaga aagggattcg 180
attgctgctt caggactgtg gaattatttg gaatgtttta caaatggttg ctacaaaaca 240
acaaaaaagg taattacaaa atgtgtacat cacaacatgc tttttaaaga cattatgcat 300
tgtgctcaca ttcccttaaa tgttgtttcc aaaggtgctc agcctctagc ccagctggat 360
tctccgggaa gaggcagaga cagtttggcg aaaaagacac agggaaggag ggggtggtga 420
aaggagaaag cagccttcca gttaaagatc agccctcagt taaaggtcag cttcccgcan 480
gctggcctca ngcggagtct gggtcagagg gaggagcagc agcagggtgg gactggggcg 540
t 541
<210>92
<211>551
<212>DNA
<213> human
<400>92
aaccggagcg cgagcagtag ctgggtgggc accatggctg ggatcaccac catcgaggcg 60
gtgaagcgca agatccaggt tctgcagcag caggcagatg atgcagagga gcgagctgag 120
cgcctccagc gagaagttga gggagaaagg cgggcccggg aacaggctga ggctgaggtg 180
gcctccttga accgtaggat ccagctggtt gaagaagagc tggaccgtgc tcaggagcgc 240
ctggccactg ccctgcaaaa gctggaagaa gctgaaaaag ctgctgatga gagtgagaga 300
ggtatgaagg ttattgaaaa ccgggcctta aaagatgaag aaaagatgga actccaggaa 360
atccaactca aagaagctaa gcacattgca gaagaggcag ataggaagta tgaagaggtg 420
gctcgtaagt tggtgatcat tgaaggagac ttggaacgca cagaggaacg agctgagctg 480
gcagagtccc gttgccgaga gatggatgag cagattagac tgatggacca gaacctgaag 540
tgtctgagtg c 551
<210>93
<211>531
<212>DNA
<213> human
<400>93
gagaacttgg cctttattgt gggcccagga gggcacaaag gtcaggaggc ccaagggagg 60
gatctggttt tctggatagc caggtcatag catgggtatc agtaggaatc cgctgtagct 120
gcacaggcct cacttgctgc agttccgggg agaacacctg cactgcatgg cgttgatgac 180
ctcgtggtac acgacagagc cattggtgca gtgcaagggc acgcgcatgg gctccgtcct 240
cgagggcagg cagcaggagc attgctcctg cacatcctcg atgtcaatgg agtacacagc 300
tttgctggca cactttccct ggcagtaatg aatgtccact tcctcttggg acttacaatc 360
tcccactttg atgtactgca ccttggctgt gatgtctttg caatcaggct cctcacatgt 420
gtcacagcag gtgcctggaa ttttcacgat tttgcctcct tcagccagac acttgtgttc 480
atcaaatggt gggcagcccg tgaccctctt ctcccagatg tactctcctc t 531
<210>94
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>517
<223> n ═ A, T, C or G
<400>94
gcctggacct tgccggatca gtgccacaca gtgacttgct tggcaaatgg ccagaccttg 60
ctgcagagtc atcgtgtcaa ttgtgaccat ggaccccggc cttcatgtgc caacagccag 120
tctcctgttc gggtggagga gacgtgtggc tgccgctgga cctgcccttg tgtgtgcacg 180
ggcagttcca ctcggcacat cgtcaccttc gatgggcaga atttcaagct tactggtagc 240
tgctcctatg tcatctttca aaacaaggag caggacctgg aagtgctcct ccacaatggg 300
gcctgcagcc ccggggcaaa acaagcctgc atgaagtcca ttgagattaa gcatgctggc 360
gtctctgctg agctgcacag taacatggag atggcagtgg atgggagact ggtccttgcc 420
ccgtacgttg gtgaaaacat ggaagtcagc atctacggcg ctatcatgta tgaagtcagg 480
tttacccatc ttggccacat cctcacatac accgccncaa aacaacgagt t 531
<210>95
<211>605
<212>DNA
<213> human
<400>95
agatcaacct ctgctggtca ggaggaatgc cttccttgtc ttggatcttt gctttgacgt 60
tctcgatagt rwcaactkkr ytsramskma agkgyratgr wmttksywgw rasyktmwwm 120
rsgraraytt agacaycccm cctcwgagac gsagkaccar gtgcagaggt ggactctttc 180
tggatgttgt agtcagacag ggtgcgtcca tcttccagct gtttcccagc aaagatcaac 240
ctctgctgat caggagggat gccttcctta tcttggatct ttgccttgac attctcgatg 300
gtgtcactgg gctccacctc gagggtgatg gtcttaccag tcagggtctt cacgaagaty 360
tgcatcccac ctctgagacg gagcaccagg tgcagggtrg actctttctg gatgttgtag 420
tcagacaggg tgcgyccatc ttccagctgc tttccsagca aagatcaacc tctgctggtc 480
aggaggratg ccttccttgt cytggatctt tgcyttgacr ttctcratgg tgtcactcgg 540
ctccacttcg agagtgatgg tcttaccagt cagggtcttc acgaagatct gcatcccacc 600
tctaa 605
<210>96
<211>531
<212>DNA
<213> human
<400>96
aagtcacaaa cagacaaaga ttattaccag ctgcaagcta tattagaagc tgaacgaaga 60
gacagaggtc atgattctga gatgattgga gaccttcaag ctcgaattac atctttacaa 120
gaggaggtga agcatctcaa acataatctc gaaaaagtgg aaggagaaag aaaagaggct 180
caagacatgc ttaatcactc agaaaaggaa aagaataatt tagagataga tttaaactac 240
aaacttaaat cattacaaca acggttagaa caagaggtaa atgaacacaa agtaaccaaa 300
gctcgtttaa ctgacaaaca tcaatctatt gaagaggcaa agtctgtggc aatgtgtgag 360
atggaaaaaa agctgaaaga agaaagagaa gctcgagaga aggctgaaaa tcgggttgtt 420
cagattgaga aacagtgttc catgctagac gttgatctga agcaatctca gcagaaacta 480
gaacatttga ctggaaataa agaaaggatg gaggatgaag ttaagaatct a 531
<210>97
<211>1017
<212>DNA
<213> human
<220>
<221>misc_feature
<222>963,995,1001,1008,1010
<223> n ═ A, T, C or G
<400>97
cgcctccacc atgtccatca gggtgaccca gaagtcctac aaggtgtcca cctctggccc 60
ccgggccttc agcagccgct cctacacgag tgggcccggt tcccgcatca gctcctcgag 120
cttctcccga gtgggcagca gcaactttcg cggtggcctg ggcggcggct atggtggggc 180
cagcggcatg ggaggcatca ccgcagttac ggtcaaccag agcctgctga gcccccttgt 240
cctggaggtg gaccccaaca tccaggccgt gcgcacccag gagaaggagc agatcaagac 300
cctcaacaac aagtttgcct ccttcataga caaggtacgg ttcctggagc agcagaacaa 360
gatgctggag accaagtgga gcctcctgca gcagcagaag acggctcgaa gcaacatgga 420
caacatgttc gagagctaca tcaacarcct taggcggcag ctggagactc tgggccagga 480
gaagctgaag ctggaggcgg agcttggcaa catgcagggg ctggtggagg acttcaagaa 540
caagtatgag gatgagatca ataagcgtac agagatggag aacgaatttg tcctcatcaa 600
gaaggatgtg gatgaagctt acatgaacaa ggtagagctg gagtctcgcc tggaagggct 660
gaccgacgag atcaacttcc tcaggcagct gtatgaagag gagatccggg agctgcagtc 720
ccagatctcg gacacatctg tggtgctgtc catggacaac agccgctccc tggacatgga 780
cagcatcatt gctgaggtca aggcacagta cgaggatatt gccaaccgca gccgggctga 840
ggctgagagc atgtaccagg tcaagtatga ggagctgcag agcctggctg ggaagcacgg 900
ggatgacctg cggcgcacaa agactgagat ctctgagatg aacccggaac atcagcccgg 960
ctncaggctg agattgaggg cctcaaaggc caganggctt ncctggangn ccgccat 1017
<210>98
<211>561
<212>DNA
<213> human
<400>98
cccggagcca gccaacgagc ggaaaatggc agacaatttt tcgctccatg atgcgttatc 60
tgggtctgga aacccaaacc ctcaaggatg gcctggcgca tgggggaacc agcctgctgg 120
ggcagggggc tacccagggg cttcctatcc tggggcctac cccgggcagg cacccccagg 180
ggcttatcct ggacaggcac ctccaggcgc ctaccctgga gcacctggag cttatcccgg 240
agcacctgca cctggagtct acccagggcc acccagcggc cctggggcct acccatcttc 300
tggacagcca agtgccaccg gagcctaccc tgccactggc ccctatggcg cccctgctgg 360
gccactgatt gtgccttata acctgccttt gcctggggga gtggtgcctc gcatgctgat 420
aacaattctg ggcacggtga agcccaatgc aaacagaatt gctttagatt tccaaagagg 480
gaatgatgtt gccttccact ttaacccacg cttcaatgag aacaacagga gagtcattgg 540
ttgcaataca aagctggata a 561
<210>99
<211>636
<212>DNA
<213> human
<400>99
gggaatgcaa caactttatt gaaaggaaag tgcaatgaaa tttgttgaaa ccttaaaagg 60
ggaaacttag acaccccccc tcragcgmag kaccargtgc araggtggac tctttctgga 120
tgttgtagtc agacagggtr cgwccatctt ccagctgttt yccrgcaaag atcaacctct 180
gctgatcagg aggratgcct tccttatctt ggatctttgc cttgacattc tcgatggtgt 240
cactgggctc cacctcgagg gtgatggtct taccagtcag ggtcttcacg aagatytgca 300
tcccacctct gagacggagc accaggtgca gggtrgactc tttctggatg ttgtagtcag 360
acagggtgcg yccatcttcc agctgctttc csagcaaaga tcaacctctg ctggtcagga 420
ggratgcctt ccttgtcytg gatctttgcy ttgacrttct caatggtgtc actcggctcc 480
acttcgagag tgatggtctt accagtcagg gtcttcacga agatctgcat cccacctcta 540
agacggagca ccaggtgcag ggtggactct ttctggatgg ttgtagtcag acagggtgcg 600
tccatcttcc agctgtttcc cagcaaagat caacct 636
<210>100
<211>697
<212>DNA
<213> human
<400>100
aggttgatct ttgctgggaa acagctggaa gatggacgca ccctgtctga ctacaaccat 60
ccagaaagag tccaccctgc acctggtgct ccgtcttaga ggtgggatgc agatcttcgt 120
gaagaccctg actggtaaga ccatcactct cgaagtggag ccgagtgaca ccattgagaa 180
ygtcaargca aagatccarg acaaggaagg catycctcct gaccagcaga ggttgatctt 240
tgctsggaaa gcagctggaa gatggrcgca ccctgtctga ctacaacatc cagaaagagt 300
cyaccctgca cctggtgctc cgtctcagag gtgggatgca ratcttcgtg aagaccctga 360
ctggtaagac catcaccctc gaggtggagc ccagtgacac catcgagaat gtcaaggcaa 420
agatccaaga taaggaaggc atccctcctg atcagcagag gttgatcttt gctgggaaac 480
agctggaaga tggacgcacc ctgtctgact acaacatcca gaaagagtcc acctytgcac 540
ytggtmctbc gtctyagagg kgggrtgcaa atctwmgtkw agacactcac tkkyaagryy 600
atcamcmwtg akktcgakys castkwcact wtcrakaamg tyrwwgcawa gatccmagac 660
aaggaaggca ttcctcctga ccagcagagg ttgatct 697
<210>101
<211>451
<212>DNA
<213> human
<400>101
atggagtctc actctgtcga ccaggctgga gcgctgtggt gcgatatcgg ctcactgcag 60
tctccacttc ctgggttcaa gcgatcctcc tgcctcagcc tcccgagtag ctgggactac 120
aggcaggcgt caccataatt tttgtatttt tagtagagac atggtttcgc catgttggct 180
gggctggtct cgaactcctg acctcaagtg atctgtcctg gcctcccaaa gtgttgggat 240
tacaggcgaa agccaacgct cccggccagg gaacaacttt agaatgaagg aaatatgcaa 300
aagaacatca catcaaggat caattaatta ccatctatta attactatat gtgggtaatt 360
atgactattt cccaagcatt ctacgttgac tgcttgagaa gatgtttgtc ctgcatggtg 420
gagagtggag aagggccagg attcttaggt t 451
<210>102
<211>571
<212>DNA
<213> human
<400>102
agcgcggtct tccggcgcga gaaagctgaa ggtgatgtgg ccgccctcaa ccgacgcatc 60
cagctcgttg aggaggagtt ggacagggct caggaacgac tggccacggc cctgcagaag 120
ctggaggagg cagaaaaagc tgcagatgag agtgagagag gaatgaaggt gatagaaaac 180
cgggccatga aggatgagga gaagatggag attcaggaga tgcagctcaa agaggccaag 240
cacattgcgg aagaggctga ccgcaaatac gaggaggtag ctcgtaagct ggtcatcctg 300
gagggtgagc tggagagggc agaggagcgt gcggaggtgt ctgaactaaa atgtggtgac 360
ctggaagaag aactcaagaa tgttactaac aatctgaaat ctctggaggc tgcatctgaa 420
aagtattctg aaaaggagga caaatatgaa gaagaaatta aacttctgtc tgacaaactg 480
aaagaggctg agacccgtgc tgaatttgca gagagaacgg ttgcaaaact ggaaaagaca 540
attgatgacc tggaagagaa acttgcccag c 571
<210>103
<211>451
<212>DNA
<213> human
<400>103
gtgcacaggt cccatttatt gtagaaaata ataataatta cagtgatgaa tagctcttct 60
taaattacaa aacagaaacc acaaagaagg aagaggaaaa accccaggac ttccaagggt 120
gaagctgtcc cctcctccct gccaccctcc caggctcatt agtgtccttg gaaggggcag 180
aggactcaga ggggatcagt ctccaggggc cctgggctga agcgggtgag gcagagagtc 240
ctgaggccac agagctgggc aacctgagcc gcctctctgg ccccctcccc caccactgcc 300
caaacctgtt tacagcacct tcgcccctcc cctctaaacc cgtccatcca ctctgcactt 360
cccaggcagg tgggtgggcc aggcctcagc catactcctg ggcgcgggtt tcggtgagca 420
aggcacagtc ccagaggtga tatcaaggcc t 451
<210>104
<211>441
<212>DNA
<213> human
<400>104
gcaaggaact ggtctgctca cacttgctgg cttgcgcatc aggactggct ttatctcctg 60
actcacggtg caaaggtgca ctctgcgaac gttaagtccg tccccagcgc ttggaatcct 120
acggccccca cagccggatc ccctcagcct tccaggtcct caactcccgt ggacgctgaa 180
caatggcctc catggggcta caggtaatgg gcatcgcgct ggccgtcctg ggctggctgg 240
ccgtcatgct gtgctgcgcg ctgcccatgt ggcgcgtgac ggccttcatc ggcagcaaca 300
ttgtcacctc gcagaccatc tgggagggcc tatggatgaa ctgcgtggtg cagagcaccg 360
gccagatgca gtgcaaggtg tacgactcgc tgctggcact gccgcaggac ctgcaggcgg 420
cccgcgccct cgtcatcatc a 441
<210>105
<211>509
<212>DNA
<213> human
<220>
<221>misc_feature
<222>195
<223> n ═ A, T, C or G
<400>105
tgcaaaaggg acacaggggt tcaaaaataa aaatttctct tccccctccc caaacctgta 60
ccccagctcc ccgaccacaa cccccttcct cccccgggga aagcaagaag gagcaggtgt 120
ggcatctgca gctgggaaga gagaggccgg ggaggtgccg agctcggtgc tggtctcttt 180
ccaaatataa atacntgtgt cagaactgga aaatcctcca gcacccacca cccaagcact 240
ctccgttttc tgccggtgtt tggagagggg cggggggcag gggcgccagg caccggctgg 300
ctgcggtcta ctgcatccgc tgggtgtgca ccccgcgagc ctcctgctgc tcattgtaga 360
agagatgaca ctcggggtcc ccccggatgg tgggggctcc ctggatcagc ttcccggtgt 420
tggggttcac acaccagcac tccccacgct gcccgttcag agacatcttg cactgtttga 480
ggttgtacag gccatgcttg tcacagttg 509
<210>106
<211>571
<212>DNA
<213> human
<400>106
gggttggagg gactggttct ttatttcaaa aagacacttg tcaatattca gtatcaaaac 60
agttgcacta ttgatttctc tttctcccaa tcggccccaa agagaccaca taaaaggaga 120
gtacatttta agccaataag ctgcaggatg tacacctaac agacctccta gaaaccttac 180
cagaaaatgg ggactgggta gggaaggaaa cttaaaagat caacaaactg ccagcccacg 240
gactgcagag gctgtcacag ccagatgggg tggccagggt gccacaaacc caaagcaaag 300
tttcaaaata atataaaatt taaaaagttt tgtacataag ctattcaaga tttctccagc 360
actgactgat acaaagcaca attgagatgg cacttctaga gacagcagct tcaaacccag 420
aaaagggtga tgagatgagt ttcacatggc taaatcagtg gcaaaaacac agtcttcttt 480
ctttctttct ttcaaggagg caggaaagca attaagtggt cacctcaaca taagggggac 540
atgatccatt ctgtaagcag ttgtgaaggg g 571
<210>107
<211>555
<212>DNA
<213> human
<400>107
caggaaccgg agcgcgagca gtagctgggt gggcaccatg gctgggatca ccaccatcga 60
ggcggtgaag cgcaagatcc aggttctgca gcagcaggca gatgatgcag aggagcgagc 120
tgagcgcctc cagcgagaag ttgagggaga aaggcgggcc cgggaacagg ctgaggctga 180
ggtggcctcc ttgaaccgta ggatccagct ggttgaagaa gagctggacc gtgctcagga 240
gcgcctggcc actgccctgc aaaagctgga agaagctgaa aaagctgctg atgagagtga 300
gagaggtatg aaggttattg aaaaccgggc cttaaaagat gaagaaaaga tggaactcca 360
ggaaatccaa ctcaaagaag ctaagcacat tgcagaagag gcagatagga agtatgaaga 420
ggtggctcgt aagttggtga tcattgaagg agacttggaa cgcacagagg aacgagctga 480
gctggcagag tcccgttgcc gagagatgga tgagcagatt agactgatgg accagaacct 540
gaagtgtctg agtgc 555
<210>108
<211>541
<212>DNA
<213> human
<400>108
atctacgtca tcaatcaggc tggagacacc atgttcaatc gagctaagct gctcaatatt 60
ggctttcaag aggccttgaa ggactatgat tacaactgct ttgtgttcag tgatgtggac 120
ctcattccga tggacgaccg taatgcctac aggtgttttt cgcagccacg gcacatttct 180
gttgcaatgg acaagttggg gtttagcctg ccatatgttc agtattttgg aggtgtctct 240
gctctcagta aacaacagtt tcttgccatc aatggattcc ctaataatta ttggggttgg 300
ggaggagaag atgacgacat ttttaacaga ttagttcata aaggcatgtc tatatcacgt 360
ccaaatgctg tagtagggag gtgtcgaatg atccggcatt caagagacaa gaaaaatgag 420
cccaatcctc agaggtttga ccggatcgca catacaaagg aaacgatgcg cttcgatggt 480
ttgaactcac ttacctacaa ggtgttggat gtcagagata cccgttatat acccaaatca 540
c 541
<210>109
<211>411
<212>DNA
<213> human
<400>109
ctagacctct aattaaaagg cacaatcatg ctggagaatg aacagtctga ccccgagggc 60
cacagcgaat tttagggaag gaggcaaaga ggtgagaagg gaaaggaaag aaggaaggaa 120
ggagaacaat aagaactgga gacgttgggt gggtcaggga gtgtggtgga ggctcggaga 180
gatggtaaac aaacctgact gctatgagtt ttcaacccca tagtctaggg ccatgagggc 240
gtcagttctt ggtggctgag ggtccttcca cccagcccac ctgggggagt ggagtgggga 300
gttctgccag gtaagcagat gttgtctccc aagttcctga cccagatgtc tggcaggata 360
acgctgacct gttccctcaa caagggacct gaaagtaatt ttgctcttta c 411
<210>110
<211>451
<212>DNA
<213> human
<400>110
ccgaattcaa gcgtcaacga tccytccctt accatcaaat caattggcca ccaatggtac 60
tgaacctacg agtacaccga ctacgggcgg actaatcttc aactcctaca tacttccccc 120
attattccta gaaccaggcg acctgcgact ccttgacgtt gacaatcgag tagtactccc 180
gattgaagcc cccattcgta taataattac atcacaagac gtcttgcact catgagctgt 240
ccccacatta ggcttaaaaa cagatgcaat tcccggacgt ctaagccaaa ccactttcac 300
cgctacacga ccgggggtat actacggtca atgctctgaa atctgtggag caaaccacag 360
tttcatgccc atcgtcctag aattaattcc cctaaaaatc tttgaaatag ggcccgtatt 420
taccctatag caccccctct accccctcta g 451
<210>111
<211>541
<212>DNA
<213> human
<400>111
gctcttcaca cttttattgt taattctctt cacatggcag atacagagct gtcgtcttga 60
agaccaccac tgaccaggaa atgccacttt tacaaaatca tccccccttt tcatgattgg 120
aacagttttc ctgaccgtct gggagcgttg aagggtgacc agcacatttg cacatgcaaa 180
aaaggagtga ccccaaggcc tcaaccacac ttcccagagc tcaccatggg ctgcaggtga 240
cttgccaggt ttggggttcg tgagctttcc ttgctgctgc ggtggggagg ccctcaagaa 300
ctgagaggcc ggggtatgct tcatgagtgt taacatttac gggacaaaag cgcatcatta 360
ggataaggaa cagccacagc acttcatgct tgtgagggtt agctgtagga gcgggtgaaa 420
ggattccagt ttatgaaaat ttaaagcaaa caacggtttt tagctgggtg ggaaacagga 480
aaactgtgat gtcggccaat gaccaccatt tttctgccca tgtgaaggtc cccatgaaac 540
c 541
<210>112
<211>521
<212>DNA
<213> human
<400>112
caagcgcttg gcgtttggac ccagttcagt gaggttcttg ggttttgtgc ctttggggat 60
tttggtttga cccaggggtc agccttagga aggtcttcag gaggaggccg agttcccctt 120
cagtaccacc cctctctccc cactttccct ctcccggcaa catctctggg aatcaacagc 180
atattgacac gttggagccg agcctgaaca tgcccctcgg ccccagcaca tggaaaaccc 240
ccttccttgc ctaaggtgtc tgagtttctg gctcttgagg catttccaga cttgaaattc 300
tcatcagtcc attgctcttg agtctttgca gagaacctca gatcaggtgc acctgggaga 360
aagactttgt ccccacttac agatctatct cctcccttgg gaagggcagg gaatggggac 420
ggtgtatgga ggggaaggga tctcctgcgc ccttcattgc cacacttggt gggaccatga 480
acatctttag tgtctgagct tctcaaatta ctgcaatagg a 521
<210>113
<211>568
<212>DNA
<213> human
<400>113
agcgtcaaat cagaatggaa aagactcaaa accatcatca acaccaagat caaaaggaca 60
agratccttc aagaaacagg aaaaaactcc taaaacacca aaaggaccta gttctgtaga 120
agacattaaa gcaaaaatgc aagcaagtat agaaaaaggt ggttctcttc ccaaagtgga 180
agccaaattc atcaattatg tgaagaattg cttccggatg actgaccaag aggctattca 240
agatctctgg cagtggagga agtctcttta agaaaatagt ttaaacaatt tgttaaaaaa 300
ttttccgtct tatttcattt ctgtaacagt tgatatctgg ctgtcctttt tataatgcag 360
agtgagaact ttccctaccg tgtttgataa atgttgtcca ggttctattg ccaagaatgt 420
gttgtccaaa atgcctgttt agtttttaaa gatggaactc caccctttgc ttggttttaa 480
gtatgtatgg aatgttatga taggacatag tagtagcggt ggtcagacat ggaaatggtg 540
ggsmgacaaa aatatacatg tgaaataa 568
<210>114
<211>483
<212>DNA
<213> human
<400>114
tccgaattcc aagcgaatta tggacaaacg attcctttta gaggattact tttttcaatt 60
tcggttttag taatctaggc tttgcctgta aagaatacaa cgatggattt taaatactgt 120
ttgtggaatg tgtttaaagg attgattcta gaacctttgt atatttgata gtatttctaa 180
ctttcatttc tttactgttt gcagttaatg ttcatgttct gctatgcaat cgtttatatg 240
cacgtttctt taattttttt agattttcct ggatgtatag tttaaacaac aaaaagtcta 300
tttaaaactg tagcagtagt ttacagttct agcaaagagg aaagttgtgg ggttaaactt 360
tgtattttct ttcttataga ggcttctaaa aaggtatttt tatatgttct ttttaacaaa 420
tattgtgtac aacctttaaa acatcaatgt ttggatcaaa acaagaccca gcttattttc 480
tgc 483
<210>115
<211>521
<212>DNA
<213> human
<400>115
tgtggtggcg cgggctgagg tggaggccca ggactctgac cctgcccctg ccttcagcaa 60
ggcccccggc agcgccggcc actacgaact gccgtgggtt gaaaaatata ggccagtaaa 120
gctgaatgaa attgtcggga atgaagacac cgtgagcagg ctagaggtct ttgcaaggga 180
aggaaatgtg cccaacatca tcattgcggg ccctccagga accggcaaga ccacaagcat 240
tctgtgcttg gcccgggccc tgctgggccc agcactcaaa gatgccatgt tggaactcaa 300
tgcttcaaat gacaggggca ttgacgttgt gaggaataaa attaaaatgt ttgctcaaca 360
aaaagtcact cttcccaaag gccgacataa gatcatcatt ctggatgaag cagacagcat 420
gaccgacgga gcccagcaag ccttgaggag aaccatggaa atctactcta aaaccactcg 480
ttcgcccttg cttgtaatgc ttcggataag atcatcgagc c 521
<210>116
<211>501
<212>DNA
<213> human
<400>116
ctttgcaaag cttttatttc atgtctgcgg catggaatcc acctgcacat ggcatcttag 60
ctgtgaagga gaaagcagtg cacgagaagg aatgagtggg cggaaccaac ggcctccaca 120
agctgccttc cagcagcctg ccaaggccat ggcagagaga gactgcaaac aaacacaagc 180
aaacagagtc tcttcacagc tggagtctga aagctcatag tggcatgtgt gaatctgaca 240
aaattaaaag tgtgcatagt ccattacatg cataaaacac taataataat cctgtttaca 300
cgtgactgca gcaggcaggt ccagctccac cactgccctc ctgccacatc acatcaagtg 360
ccatggttta gagggttttt catatgtaat tcttttattc tgtaaaaggt aacaaaatat 420
acagaacaaa actttccctt tttaaaacta atgttacaaa tctgtattat cacttggata 480
taaatagtat ataagctgat c 501
<210>117
<211>451
<212>DNA
<213> human
<220>
<221>misc_feature
<222>320
<223> n ═ A, T, C or G
<400>117
caagggatat atgttgaggg tacrgrgtga cactgaacag atcacaaagc acgagaaaca 60
ttagttctct ccctccccag cgtctccttc gtctccctgg ttttccgatg tccacagagt 120
gagattgtcc ctaagtaact gcatgatcag agtgctgkct ttataagact cttcattcag 180
cgtatccaat tcagcaattg cttcatcaaa tgccgttttt gccaggctac aggccttttc 240
aggagagttt agaatctcat agtaaaagac tgagaaattt agtgccagac caagacgaat 300
tgggtgtgta ggctgcattn ctttcttact aatttcaaat gcttcctggt aagcctgctg 360
ggagttcgac acaagtggtt tgtttgttgc tccagatgcc acttcagaaa gatacctaaa 420
ataatctcct ttcattttca aagtagaaca c 451
<210>118
<211>501
<212>DNA
<213> human
<400>118
tccggagccg gggtagtcgc cgccgccgcc gccggtgcag ccactgcagg caccgctgcc 60
gccgcctgag tagtgggctt aggaaggaag aggtcatctc gctcggagct tcgctcggaa 120
gggtctttgt tccctgcagc cctcccacgg gaatgacaat ggataaaagt gagctggtac 180
agaaagccaa actcgctgag caggctgagc gatatgatga tatggctgca gccatgaagg 240
cagtcacaga acaggggcat gaactctcca acgaagagag aaatctgctc tctgttgcct 300
acaagaatgt ggtaaggccg cccgccgctc ttcctggcgt gtcatctcca gcattgagca 360
gaaaacagag aggaatgaga agaagcagca gatgggcaaa gagtaccgtg agaagataga 420
ggcagaactg caggacatct gcaatgatgt tctggagctt gttggacaaa tatcttattc 480
caatgctaca caacccagaa a 501
<210>119
<211>391
<212>DNA
<213> human
<400>119
aaaaagcagc argttcaaca caaaatagaa atctcaaatg taggatagaa caaaaccaag 60
tgtgtgaggg gggaagcaac agcaaaagga agaaatgaga tgttgcaaaa aagatggagg 120
agggttcccc tctcctctgg ggactgactc aaacactgat gtggcagtat acaccattcc 180
agagtcaggg gtgttcattc ttttttggga gtaagaaaag gtggggatta agaagacgtt 240
tctggaggct tagggaccaa ggctggtctc tttcccccct cccaaccccc ttgatccctt 300
tctctgatca ggggaaagga gctcgaatga gggaggtaga gttggaaagg gaaaggattc 360
cacttgacag aatgggacag actccttccc a 391
<210>120
<211>421
<212>DNA
<213> human
<220>
<221>misc_feature
<222>409
<223> n ═ A, T, C or G
<400>120
tggcaatagc acagccatcc aggagctctt cargcgcatc tcggagcagt tcactgccat 60
gttccgccgg aaggccttcc tccactggta cacaggcgag ggcatggacg agatggagtt 120
caccgaggct gagagcaaca tgaacgacct cgtctctgag tatcaagcag taccaggatg 180
ccaccgcaga agaggaggag gatttcggtg aggaggccga agaggaggcc taaggcagag 240
cccccatcac ctcaggcttc tcagttccct tagccgtctt actcaactgc ccctttcctc 300
tccctcagaa tttgtgtttg ctgcctctat cttgtttttt gttttttctt ctgggggggt 360
ctagaacagt gcctggcaca tagtaggcgc tcaataaata cttggttgnt gaatgtctcc 420
t 421
<210>121
<211>206
<212>DNA
<213> human
<400>121
agctggcgct agggctcggt tgtgaaatac agcgtrgtca gcccttgcgc tcagtgtaga 60
aacccacgcc tgtaaggtcg gtcttcgtcc atctgctttt ttctgaaata cactaagagc 120
agccacaaaa ctgtaacctc aaggaaacca taaagcttgg agtgccttaa tttttaacca 180
gtttccaata aaacggttta ctacct 206
<210>122
<211>131
<212>DNA
<213> human
<400>122
ggagatgaag atgaggaagc tgagtcagct acgggcargc gggcagctga agatgatgag 60
gatgacgatg tcgataccaa gaagcagaag accgacgagg atgactagac agcaaaaaag 120
gaaaagttaa a 131
<210>123
<211>231
<212>DNA
<213> human
<220>
<221>misc_feature
<222>166,202,222,225
<223> n ═ A, T, C or G
<400>123
gatgaaaatt aaatacttaa attaatcaaa aggcactacg ataccaccta aaacctactg 60
cctcagtggc agtakgctaa kgaagatcaa gctacagsac atyatctaat atgaatgtta 120
gcaattacat akcargaagc atgtttgctt tccagaagac tatggnacaa tggtcattwg 180
ggcccaagag gatatttggc cnggaaagga tcaagataga tnaangtaaa g 231
<210>124
<211>521
<212>DNA
<213> human
<220>
<221>misc_feature
<222>284,412,513
<223> n ═ A, T, C or G
<400>124
gagtagcaac gcaaagcgct tggtattgag tctgtgggsg acttcggttc cggtctctgc 60
agcagccgtg atcgcttagt ggagtgctta gggtagttgg ccaggatgcc gaatatcaaa 120
atcttcagca ggcagctccc accaggactt atctcasaaa attgctgacc gcctgggcct 180
ggagctaggc aaggtggtga ctaagaaatt cagcaaccag gagacctgtg tggaaattgg 240
tgaaagtgta ccgtggagag gatgtctaca ttgttcagag tggntgtggc gaaatcaatg 300
acaatttaat ggagcttttg atcatgatta atgcctgcaa gattgcttca gccagccggg 360
ttactgcagt catcccatgc ttcccttatg ccccggcagg ataagaaaga tnagagccgg 420
gccgccaatc tcagccaagc ttggtgcaaa tatgctatct gtagcagtgc agatcatatt 480
atcaccatgg acctacatgc ttctcaaatt canggctttt t 521
<210>125
<211>341
<212>DNA
<213> human
<220>
<221>misc_feature
<222>277
<223> n ═ A, T, C or G
<400>125
atgcaaaagg ggacacaggg ggttcaaaaa taaaaatttc tcttccccct ccccaaacct 60
gtaccccagc tccccgacca caaccccctt cctcccccgg ggaaagcaag aaggagcagg 120
tgtggcatct gcagctggga agagagaggc cggggaggtg ccgagctcgg tgctggtctc 180
tttccaaata taaatacgtg tgtcagaact ggaaaatcct ccagcaccca ccacccaagc 240
actctccgtt ttctgccggt gtttggagag gggcggnggg caggggcgcc aggcaccggc 300
tggctgcggt ctactgcatc cgctgggtgt gcaccccgcg a 341
<210>126
<211>521
<212>DNA
<213> human
<220>
<221>misc_feature
<222>353,399,455
<223> n ═ A, T, C or G
<400>126
aggttggaga aggtcatgca ggtgcagatt gtccaggskc agccacaggg tcaagcccaa 60
caggcccaga gtggcactgg acagaccatg caggtgatgc agcagatcat cactaacaca 120
ggagagatcc agcagatccc ggtgcagctg aatgccggcc agctgcagta tatccgctta 180
gcccagcctg tatcaggcac tcaagttgtg cagggacaga tccagacact tgccaccaat 240
gctcaacaga ttacacagac agaggtccag caaggacagc agcagttcaa gccagttcac 300
aagatggaca gcagctctac cagatccagc aagtcaccat gcctgcgggc cangacctcg 360
ccagcccatg ttcatccagt caagccaacc agcccttcna cgggcaggcc ccccaggtga 420
ccggcgactg aagggcctga gctggcaagg ccaangacac ccaacacaat ttttgccata 480
cagcccccag gcaatgggca cagcctttct tcccagagga c 521
<210>127
<211>351
<212>DNA
<213> human
<400>127
tgagatttat tgcatttcat gcagcttgaa gtccatgcaa aggrgactag cacagttttt 60
aatgcattta aaaaataaaa gggaggtggg cagcaaacac acaaagtcct agtttcctgg 120
gtccctggga gaaaagagtg tggcaatgaa tccacccact ctccacaggg aataaatctg 180
tctcttaaat gcaaagaatg tttccatggc ctctggatgc aaatacacag agctctgggg 240
tcagagcaag ggatggggag aggaccacga gtgaaaaagc agctacacac attcacctaa 300
ttccatctga gggcaagaac aacgtggcaa gtcttggggg tagcagctgt t 351
<210>128
<211>521
<212>DNA
<213> human
<400>128
tccagacatg ctcctgtcct aggcggggag caggaaccag acctgctatg ggaagcagaa 60
agagttaagg gaaggtttcc tttcattcct gttccttctc ttttgctttt gaacagtttt 120
taaatatact aatagctaag tcatttgcca gccaggtccc ggtgaacagt agagaacaag 180
gagcttgcta agaattaatt ttgctgtttt tcaccccatt caaacagagc tgccctgttc 240
cctgatggag ttccattcct gccagggcac ggctgagtaa cacgaagcca ttcaagaaag 300
gcgggtgtga aatcactgcc accccatgga cagacccctc actcttcctt cttagccgca 360
gcgctactta ataaatatat ttatactttg aaattatgat aaccgatttt tcccatgcgg 420
catcctaagg gcacttgcca gctcttatcc ggacagtcaa gcactgttgt tggacaacag 480
ataaaggaaa agaaaaagaa gaaaacaacc gcaacttctg t 521
<210>129
<211>521
<212>DNA
<213> human
<400>129
tgagacggac cactggcctg gtcccccctc atktgctgtc gtaggacctg acatgaaacg 60
cagatctagt ggcagagagg aagatgatga ggaacttctg agacgtcggc agcttcaaga 120
agagcaatta atgaagctta actcaggcct gggacagttg atcttgaaag aagagatgga 180
gaaagagagc cgggaaaggt catctctgtt agccagtcgc tacgattctc ccatcaactc 240
agcttcacat attccatcat ctaaaactgc atctctccct ggctatggaa gaaatgggct 300
tcaccggcct gtttctaccg acttcgctca gtataacagc tatggggatg tcagcggggg 360
agtgcgagat taccagacac ttccagatgg ccacatgcct gcaatgagaa tggaccgagg 420
agtgtctatg cccaacatgt tggaaccaaa gatatttcca tatgaaatgc tcatggtgac 480
caacagaggg ccgaaaccaa atctcagaga ggtggacaga a 521
<210>130
<211>270
<212>DNA
<213> human
<400>130
tcactttatt tttcttgtat aaaaacccta tgttgtagcc acagctggag cctgagtccg 60
ctgcacggag actctggtgt gggtcttgac gaggtggtca gtgaactcct gatagggaga 120
cttggtgaat acagtctcct tccagaggtc gggggtcagg tagctgtagg tcttagaaat 180
ggcatcaaag gtggccttgg cgaagttgcc cagggtggca gtgcagcccc gggctgaggt 240
gtagcagtca tcgataccag ccatcatgag 270
<210>131
<211>341
<212>DNA
<213> human
<400>131
ctggaatata gacccgtgat cgacaaaact ttgaacgagg ctgactgtgc caccgtcccg 60
ccagccattc gctcctactg atgagacaag atgtggtgat gacagaatca gcttttgtaa 120
ttatgtataa tagctcatgc atgtgtccat gtcataactg tcttcatacg cttctgcact 180
ctggggaaga aggagtacat tgaagggaga ttggcaccta gtggctggga gcttgccagg 240
aacccagtgg ccagggagcg tggcacttac ctttgtccct tgcttcattc ttgtgagatg 300
ataaaactgg gcacagctct taaataaaat ataaatgaac a 341
<210>132
<211>844
<212>DNA
<213> human
<220>
<221>misc_feature
<222>37
<223> n ═ A, T, C or G
<400>132
tgaatgggga ggagctgacc caggaaatgg agcttgngga gaccaggcct gcaggggatg 60
gaaccttcca gaagtgggca tctgtggtgg tgcctcttgg gaaggagcag aagtacacat 120
gccatgtgga acatgagggg ctgcctgagc ccctcaccct gagatggggc aaggaggagc 180
ctccttcatc caccaagact aacacagtaa tcattgctgt tccggttgtc cttggagctg 240
tggtcatcct tggagctgtg atggcttttg tgatgaagag gaggagaaac acaggtggaa 300
aaggagggga ctatgctctg gctccaggct cccagagctc tgatatgtct ctcccagatt 360
gtaaagtgtg aagacagctg cctggtgtgg acttggtgac agacaatgtc ttcacacatc 420
tcctgtgaca tccagagacc tcagttctct ttagtcaagt gtctgatgtt ccctgtgagt 480
ctgcgggctc aaagtgaaga actgtggagc ccagtccacc cctgcacacc aggaccctat 540
ccctgcactg ccctgtgttc ccttccacag ccaaccttgc tgctccagcc aaacattggt 600
ggacatctgc agcctgtcag ctccatgcta ccctgacctt caactcctca cttccacact 660
gagaataata atttgaatgt gggtggctgg agagatggct cagcgctgac tgctcttcca 720
aaggtcctga gttcaaatcc cagcaaccac atggtggctc acaaccatct gtaatgggat 780
ctaataccct cttctgcagt gtctgaagac asctacagtg tacttacata taataataaa 840
taag 844
<210>133
<211>601
<212>DNA
<213> human
<400>133
ggccgggcgc gcgcgccccc gccacacgca cgccgggcgt gccagtttat aaagggagag 60
agcaagcagc gagtcttgaa gctctgtttg gtgctttgga tccatttcca tcggtcctta 120
cagccgctcg tcagactcca gcagccaaga tggtgaagca gatcgagagc aagactgctt 180
ttcaggaagc cttggacgct gcaggtgata aacttgtagt agttgacttc tcagccacgt 240
ggtgtgggcc ttgcaaaatg atcaagcctt tctttcattc cctctctgaa aagtattcca 300
acgtgatatt ccttgaagta gatgtggatg actgtcagga tgttgcttca gagtgtgaag 360
tcaaatgcat gccaacattc cagtttttta agaagggaca aaaggtgggt gaattttctg 420
gagccaataa ggaaaagctt gaagccacca ttaatgaatt agtctaatca tgttttctga 480
aaatataacc agccattggc tatttaaaac ttgtaatttt tttaatttac aaaaatataa 540
aatatgaaga cataaacccm gttgccatct gcgtgacaat aaaacattaa tgctaacact 600
t 601
<210>134
<211>421
<212>DNA
<213> human
<400>134
tcacataaga aatttaagca agttacrcta tcttaaaaaa cacaacgaat gcattttaat 60
agagaaaccc ttccctccct ccacctccct cccccaccct cctcatgaat taagaatcta 120
agagaagaag taaccataaa accaagtttt gtggaatcca tcatccagag tgcttacatg 180
gtgattaggt taatattgcc ttcttacaaa atttctattt taaaaaaaat tataaccttg 240
attgcttatt acaaaaaaat tcagtacaaa agttcaatat attgaaaaat gcttttcccc 300
tccctcacag caccgtttta tatatagcag agaataatga agagattgct agtctagatg 360
gggcaatctt caaattacac caagacgcac agtggtttat ttaccctccc cttctcataa 420
g 421
<210>135
<211>511
<212>DNA
<213> human
<400>135
ggaaaggatt caagaattag aggacttgct tgctrragaa aaagacaact ctcgtcgcat 60
gctgacagac aaagagagag agatggcgga aataagggat caaatgcagc aacagctgaa 120
tgactatgaa cagcttcttg atgtaaagtt agccctggac atggaaatca gtgcttacag 180
gaaactctta gaaggcgaag aagagaggtt gaagctgtct ccaagccctt cttcccgtgt 240
gacagtatcc cgagcatcct caagtcgtag tgtaccgtac aactagagga aagcggaaga 300
gggttgatgt ggaagaatca gaggcgaagt agtagtgtta gcatctctca ttccgcctca 360
accactggaa atgtttgcat cgaagaaatt gatgttgatg ggaaatttat cccgcttgaa 420
gaacacttct gaacaggatc aaccaatggg aaggcttggg agatgatcag aaaaattgga 480
gacacatcag tcagttataa atatacctca a 511
<210>136
<211>341
<212>DNA
<213> human
<400>136
catgggtttc accaggttgg ccaggctgct cttgaactsc tgacctcagg tgatccaccc 60
gcctcggcct cccaaagtgc tgggattaca ggcgtgagcc accacgcccg gcccccaaag 120
ctgtttcttt tgtctttagc gtaaagctct cctgccatgc agtatctaca taactgacgt 180
gactgccagc aagctcagtc actccgtggt ctttttctct ttccagttct tctctctctc 240
ttcaagttct gcctcagtga aagctgcagg tccccagtta agtgatcagg tgagggttct 300
ttgaacctgg ttctatcagt cgaattaatc cttcatgatg g 341
<210>137
<211>551
<212>DNA
<213> human
<400>137
gatgtgttgg accctctgtg tcaaaaaaaa cctcacaaag aatcccctgc tcattacaga 60
agaagatgca tttaaaatat gggttatttt caacttttta tctgaggaca agtatccatt 120
aattattgtg tcagaagaga ttgaatacct gcttaagaag cttacagaag ctatgggagg 180
aggttggcag caagaacaat ttgaacatta taaaatcaac tttgatgaca gtaaaaatgg 240
cctttctgca tgggaactta ttgagcttat tggaaatgga cagtttagca aaggcatgga 300
ccggcagact gtgtctatgg caattaatga agtctttaat gaacttatat tagatgtgtt 360
aaagcagggt tacatgatga aaaagggcca cagacggaaa aactggactg aaagatggtt 420
tgtactaaaa cccaacataa tttcttacta tgtgagtgag gatctgaagg ataagaaagg 480
agacattctc ttggatgaaa attgctgtgt agaagtcctt gcctgacaaa agatggaaag 540
aaatgccttt t 551
<210>138
<211>531
<212>DNA
<213> human
<220>
<221>misc_feature
<222>490
<223> n ═ A, T, C or G
<400>138
gactggttct ttatttcaaa aagacacttg tcaatattca gtrtcaaaac agttgcacta 60
ttgatttctc tttctcccaa tcggccccaa agagaccaca taaaaggaga gtacatttta 120
agccaataag ctgcaggatg tacacctaac agacctccta gaaaccttac cagaaaatgg 180
ggactgggta gggaaggaaa cttaaaagat caacaaactg ccagcccacg gactgcagag 240
gctgtcacag ccagatgggg tggccagggt gccacaaacc caaagcaaag tttcaaaata 300
atataaaatt taaaaagttt tgtacataag ctattcaaga tttctccagc actgactgat 360
acaaagcaca attgagatgg cacttctaga gacagcagct tcaaacccag aaaagggtga 420
tgagatgaag tttcacatgg ctaaatcagt ggcaaaaaca cagtcttctt tctttctttc 480
tttcaaggan gcaggaaagc aattaagtgg tcaccttaac ataaggggga c 531
<210>139
<211>521
<212>DNA
<213> human
<220>
<221>misc_feature
<222>517
<223> n ═ A, T, C or G
<400>139
tgggtgggca ccatggctgg gatcaccacc atcgaggcgg tgaagcgcaa gatccaggtt 60
ctgcagcagc aggcagatga tgcagaggag cgagctgagc gcctccagcg agaagttgag 120
ggagaaaggc gggcccggga acaggctgag gctgaggtgg cctccttgaa ccgtaggatc 180
cagctggttg aagaagagct ggaccgtgct caggagcgcc tggccactgc cctgcaaaag 240
ctggaagaag ctgaaaaagc tgctgatgag agtgagagag gtatgaaggt tattgaaaac 300
cgggccttaa aagatgaaga aaagatggaa ctccaggaaa tccaactcaa agaagctaag 360
cacattgcag aagaggcaga taggaagtat gaagaggtgg ctcgtaagtt ggtgatcatt 420
gaaggagact tggaaccgca cagaaggaac gagcttgagc ttggcaaaag tcccgttgcc 480
cagagatggg atgaaccaga ttagactgat ggaccanaac c 521
<210>140
<211>571
<212>DNA
<213> human
<220>
<221>misc_feature
<222>7
<223> n ═ A, T, C or G
<400>140
aggggcngcg ggtgcgtggg ccactgggtg accgacttag cctggccaga ctctcagcac 60
ctggaagcgc cccgagagtg acagcgtgag gctgggaggg aggacttggc ttgagcttgt 120
taaactctgc tctgagcctc cttgtcgcct gcatttagat ggctcccgca aagaagggtg 180
gcgagaagaa aaagggccgt tctgccatca acgaagtggt aacccgagaa tacaccatca 240
acattcacaa gcgcatccat ggagtgggct tcaagaagcg tgcacctcgg gcactcaaag 300
agattcggaa atttgccatg aaggagatgg gaactccaga tgtgcgcatt gacaccaggc 360
tcaacaaagc tgtctgggcc aaaggaataa ggaatgtgcc ataccgaatc cggtgtgcgg 420
ctgtccagaa aacgtaatga ggatgaagat tcaccaaata agctatatac tttggttacc 480
tatgtacctg ttaccacttt caaaaatcta cagacagtca atgtggatga gaactaatcg 540
ctgatcgtca gatcaaataa agttataaaa t 571
<210>141
<211>531
<212>DNA
<213> human
<400>141
tcgggagcca cacttggccc tcttcctctc caaagsgcca gaacctcctt ctctttggag 60
aatggggagg cctcttggag acacagaggg tttcaccttg gatgacctct agagaaattg 120
cccaagaagc ccaccttctg gtcccaacct gcagacccca cagcagtcag ttggtcaggc 180
cctgctgtag aaggtcactt ggctccattg cctgcttcca accaatgggc aggagagaag 240
gcctttattt ctcgcccacc cattcctcct gtaccagcac ctccgttttc agtcagtgtt 300
gtccagcaac ggtaccgttt acacagtcac ctcagacaca ccatttcacc tcccttgcca 360
agctgttagc cttagagtga ttgcagtgaa cactgtttac acaccgtgaa tccattccca 420
tcagtccatt ccagttggca ccagcctgaa ccatttggta cctggtgtta actggagtcc 480
tgtttacaag gtggagtcgg ggcttgctga cttctcttca tttgagggca c 531
<210>142
<211>491
<212>DNA
<213> human
<220>
<221>misc_feature
<222>410
<223> n ═ A, T, C or G
<400>142
acctagacag aaggtgggtg agggaggact ggtaggaggc tgaggcaatt ccttggtagt 60
ttgtcctgaa accctactgg agaagtcagc atgaggcacc tactgagaga agtgcccaga 120
aactgctgac tgcatctgtt aagagttaac agtaaagagg tagaagtgtg tttctgaatc 180
agagtggaag cgtctcaagg gtcccacagt ggaggtccct gagctacctc ccttccgtga 240
gtgggaagag tgaagcccat gaagaactga gatgaagcaa ggatggggtt cctgggctcc 300
aggcaagggc tgtgctctct gcagcaggga gccccacgag tcagaagaaa agaactaatc 360
atttgttgca agaaaccttg cccggatact agcggaaaac tggaggcggn ggtgggggca 420
caggaaagtg gaagtgattt gatggagagc agagaagcct atgcacagtg gccgagtcca 480
cttgtaaagt g 491
<210>143
<211>515
<212>DNA
<213> human
<400>143
ttcaagcaat tgtaacaagt atatgtagat tagagtgagc aaaatcatat acaattttca 60
tttccagttg ctattttcca aattgttctg taatgtcgtt aaaattactt aaaaattaac 120
aaagccaaaa attatattta tgacaagaaa gccatcccta cattaatctt acttttccac 180
tcaccggccc atctccttcc tctttttcct aactatgcca ttaaaactgt tctactgggc 240
cgggcgtgtg gctcatgcct gtaatcccag cattttggga ggccaaggca ggcggatcat 300
gaggtcaaga gattgagacc atcctggcca acatggtgaa accccgcctc gactaagaat 360
acaaaaatta gctgggcatg gtggcgcatg cctgtagtct cagctactcg ggaggctgag 420
gcagaagaat cgcttgaacc cgggaggcag aggatgcagt gagccccgat cgcgccactg 480
cactctagcc tgggcgacag actgagactc tgctc 515
<210>144
<211>340
<212>DNA
<213> human
<400>144
tgtgccagtc tacaggccta tcagcagcga ctccttcagc aacagatggg gtcccctgtt 60
cagcccaacc ccatgagccc ccagcagcat atgctcccaa atcaggccca gtccccacac 120
ctacaaggcc agcagatccc taattctctc tccaatcaag tgcgctctcc ccagcctgtc 180
ccttctccac ggccacagtc ccagcccccc cactccagtc cttccccaag gatgcagcct 240
cagccttctc cacaccacgt ttccccacag acaagttccc cacatcctgg actggtagtt 300
gcccaggcca accccatgga acaagggcat tttgccagcc 340
<210>145
<211>630
<212>DNA
<213> human
<400>145
tgtaaaaact tgtttttaat tttgtataaa ataaaggtgg tccatgccca cgggggctgt 60
aggaaatcca agcagaccag ctggggtggg gggatgtagc ctacctcggg ggactgtctg 120
tcctcaaaac gggctgagaa ggcccgtcag gggcccaggt cccacagaga ggcctgggat 180
actcccccaa cccgaggggc agactgggca gtggggagcc cccatcgtgc cccagaggtg 240
gccacaggct gaaggagggg cctgaggcac cgcagcctgc aacccccagg gctgcagtcc 300
actaactttt tacagaataa aaggaacatg gggatgggga aaaaagcacc aggtcaggca 360
gggcccgagg gccccagatc ccaggagggc caggactcag gatgccagca ccaccctagc 420
agctcccaca gctcctggca caggaggccg ccacggattg gcacaggccg ctgctggcca 480
tcacgccaca tttggagaac ttgtcccgac agaggtcagc tcggaggagc tcctcgtggg 540
cacacactgt acgaacacag atctccttgt taatgacgta cacacggcgg aggctgcggg 600
gacagggcac gggaggtctc agccccactt 630
<210>146
<211>521
<212>DNA
<213> human
<400>146
atggctgctg gatttaggtg gtaatagggg ctgtgggcca taaatctgaa gccttgagaa 60
ccttgggtct ggagagccat gaagagggaa ggaaaagagg gcaagtcctg aacctaacca 120
atgacctgat ggattgctcg accaagacac agaagtgaag tctgtgtctg tgcacttccc 180
acagactgga gtttttggtg ctgaatagag ccagttgcta aaaaattggg ggtttggtga 240
agaaatctga ttgttgtgtg tattcaatgt gtgattttaa aaataaacag caacaacaat 300
aaaaaccctg actggctgtt ttttccctgt attctttaca actatttttt gaccctctga 360
aaattattat acttcaccta aatggaagac tgctgtgttt gtggaaattt tgtaattttt 420
taatttattt tattctctct cctttttatt ttgcctgcag aatccgttga gagactaata 480
aggcttaata tttaattgat ttgtttaata tgtatataaa t 521
<210>147
<211>562
<212>DNA
<213> human
<400>147
ggcatgcgag cgcactcggc ggacgcaagg gcggcgggga gcacacggag cactgcaggc 60
gccgggttgg gacagcgtct tcgctgctgc tggatagtcg tgttttcggg gatcgaggat 120
actcaccaga aaccgaaaat gccgaaacca atcaatgtcc gagttaccac catggatgca 180
gagctggagt ttgcaatcca gccaaataca actggaaaac agctttttga tcaggtggta 240
aagactatcg gcctccggga agtgtggtac tttggcctcc actatgtgga taataaagga 300
tttcctacct ggctgaagct ggataagaag gtgtctgccc aggaggtcag gaaggagaat 360
cccctccagt tcaagttccg ggccaaagtt ctaccctgaa gatgtggctg aggagctcat 420
ccaggacatc acccagaaac ttttcttcct tcaagtgaag gaaggaatcc ttagcgatga 480
gatctactgc cccccttgar actgccgtgc tcttggggtc ctacgcttgt gcatgccaag 540
tttggggact accaccaaga ag 562
<210>148
<211>820
<212>DNA
<213> human
<400>148
gaaggagtcg ggatactcag cattgatgca ccccaatttc aaagcggcat tcttcggcag 60
gtctctggga caatctctag ggtcactacc tggaaactcg ttagggtaca actgaatgct 120
gaaaggaaag aacacctgca gaaccggaca gaaattcacc ccggcgatca gctgattgat 180
ctcggtcgac cagaagtcat ggctaaagat gacgaggacg ttgtcaattc cctgggcttt 240
tcgaagtgag tccagcagca gtctgaggta ttcgggccgg ttatgcacct ggaccaccag 300
caccagctcc cggggggccc aggtgccagc cttatctaca ttcctcaggg tctgatcaaa 360
gttcagctgg tacaccaggg accggtaccg cagcgtcagg ttgtccgctc gggctggggg 420
accgccggga ccagggaagc cgccgacacg ttggagaccc tgcggatgcc cacagccaca 480
gaggggtggt ccccaccgcg gccgccggca ccccgcgcgg gttcggcgtc cagcaacggt 540
ggggcgaggg cctcgttctt cctttgtcgc ccattgctgc tccagaggac gaagccgcag 600
gcggccacca cgagcgtcag gattagcacc ttccgtttgt agatgcggaa cctcatggtc 660
tccagggccg ggagcgcagc tacagctcga gcgtcggcgc cgccgctagg agccgcggct 720
cggcttcgtc tccgtcctct ccattcagca ccacgggtcc cggaaaaagc tcagccscgg 780
tcccaaccgc accctagctt cgttacctgc gcctcgcttg 820
<210>149
<211>501
<212>DNA
<213> human
<400>149
cagattttta tttgcagtcg tcactggggc cgtttcttgc tgcttatttg tctgctagcc 60
tgctcttcca gctgcatggc caggcgcaag gccttgatga catctcgcag ggctgagaaa 120
tgcttggctt gctgggccag agcagattcc gctttgttca caaaggtctc caggtcatag 180
tctggctgct cggtcatctc agagagctca agccagtctg gtccttgctg tatgatctcc 240
ttgagctctt ccatagcctt ctcctccagc tccctgatct gagtcatggc ttcgttaaag 300
ctggacatct gggaagacag ttcctcctct tccttggata aattgcctgg aatcagcgcc 360
ccgttagagc aggcttccat ctcttctgtt tccatttgaa tcaactgctc tccactgggc 420
ccactgtggg ggctcagctc cttgaccctg ctgcatatct taagggtgtt taaaggatat 480
tcacaggagc ttatgcctgg t 501
<210>150
<211>511
<212>DNA
<213> human
<220>
<221>misc_feature
<222>457,479
<223> n ═ A, T, C or G
<400>150
ctcctcttgg tacatgaacc caagttgaaa gtggacttaa caaagtatct ggagaaccaa 60
gcattctgct ttgactttgc atttgatgaa acagcttcga atgaagttgt ctacaggttc 120
acagcaaggc cactggtaca gacaatcttt gaaggtggaa aagcaacttg ttttgcatat 180
ggccagacag gaagtggcaa gacacatact atgggcggag acctctctgg gaaagcccag 240
aatgcatcca aagggatcta tgccatggcc ttccgggacg tcttcttctg aagaatcaac 300
cctgctaccg gaagttgggc ctggaagtct atgtgacatt cttcgagatc tacaatggga 360
agctgtttga cctgctcaac aagaaggcca agcttgcgcg tgctggaaga cggcaagcaa 420
caggtgcaag tggtgggggc ttgcaggaac atctggntaa ctctgcttga tgatggcant 480
caagatgatc gacatgggca gcgcctgcag a 511
<210>151
<211>566
<212>DNA
<213> human
<400>151
tcccgaattc aagcgacaaa ttggawagtg aaatggaaga tgcctatcat gaacatcagg 60
caaatctttt gcgccaagat ctgatgagac gacaggaaga attaagacgc atggaagaac 120
ttcacaatca agaaatgcag aaacgtaaag aaatgcaatt gaggcaagag gaggaacgac 180
gtagaagaga ggaagagatg atgattcgtc aacgtgagat ggaagaacaa atgaggcgcc 240
aaagagagga aagttacagc cgaatgggct acatggatcc acgggaaaga gacatgcgaa 300
tgggtggcgg aggagcaatg aacatgggag atccctatgg ttcaggaggc cagaaatttc 360
cacctctagg aggtggtggt ggcataggtt atgaagctaa tcctggcgtt ccaccagcaa 420
ccatgagtgg ttccatgatg ggaagtgaca tgcgtactga gcgctttggg cagggaggtg 480
cggggcctgt gggtggacag ggtcctagag gaatggggcc tggaactcca gcaggatatg 540
gtagagggag agaagagtac gaaggc 566
<210>152
<211>518
<212>DNA
<213> human
<400>152
ttcgtgaaga ccctgactgg taagaccatc actctcgaag tggagcccga gtgacaccat 60
tgagaatgtc aaggcaaaga tccaagacaa ggaaggcatc cctcctgacc agcakaggtt 120
gatctttgct gggaaacagc tggaagatgg acgcaccctg tctgactaca acatccagaa 180
agagtccacc ctgcacctgg tgctccgtct cagaggtggg atgcaaatct tcgtgaagac 240
cctgactggt aagaccatca ccctcgaggt ggagcccagt gacaccatcg agaatgtcaa 300
ggcaaagatc caagataagg aaggcatccc tcctgatcag cagaggttga tctttgctgg 360
gaaacagctg gaagatggac gcaccctgtc tgactacaac atccagaaag agtccactct 420
gcacttggtc ctgcgcttga gggggggtgt ctaagtttcc ccttttaagg tttcaacaaa 480
tttcattgca ctttcctttc aataaagttg ttgcattc 518
<210>153
<211>542
<212>DNA
<213> human
<400>153
gcgcgggtgc gtgggccact gggtgaccga cttagcctgg ccagactctc agcacctgga 60
agcgccccga gagtgacagc gtgaggctgg gagggaggac ttggcttgag cttgttaaac 120
tctgctctga gcctccttgt cgcctgcatt tagatggctc ccgcaaagaa gggtggcgag 180
aagaaaaagg gccgttctgc catcaacgaa gtggtaaccc gagaatacac catcaacatt 240
cacaagcgca tccatggagt gggcttcaag aagcgtgcac ctcgggcact caaagagatt 300
cggaaatttg ccatgaagga gatgggaact ccagatgtgc gcattgacac caggctcaac 360
aaagctgtct gggccaaagg aataaggaat gtgccatacc gaatccgtgt gcggctgtcc 420
agaaaacgta atgaggatga agattcacca aataagctat atactttggt tacctatgta 480
cctgttacca ctttcaaaaa tctacagaca gtcaatgtgg atgagaacta atcgctgatc 540
gt 542
<210>154
<211>411
<212>DNA
<213> human
<400>154
aattctttat ttaaatcaac aaactcatct tcctcaagcc ccagaccatg gtaggcagcc 60
ctccctctcc atcccctcac cccacccctt agccacagtg aagggaatgg aaaatgagaa 120
gccacgaggg cccctgccag ggaaggctgc cccagatgtg tggtgagcac agtcagtgca 180
gctgtggctg gggcagcagc tgccacaggc tcctccctat aaattaagtt cctgcagcca 240
cagctgtggg agaagcatac ttgtagaagc aaggccagtc cagcatcaga aggcagaggc 300
agcatcagtg actcccagcc atggaatgaa cggaggacac agagctcaga gacagaacag 360
gccaggggga agaaggagag acagaatagg ccagggcatg gcggtgaggg a 411
<210>155
<211>421
<212>DNA
<213> human
<220>
<221>misc_feature
<222>173
<223> n ═ A, T, C or G
<400>155
tgatgaatct gggtgggctg gcagtagccc gagatgatgg gctcttctct ggggatccca 60
actggttccc taagaaatcc aaggagaatc ctcggaactt ctcggataac cagctgcaag 120
agggcaagaa cgtgatcggg ttacagatgg gcaccaaccg cggggcgtct cangcaggca 180
tgactggcta cgggatgcca cgccagatcc tctgatccca ccccaggcct tgcccctgcc 240
ctcccacgaa tggttaatat atatgtagat atatatttta gcagtgacat tcccagagag 300
ccccagagct ctcaagctcc tttctgtcag ggtggggggt tcaagcctgt cctgtcacct 360
ctgaagtgcc tgctggcatc ctctccccca tgcttactaa tacattccct tccccatagc 420
c 421
<210>156
<211>670
<212>DNA
<213> human
<400>156
agcggagctc cctcccctgg tggctacaac ccacacacgc caggctcagg catcgagcag 60
aactccagcg actgggtaac cactgacatt caggtgaagg tgcgggacac ctacctggat 120
acacaggtgg tgggacagac aggtgtcatc cgcagtgtca cggggggcat gtgctctgtg 180
tacctgaagg acagtgagaa ggttgtcagc atttccagtg agcacctgga gcctatcacc 240
cccaccaaga acaacaaggt gaaagtgatc ctgggcgagg atcgggaagc cacgggcgtc 300
ctactgagca ttgatggtga ggatggcatt gtccgtatgg accttgatga gcagctcaag 360
atcctcaacc tccgcttcct ggggaagctc ctggaagcct gaagcaggca gggccggtgg 420
acttcgtcgg atgaagagtg atcctccttc cttccctggc ccttggctgt gacacaagat 480
cctcctgcag ggctaggcgg attgttctgg atttcctttt gtttttcctt ttaggtttcc 540
atcttttccc tccctggtgc tcattggaat ctgagtagag tctgggggag ggtccccacc 600
ttcctgtacc tcctccccac agcttgcttt tgttgtaccg tctttcaata aaaagaagct 660
gtttggtcta 670
<210>157
<211>421
<212>DNA
<213> human
<400>157
ggttcacagc actgctgctt gtgtgttgcc ggccaggaat tccaggctca caaggctatc 60
ttagcagctc gttctccggt ttttagtgcc atgtttgaac atgaaatgga ggagagcaaa 120
aagaatcgag ttgaaatcaa tgatgtggag cctgaagttt ttaaggaaat gatgtgcttc 180
atttacacgg ggaaggctcc aaacctcgac aaaatggctg atgatttgct ggcagctgct 240
gacaagtatg ccctggagcg cttaaaggtc atgtgtgagg atgccctctg cagtaacctg 300
tccgtggaga acgctgcaga aattctcatc ctggccgacc tccacagtgc agatcagttg 360
aaaactcagg cagtggattt catcaactat catgcttcgg atgtcttgga gacctcttgg 420
g 421
<210>158
<211>321
<212>DNA
<213> human
<400>158
tcgtagccat ttttctgctt ctttggagaa tgacgccaca ctgactgctc attgtcgttg 60
gttccatgcc aattggtgaa atagaacctc atccggtagt ggagccggag ggacatcttg 120
tcatcaacgg tgatggtgcg atttggagca taccagagct tggtgttctc gccatacagg 180
gcaaagaggt tgtgacaaag aggagagata cggcatgcct gtgcagccct gatgcacagt 240
tcctctgctg tgtactctcc actgcccagc cggaggggct ccctgtccga cagatagaag 300
atcacttcca cccctggctt g 321
<210>159
<211>596
<212>DNA
<213> human
<400>159
tggcacactg ctcttaagaa actatgawga tctgagattt ttttgtgtat gtttttgact 60
cttttgagtg gtaatcatat gtgtctttat agatgtacat acctccttgc acaaatggag 120
gggaattcat tttcatcact gggagtgtcc ttagtgtata aaaaccatgc tggtatatgg 180
cttcaagttg taaaaatgaa agtgacttta aaagaaaata ggggatggtc caggatctcc 240
actgataaga ctgtttttaa gtaacttaag gacctttggg tctacaagta tatgtgaaaa 300
aaatgagact tactgggtga ggaaattcat tgtttaaaga tggtcgtgtg tgtgtgtgtg 360
tgtgtgtgtg ttgtgttgtg ttttgttttt taagggaggg aatttattat ttaccgttgc 420
ttgaaattac tgkgtaaata tatgtytgat aatgatttgc tytttgvcma ctaaaattag 480
gvctgtataa gtwctaratg cmtccctggg kgttgatytt ccmagatatt gatgatamcc 540
cttaaaattg taaccygcct ttttcccttt gctytcmatt aaagtctatt cmaaag 596
<210>160
<211>515
<212>DNA
<213> human
<400>160
gggggtaggc tctttattag acggttattg ctgtactaca gggtcagagt gcagtgtaag 60
cagtgtcaga ggcccgcgtt cagcccaaga atgtggattt tctctcccta ttgatcacag 120
tgggtgggtt tcttcagaaa agccccagag gcagggacca gtgagctcca aggttagaag 180
tggaactgga aggcttcagt cacatgctgc ttccacgctt ccaggctggg cagcaaggag 240
gagatgccca tgacgtgcca ggtctcccca tctgacacca gtgaagtctg gtaggacagc 300
agccgcacgc ctgcctctgc caggaggcca atcatggtag gcagcattgc agggtcagag 360
gtctgagtcc ggaataggag caggggcagg tccctgcgga gaggcacttc tggcctgaag 420
acagctccat tgagcccctg cagtacaggy gtagtgcctt ggaccaagcc cacagcctgg 480
taaggggcgc ctgccagggc cacggccagg aggca 515
<210>161
<211>936
<212>DNA
<213> human
<400>161
taatttctta gtcgtttgga atccttaagc atgcaaaagc tttgaacaga agggttcaca 60
aaggaaccag ggttgtctta tggcatccag ttaagccaga gctgggaatg cctctgggtc 120
atccacatca ggagcagaag cacttgactt gtcggtcctg ctgccacggt ttgggcgccc 180
accacgccca cgtccacctc gtcctcccct gccgccacgt cctgggcggc caaggtctcc 240
aaaattgatc tccagctgag acgttatatc atttgctggc ttccggaaat gatggtccat 300
aaccgaatct tcagcatgag cctcttcact ctttgattta tgaagaacaa atcccttctt 360
ccactgccca tcagcacctt catttggttt tcggatatta aattctactt ttgcccggtc 420
cttattttga atagccttcc actcatccaa agtcatctct tttggaccct cctcttttac 480
ctcttcaact tcattctcct tattttcagt gtctgccact ggatgatgtt cttcaccttc 540
aggtgtttcc tcagtcacat ttgattgatc caagtcagtt aattcgtctt tgacagttcc 600
ccagttgtga gatccgctac ctccacgttt gtcctcgtgc ttcaggccag atctatcact 660
tccactatgc ctatcaaatt cacgtttgcc acgagaatca aatccatctc ctcggcccat 720
tccacgtcca cggccccctc gacctcttcc aagaccacca cgacctcgaa taggtcggtc 780
aataatcggt ctatcaactg aaaattcgcc tccttcaccc ttttcttcaa gtggcttttc 840
gaatcttcgt tcacgaggtg gtcgcctttc tggtcttcta tcaattattt tcccttcacc 900
ctgaagttgt tgatcaggtc ttcttccaac tcgtgc 936
<210>162
<211>950
<212>DNA
<213> human
<400>162
aagcggatgg acctgagtca gccgaatcct agccccttcc cttgggcctg ctgtggtgct 60
cgacatcagt gacagacgga agcagcagac catcaaggct acgggaggcc cggggcgctt 120
gcgaagatga agtttggctg cctctccttc cggcagcctt atgctggctt tgtcttaaat 180
ggaatcaaga ctgtggagac gcgctggcgt cctctgctga gcagccagcg gaactgtacc 240
atcgccgtcc acattgctca cagggactgg gaaggcgatg cctgtcggga gctgctggtg 300
gagagactcg ggatgactcc tgctcagatt caggccttgc tcaggaaagg ggaaaagttt 360
ggtcgaggag tgatagcggg actcgttgac attggggaaa ctttgcaatg ccccgaagac 420
ttaactcccg atgaggttgt ggaactagaa aatcaagctg cactgaccaa cctgaagcag 480
aagtacctga ctgtgatttc aaaccccagg tggttactgg agcccatacc taggaaagga 540
ggcaaggatg tattccaggt agacatccca gagcacctga tccctttggg gcatgaagtg 600
tgacaagtgt gggctcctga aaggaatgtt ccrgagaaac cagctaaatc atggcacctt 660
caatttgcca tcgtgacgca gacctgtata aattaggtta aagatgaatt tccactgctt 720
tggagagtcc cacccactaa gcactgtgca tgtaaacagg ttcctttgct cagatgaagg 780
aagtaggggg tggggctttc cttgtgtgat gcctccttag gcacacaggc aatgtctcaa 840
gtactttgac cttagggtag aaggcaaagc tgccagtaaa tgtctcagca ttgctgctaa 900
ttttggtcct gctagtttct ggattgtaca aataaatgtg ttgtagatga 950
<210>163
<211>475
<212>DNA
<213> human
<220>
<221>misc_feature
<222>301,317,331,458,464,470
<223> n ═ A, T, C or G
<400>163
tcgagcggcc gcccgggcag gtgtcggagt ccagcacggg aggcgtggtc ttgtagttgt 60
tctccggctg cccattgctc tcccactcca cggcgatgtc gctgggatag aagcctttga 120
ccaggcaggt caggctgacc tggttcttgg tcatctcctc ccgggatggg ggcagggtgt 180
acacctgtgg ttctcggggc tgccctttgg ctttggagat ggttttctcg atgggggctg 240
ggagggcttt gttggagacc ttgcacttgt actccttgcc attcaaccag tcctggtgca 300
ngacggtgag gacgctnacc acacggtacg ngctggtgta ctgctcctcc cgcggctttg 360
tcttggcatt atgcacctcc acgccgtcca cgtaccaatt gaacttgacc tcagggtctt 420
cgtggctcac gtccaccacc acgcatgtaa cctcaaanct cggncgcgan cacgc 475
<210>164
<211>476
<212>DNA
<213> human
<400>164
agcgtggtcg cggccgaggt ctgaggttac atgcgtggtg gtggacgtga gccacgaaga 60
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa 120
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca 180
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc 240
ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac 300
cctgccccca tcccgggagg agatgaccaa gaaccaggtc agcctgacct gcctggtcaa 360
aggcttctat cccagcgaca tcgcccgtgg agtgggagag caatgggcag ccggagaaca 420
actacaagac cacgcctccc gtgctggact ccgacacctg ccgggcggcc gctcga 476
<210>165
<211>256
<212>DNA
<213> human
<220>
<221>misc_feature
<222>10,37,249
<223> n ═ A, T, C or G
<400>165
agcgtggttn cggccgaggt cccaaccaag gctgcancct ggatgccatc aaagtcttct 60
gcaacatgga gactggtgag acctgcgtgt accccactca gcccagtgtg gcccagaaga 120
actggtacat cagcaagaac cccaaggaca agaggcatgt ctggttcggc gagagcatga 180
ccgatggatt ccagttcgag tatggcggcc agggctccga ccctgccgat gtggacctgc 240
ccgggcggnc gctcga 256
<210>166
<211>332
<212>DNA
<213> human
<400>166
agcgtggtcg cggccgaggt caagaacccc gcccgcacct gccgtgacct caagatgtgc 60
cactctgact ggaagagtgg agagtactgg attgacccca accaaggctg caacctggat 120
gccatcaaag tcttctgcaa catggagact ggtgagacct gcgtgtaccc cactcagccc 180
agtgtggccc agaagaactg gtacatcagc aagaacccca aggacaagag gcatgtctgg 240
ttcggcgaga gcatgaccga tggattccag ttcgagtatg gcggccaggg ctccgaccct 300
gccgatgtgg acctgcccgg gcggccgctc ga 332
<210>167
<211>332
<212>DNA
<213> human
<220>
<221>misc_feature
<222>77,109,136,184,198
<223> n ═ A, T, C or G
<400>167
tcgagcggtc gcccgggcag gtccacatcg gcagggtcgg agccctggcc gccatactcg 60
aactggaatc catcggncat gctctcgccg aaccagacat gcctcttgnc cttggggttc 120
ttgctgatgt accagntctt ctgggccaca ctgggctgag tggggtacac gcaggtctca 180
ccantctcca tgttgcanaa gactttgatg gcatccaggt tgcagccttg gttggggtca 240
atccagtact ctccactctt ccagacagag tggcacatct tgaggtcacg gcaggtgcgg 300
gcggggttct tgacctcggt cgcgaccacg ct 332
<210>168
<211>276
<212>DNA
<213> human
<220>
<221>misc_feature
<222>72,84
<223> n ═ A, T, C or G
<400>168
tcgagcggcc gcccgggcag gtcctcctca gagcggtagc tgttcttatt gccccggcag 60
cctccataga tnaagttatt gcangagttc ctctccacgt caaagtacca gcgtgggaag 120
gatgcacggc aaggcccagt gactgcgttg gcggtgcagt attcttcata gttgaacata 180
tcgctggagt ggacttcaga atcctgcctt ctgggagcac ttgggacaga ggaatccgct 240
gcattcctgc tggtggacct cggccgcgac cacgct 276
<210>169
<211>276
<212>DNA
<213> human
<400>169
agcgtggtcg cggccgaggt ccaccagcag gaatgcagcg gattcctctg tcccaagtgc 60
tcccagaagg caggattctg aagaccactc cagcgatatg ttcaactatg aagaatactg 120
caccgccaac gcagtcactg ggccttgccg tgcatccttc ccacgctggt actttgacgt 180
ggagaggaac tcctgcaata acttcatcta tggaggctgc cggggcaata agaacagcta 240
ccgctctgag gaggacctgc ccgggcggcc gctcga 276
<210>170
<211>332
<212>DNA
<213> human
<220>
<221>misc_feature
<222>294
<223> n ═ A, T, C or G
<400>170
tcgagcggcc gcccgggcag gtccacatcg gcagggtcgg agccctggcc gccatactcg 60
aactggaatc catcggtcat gctctcgccg aaccagacat gcctcttgtc cttggggttc 120
ttgctgatgt accagttctt ctgggccaca ctgggctgag tggggtacac gcaggtctca 180
ccagtctcca tgttgcagaa gactttgatg gcatccaggt tgcagccttg gttggggtca 240
atccagtact ctccactctt ccagccagaa tggcacatct tgaggtcacg gcangtgcgg 300
gcggggttct tgacctcggc cgcgaccacg ct 332
<210>171
<211>333
<212>DNA
<213> human
<400>171
agcgtggtcg cggccgaggt caagaaaccc cgcccgcacc tgccgtgacc tcaagatgtg 60
ccactctggc tggaagagtg gagagtactg gattgacccc aaccaaggct gcaacctgga 120
tgccatcaaa gtcttctgca acatggagac tggtgagacc tgcgtgtacc ccactcagcc 180
cagtgtggcc cagaagaact ggtacatcag caagaacccc aaggacaaga ggcatgtctg 240
gctcggcgag agcatgaccg atggattcca gttcgagtat ggcggccagg gctccgaccc 300
tgccgatgtg gacctgcccg ggcggccgct cga 333
<210>172
<211>527
<212>DNA
<213> human
<220>
<221>misc_feature
<222>46,125,140,148,220,229,291,388,456
<223> n ═ A, T, C or G
<400>172
agcgtggtcg cggccgaggt cctgtcagag tggcactggt agaagntcca ggaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagtgt 120
cctgnaatgg ggcccatgan atggttgnct gagagagagc ttcttgtcct acattcggcg 180
ggtatggtct tggcctatgc cttatggggg tggccgttgn gggcggtgng gtccgcctaa 240
aaccatgttc ctcaaagatc atttgttgcc caacactggg ttgctgacca naagtgccag 300
gaagctgaat accatttcca gtgtcatacc cagggtgggt gacgaaaggg gtcttttgaa 360
ctgtggaagg aacatccaag atctctgntc catgaagatt ggggtgtgga agggttacca 420
gttggggaag ctcgctgtct ttttccttcc aatcangggc tcgctcttct gaatattctt 480
cagggcaatg acataaattg tatattcggt tcccggttcc aggccag 527
<210>173
<211>635
<212>DNA
<213> human
<220>
<221>misc_feature
<222>444,453,517,540,546,551,573,593
<223> n ═ A, T, C or G
<400>173
tcgagcggcc gcccgggcag gtccaccaca cccaattcct tgctggtatc atggcagccg 60
ccacgtgcca ggattaccgg ctacatcatc aagtatgaga agcctgggtc tcctcccaga 120
gaagtggtcc ctcggccccg ccctggtgtc acagaggcta ctattactgg cctggaaccg 180
ggaaccgaat atacaattta tgtcattgcc ctgaagaata atcagaagag cgagcccctg 240
attggaagga aaaagacaga cgagcttccc caactggtaa cccttccaca ccccaatctt 300
catggaccag agatcttgga tgttccttcc acagttcaaa agaccccttt cgtcacccac 360
cctgggtatg acactggaaa tggtattcag cttcctggca cttctggtca gcaacccagt 420
gttgggcaac aaatgatctt tgangaacat ggntttaggc ggaccacacc ggccacaacg 480
ggcaccccca taaggcatag gccaagaaca tacccgncga atgtaggaca agaagctctn 540
tctcanacaa ncatctcatg ggccccattc cangacactt ctgagtacat canttcatgg 600
catcctggtg gcactgataa aaacccttac agtta 635
<210>174
<211>572
<212>DNA
<213> human
<220>
<221>misc_feature
<222>457,511,520,552,568
<223> n ═ A, T, C or G
<400>174
agcgtggtcg cgggcgaggt cctgtcagag tggcactggt agaagttcca ggaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagtgt 120
cctggaatgg ggcccatgag atggttgtct gagagagagc ttcttgtcct acattcggcg 180
ggtatggtct tggcctatgc cttatggggg tggccgttgt gggcggtgtg gtccgcctaa 240
aaccatgttc ctcaaagatc atttgttgcc caacactggg ttgctgacca gaagtgccag 300
gaagctgaat accatttcca gtgtcatacc cagggtgggt gacgaaaggg gtcttttgaa 360
ctgtggaagg aacatccaag atctctggtc catgaagatt ggggtgtgga agggttacca 420
gttggggaag ctcgtctgtc tttttccttc caatcanggg ctcgctcttc tgattattct 480
tcagggcaat gacataaatt gtatattcgg ntcccgggtn cagccaataa taataaccct 540
ctgtgacacc anggcggggc cgaagganca ct 572
<210>175
<211>372
<212>DNA
<213> human
<220>
<221>misc_feature
<222>247
<223> n ═ A, T, C or G
<400>175
agcgtggtcg cggccgaggt cctcaccaga ggtaccacct acaacatcat agtggaggca 60
ctgaaagacc agcagaggca taaggttcgg gaagaggttg ttaccgtggg caactctgtc 120
aacgaaggct tgaaccaacc tacggatgac tcgtgctttg acccctacac agtttcccat 180
tatgccgttg gagatgagtg ggaacgaatg tctgaatcag gctttaaact gttgtgccag 240
tgcttangct ttggaagtgg tcatttcaga tgtgattcat ctagatggtg ccatgacaat 300
ggtgtgaact acaagattgg agagaagtgg gaccgtcagg gagaaaatgg acctgcccgg 360
gcggccgctc ga 372
<210>176
<211>372
<212>DNA
<213> human
<220>
<221>misc_feature
<222>251
<223> n ═ A, T, C or G
<400>176
tcgagcggcc gcccgggcag gtccattttc tccctgacgg tcccacttct ctccaatctt 60
gtagttcaca ccattgtcat ggcaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ntgacagagt tgcccacggt aacaacctct tcccgaacct tatgcctctg 300
ctggtctttc agtgcctcca ctatgatgtt gtaggtggta cctctggtga ggacctcggc 360
cgcgaccacg ct 372
<210>177
<211>269
<212>DNA
<213> human
<220>
<221>misc_feature
<222>94,225
<223> n ═ A, T, C or G
<400>177
agcgtggccg cggccgaggt ccattggctg gaacggcatc aacttggaag ccagtgatcg 60
tctcagcctt ggttctccag ctaatggtga tggnggtctc agtagcatct gtcacacgag 120
cccttcttgg tgggctgaca ttctccagag tggtgacaac accctgagct ggtctgcttg 180
tcaaagtgtc cttaagagca tagacactca cttcatattt ggcgnccacc ataagtcctg 240
atacaaccac ggaatgacct gtcaggaac 269
<210>178
<211>529
<212>DNA
<213> human
<400>178
tcgagcggcc gcccgggcag gtcctcagac cgggttctga gtacacagtc agtgtggttg 60
ccttgcacga tgatatggag agccagcccc tgattggaac ccagtccaca gctattcctg 120
caccaactga cctgaagttc actcaggtca cacccacaag cctgagcgcc cagtggacac 180
cacccaatgt tcagctcact ggatatcgag tgcgggtgac ccccaaggag aagaccggac 240
caatgaaaga aatcaacctt gctcctgaca gctcatccgt ggttgtatca ggacttatgg 300
cggccaccaa atatgaagtg agtgtctatg ctcttaagga cactttgaca agcagaccag 360
ctcagggtgt tgtcaccact ctggagaatg tcagcccacc aagaagggct cgtgtgacag 420
atgctactga gaccaccatc accattagct ggagaaccaa gactgagacg atcactggct 480
tccaagttga tgccgttcca gccaatggac ctcggccgcg accacgctt 529
<210>179
<211>454
<212>DNA
<213> human
<220>
<221>misc_feature
<222>64
<223> n ═ A, T, C or G
<400>179
agcgtggtcg cggccgaggt ctggccgaac tgccagtgta cagggaagat gtacatgtta 60
tagntcttct cgaagtcccg ggccagcagc tccacggggt ggtctcctgc ctccaggcgc 120
ttctcattct catggatctt cttcacccgc agcttctgct tctcagtcag aaggttgttg 180
tcctcatccc tctcatacag ggtgaccagg acgttcttga gccagtcccg catgcgcagg 240
gggaattcgg tcagctcaga gtccaggcaa ggggggatgt atttgcaagg cccgatgtag 300
tccaagtgga gcttgtggcc cttcttggtg ccctccaagg tgcactttgt ggcaaagaag 360
tggcaggaag agtcgaaggt cttgttgtca ttgctgcaca ccttctcaaa ctcgccaatg 420
ggggctgggc agacctgccc gggcggccgc tcga 454
<210>180
<211>454
<212>DNA
<213> human
<220>
<221>misc_feature
<222>55,299,317,332,342,348
<223> n ═ A, T, C or G
<400>180
tcgagcggcc gcccgggcag gtctgcccag cccccattgg cgagtttgag aaggngtgca 60
gcaatgacaa caagaccttc gactcttcct gccacttctt tgccacaaag tgcaccctgg 120
agggcaccaa gaagggccac aagctccacc tggactacat cgggccttgc aaatacatcc 180
ccccttgcct ggactctgag ctgaccgaat tccccctgcg catgcgggac tggctcaaga 240
acgtcctggt caccctgtat gagagggatg aggacaacaa ccttctgact gagaagcana 300
agctgcgggt gaagaanatc catgagaatg anaagcgcct gnaggcanga gaccaccccg 360
tggagctgct ggcccgggac ttcgagaaga actataacat gtacatcttc cctgtacact 420
ggcagttcgg ccagacctcg gccgcgacca cgct 454
<210>181
<211>102
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,47,60,67
<223> n ═ A, T, C or G
<400>181
agcgtggntg cggacgacgc ccacaaagcc attgtatgta gttttanttc agctgcaaan 60
aataccncca gcatccacct tactaaccag catatgcaga ca 102
<210>182
<211>337
<212>DNA
<213> human
<220>
<221>misc_feature
<222>169,195,253,314
<223> n ═ A, T, C or G
<400>182
tcgagcggtc gcccgggcag gtctgggcgg atagcaccgg gcatattttg gaatggatga 60
ggtctggcac cctgagcagc ccagcgagga cttggtctta gttgagcaat ttggctagga 120
ggatagtatg cagcacggtt ctgagtctgt gggatagctg ccatgaagna acctgaagga 180
ggcgctggct ggtangggtt gattacaggg ctgggaacag ctcgtacact tgccattctc 240
tgcatatact ggntagtgag gcgagcctgg cgctcttctt tgcgctgagc taaagctaca 300
tacaatggct ttgnggacct cggccgcgac cacgctt 337
<210>183
<211>374
<212>DNA
<213> human
<400>183
tcgagcggcc gcccgggcag gtccattttc tccctgacgg tcccacttct ctccaatctt 60
gtagttcaca ccattgtcat gacaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ttgacagaag ttgcccacgg taacaacctc ttcccgaacc ttatgcctct 300
gctggtcttt caagtgcctc cactatgatg ttgtaggtgg cacctctggt gaggacctcg 360
gccgcgacca cgct 374
<210>184
<211>375
<212>DNA
<213> human
<220>
<221>misc_feature
<222>30,174,248,285,306,332,345,368
<223> n ═ A, T, C or G
<400>184
agcgtggttt gcggccgagg tcctcaccan aggtgccacc tacaacatca tagtggaggc 60
actgaaagac cagcagaggc ataaggttcg ggaagaggtt gttaccgtgg gcaactctgt 120
caacgaaggc ttgaaccaac ctacggatga ctcgtgcttt gacccctaca cagnttccca 180
ttatgccgtt ggagatgagt gggaacgaat gtctgaatca ggctttaaac tgttgtgcca 240
gtgcttangc tttggaagtg gtcatttcag atgtgattca tctanatggt gtcatgacaa 300
tggtgngaac tacaagattg gagagaagtg gnaccgtcag ggganaaaat ggacctgccc 360
gggcggcncg ctcga 375
<210>185
<211>148
<212>DNA
<213> human
<220>
<221>misc_feature
<222>28,36,86
<223> n ═ A, T, C or G
<400>185
agcgtggtcg cggccgaggt ctggcttnct gctcangtga ttatcctgaa ccatccaggc 60
caaataagcg ccggctatgc ccctgnattg gattgccaca cggctcacat tgcatgcaag 120
tttgctgagc tgaaggaaaa gattgatc 148
<210>186
<211>397
<212>DNA
<213> human
<220>
<221>misc_feature
<222>78
<223> n ═ A, T, C or G
<400>186
tcgagcggcc gcccgggcag gtccaattga aacaaacagt tctgagaccg ttcttccacc 60
actgattaag agtggggngg cgggtattag ggataatatt catttagcct tctgagcttt 120
ctgggcagac ttggtgacct tgccagctcc agcagccttc tggtccactg ctttgatgac 180
acccaccgca actgtctgtc tcatatcacg aacagcaaag cgacccaaag gtggatagtc 240
tgagaagctc tcaacacaca tgggcttgcc aggaaccata tcaacaatgg gcagcatcac 300
cagacttcaa gaatttaagg gccatcttcc agctttttac cagaacggcg atcaatcttt 360
tccttcagct cagcaaactt gcatgcaatg tgagccg 397
<210>187
<211>584
<212>DNA
<213> human
<220>
<221>misc_feature
<222>145,286,363,365,425,433,452,462,471,512,514,534,
536,540,565,583
<223> n ═ A, T, C or G
<400>187
tcgagcggcc gcccgggcag gtccagaggg ctgtgctgaa gtttgctgct gccactggag 60
ccactccaat tgctggccgc ttcactcctg gaaccttcac taaccagatc caggcagcct 120
tccgggagcc acggcttctt gtggntactg accccagggc tgaccaccag cctctcacgg 180
aggcatctta tgttaaccta cctaccattg cgctgtgtaa cacagattct cctctgcgct 240
atgtggacat tgccatccca tgcaacaaca agggagctca ctcagngggg tttgatgtgg 300
tggatgctgg ctcgggaagt tctgcgcatg cgtggcacca tttcccgtga acacccatgg 360
gangncatgc ctgatctgga cttctacaga gatcctgaag agattgaaaa agaagaacag 420
gctgnttgct ganaaagcaa gtgaccaagg angaaatttc angggtgaaa nggactgctc 480
ccgctcctga attcactgct actcaacctg angntgcaga ctggtcttga aggngnacan 540
gggccctctg ggcctattta agcancttcg gtcgcgaaca cgnt 584
<210>188
<211>579
<212>DNA
<213> human
<220>
<221>misc_feature
<222>7,136,486
<223> n ═ A, T, C or G
<400>188
agcgtgngtc gcggccgagg tgctgaatag gcacagaggg cacctgtaca ccttcagacc 60
agtctgcaac ctcaggctga gtagcagtga actcaggagc gggagcagtc cattcaccct 120
gaaattcctc cttggncact gccttctcag cagcagcctg ctcttctttt tcaatctctt 180
caggatctct gtagaagtac agatcaggca tgacctccca tgggtgttca cgggaaatgg 240
tgccacgcat gcgcagaact tcccgagcca gcatccacca catcaaaccc actgagtgag 300
ctcccttgtt gttgcatggg atgggcaatg tccacatagc gcagaggaga atctgtgtta 360
cacagcgcaa tggtaggtag gttaacataa gatgcctccg cgagaagctg gtggtcagcc 420
ctggggtcaa gtaaccacaa gaagccgtgg ctcccggaag gctgcctgga tctggttagt 480
gaaggntcca ggagtgaagc ggccaacaat tggagtggct tcagtggcaa gcagcaaact 540
tcagcacaag ccctctggac ctgcccggcg gccgctcga 579
<210>189
<211>374
<212>DNA
<213> human
<220>
<221>misc_feature
<222>41,280,314,330,350,353
<223> n ═ A, T, C or G
<400>189
tcgagcggcc gcccgggcag gtccattttc tccctgacgg ncccacttct ctccaatctt 60
gtagttcaca ccattgtcat ggcaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ttgacagagt tgcccacggt aacaacctcn tccccgaacc ttatgcctct 300
gctgggcttt cagngcctcc actatgatgn tgtagggggg cacctctggn gangacctcg 360
gccgcgacca cgct 374
<210>190
<211>373
<212>DNA
<213> human
<220>
<221>misc_feature
<222>247,304,306,332,337
<223> n ═ A, T, C or G
<400>190
agcgtggtcg cggccgaggt cctcaccaga ggtgccacct acaacatcat agtggaggca 60
ctgaaagacc agcagaggca taaggctcgg gaagaggttg ttaccgtggg caactctgtc 120
aacgaaggct tgaaccaacc tacggatgac tcgtgctttg acccctacac agtttcccat 180
tatgccgttg gagatgagtg ggaacgaatg tctgaatcag gctttaaact gttgtgccag 240
tgcttangct ttggaagtgg gtcatttcag atgtgattca tctagatggt gccatgacaa 300
tggngngaac tacaagattg gagagaagtg gnaccgncag ggagaaaatg gacctgcccg 360
ggcggccgct cga 373
<210>191
<211>354
<212>DNA
<213> human
<220>
<221>misc_feature
<222>218,299,306,326,333,337,341
<223> n ═ A, T, C or G
<400>191
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacacgc aggtctcacc 180
agtctccatg ttgcagaaga ctttgatggc atccaggntg caaccttggt tggggtcaat 240
ccagtactct ccactcttcc agccagagtg gcacatcttg aggtcacggc aggtgcggnc 300
gggggntttt gcggctgccc tctggncttc ggntgtnctc natctgctgg ctca 354
<210>192
<211>587
<212>DNA
<213> human
<220>
<221>misc_feature
<222>276
<223> n ═ A, T, C or G
<400>192
tcgagcggcc gcccgggcag gtctcgcggt cgcactggtg atgctggtcc tgttggtccc 60
cccggccctc ctggacctcc tggcccccct ggtcctccca gcgctggttt cgacttcagc 120
ttcctgcccc agccacctca agagaaggct cacgatggtg gccgctacta ccgggctgat 180
gatgccaatg tggttcgtga ccgtgacctc gaggtggaca ccaccctcaa gagcctgagc 240
cagcagatcg agaacatccg gagcccagag ggcagncgca agaaccccgc ccgcacctgc 300
cgtgacctca agatgtgcca ctctgactgg aagagtggag agtactggat tgaccccaac 360
caagctgcaa cctggatgcc atcaaagtct tctgcaacat ggagactggt gagacctgcg 420
tgtaccccac tcagcccagt gtggcccaaa agaactggta catcagcaag aaccccaagg 480
acaagaagca tgtctggttc ggcgagaaca tgaccgatgg attccagttc gagtatggcg 540
ggcagggctc cgaccctgcc gatggggacc ttggccgcga acacgct 587
<210>193
<211>98
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,9,33,58,71,90
<223> n ═ A, T, C or G
<400>193
agcgtggnng cggccgaggt ataaatatcc agnccatatc ctccctccac acgctganag 60
atgaagctgt ncaaagatct cagggtggan aaaaccat 98
<210>194
<211>240
<212>DNA
<213> human
<400>194
tcgagcggcc gcccgggcag gtccttcaga cttggactgt gtcacactgc caggcttcca 60
gggctccaac ttgcagacgg cctgttgtgg gacagtctct gtaatcgcga aagcaaccat 120
ggaagacctg ggggaaaaca ccatggtttt atccaccctg agatctttga acaacttcat 180
ctctcagcgt gcggagggag gctctggact ggatatttct acctcggccg cgaccacgct 240
<210>195
<211>400
<212>DNA
<213> human
<220>
<221>misc_feature
<222>22,37,39,105,268,276,302,323,331,335,347,351,
371,378
<223> n ═ A, T, C or G
<400>195
cgagcgggcg accgggcagg tncagactcc aatccanana accatcaagc cagatgtcag 60
aagctacacc atcacaggtt tacaaccagg cactgactac aaganctacc tgcacacctt 120
gaatgacaat gctcggagct cccctgtggt catcgacgcc tccactgcca ttgatgcacc 180
atccaacctg cgtttcctgg ccaccacacc caattccttg ctggtatcat ggcagccgcc 240
acgtgccagg attaccggta catcatcnag tatganaagc ctgggcctcc tcccagagaa 300
gnggtccctc ggccccgccc tgntgtccca naggntacta ttactgngcc ngcaaccggc 360
aaccgatatc nattttgnca ttggccttca acaataatta 400
<210>196
<211>494
<212>DNA
<213> human
<220>
<221>misc_feature
<222>19,83,168,252,271,292,430
<223> n ═ A, T, C or G
<400>196
agcgtggttc gcggccgang tcctgtcaga gtggcactgg tagaagttcc aggaaccctg 60
aactgtaagg gttcttcatc agngccaaca ggatgacatg aaatgatgta ctcagaagtg 120
tcctggaatg gggcccatga gatggttgtc tgagagagag cttcttgncc tgtctttttc 180
cttccaatca ggggctcgct cttctgatta ttcttcaggg caatgacata aattgtatat 240
tcgggtcccg gntccaggcc agtaatagta ncctctgtga caccagggcg gngccgaggg 300
accacttctc tgggaggaga cccaggcttc tcatacttga tgatgtaacc ggtaatcctg 360
gcacgtggcg gctgccatga taccagcaag gaattggggt gtggtggcca ggaaacgcag 420
gttggatggn gcatcaatgg cagtggaggc cgtcgatgac cacaggggga gctccgacat 480
tgtcattcaa ggtg 494
<210>197
<211>118
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,71,96
<223> n ═ A, T, C or G
<400>197
agcgtggncg cggccgaggt gcagcgcggg ctgtgccacc ttctgctctc tgcccaacga 60
taaggagggt ncctgccccc aggagaacat taactntccc cagctcggcc tctgccgg 118
<210>198
<211>403
<212>DNA
<213> human
<220>
<221>misc_feature
<222>41,53,98,195,350
<223> n ═ A, T, C or G
<400>198
tcgagcggcc gcccgggcag gttttttttg ctgaaagtgg ntactttatt ggntgggaaa 60
gggagaagct gtggtcagcc caagagggaa tacagagncc cgaaaaaggg gagggcaggt 120
gggctggaac cagacgcagg gccaggcaga aactttctct cctcactgct cagcctggtg 180
gtggctggag ctcanaaatt gggagtgaca caggacacct tcccacagcc attgcggcgg 240
catttcatct ggccaggaca ctggctgtcc acctggcact ggtcccgaca gaagcccgag 300
ctggggaaag ttaatgttca cctgggggca ggaaccctcc ttatcattgn gcagagagca 360
gaaggtggca cagcccgcgc tgcacctcgg ccgcgaccac gct 403
<210>199
<211>167
<212>DNA
<213> human
<220>
<221>misc_feature
<222>92,107
<223> n ═ A, T, C or G
<400>199
tcgagcggcc gcccgggcag gtccaccata agtcctgata caaccacgga tgagctgtca 60
ggagcaaggt tgatttcttt cattggtccg gncttctcct tgggggncac ccgcactcga 120
tatccagtga gctgaacatt gggtggcgtc cactgggcgc tcaggct 167
<210>200
<211>252
<212>DNA
<213> human
<220>
<221>misc_feature
<222>210,226,227,230,236
<223> n ═ A, T, C or G
<400>200
tcgagcggtt cgcccgggca ggtccaccac acccaattcc ttgctggtat catggcagcc 60
gccacgtgcc aggattaccg gctacatcat caagtatgag aagcctgggt ctcctcccag 120
agaagcggtc cctcggcccc gccctggtgt cacagaggct actattactg gcctggaacc 180
gggaaccgaa tatacaattt atgtcattgn cctgaagaat aatcannaan agcgancccc 240
tgattggaag ga 252
<210>201
<211>91
<212>DNA
<213> human
<400>201
agcgtggtcg cggccgaggt tgtacaagct tttttttttt tttttttttt tttttttttt 60
tttttttttt tttttttttt tttttttttt t 91
<210>202
<211>368
<212>DNA
<213> human
<220>
<221>misc_feature
<222>9,354
<223> n ═ A, T, C or G
<400>202
tcgagcggnc gcccgggcag gtctgccaac accaagattg gcccccgccg catccacaca 60
gtccgtgtgc ggggaggtaa caagaaatac cgtgccctga ggttggacgt ggggaatttc 120
tcctggggct cagagtgttg tactcgtaaa acaaggatca tcgatgttgt ctacaatgca 180
tctaataacg agctggttcg taccaagacc ctggtgaaga attgcatcgt gctcatcgac 240
agcacaccgt accgacagtg gtacgagtcc cactatgcgc tgcccctggg ccgcaagaag 300
ggagccaagc tgactcctga ggaagaagag attttaaaca aaaaacgatc taanaaaaaa 360
aaaacaat 368
<210>203
<211>340
<212>DNA
<213> human
<400>203
agcgtggtcg cggccgaggt gaaatggtat tcagcttcct ggcacttctg gtcagcaacc 60
cagtgttggg caacaaatga tctttgagga acatggtttt aggcggacca caccgcccac 120
aacggccacc cccataaggc ataggccaag accatacccg ccgaatgtag gacaagaagc 180
tctctctcag acaaccatct catgggcccc attccaggac acttctgagt acatcatttc 240
atgtcatcct gttggcactg atgaagaacc cttacagttc agggttcctg gaacttctac 300
cagtgccact ctgacaggac ctgcccgggc ggccgctcga 340
<210>204
<211>341
<212>DNA
<213> human
<400>204
tcgagcggcc gcccgggcag gtcctgtcag agtggcactg gtagaagttc caggaaccct 60
gaactgtaag ggttcttcat cagtgccaac aggatgacat gaaatgatgt actcagaagt 120
gtcctggaat ggggcccatg agatggttgt ctgagagaga gcttcttgtc ctacattcgg 180
cgggtatggt cttggcctat gccttatggg ggtggccgtt gtgggcggtg tggtccgcct 240
aaaaccatgt tcctcaaaga tcatttgttg cccaacactg ggttgctgac cagaagtgcc 300
aggaagctga ataccatttc acctcggccg cgaccacgct a 341
<210>205
<211>770
<212>DNA
<213> human
<220>
<221>misc_feature
<222>529,591,623,626,629,630,656,702,709,712,717,743,
746,749,759,762,766
<223> n ═ A, T, C or G
<400>205
tcgagcggcc gcccgggcag gtctcccttc ttgcggccca ggggcagcgc atagtgggac 60
tcgtaccact gtcggtacgg tgtgctgtcg atgagcacga tgcaattctt caccagggtc 120
ttggtacgaa ccagctcgtt attagatgca ttgtagacaa catcgatgat ccttgtttta 180
cgagtacaac actctgagcc ccaggagaaa ttccccacgt ccaacctcag ggcacggtat 240
ttcttgttac ctccccgcac acggactgtg tggatgcggc gggggccaag ctgactcctg 300
aggaagaaga gattttaaac aaaaaacgat ctaaaaaaat tcagaagaaa tatgatgaaa 360
ggaaaaagaa tgccaaaatc agcagtctcc tggaggagca gttccagcag ggcaagcttc 420
ttgcgtgcat cgcttcaagg ccgggacagt gtgaccgagc agatggctat gtgctagagg 480
gcaaagaagt ggagttctat cttaagaaaa tcagggccca gaatggtgng tcttcaacta 540
atccaaaggg gagtttcaga ccagtgcaat cagcaaaaac attgatactg ntggccaaat 600
ttattggtgc agggcttgca cantangann ggctgggtct tggggcttgg attggnacaa 660
gctttggcag ccttttcttt ggttttgcca aaaacctttt gntgaagang anacctnggg 720
cggacccctt aaccgattcc acnccnggng gcgttctang gncccncttg 770
<210>206
<211>810
<212>DNA
<213> human
<220>
<221>misc_feature
<222>574,621,625,636,668,673,704,728,743,767,772,786,
789,807,809,810
<223> n ═ A, T, C or G
<400>206
agcgtggtcg cggccgaggt ctgctgcttc agcgaagggt ttctggcata accaatgata 60
aggctgccaa agactgttcc aataccagca ccagaaccag ccactcctac tgttgcagca 120
cctgcaccaa taaatttggc agcagtatca atgtctctgc tgattgcact ggtctgaaac 180
tccctttgga ttagctgaga cacaccattc tgggccctga ttttcctaag atagaactcc 240
aactctttgc cctctagcac atagccatct gctcggtcac actgtcccgg ccttgaagcg 300
atgcacgcaa gaagcttgcc ctgctggaac tgctcctcca ggagactgct gattttggca 360
ttctttttcc tttcatcata tttcttctga atttttttag atcgtttttt gtttaaaatc 420
tcttcttcct caggagtcag cttggccccc gccgcatcca cacagtccgt gtgcggggag 480
gtaacaagaa ataccgtgcc ctgaggttgg acgtggggaa tttctcctgg ggctcagagt 540
ggtgtactcg taaaacaagg atcatcgatg gtgnctacaa tgcatctaat aacgagctgg 600
gtcggaccca aagaacctgg ngaanaaatg gatcgnctca tcgacaggac accgtacccg 660
acaggggnac gantcccact atgcgcttgc ccctgggccg caanaaagga aaactgcccg 720
ggcggccntc gaaagcccaa ttntggaaaa aatccatcac actgggnggc cngtcgagca 780
tgcatntana ggggcccatt ccccctnann 810
<210>207
<211>257
<212>DNA
<213> human
<400>207
tcgagcggcc gcccgggcag gtccccaacc aaggctgcaa cctggatgcc atcaaagtct 60
tctgcaacat ggagactggt gagacctgcg tgtaccccac tcagcccagt gtggcccaga 120
agaactggta catcagcaag aaccccaagg acaagaggca tgtctggttc ggcgagagca 180
tgaccgatgg attccagttc gagtatggcg gccagggctc cgaccctgcc gatgtggacc 240
tcggccgcga ccacgct 257
<210>208
<211>257
<212>DNA
<213> human
<400>208
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacacgc aggtctcacc 180
agtctccatg ttgcagaaga ctttgatggc atccaggttg cagccttggt tggggacctg 240
cccgggcggc cgctcga 257
<210>209
<211>747
<212>DNA
<213> human
<220>
<221>misc_feature
<222>453,538,540,542,546,554,556,598,659,670,679,689,
693,711,723,724,731,747
<223> n ═ A, T, C or G
<400>209
tcgagcggcc gcccgggcag gtccaccaca cccaattcct tgctggtatc atggcagccg 60
ccacgtgcca ggattaccgg ctacatcatc aagtatgaga agcctgggtc tcctcccaga 120
gaagtggtcc ctcggccccg ccctggtgtc acagaggcta ctattactgg cctggaaccg 180
ggaaccgaat atacaattta tgtcattgcc ctgaagaata atcagaagag cgagcccctg 240
attggaagga aaaagacaga cgagcttccc caactggtaa cccttccaca ccccaatctt 300
catggaccag agatcttgga tgttccttcc acagttcaaa agaccccttt cgtcacccac 360
cctgggtatg acactggaaa tggtattcag cttcctggca cttctggtca gcaacccagt 420
gttgggcaac aaatgatctt tgaggaacat ggntttaggc ggaccacacc gcccacaacg 480
gccaccccca taaggcatag gccaagacca tacccgccga atgtaggaca agaagctntn 540
tntcanacac catntnatgg gccccattcc aggacacttc tgagtacatc atttatgnca 600
tctgtggcac ttgatgaaaa cccttacagt tcagggttct ggaactttta ccaggcctnt 660
tacaggactn ggccggacnc cttaagccna ttncaccctg gggcgttcta nggtcccact 720
cgnncactgg ngaaaatggc tactgtn 747
<210>210
<211>872
<212>DNA
<213> human
<220>
<221>misc_feature
<222>165,174,181,256,260,269,271,277,286,289,294,298,
300,301,303,308,311,321,325,328,329,333,338,342,
346,349,351,357,359,364,366,379,385,395,396,397,
407,408,410,414,415,429,431,434,435,440,443
<223> n ═ A, T, C or G
<221>misc_feature
<222>444,446,447,448,449,450,451,464,470,472,475,479,
483,484,485,488,494,496,497,504,508,509,511,513,
517,522,524,526,532,533,542,543,553,559,566,567,
571,572,578,582,588,591,594,595,596,600,606
<223> n ═ A, T, C or G
<221>misc_feature
<222>612,614,617,618,629,630,631,652,654,655,661,663,
664,666,671,673,678,679,681,688,690,691,698,706,
707,708,714,719,721,723,726,741,751,761,762,769,
770,778,779,781,782,785,791,802,807,808,812
<223> n ═ A, T, C or G
<221>misc_feature
<222>815,820,827,828,838,841,844,851,857,864,866,869,
872
<223> n ═ A, T, C or G
<400>210
agcgtggtcg cggccgaggt ccactagagg tctgtgtgcc attgcccagg cagagtctct 60
gcgttacaaa ctcctaggag ggcttgctgt gcggagggcc tgctatggtg tgctgcggtt 120
catcatggag agtggggcca aaggctgcga ggttgtggtg tctgngaaac tccnaggaca 180
ngagggctaa attccatgaa gtttgtggat ggcctgatga tccacaatcg gagaccctgt 240
taactactac cgtctnaccn cctgctgtnc ncccccnttt ctgctnaana catngggntn 300
ntncttgncc ntccttgggt ngaanatnna atngcctncc cnttcntanc nctactngnt 360
ccananttgg cctttaaana atccnccttg ccttnnncac tgttcanntn tttnntcgta 420
aaccctatna nttnnattan atnntnnnnn nctcaccccc ctcntcattn anccnatang 480
ctnnnaantc cttnanncct cccncccnnt ncnctcntac tnantncttc tnncccatta 540
cnnagctctt tcntttaana taatgnngcc nngctctnca tntctacnat ntgnnnaatn 600
cccccncccc cnancgnntt tttgacctnn naacctcctt tcctcttccc tncnnaaatt 660
ncnnanttcc ncnttccnnc ntttcggntn ntcccatnct ttccannnct tcantctanc 720
ncnctncaac ttattttcct ntcatccctt nttctttaca nnccccctnn tctactcnnc 780
nnttncatta natttgaaac tnccacnnct anttncctcn ctctacnntt ttattttncg 840
ntcnctctac ntaatanttt aatnanttnt cn 872
<210>211
<211>517
<212>DNA
<213> human
<220>
<221>misc_feature
<222>462,464,506
<223> n ═ A, T, C or G
<400>211
tcgagcggcc gcccgggcag gtctgccaag gagaccctgt tatgctgtgg ggactggctg 60
gggcatggca ggcggctctg gcttcccacc cttctgttct gagatggggg tggtgggcag 120
tatctcatct ttgggttcca caatgctcac gtggtcaggc aggggcttct tagggccaat 180
cttaccagtt gggtcccagg gcagcatgat cttcaccttg atgcccagca caccctgtct 240
gagcaacacg tggcgcacaa gcagtgtcaa cgtagtaagt taacagggtc tccgctgtgg 300
atcatcaggc catccacaaa cttcatggat ttagccctct gtcctcggag tttcccagac 360
accacaacct cgcagccttt ggccccactc tccatgatga accgcagcac accatagcag 420
gccctccgca caagcaagcc ctcctaagaa tttgtaacgc ananactctg ctggcaatgg 480
cacacaaacc tctagtggac ctcggncgcg accacgc 517
<210>212
<211>695
<212>DNA
<213> human
<220>
<221>misc_feature
<222>432,476,522,547,621,624,647,679
<223> n ═ A, T, C or G
<400>212
tcgagcggcc gcccgggcag gtctggtcca ggatagcctg cgagtcctcc tactgctact 60
ccagacttga catcatatga atcatactgg ggagaatagt tctgaggacc agtagggcat 120
gattcacaga ttccaggggg gccaggagaa ccaggggacc ctggttgtcc tggaatacca 180
gggtcaccat ttctcccagg aataccagga gggcctggat ctcccttggg gccttgaggt 240
ccttgaccat taggagggcg agtaggagca gttggaggct gtgggcaaac tgcacaacat 300
tctccaaatg gaatttctgg gttggggcag tctaattctt gatccgtcac atattatgtc 360
atcgcagaga acggatcctg agtcacagac acatatttgg catggttctg gcttccagac 420
atctctatcc gncataggac tgaccaagat gggaacatcc tccttcaaca agcttnctgt 480
tgtgccaaaa ataatagtgg gatgaagcag accgagaagt anccagctcc cctttttgca 540
caaagcntca tcatgtctaa atatcagaca tgagacttct ttgggcaaaa aaggagaaaa 600
agaaaaagca gttcaaagta nccnccatca agttggttcc ttgcccnttc agcacccggg 660
ccccgttata aaacacctng ggccggaccc ccctt 695
<210>213
<211>804
<212>DNA
<213> human
<220>
<221>misc_feature
<222>552,555,592,624,629,633,658,695,697,698,700,702,
745,753,755,762,773,786,788,793,795
<223> n ═ A, T, C or G
<400>213
agcgtggtcg cggccgaggt gttttatgac gggcccggtg ctgaagggca gggaacaact 60
tgatggtgct actttgaact gcttttcttt tctccttttt gcacaaagag tctcatgtct 120
gatatttaga catgatgagc tttgtgcaaa aggggagctg gctacttctc gctctgcttc 180
atcccactat tattttggca caacaggaag ctgttgaagg aggatgttcc catcttggtc 240
agtcctatgc ggatagagat gtctggaagc cagaaccatg ccaaatatgt gtctgtgact 300
caggatccgt tctctgcgat gacataatat gtgacgatca agaattagac tgccccaacc 360
cagaaattcc atttggagaa tgttgtgcag tttgcccaca gcctccaact gctcctactc 420
gccctcctaa tggtcaagga cctcaaggcc ccaagggaga tccaggccct cctggtattc 480
ctgggagaaa tggtgaccct ggtattccag gacaaccagg gtcccctggt tctcctggcc 540
cccctggaat cnggngaatc atgccctact ggtcctcaaa ctattctccc anatgattca 600
tatgatgtca agtctgggat agcnagtang ganggactcg caggctattc tggaccanac 660
ctgccggggg ggcgttcgaa agcccgaatc tgcananntn cnttcacact ggcggccgtc 720
gagctgcttt aaaagggcca ttccnccttt agngnggggg antacaatta ctnggcggcg 780
ttttanancg cgngnctggg aaat 804
<210>214
<211>594
<212>DNA
<213> human
<220>
<221>misc_feature
<222>452,509,585
<223> n ═ A, T, C or G
<400>214
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacacgc aggtctcacc 180
agtctccatg ttgcagaaga ctttgatggc atccaggttg cagccttggt tggggtcaat 240
ccagtactct ccactcttcc agtcagagtg gcacatcttg aggtcacggc aggtgcgggc 300
ggggttcttg cggctgccct ctgggctccg gatgttctcg atctgctggc tcaggctctt 360
gagggtggtg tccacctcga ggtcacggtc acgaaccaca ttggcatcat cagcccggta 420
gtagcggcca ccatcgtgag ccttctcttg angtggctgg ggcaggaact gaagtcgaaa 480
ccagcgctgg gaggaccagg gggaccaana ggtccaggaa gggcccgggg gggaccaaca 540
ggaccagcat caccaagtgc gacccgcgag aacctgcccg gccgnccgct cgaa 594
<210>215
<211>590
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,9
<223> n ═ A, T, C or G
<400>215
tcgagcgnnc gcccgggcag gtctcgcggt cgcactggtg atgctggtcc tgttggtccc 60
cccggccctc ctggacctcc tggtccccct ggtcctccca gcgctggttt cgacttcagc 120
ttcctgcccc agccacctca agagaaggct cacgatggtg gccgctacta ccgggctgat 180
gatgccaatg tggttcgtga ccgtgacctc gaggtggaca ccaccctcaa gagcctgagc 240
cagcagatcg agaacatccg gagcccagag ggcagccgca agaaccccgc ccgcacctgc 300
cgtgacctca agatgtgcca ctctgactgg aagagtggag agtactggat tgaccccaac 360
caaggctgca acctggatgc catcaaagtc ttctgcaaca tggagactgg tgagacctgc 420
gtgtacccca ctcagcccag tgtggcccag aagaactggt acatcagcaa gaaccccaag 480
gacaagaggc atgtctggtt cggcgagagc atgaccgatg gattccagtt cgagtatggc 540
ggccagggct cccaccctgc cgatgtggac ctccggccgc gaccaccctt 590
<210>216
<211>801
<212>DNA
<213> human
<220>
<221>misc_feature
<222>2,22,25,26,328,373,385,440,473,534,571,572,573,
582,587,589,593,600,605,617,633,642,653,672,681,
685,696,699,709,715,717,726,731,739,742,745,758,
769,772,778,780,788,789,791,793,796
<223> n ═ A, T, C or G
<400>216
tngagcggcc gcccgggcag gntgnnaacg ctggtcctgc tggtcctcct ggcaaggctg 60
gtgaagatgg tcaccctgga aaacccggac gacctggtga gagaggagtt gttggaccac 120
agggtgctcg tggtttccct ggaactcctg gacttcctgg cttcaaaggc attaggggac 180
acaatggtct ggatggattg aagggacagc ccggtgctcc tggtgtgaag ggtgaacctg 240
gtgcccctgg tgaaaatgga actccaggtc aaacaggagc ccgtgggctt cctggtgaga 300
gaggaccgtg ttggtgcccc tggcccanac ctcggccgcg accacgctaa gcccgaattt 360
ccagcacact ggnggccgtt actantggat ccgagctcgg taccaagctt ggcgtaatca 420
tggtcatagc tgtttcctgn gtgaaattgt tatccgctca caatttcaca cancatacga 480
agccggaaag cataaagtgt aaagccttgg ggtgctaatg agtgagctaa ctcncattaa 540
attgcgttgc gctcactgcc cgcttttcca nnngggaaac cntggcntng ccngcttgcn 600
ttaantgaaa tccgccnacc cccggggaaa agncggtttg cngtattggg gcnctttttc 660
cctttcctcg gnttacttga nttantgggc tttggncgnt tcgggttgng gcgancnggt 720
tcaacntcac nccaaaggng gnaanacggt tttcccanaa tccgggggnt ancccaangn 780
aaaacatnng ncnaangggc t 801
<210>217
<211>349
<212>DNA
<213> human
<220>
<221>misc_feature
<222>10,157,170
<223> n ═ A, T, C or G
<400>217
agcgtggttn gcggccgagg tctgggccag gggcaccaac acgtcctctc tcaccaggaa 60
gcccacgggc tcctgtttga cctggagttc cattttcacc aggggcacca ggttcaccct 120
tcacaccagg agcaccgggc tgtcccttca atccatncag accattgtgn cccctaatgc 180
ctttgaagcc aggaagtcca ggagttccag ggaaaccacc gagcaccctg tggtccaaca 240
actcctctct caccaggtcg tccgggtttt ccagggtgac catcttcacc agccttgcca 300
ggaggaccag caggaccagc gttaccaacc tgcccgggcg gccgctcga 349
<210>218
<211>372
<212>DNA
<213> human
<400>218
tcgagcggcc gcccgggcag gtccattttc tccctgacgg tcccacttct ctccaatctt 60
gtagttcaca ccattgtcat ggcaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ttgacagagt tgcccacggt aacaacctct tcccgaacct tatgcctctg 300
ctggtctttc agtgcctcca ctatgatgtt gtaggtggca cctctggtga ggacctcggc 360
cgcgaccacg ct 372
<210>219
<211>374
<212>DNA
<213> human
<400>219
agcgtggtcg cggccgaggt cctcaccaga ggtgccacct acaacatcat agtggaggca 60
ctgaaagacc agcagaggca taaggttcgg gaagaggttg ttaccgtggg caactctgtc 120
aacgaaggct tgaaccaacc tacggatgac tcgtgctttg acccctacac agtttcccat 180
tatgccgttg gagatgagtg ggaacgaatg tctgaatcag gctttaaact gttgtgccag 240
tgcttaggct ttggaagtgg tcatttcaag atgtgattca tctagatggt gccatgacaa 300
tggtgtgaac tacaagattg gagagaagtg ggaccgtcag ggagaaaatg gacctgcccg 360
ggccggccgc tcga 374
<210>220
<211>828
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,9,557,571,587,588,601,642,643,647,654,664,681,
688,698,719,720,725,734,738,743,744,757,765,773,
778,780,782,783,793,798,805,809,822,827
<223> n ═ A, T, C or G
<400>220
tcgagcgnnc gcccgggcag gtccagtagt gccttcggga ctgggttcac ccccaggtct 60
gcggcagttg tcacagcgcc agccccgctg gcctccaaag catgtgcagg agcaaatggc 120
accgagatat tccttctgcc actgttctcc tacgtggtat gtcttcccat catcgtaaca 180
cgttgcctca tgagggtcac acttgaattc tccttttccg ttcccaagac atgtgcagct 240
catttggctg gctctatagt ttggggaaag tttgttgaaa ctgtgccact gacctttact 300
tcctccttct ctactggagc tttcgtacct tccacttctg ctgttggtaa aatggtggat 360
cttctatcaa tttcattgac agtacccact tctcccaaac atccagggaa atagtgattt 420
cagagcgatt aggagaacca aattatgggg cagaaataag gggcttttcc acaggttttc 480
ctttggagga agatttcagt ggtgacttta aaagaatact caacagtgtc ttcatcccca 540
tagcaaaaga agaaacngta aatgatggaa ngcttctgga gatgccnnca tttaagggac 600
ncccagaact tcaccatcta caggacctac ttcagtttac annaagncac atantctgac 660
tcanaaagga cccaagtagc nccatggnca gcactttnag cctttcccct ggggaaaann 720
ttacnttctt aaancctngg ccnngacccc cttaagncca aattntggaa aanttccntn 780
cnnctggggg gcngttcnac atgcntttna agggcccaat tnccccnt 828
<210>221
<211>476
<212>DNA
<213> human
<400>221
tcgagcggcc gcccgggcag gtgtcggagt ccagcacggg aggcgtggtc ttgtagttgt 60
tctccggctg cccattgctc tcccactcca cggcgatgtc gctgggatag aagcctttga 120
ccaggcaggt caggctgacc tggttcttgg tcatctcctc ccgggatggg ggcagggtgt 180
acacctgtgg ttctcggggc tgccctttgg ctttggagat ggttttctcg atgggggctg 240
ggagggcttt gttggagacc ttgcacttgt actccttgcc attcagccag tcctggtgca 300
ggacggtgag gacgctgacc acacggtacg tgctgttgta ctgctcctcc cgcggctttg 360
tcttggcatt atgcacctcc acgccgtcca cgtaccagtt gaacttgacc tcagggtctt 420
cgtggctcac gtccaccacc acgcatgtaa cctcagacct cggccgcgac cacgct 476
<210>222
<211>477
<212>DNA
<213> human
<400>222
agcgtggtcg cggccgaggt ctgaggttac atgcgtggtg gtggacgtga gccacgaaga 60
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa 120
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca 180
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc 240
ccccatcgag aaaaccatct ccaaagccaa agggcaagcc ccgagaacca caggtgtaca 300
ccctgccccc atcccgggag gagatgacca agaaccaggt cagcctgacc tgcctggtca 360
aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag ccggagaaca 420
actacaagac cacgcctccc gtgctggact ccgacacctg cccgggcggc cgctcga 477
<210>223
<211>361
<212>DNA
<213> human
<400>223
tcgagcggcc gcccgggcag gttgaatggc tcctcgctga ccaccccggt gctggtggtg 60
ggtacagagc tccgatgggt gaaaccattg acatagagac tgtccctgtc cagggtgtag 120
gggcccagct cagtgatgcc gtgggtcagc tggctcagct tccagtacag ccgctctctg 180
tccagtccag ggcttttggg gtcaggacga tgggtgcaga cagcatccac tctggtggct 240
gccccatcct tctcaggcct gagcaaggtc agtctgcaac cagagtacag agagctgaca 300
ctggtgttct tgaacaaggg cataagcaga ccctgaagga cacctcggcc gcgaccacgc 360
t 361
<210>224
<211>361
<212>DNA
<213> human
<400>224
agcgtggtcg cggccgaggt gtccttcagg gtctgcttat gcccttgttc aagaacacca 60
gtgtcagctc tctgtactct ggttgcagac tgaccttgct caggcctgag aaggatgggg 120
cagccaccag agtggatgct gtctgcaccc atcgtcctga ccccaaaagc cctggactgg 180
acagagagcg gctgtactgg aagctgagcc agctgaccca cggcatcact gagctgggcc 240
cctacaccct ggacagggac agtctctatg tcaatggttt cacccatcgg agctctgtac 300
ccaccaccag caccggggtg gtcagcgagg agccattcaa cctgcccggg cggccgctcg 360
a 361
<210>225
<211>766
<212>DNA
<213> human
<220>
<221>misc_feature
<222>574,610,631,643,657,660,666,688,712,735,747
<223> n ═ A, T, C or G
<400>225
agcgtggtcg cggccgaggt cctgtcagag tggcactggt agaagttcca ggaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagtgt 120
cctggaatgg ggcccatgag atggttgtct gagagagagc ttcttgtcct acattcggcg 180
ggtatggtct tggcctatgc cttatggggg tggccgttgt gggcggtgtg gtccgcctaa 240
aaccatgttc ctcaaagatc atttgttgcc caacactggg ttgctgacca gaagtgccag 300
gaagctgaat accatttcca gtgtcatacc cagggtgggt gacgaaaggg gtcttttgaa 360
ctgtggaagg aacatccaag atctctggtc catgaagatt ggggtgtgga agggttacca 420
gttggggaag ctcgtctgtc tttttccttc caatcagggg ctcgctcttc tgattattct 480
tcagggcaat gacataaatt gtatattcgg tcccggttcc aggccagtaa tagtagcctc 540
tgtgacacca gggcggggcc gagggaccct tctnttggaa gagaccagct tctcatactt 600
gatgatgagn ccggtaatcc tggcacgtgg nggttgcatg atnccaccaa ggaaatnggn 660
gggggnggac ctgcccggcg gccgttcnaa agcccaattc cacacacttg gnggccgtac 720
tatggatccc actcngtcca acttggngga atatggcata actttt 766
<210>226
<211>364
<212>DNA
<213> human
<400>226
tcgagcggcc gcccgggcag gtccttgacc ttttcagcaa gtgggaaggt gtaatccgtc 60
tccacagaca aggccaggac tcgtttgtac ccgttgatga tagaatgggg tactgatgca 120
acagttgggt agccaatctg cagacagaca ctggcaacat tgcggacacc ctccaggaag 180
cgagaatgca gagtttcctc tgtgatatca agcacttcag ggttgtagat gctgccattg 240
tcgaacacct gctggatgac cagcccaaag gagaaggggg agatgttgag catgttcagc 300
agcgtggctt cgctggctcc cactttgtct ccagtcttga tcagacctcg gccgcgacca 360
cgct 364
<210>227
<211>275
<212>DNA
<213> human
<400>227
agcgtggtcg cggccgaggt ctgtcctaca gtcctcagga ctctactccc tcagcagcgt 60
ggtgaccgtg ccctccagca acttcggcac ccagacctac acctgcaacg tagatcacaa 120
gcccagcaac accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac 180
atgcccaccg tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccg 240
catccccctt ccaaacctgc ccgggcggcc gctcg 275
<210>228
<211>275
<212>DNA
<213> human
<400>228
cgagcggccg cccgggcagg tttggaaggg ggatgcgggg gaagaggaag actgacggtc 60
cccccaggag ttcaggtgct gggcacggtg ggcatgtgtg agttttgtca caagatttgg 120
gctcaactct cttgtccacc ttggtgttgc tgggcttgtg atctacgttg caggtgtagg 180
tctgggtgcc gaagttgctg gagggcacgg tcaccacgct gctgagggag tagagtcctg 240
aggactgtag gacagacctc ggccgcgacc acgct 275
<210>229
<211>40
<212>DNA
<213> human
<220>
<221>misc_feature
<222>1,4,5,13,15,17,29
<223> n ═ A, T, C or G
<400>229
nggnnggtcc ggncngncag gaccactcnt cttcgaaata 40
<210>230
<211>208
<212>DNA
<213> human
<400>230
agcgtggtcg cggccgaggt cctcacttgc ctcctgcaaa gcaccgatag ctgcgctctg 60
gaagcgcaga tctgttttaa agtcctgagc aatttctcgc accagacgct ggaagggaag 120
tttgcgaatc agaagttcag tggacttctg ataacgtcta atttcacgga gcgccacagt 180
accaggacct gcccgggcgg ccgctcga 208
<210>231
<211>208
<212>DNA
<213> human
<220>
<221>misc_feature
<222>33
<223> n ═ A, T, C or G
<400>231
tcgagcggcc gcccgggcag gtcctggtac tgnggcgctc cgtgaaatta gacgttatca 60
gaagtccact gaacttctga ttcgcaaact tcccttccag cgtctggtgc gagaaattgc 120
tcaggacttt aaaacagatc tgcgcttcca gagcgcagct atcggtgctt tgcaggaggc 180
aagtgaggac ctcggccgcg accacgct 208
<210>232
<211>332
<212>DNA
<213> human
<400>232
tcgagcggcc gcccgggcag gtccacatcg gcagggtcgg agccctggcc gccatactcg 60
aactggaatc catcggtcat gctctcgccg aaccagacat gcctcttgtc cttggggttc 120
ttgctgatgt accagttctt ctgggccaca ctgggctgag tggggtacac gcaggtctca 180
ccagtctcca tgttgcagaa gactttgatg gcatccaggt tgcagccttg gttggggtca 240
atccagtact ctccactctt ccagtcagag tggcacatct tgaggtcacg gcaggtgcgg 300
gcggggttct tgacctcggc cgcgaccacg ct 332
<210>233
<211>415
<212>DNA
<213> human
<220>
<221>misc_feature
<222>6,15,19,21
<223> n ═ A, T, C or G
<400>233
gtgggnttga acccntttna nctccgcttg gtaccgagct cggatccact agtaacggcc 60
gccagtgtgc tggaattcgg cttagcgtgg tcgcggccga ggtcaagaac cccgcccgca 120
cctgccgtga cctcaagatg tgccactctg actggaagag tggagagtac tggattgacc 180
ccaaccaagg ctgcaacctg gatgccatca aagtcttctg caacatggag actggtgaga 240
cctgcgtgta ccccactcag cccagtgtgg cccagaagaa ctggtacatc agcaagaacc 300
ccaaggacaa gaggcatgtc tggttcggcg agagcatgac cgatggattc cagttcgagt 360
atggcggcca gggctccgac cctgccgatg tggacctgcc cgggcggccg ctcga 415
<210>234
<211>776
<212>DNA
<213> human
<220>
<221>misc_feature
<222>505,550,574,601,604,608,612,649,656,657,680,711,
750,776
<223> n ═ A, T, C or G
<400>234
agcgtggtcg cggccgaggt ctgggatgct cctgctgtca cagtgagata ttacaggatc 60
acttacggag aaacaggagg aaatagccct gtccaggagt tcactgtgcc tgggagcaag 120
tctacagcta ccatcagcgg ccttaaacct ggagttgatt ataccatcac tgtgtatgct 180
gtcactggcc gtggagacag ccccgcaagc agcaagccaa tttccattaa ttaccgaaca 240
gaaattgaca aaccatccca gatgcaagtg accgatgttc aggacaacag cattagtgtc 300
aagtggctgc cttcaagttc ccctgttact ggttacagag taaccaccac tcccaaaaat 360
ggaccaggac caacaaaaac taaaactgca ggtccagatc aaacagaaat gactattgaa 420
ggcttgcagc ccacagtgga gtatgtggtt aagtgtctat gctcagaatc caagcggaga 480
gaagtcagcc tctggttcag actgnaagta accaacattg atcgcctaaa ggactggcat 540
tcactgatgn ggatgccgat tccatcaaaa ttgnttggga aaacccacag gggcaagttt 600
ncangtcnag gnggacctac tcgagccctg aggatggaat ccttgactnt tccttnncct 660
gatggggaaa aaaaaccttn aaaacttgaa ggacctgccc gggcggccgt ncaaaaccca 720
attccacccc cttgggggcg ttctatgggn cccactcgga ccaaacttgg ggtaan 776
<210>235
<211>805
<212>DNA
<213> human
<220>
<221>misc_feature
<222>637,684,705,724,733,756,778,793,796,804
<223> n ═ A, T, C or G
<400>235
tcgagcggcc gcccgggcag gtccttgcag ctctgcagtg tcttcttcac catcaggtgc 60
agggaatagc tcatggattc catcctcagg gctcgagtag gtcaccctgt acctggaaac 120
ttgcccctgt gggctttccc aagcaatttt gatggaatcg gcatccacat cagtgaatgc 180
cagtccttta gggcgatcaa tgttggttac tgcagtctga accagaggct gactctctcc 240
gcttggattc tgagcataga cactaaccac atactccact gtgggctgca agccttcaat 300
agtcatttct gtttgatctg gacctgcagt tttagttttt gttggtcctg gtccattttt 360
gggagtggtg gttactctgt aaccagtaac aggggaactt gaaggcagcc acttgacact 420
aatgctgttg tcctgaacat cggtcacttg catctgggat ggtttgtcaa tttctgttcg 480
gtaattaatg gaaattggct tgctgcttgc ggggcttgtc tccacggcca gtgacagcat 540
acacagtgat ggtataatca actccaggtt taagccgctg atggtagctg aaactttgct 600
ccaggcacaa gtgaactcct gacagggcta tttcctnctg ttctccgtaa gtgatcctgt 660
aatatctcac tgggacagca ggangcattc caaaacttcg ggcgngaccc cctaagccga 720
attntgcaat atncatcaca ctggcgggcg ctcgancatt cattaaaagg cccaatcncc 780
cctataggga gtntantaca attng 805
<210>236
<211>262
<212>DNA
<213> human
<400>236
tcgagcggcc gcccgggcag gtcacttttg gtttttggtc atgttcggtt ggtcaaagat 60
aaaaactaag tttgagagat gaatgcaaag gaaaaaaata ttttccaaag tccatgtgaa 120
attgtctccc atttttttgg cttttgaggg ggttcagttt gggttgcttg tctgtttccg 180
ggttgggggg aaagttggtt gggtgggagg gagccaggtt gggatggagg gagtttacag 240
gaagcagaca gggccaacgt cg 262
<210>237
<211>372
<212>DNA
<213> human
<400>237
agcgtggtcg cggccgaggt cctcaccaga ggtgccacct acaacatcat agtggaggca 60
ctgaaagacc agcagaggca taaggttcgg gaagaggttg ttaccgtggg caactctgtc 120
aacgaaggct tgaaccaacc tacggatgac tcgtgctttg acccctacac agtttcccat 180
tatgccgttg gagatgagtg ggaacgaatg tctgaatcag gctttaaact gttgtgccag 240
tgcttaggct ttggaagtgg tcatttcaga tgtgattcat ctagatggtg ccatgacaat 300
ggtgtgaact acaagattgg agagaagtgg gaccgtcagg gagaaaatgg acctgcccgg 360
gcggccgctc ga 372
<210>238
<211>372
<212>DNA
<213> human
<400>238
tcgagcggcc gcccgggcag gtccattttc tccctgacgg tcccacttct ctccaatctt 60
gtagttcaca ccattgtcat ggcaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ttgacagagt tgcccacggt aacaacctct tcccgaacct tatgcctctg 300
ctggtctttc agtgcctcca ctatgatgtt gtaggtggca cctctggtga ggacctcggc 360
cgcgaccacg ct 372
<210>239
<211>720
<212>DNA
<213> human
<220>
<221>misc_feature
<222>478,557,563,566,620,660,663,672,673,684,693,695
<223> n ═ A, T, C or G
<400>239
tcgagcggcc gcccgggcag gtccaccata agtcctgata caaccacgga tgagctgtca 60
ggagcaaggt tgatttcttt cattggtccg gtcttctcct tgggggtcac ccgcactcga 120
tatccagtga gctgaacatt gggtggtgtc cactgggcgc tcaggcttgt gggtgtgacc 180
tgagtgaact tcaggtcagt tggtgcagga atagtggtta ctgcagtctg aaccagaggc 240
tgactctctc cgcttggatt ctgagcatag acactaacca catactccac tgtgggctgc 300
aagccttcaa tagtcatttc tgtttgatct ggacctgcag ttttagtttt tgttggtcct 360
ggtccatttt tgggagtggt ggttactctg taaccagtaa caggggaact tgaaggcagc 420
cacttgacac taatgctgtt gtcctgaaca tcggtcactt gcatctggga tggtttgnca 480
atttctgttc ggtaattaat ggaaattggc ttgctgcttg cggggctgtc tccacggcca 540
gtgacagcat acacagngat ggnatnatca actccaagtt taaggccctg atggtaactt 600
taaacttgct cccagccagn gaacttccgg acagggtatt tcttctggtt ttccgaaagn 660
gancctggaa tnntctcctt ggancagaag gancntccaa aacttgggcc ggaacccctt 720
<210>240
<211>691
<212>DNA
<213> human
<220>
<221>misc_feature
<222>564,582,640,651,666,669,690
<223> n ═ A, T, C or G
<400>240
agcgtggtcg cggccgaggt cctgtcagag tggcactggt agaagttcca ggaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagtgt 120
cctggaatgg ggcccatgag atggttgtct gagagagagc ttcttgtcct acattcggcg 180
ggtatggtct tggcctatgc cttatggggg tggccgttgt gggcggtgtg gtccgcctaa 240
aaccatgttc ctcaaagatc atttgttgcc caacactggg ttgctgacca gaagtgccag 300
gaagctgaat accatttcca gtgtcatacc cagggtgggt gacgaaaggg gtcttttgaa 360
ctgtggaagg aacatccaag atctctggtc catgaagatt ggggtgtgga agggttacca 420
gttggggaag ctcgtctgtc tttttccttc caatcagggg ctcgctcttc tgattattct 480
tcagggcaat gacataaatt gtatattcgg ttcccggttc caggccagta atagtagcct 540
cttgtgacac caggcggggc ccanggacca cttctctggg angagaccca gcttctcata 600
cttgatgatg taacccggta atcctgcacg tggcggctgn catgatacca ncaaggaatt 660
gggtgnggng gacctgcccg gcggccctcn a 691
<210>241
<211>808
<212>DNA
<213> human
<220>
<221>misc_feature
<222>680,715,721,728,735,749,757,762,772,776,779,781,
792,796,800,808
<223> n ═ A, T, C or G
<400>241
agcgtggtcg cggccgaggt ctgggatgct cctgctgtca cagtgagata ttacaggatc 60
acttacggag aaacaggagg aaatagccct gtccaggagt tcactgtgcc tgggagcaag 120
tctacagcta ccatcagcgg ccttaaacct ggagttgatt ataccatcac tgtgtatgct 180
gtcactggcc gtggagacag ccccgcaagc agcaagccaa tttccattaa ttaccgaaca 240
gaaattgaca aaccatccca gatgcaagtg accgatgttc aggacaacag cattagtgtc 300
aagtggctgc cttcaagttc ccctgttact ggttacagag taaccaccac tcccaaaaat 360
ggaccaggac caacaaaaac taaaactgca ggtccagatc aaacagaaat gactattgaa 420
ggcttgcagc ccacagtgga gtatgtggtt agtgtctatg ctcagaatcc aagcggagag 480
agtcagcctc tggttcagac tgcagtaacc actattcctg caccaactga cctgaagttc 540
actcaggtca cacccacaag cctgagccgc cagtggacac cacccaatgt tcactcactg 600
gatatcgagt gcgggtgacc cccaaggaga agacccggac ccatgaaaga aatcaacctt 660
gctcctgaca gctcatccgn gggtgtatca ggacttatgg gggactgccc cggcnggccg 720
ntcgaaancg aattntgaaa tttccttcnc actgggnggc gnttcgagct tncttntana 780
nggcccaatt cncctntagn gggtcgtn 808
<210>242
<211>26
<212>DNA
<213> human
<220>
<221>misc_feature
<222>22
<223> n ═ A, T, C or G
<400>242
agcgtggtcg cggccgaggt cnagga 26
<210>243
<211>697
<212>DNA
<213> human
<220>
<221>misc_feature
<222>496,541,624,662,679,688
<223> n ═ A, T, C or G
<400>243
tcgagcggcc gcccgggcag gtccaccaca cccaattcct tgctggtatc atggcagccg 60
ccacgtgcca ggattaccgg ctacatcatc aagtatgaga agcctgggtc tcctcccaga 120
gaagtggtcc ctcggccccg ccctggtgtc acagaggcta ctattactgg cctggaaccg 180
ggaaccgaat atacaattta tgtcattgcc ctgaagaata atcagaagag cgagcccctg 240
attggaagga aaaagacaga cgagcttccc caactggtaa cccttccaca ccccaatctt 300
catggaccag agatcttgga tgttccttcc acagttcaaa agaccccttt cgtcacccac 360
cctgggtatg acactggaaa tggtattcag cttcctggca cttctggtca gcaacccagt 420
gttgggcaac aaatgatctt tgaggaacat ggttttaggc ggaccacacc gcccacaacg 480
ggcaccccca taaggnatag gccaagacca taccccgccg aatgtaggac aagaagctct 540
ntctcaacaa ccatctcatg ggccccattc caggacactt ctgagtacat catttcatgt 600
catcctggtg ggcacttgat gaanaaccct tacagttcag ggttcctgga acttctacca 660
gngccacttc tgacagganc ttgggcgnga ccaccct 697
<210>244
<211>373
<212>DNA
<213> human
<400>244
agcgtggtcg cggccgaggt ccattttctc cctgacggtc ccacttctct ccaatcttgt 60
agttcacacc attgtcatgg caccatctag atgaatcaca tctgaaatga ccacttccaa 120
agcctaagca ctggcacaac agtttaaagc ctgattcaga cattcgttcc cactcatctc 180
caacggcata atgggaaact gtgtaggggt caaagcacga gtcatccgta ggttggttca 240
agccttcgtt gacagagttg cccacggtaa caacctcttc ccgaacctta tgcctctgct 300
ggtctttcag tgcctccact atgatgttgt aggtggcacc tctggtgagg acctgcccgg 360
gcggcccgct cga 373
<210>245
<211>307
<212>DNA
<213> human
<400>245
agcgtggtcg cggccgaggt gtgccccaga ccaggaattc ggcttcgacg ttggccctgt 60
ctgcttcctg taaactccct ccatcccaac ctggctccct cccacccaac caactttccc 120
cccaacccgg aaacagacaa gcaacccaaa ctgaaccccc tcaaaagcca aaaaaatggg 180
agacaatttc acatggactt tggaaaatat ttttttcctt tgcattcatc tctcaaactt 240
agtttttatc tttgaccaac cgaacatgac caaaaaccaa aagtgacctg cccgggcggc 300
cgctcga 307
<210>246
<211>372
<212>DNA
<213> human
<400>246
tcgagcggcc gcccgggcag gtcctcacca gaggtgccac ctacaacatc atagtggagg 60
cactgaaaga ccagcagagg cataaggttc gggaagaggt tgttaccgtg ggcaactctg 120
tcaacgaagg cttgaaccaa cctacggatg actcgtgctt tgacccctac acagtttccc 180
attatgccgt tggagatgag tgggaacgaa tgtctgaatc aggctttaaa ctgttgtgcc 240
agtgcttagg ctttggaagt ggtcatttca gatgtgattc atctagatgg tgccatgaca 300
atggtgtgaa ctacaagatt ggagagaagt gggaccgtca gggagaaaat ggacctcggc 360
cgcgaccacg ct 372
<210>247
<211>348
<212>DNA
<213> human
<220>
<221>misc_feature
<222>284,297,299,322,325,338,342,345
<223> n ═ A, T, C or G
<400>247
tcgagcggcc gcccgggcag gtaccggggt ggtcagcgag gagccattca cactgaactt 60
caccatcaac aacctgcggt atgaggagaa catgcagcac cctggctcca ggaagttcaa 120
caccacggag agggtccttc agggcctgct caggtccctg ttcaagagca ccagtgttgg 180
ccctctgtac tctggctgca gactgacttt gctcagacct gagaaacatg gggcagccac 240
tggagtggac gccatctgca ccctccgcct tgatcccact ggtnctggac tggacanana 300
gcggctatac ttgggagctg anccnaacct ttggcggnga cnccnctt 348
<210>248
<211>304
<212>DNA
<213> human
<220>
<221>misc_feature
<222>125
<223> n ═ A, T, C or G
<400>248
gaggactggc tcagctccca gtatagccgc tctctgtcca gtccaggacc agtgggatca 60
aggcggaggg tgcagatggc gtccactcca gtggctgccc catgtttctc aagtctgagc 120
aaagncagtc tgcagccaga gtacagaggg ccaacactgg tgctcttgaa cagggacctg 180
agcaggccct gaaggaccct ctccgtggtg ttgaacttcc tggagccagg gtgctgcatg 240
ttctcctcat accgcaggtt gttgatggtg aagttcagtg tgaatggctc ctcgctgacc 300
accc 304
<210>249
<211>400
<212>DNA
<213> human
<220>
<221>misc_feature
<222>308,310,312,320,331,336,383,392,396
<223> n ═ A, T, C or G
<400>249
agcgtggtcg cggccgaggt ccaccacacc caattccttg ctggtatcat ggcagccgcc 60
acgtgccagg attaccggct acatcatcaa gtatgagaag cctgggtctc ctcccagaga 120
agtggtccct cggccccgcc ctggtgtcac agaggctact attactggcc tggaaccggg 180
aaccgaatat acaatttatg tcattgccct gaagaataat cagaagagcg agcccctgat 240
tggaaggaaa aagacagacg agcttcccca actggtaacc cttccacacc ccaatcttca 300
tggaccanan ancttggatn gtcctttcac nggttnaaaa aacccttttc gcccccccac 360
cttggggatt aaccttggga aanggggatt tnaccnttcc 400
<210>250
<211>400
<212>DNA
<213> human
<220>
<221>misc_feature
<222>338,357,361,369,388,394
<223> n ═ A, T, C or G
<400>250
tcgagcggcc gcccgggcag gtcctgtcag agtggcactg gtagaagttc caggaaccct 60
gaactgtaag ggttcttcat cagtgccaac aggatgacat gaaatgatgt actcagaagt 120
gtcctggaat ggggcccatg agatggttgt ctgagagaga gcttcttgtc ctacattcgg 180
cgggtatggt cttggcctat gccttatggg ggtggccgtt gtgggcggtg tggtccgcct 240
aaaaccatgt tcctcaaaga tcatttgttg cccaacactg ggttgctgac cagaagtgcc 300
aggaagctga ataccatttc cagtgtcata cccagggngg gtgaccaaag ggggtcnttt 360
ngacctggng aaaggaacca tccaaaanct ctgncccatg 400
<210>251
<211>514
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,107,312,338,351,352,357,363,366,373,380,405,
421,444,508
<223> n ═ A, T, C or G
<400>251
agcgtggncg cggccgaggt ctgaggatgt aaactcttcc caggggaagg ctgaagtgct 60
gaccatggtg ctactgggtc cttctgagtc agatatgtga ctgatgngaa ctgaagtagg 120
tactgtagat ggtgaagtct gggtgtccct aaatgctgca tctccagagc cttccatcat 180
taccgtttct tcttttgcta tgggatgaga cactgttgag tattctctaa agtcaccact 240
gaaatcttcc tccaaaggaa aacctgtgga aaagcccctt atttctgccc cataatttgg 300
ttctcctaat cnctctgaaa tcactatttc cctggaangt ttgggaaaaa nngggcnacc 360
tgncantgga aantggatan aaagatccca ccattttacc caacnagcag aaagtgggaa 420
nggtaccgaa aagctccaag taanaaaaag gagggaagta aaggtcaagt gggcaccagt 480
ttcaaacaaa actttcccca aactatanaa ccca 514
<210>252
<211>501
<212>DNA
<213> human
<220>
<221>misc_feature
<222>20,21,25,44,343,347,356,362,387,391,398,409,428,
430,453,494
<223> n ═ A, T, C or G
<400>252
aagcggccgc ccgggcaggn ncagnagtgc cttcgggact gggntcaccc ccaggtctgc 60
ggcagttgtc acagcgccag ccccgctggc ctccaaagca tgtgcaggag caaatggcac 120
cgagatattc cttctgccac tgttctccta cgtggtatgt cttcccatca tcgtaacacg 180
ttgcctcatg agggtcacac ttgaattctc cttttccgtt cccaagacat gtgcagctca 240
tttggctggc tctatagttt ggggaaagtt tgttgaaact gtgccactga cctttacttc 300
ctccttctct actggagctt tccgtacctt ccacttctgc tgntggnaaa aagggnggaa 360
cntcttatca atttcattgg acagtanccc nctttctncc caaaacatnc aagggaaaat 420
attgattncn agagcggatt aaggaacaac ccnaattatg ggggccagaa ataaaggggg 480
cttttccaca ggtnttttcc t 501
<210>253
<211>226
<212>DNA
<213> human
<400>253
tcgagcggcc gcccgggcag gtctgcaggc tattgtaagt gttctgagca catatgagat 60
aacctgggcc aagctatgat gttcgatacg ttaggtgtat taaatgcact tttgactgcc 120
atctcagtgg atgacagcct tctcactgac agcagagatc ttcctcactg tgccagtggg 180
caggagaaag agcatgctgc gactggacct cggccgcgac cacgct 226
<210>254
<211>226
<212>DNA
<213> human
<400>254
agcgtggtcg cggccgaggt ccagtcgcag catgctcttt ctcctgccca ctggcacagt 60
gaggaagatc tctgctgtca gtgagaaggc tgtcatccac tgagatggca gtcaaaagtg 120
catttaatac acctaacgta tcgaacatca tagcttggcc caggttatct catatgtgct 180
cagaacactt acaatagcct gcagacctgc ccgggcggcc gctcga 226
<210>255
<211>427
<212>DNA
<213> human
<220>
<221>misc_feature
<222>327,403
<223> n ═ A, T, C or G
<400>255
cgagcggccg cccgggcagg tccagactcc aatccagaga accaccaagc cagatgtcag 60
aagctacacc atcacaggtt tacaaccagg cactgactac aagatctacc tgtacacctt 120
gaatgacaat gctcggagct cccctgtggt catcgacgcc tccactgcca ttgatgcacc 180
atccaacctg cgtttcctgg ccaccacacc caattccttg ctggtatcat ggcagccgcc 240
acgtgccagg attaccggct acatcatcaa gtatgagaag cctgggtctc ctcccagaga 300
agtggtccct cggccccgcc ctggtgncac agaagctact attactggcc tggaaccggg 360
aaccgaatat acaatttatg tcattgccct gaagaataat canaagagcg agcccctgat 420
tggaagg 427
<210>256
<211>535
<212>DNA
<213> human
<220>
<221>misc_feature
<222>347,456,475
<223> n ═ A, T, C or G
<400>256
agcgtggtcg cggccgaggt cctgtcagag tggcactggt agaagttcca ggaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagtgt 120
cctggaatgg ggcccatgag atggttgtct gagagagagc ttcttgtcct gtctttttcc 180
ttccaatcag gggctcgctc ttctgattat tcttcagggc aatgacataa attgtatatt 240
cggttcccgg ttccaggcca gtaatagtag cctctgtgac accagggcgg ggccgaggga 300
ccacttctct gggaggagac ccaggcttct catacttgat gatgtanccg gtaatcctgg 360
caccgtggcg gctgccatga taccagcaag gaattgggtg tggtggccaa gaaacgcagg 420
ttggatggtg catcaatggc agtggaggcg tcgatnacca caggggagct ccgancattg 480
tcattcaagg tggacaggta gaatcttgta atcaggtgcc tggtttgtaa acctg 535
<210>257
<211>544
<212>DNA
<213> human
<220>
<221>misc_feature
<222>495,511
<223> n ═ A, T, C or G
<400>257
tcgagcggcc gcccgggcag gtttcgtgac cgtgacctcg aggtggacac caccctcaag 60
agcctgagcc agcagatcga gaacatccgg agcccagagg gcagccgcaa gaaccccgcc 120
cgcacctgcc gtgacctcaa gatgtgccac tctgactgga agagtggaga gtactggatt 180
gaccccaacc aaggctgcaa cctggatgcc atcaaagtct tctgcaacat ggagactggt 240
gagacctgcg tgtaccccac tcagcccagt gtggcccaga agaactggta catcagcaag 300
aaccccaagg acaagaagca tgtctggttc ggcgaaagca tgaccgatgg attccagttc 360
gagtatggcg gccagggctc cgaccctgcc gatgtggacc tcggccgcga ccacgctaag 420
cccgaattcc agcacactgg cggccgttac tagtgggatc cgagcttcgg taccaagctt 480
ggcgtaatca tgggncatag ctgtttcctg ngtgaaaatg gtattccgct tcacaatttc 540
ccac 544
<210>258
<211>418
<212>DNA
<213> human
<400>258
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacacgc aggtctcacc 180
agtctccatg ttgcagaaga ctttgatggc atccaggttg cagccttggt tggggtcaat 240
ccagtactct ccactcttcc agtcagagtg gcacatcttg aggtcacggc aggtgcgggc 300
ggggttcttg cggctgccct ctgggctccg gatgttctcg atctgctggc tcaagctctt 360
gaagggtggt gtccacctcg aggtcacggt cacgaaacct gcccgggcgg ccgctcga 418
<210>259
<211>377
<212>DNA
<213> human
<220>
<221>misc_feature
<222>320,326,342,352
<223> n ═ A, T, C or G
<400>259
agcgtggtcg cggccgaggt caagaacccc gcccgcacct gccgtgacct caagatgtgc 60
cactctgact ggaagagtgg agagtactgg attgacccca accaaggctg caacctggat 120
gccatcaaag tcttctgcaa catggagact ggtgagacct gcgtgtaccc cactcagccc 180
agtgtggccc agaagaactg gtacatcagc aagaacccca aggacaagag gcatgtctgg 240
ttcggcgaga gcatgaccga tggattccag ttcgagtatg gcggccaggg ctccgaccct 300
gccgatgtgg acctgcccgn gccggnccgc tcgaaaagcc cnaatttcca gncacacttg 360
gccggccgtt actactg 377
<210>260
<211>332
<212>DNA
<213> human
<400>260
tcgagcggcc gcccgggcag gtccacatcg gcagggtcgg agccctggcc gccatactcg 60
aactggaatc catcggtcat gctctcgccg aaccagacat gcctcttgtc cttggggttc 120
ttgctgatgt accagttctt ctgggccaca ctgggctgag tggggtacac gcaggtctca 180
ccagtctcca tgttgcagaa gactttgatg gcatccaggt tgcagccttg gttggggtca 240
atccagtact ctccactctt ccagtcagag tggcacatct tgaggtcacg gcaggtgcgg 300
gcggggttct tgacctcggc cgcgaccacg ct 332
<210>261
<211>94
<212>DNA
<213> human
<400>261
cgagcggccg cccgggcagg tcccccccct tttttttttt tttttttttt tttttttttt 60
tttttttttt tttttttttt tttttttttt tttt 94
<210>262
<211>650
<212>DNA
<213> human
<220>
<221>misc_feature
<222>412,582,612,641,646
<223> n ═ A, T, C or G
<400>262
agcgtggtcg cggccgaggt ctggcattcc ttcgacttct ctccagccga gcttcccaga 60
acatcacata tcactgcaaa aatagcattg catacatgga tcaggccagt ggaaatgtaa 120
agaaggccct gaagctgatg gggtcaaatg aaggtgaatt caaggctgaa ggaaatagca 180
aattcaccta cacagttctg gaggatggtt gcacgaaaca cactggggaa tggagcaaaa 240
cagtctttga atatcgaaca cgcaaggctg tgagactacc tattgtagat attgcaccct 300
atgacattgg tggtcctgat caagaatttg gtgtggacgt tggccctgtt tgctttttat 360
aaaccaaact ctatctgaaa tcccaacaaa aaaaatttaa ctccatatgt gntcctcttg 420
ttctaatctt ggcaaccagt gcaagtgacc gacaaaattc cagttattta tttccaaaat 480
gtttggaaac agtataattt gacaaagaaa aaaggatact tctctttttt tggctggtcc 540
accaaataca attcaaaagg ctttttggtt ttattttttt anccaattcc aatttcaaaa 600
tgtctcaatg gngcttataa taaaataaac tttcaccctt nttttntgat 650
<210>263
<211>573
<212>DNA
<213> human
<220>
<221>misc_feature
<222>453,458,544
<223> n ═ A, T, C or G
<400>263
agcgtggtcg cggccgaggt ctgggatgct cctgctgtca cagtgagata ttacaggatc 60
acttacggag aaacaggagg aaatagccct gtccaggagt tcactgtgcc tgggagcaag 120
tctacagcta ccatcagcgg ccttaaacct ggagttgatt ataccatcac tgtgtatgct 180
gtcactggcc gtggagacag ccccgcaagc agcaagccaa tttccattaa ttaccgaaca 240
gaaattgaca aaccatccca gatgcaagtg accgatgttc aggacaacag cattagtgtc 300
aagtggctgc cttcaagttc ccctgttact ggttacagaa gtaaccacca ctcccaaaaa 360
tggaccagga ccaacaaaaa ctaaaactgc aggtccagat caaacagaaa atggactatt 420
gaaggcttgc agcccacagt ggaagtatgt ggntaggngt ctatgctcag aatcccaagc 480
cggagaaagt cagccttctg gtttagactg cagtaaccaa cattgatcgc cctaaaggac 540
tggncattca cttggatggt ggatgtccaa ttc 573
<210>264
<211>550
<212>DNA
<213> human
<220>
<221>misc_feature
<222>39,174,352,526
<223> n ═ A, T, C or G
<400>264
tcgagcggcc gcccgggcag gtccttgcag ctctgcagng tcttcttcac catcaggtgc 60
agggaatagc tcatggattc catcctcagg gctcgagtag gtcaccctgt acctggaaac 120
ttgcccctgt gggctttccc aagcaatttt gatggaatcg acatccacat cagngaatgc 180
cagtccttta gggcgatcaa tgttggttac tgcagtctga accagaggct gactctctcc 240
gcttggattc tgagcataga cactaaccac atactccact gtgggctgca agccttcaat 300
agtcatttct gtttgatctg gacctgcagt tttaagtttt tggtggtcct gncccatttt 360
tgggaagtgg ggggttactc tgtaaccagt aacaggggaa cttgaaggca gccacttgac 420
actaatgctg ttgtcctgaa catcggtcac ttgcatctgg ggatggtttt gacaatttct 480
ggttcggcaa attaatggaa attggcttgc tgcttggcgg ggctgnctcc acgggccagt 540
gacagcatac 550
<210>265
<211>596
<212>DNA
<213> human
<220>
<221>misc_feature
<222>347,352,353,534,555,587
<223> n ═ A, T, C or G
<400>265
tcgagcggcc gcccgggcag gtccttgcag ctctgcagtg tcttcttcac catcaggtgc 60
agggaatagc tcatggattc catcctcagg gctcgagtag gtcaccctgt acctggaaac 120
ttgcccctgt gggctttccc aagcaatttt gatggaatcg acatccacat cagtgaatgc 180
cagtccttta gggcgatcaa tgttggttac tgcagtctga accagaggct gactctctcc 240
gcttggattc tgagcataga cactaaccac atactccact gtgggctgca agccttcaat 300
agtcatttct gtttgatctg gacctgcagt tttaagtttt tgttggncct gnnccatttt 360
tggggaaggg gtggttactc ttgtaaccag taacagggga acttgaagca gccacttgac 420
actaatgctg gtggcctgaa catcggtcac ttgcatctgg gatggtttgg tcaatttctg 480
ttcggtaatt aatgggaaat tggcttactg gcttgcgggg gctgtctcca cggncagtga 540
caagcataca caggngatgg gtataatcaa ctccaggttt aaggccnctg atggta 596
<210>266
<211>506
<212>DNA
<213> human
<220>
<221>misc_feature
<222>393,473
<223> n ═ A, T, C or G
<400>266
agcgtggtcg cggccgaggt ctgggatgct cctgctgtca cagtgagata ttacaggatc 60
acttacggag aaacaggagg aaatagccct gtccaggagt tcactgtgcc tgggagcaag 120
tctacagcta ccatcagcgg ccttaaacct ggagttgatt ataccatcac tgtgtatgct 180
gtcactggcc gtggagacag ccccgcaagc agtaagccaa tttccattaa ttaccgaaca 240
gaaattgaca aaccatccca gatgcaagtg accgatgttc aggacaacag cattagtgtc 300
aagtggctgc cttcaagttc ccctgttact ggttacagag taaccaccac tcccaaaaat 360
gggaccagga ccaacaaaaa actaaaactg canggtccag atcaaacaga aatgactatt 420
gaaggcttgc agcccacagt ggagtatgtg ggttagtgtc tatgctcaga atnccaagcg 480
gagagagtca gcctctggtt cagact 506
<210>267
<211>548
<212>DNA
<213> human
<220>
<221>misc_feature
<222>346,358,432,510,512
<223> n ═ A, T, C or G
<400>267
tcgagcggcc gcccgggcag gtcagcgctc tcaggacgtc accaccatgg cctgggctct 60
gctcctcctc accctcctca ctcagggcac agggtcctgg gcccagtctg ccctgactca 120
gcctccctcc gcgtccgggt ctcctggaca gtcagtcacc atctcctgca ctggaaccag 180
cagtgacgtt ggtgcttatg aatttgtctc ctggtaccaa caacacccag gcaaggcccc 240
caaactcatg atttctgagg tcactaagcg gccctcaggg gtccctgatc gcttctctgg 300
ctccaagtct ggcaacacgg cctccctgac cgtctctggg ctccangctg aggatgangc 360
tgattattac tggaagctca tatgcaggca acaacaattg ggtgttcggc ggaagggacc 420
aagctgaccg tnctaaggtc aagcccaagg cttgcccccc tcggtcactc tgttcccacc 480
ctcctctgaa gaagctttca agccaacaan gncacactgg gtgtgtctca taagtggact 540
ttctaccc 548
<210>268
<211>584
<212>DNA
<213> human
<220>
<221>misc_feature
<222>98,380,421,454,495,506,512,561,565,579
<223> n ═ A, T, C or G
<400>268
agcgtggtcg cggccgaggt ctgtagcttc tgtgggactt ccactgctca ggcgtcaggc 60
tcaggtagct gctggccgcg tacttgttgt tgctttgntt ggagggtgtg gtggtctcca 120
ctcccgcctt gacggggctg ctatctgcct tccaggccac tgtcacggct cccgggtaga 180
agtcacttat gagacacacc agtgtggcct tgttggcttg aagctcctca gaggagggtg 240
ggaacagagt gaccgagggg gcagccttgg gctgacctag gacggtcagc ttggtccctc 300
cgccgaacac ccaattgttg ttgcctgcat atgagctgca gtaataatca gcctcatcct 360
cagcctggag cccagagacn gtcaagggag gcccgtgttt gccaagactt ggaagccaga 420
naagcgatca gggacccctg agggccgctt tacngacctc aaaaaatcat gaatttgggg 480
ggcctttgcc tgggngttgg ttggtnacca gnaaaacaaa atttcataaa gcaccaacgt 540
cactgctggt ttccagtgca ngaanatggt gaactgaant gtcc 584
<210>269
<211>368
<212>DNA
<213> human
<220>
<221>misc_feature
<222>265,329
<223> n ═ A, T, C or G
<400>269
agcgtggtcg cggccgaggt ccagcatcag gagccccgcc ttgccggctc tggtcatcgc 60
ctttcttttt gtggcctgaa acgatgtcat caattcgcag tagcagaact gccgtctcca 120
ctgctgtctt ataagtctgc agcttcacag ccaatggctc ccatatgccc agttccttca 180
tgtccaccaa agtacccgtc tcaccattta caccccaggt ctcacagttc tcctgggtgt 240
gcttggcccg aagggaggta agtanacgga tggtgctggt cccacagttc tggatcaggg 300
tacgaggaat gacctctagg gcctgggcna caagccctgt atggacctgc ccgggcgggc 360
ccgctcga 368
<210>270
<211>368
<212>DNA
<213> human
<220>
<221>misc_feature
<222>54,163,219,229,316
<223> n ═ A, T, C or G
<400>270
tcgagcggcc gcccgggcag gtccatacag ggctgttgcc caggccctag aggncattcc 60
ttgtaccctg atccagaact gtgggaccag caccatccgt ctacttacct cccttcgggc 120
caagcacacc caggagaact gtgagacctg gggtgtaaat ggngagacgg gtactttggt 180
ggacatgaag gaactgggca tatgggagcc attggctgng aagctgcana cttataagac 240
agcagtggag acggcagttc tgctactgcg aattgatgac atcgtttcag gccacaaaaa 300
gaaaggcgat gaccanagcc ggcaaggcgg ggcttcctga tgctggacct cggccgccga 360
ccacgctt 368
<210>271
<211>424
<212>DNA
<213> human
<220>
<221>misc_feature
<222>279,329,362,384,400
<223> n ═ A, T, C or G
<400>271
agcgtggtcg cggccgaggt ccactagagg tctgtgtgcc attgcccagg cagagtctct 60
gcgttacaaa ctcctaggag ggcttgctgt gcggagggcc tgctatggtg tgctgcggtt 120
catcatggag agtggggcca aaggctgcga ggttgtggtg tctgggaaac tccgaggaca 180
gagggctaaa tccatgaagt ttgtggatgg cctgatgatc cacagcggag accctgttaa 240
ctactacgtt gacactgctg tgcgccacgt gttgctcana cagggtgtgc tgggcatcaa 300
ggtgaagatc atgctgccct gggacccanc tggcaaaaat ggcccttaaa aaccccttgc 360
cntgaccacg tgaaccattt gtgngaaccc caagatgaan atacttgccc accacccccc 420
attc 424
<210>272
<211>541
<212>DNA
<213> human
<220>
<221>misc_feature
<222>422,442,510,513,515,525
<223> n ═ A, T, C or G
<400>272
tcgagcggcc gcccgggcag gtctgccaag gagaccctgt tatgctgtgg ggactggctg 60
gggcatggca ggcggctctg gcttcccacc cttctgttct gagatggggg tggtgggcag 120
tatctcatct ttgggttcca caatgctcac gtggtcaggc aggggcttct tagggccaat 180
cttaccagtt gggtcccagg gcagcatgat cttcaccttg atgcccagca caccctgtct 240
gagcaacacg tggcgcacag cagtgtcaac gtagtagtta acagggtctc cgctgtggat 300
catcaggcca tccacaaact tcatggattt agccctctgt cctcggagtt tcccaaaaca 360
ccacaacctc gccagccttt gggccccact tcttcatgaa tgaaaccgca gcacaccatt 420
ancaaggccc ttccgcacag gnaagccctt cctaaggagt tttgtaaacg caaaaaactc 480
ttgcctgggg caaatgggca cacagacctn tantnggacc ttggnccgcg aaccaccgct 540
t 541
<210>273
<211>579
<212>DNA
<213> human
<220>
<221>misc_feature
<222>223,265,277,308,329,346,360,366,429,448,517,524,
531,578
<223> n ═ A, T, C or G
<400>273
agcgtggtcg cggccgaggt ctggccctcc tggcaaggct ggtgaagatg gtcaccctgg 60
aaaacccgga cgacctggtg agagaggagt tgttggacca cagggtgctc gtggtttccc 120
tggaactcct ggacttcctg gcttcaaagg cattagggga cacaatggtc tggatggatt 180
gaagggacag cccggtgctc ctggtgtgaa gggtgaacct ggngcccctg gtgaaaatgg 240
aactccaggt caaacaggag cccgngggct tcctggngag agaggacgtg ttggtgcccc 300
tggcccanac ctgcccgggc ggccgctcna aaagccgaaa tccagnacac tggcggccgn 360
tactantgga atccgaactt cggtaccaaa gcttggccgt aatcatggcc atagcttgtt 420
ccctggggng gaaattggta ttccgctncc aattccacac aacataccga acccggaaag 480
cattaaagtg taaaagccct gggggggcct aaatgangtg agcntaactc ncatttaatt 540
ggcgttgcgc ttcactgccc cgcttttcca gtccgggna 579
<210>274
<211>330
<212>DNA
<213> human
<220>
<221>misc_feature
<222>171
<223> n ═ A, T, C or G
<400>274
tcgagcggcc gcccgggcag gtctgggcca ggggcaccaa cacgtcctct ctcaccagga 60
agcccacggg ctcctgtttg acctggagtt ccattttcac caggggcacc aggttcaccc 120
ttcacaccag gagcaccggg ctgtcccttc aatccatcca gaccattgtg ncccctaatg 180
cctttgaagc caggaagtcc aggagttcca gggaaaccac gagcaccctg tggtccaaca 240
actcctctct caccaggtcg tccgggtttt ccagggtgac catcttcacc agccttgcca 300
ggagggccag acctcggccg cgaccacgct 330
<210>275
<211>97
<212>DNA
<213> human
<220>
<221>misc_feature
<222>2,35,72
<223> n ═ A, T, C or G
<400>275
ancgtggtcg cggccgaggt cctcaccaga ggtgncacct acaacatcat agtggaggca 60
ctgaaagacc ancagaggca taaggttcgg gaagagg 97
<210>276
<211>610
<212>DNA
<213> human
<220>
<221>misc_feature
<222>358,360,363,382,424,433,464,468,477,491,499,511,
558,584,588,590
<223> n ═ A, T, C or G
<400>276
tcgagcggcc gcccgggcag gtccattttc tccctgacgg tcccacttct ctccaatctt 60
gtagttcaca ccattgtcat ggcaccatct agatgaatca catctgaaat gaccacttcc 120
aaagcctaag cactggcaca acagtttaaa gcctgattca gacattcgtt cccactcatc 180
tccaacggca taatgggaaa ctgtgtaggg gtcaaagcac gagtcatccg taggttggtt 240
caagccttcg ttgacagagt tgtccacggt aacaacctct tcccgaacct tatgcctctg 300
ctggtctttc agtgcctcca ctatgatgtt gtaggtggca cctctggtga ggacctcngn 360
ccngaacaac gcttaagccc gnattctgca gaataatccc atcacacttg gcggccgctt 420
cgancatgca tcntaaaagg ggccccaatt tcccccttat aagngaancc gtatttncca 480
atttcactgg ncccgccgnt tttacaaacg ncggtgaact ggggaaaaac cctggcggtt 540
acccaacttt aatcgccntt ggcagcacaa tccccccttt tcgnccancn tgggcgtaaa 600
taaccgaaaa 610
<210>277
<211>38
<212>DNA
<213> human
<220>
<221>misc_feature
<222>2,5,18,21,31
<223> n ═ A, T, C or G
<400>277
ancgnggtcg cggccgangt nttttttctt nttttttt 38
<210>278
<211>443
<212>DNA
<213> human
<220>
<221>misc_feature
<222>156,212,233,245,327,331,336,361,364,381,391,397,
419,437
<223> n ═ A, T, C or G
<400>278
agcgtggtcg cggccgaggt ctgaggttac atgcgtggtg gtggacgtga gccacgaaga 60
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa 120
gccgcgggag gagcagtaca acagcacgta ccgggnggtc agcgtcctca ccgtcctgca 180
ccagaattgg ttgaatggca aggagtacaa gngcaaggtt tccaacaaag ccntcccagc 240
ccccntcgaa aaaaccattt ccaaagccaa agggcagccc cgagaaccac aggtgtacac 300
cctgccccca tcccgggagg aaaagancaa naaccnggtt cagccttaac ttgcttggtc 360
naangctttt tatcccaacg nacttccccc ntggaantgg gaaaaaccaa tgggccaanc 420
cgaaaaacaa ttacaanaac ccc 443
<210>279
<211>348
<212>DNA
<213> human
<220>
<221>misc_feature
<222>219,256,291,297,307,314,317
<223> n ═ A, T, C or G
<400>279
tcgagcggcc gcccgggcag gtgtcggagt ccagcacggg aggcgtggtc ttgtagttgt 60
tctccggctg cccattgctc tcccactcca cggcgatgtc gctgggatag aagcctttga 120
ccaggcaggt caggctgacc tggttcttgg tcatctcctc ccgggatggg ggcagggtga 180
acacctgggg ttctcggggc ttgccctttg gttttgaana tggttttctc gatgggggct 240
ggaagggctt tgttgnaaac cttgcacttg actccttgcc attcacccag ncctggngca 300
ggacggngag gacnctnacc acacggaacc gggctggtgg actgctcc 348
<210>280
<211>149
<212>DNA
<213> human
<220>
<221>misc_feature
<222>18,34,51,118,120,140
<223> n ═ A, T, C or G
<400>280
agcgtggtcg cggacgangt cctgtcagag tggnactggt agaagttcca ngaaccctga 60
actgtaaggg ttcttcatca gtgccaacag gatgacatga aatgatgtac tcagaagngn 120
cctggaatgg ggcccatgan atggttgcc 149
<210>281
<211>404
<212>DNA
<213> human
<220>
<221>misc_feature
<222>383,386,388,393
<223> n ═ A, T, C or G
<400>281
tcgagcggcc gcccgggcag gtccaccaca cccaattcct tgctggtatc atggcagccg 60
ccacgtgcca ggattaccgg ctacatcatc aagtatgaga agcctgggtc tcctcccaga 120
gaagtggtcc ctcggccccg ccctggtgtc acagaggcta ctattactgg cctggaaccg 180
ggaaccgaat atacaattta tgtcattgcc ctgaagaata atcagaagag cgagcccctg 240
attggaagga aaaagacaga cgagcttccc caactggtaa cccttccaca ccccaatctt 300
catggaccag agatcttgga tgttccttcc acagttcaaa agaccccttt cggcaccccc 360
cctgggtatg aacctgggaa aanggnantt aanctttcct ggca 404
<210>282
<211>507
<212>DNA
<213> human
<220>
<221>misc_feature
<222>320,341,424,450,459,487,498
<223> n ═ A, T, C or G
<400>282
agcgtggtcg cggccgaggt ctgggatgct cctgctgtca cagtgagata ttacaggatc 60
acttacggag aaacaggagg aaatagccct gtccaggagt tcactgtgcc tgggagcaag 120
tctacagcta ccatcagcgg ccttaaacct ggagttgatt ataccatcac tgtgtatgct 180
gtcactggcc gtggagacag ccccgcaagc agcaagccaa tttccattaa ttaccgaaca 240
gaaattgaca aaccatccca gatgcaagtg accgatgttc aggacaacag cattagtgtc 300
aagtggctgc cttcaaggtn ccctggtact gggttacaga ntaaccacca ctcccaaaaa 360
tggaccagga accacaaaaa cttaaactgc agggtccaga tcaaaacaga aatgactatt 420
gaangcttgc agcccacagt gggagtatgn gggtagtgnc tatgcttcag aatccaagcg 480
gaaaaangtc aagccttntg ggttcaa 507
<210>283
<211>325
<212>DNA
<213> human
<220>
<221>misc_feature
<222>216,292,303,304
<223> n ═ A, T, C or G
<400>283
tcgagcggcc gcccgggcag gtccttgcag ctctgcagtg tcttcttcac catcaggtgc 60
agggaatagc tcatggattc catcctcagg gctcgagtag gtcaccctgt acctggaaac 120
ttgcccctgt gggctttccc aagcaatttt gatggaatcg acatccacat cagtgaatgc 180
cagtccttta gggcgatcaa tgttggttac tgcagnctga accagaggct gactctctcc 240
gcttggattc tgagcataga cactaaccac atactccact gtgggctgca anccttcaat 300
aanncatttc tgtttgatct ggacc 325
<210>284
<211>331
<212>DNA
<213> human
<220>
<221>misc_feature
<222>54,59,63,121,312,327
<223> n ═ A, T, C or G
<400>284
tcgagcggcc gcccgggcag gtctggtggg gtcctggcac acgcacatgg gggngttgnt 60
ctnatccagc tgcccagccc ccattggcga gtttgagaag gtgtgcagca atgacaacaa 120
naccttcgac tcttcctgcc acttctttgc cacaaagtgc accctggagg gcaccaagaa 180
gggccacaag ctccacctgg actacatcgg gccttgcaaa tacatccccc cttgcctgga 240
ctctgagctg accgaattcc cccttgcgca tgcgggactg gctcaagaac cgtcctggca 300
cccttgtatg anagggatga agacacnacc c 331
<210>285
<211>509
<212>DNA
<213> human
<220>
<221>misc_feature
<222>316,319,327,329,339,344,357,384,398,427,443,450,
478
<223> n ═ A, T, C or G
<400>285
agcgtggtcg cggccgaggt ctgtcctaca gtcctcagga ctctactccc tcagcagcgt 60
ggtgaccgtg ccctccagca acttcggcac ccagacctac acctgcaacg tagatcacaa 120
gcccagcaac accaaggtgg acaagagagt tgagcccaaa tcttgtgaca aaactcacac 180
atgcccaccg tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccg 240
catccccctt ccaaacctgc ccgggcggcc gctcgaaagc cgaattccag cacactggcg 300
gccggtacta gtgganccna acttggnanc caacctggng gaantaatgg gcataanctg 360
tttctggggg gaaattggta tccngtttac aattcccnca caacatacga gccggaagca 420
taaaagngta aaagcctggg ggnggcctan tgaagtgaag ctaaactcac attaattngc 480
gttgccgctc actggcccgc ttttccagc 509
<210>286
<211>336
<212>DNA
<213> human
<220>
<221>misc_feature
<222>188,251,267
<223> n ═ A, T, C or G
<400>286
tcgagcggcc gcccgggcag gtttggaagg gggatgcggg ggaagaggaa gactgacggt 60
ccccccagga gttcaggtgc tgggcacggt gggcatgtgt gagttttgtc acaagatttg 120
ggctcaactc tcttgtccac cttggtgttg ctgggcttgt gatctacgtt gcaggtgtag 180
gtctgggngc cgaagttgct ggagggcacg gtcaccacgc tgctgaggga gtagagtcct 240
gaggactgta ngacagacct cggccgngac cacgctaagc cgaattctgc agatatccat 300
cacactggcg gccgctccga gcatgcattt tagagg 336
<210>287
<211>30
<212>DNA
<213> human
<220>
<221>misc_feature
<222>8,18
<223> n ═ A, T, C or G
<400>287
agcgtggncg cggacganga caacaacccc 30
<210>288
<211>316
<212>DNA
<213> human
<220>
<221>misc_feature
<222>22,130
<223> n ═ A, T, C or G
<400>288
tcgagcggcc gcccgggcag gnccacatcg gcagggtcgg agccctggcc gccatactcg 60
aactggaatc catcggtcat gctcttgccg aaccagacat gcctcttgtc cttggggttc 120
ttgctgatgn accagttctt ctgggccaca ctgggctgag tggggtacac gcaggtctca 180
ccagtctcca tgttgcagaa gactttgatg gcatccaggt tgcagccttg gttggggtca 240
atccagtact ctccactctt ccagtcagag tggcacatct tgaggtcacg gcaggtgcgg 300
gcggggttct tgacct 316
<210>289
<211>308
<212>DNA
<213> human
<220>
<221>misc_feature
<222>36,165,191,195,218,235
<223> n ═ A, T, C or G
<400>289
agcgtggtcg cggccgaggt ccagcctgga gataanggtg aaggtggtgc ccccggactt 60
ccaggtatag ctggacctcg tggtagccct ggtgagagag gtgaaactgg ccctccagga 120
cctgctggtt tccctggtgc tcctggacag aatggtgaac ctggnggtaa aggagaaaga 180
ggggctccgg ntganaaagg tgaaggaggc cctcctgnat tggcaggggc cccangactt 240
agaggtggag ctggcccccc tggccccgaa ggaggaaagg gtgctgctgg tcctcctggg 300
ccacctgg 308
<210>290
<211>324
<212>DNA
<213> human
<220>
<221>misc_feature
<222>184
<223> n ═ A, T, C or G
<400>290
tcgagcggcc gcccgggcag gtctgggcca ggaggaccaa taggaccagt aggacccctt 60
gggccatctt tccctgggac accatcagca cctggaccgc ctggttcacc cttgtcaccc 120
tttggaccag gacttccaag acctcctctt tctccaggca ttccttgcag accaggagta 180
ccancagcac caggtggccc aggaggacca gcagcaccct ttcctccttc gggaccaggg 240
ggaccagctc cacctctaag tcctggggcc cctgccaatc caggagggcc tccttcacct 300
ttctcacccg gagcccctct ttct 324
<210>291
<211>278
<212>DNA
<213> human
<220>
<221>misc_feature
<222>249,267
<223> n ═ A, T, C or G
<400>291
tcgagcggcc gcccgggcag gtccaccggg atattcgggg gtctggcagg aatgggaggc 60
atccagaacg agaaggagac catgcaaagc ctgaacgacc gcctggcctc ttacctggac 120
agagtgagga gcctggagac cgacaaccgg aggctggaga gcaaaatccg ggagcacttg 180
gagaagaagg gaccccaggt cagagactgg agccattact tcaagatcat cgaggacctg 240
agggctcana tcttcgcaaa tactgcngac aatgcccg 278
<210>292
<211>299
<212>DNA
<213> human
<220>
<221>misc_feature
<222>6,19,25,51,53,61,63,70,109,136,157,241,276
<223> n ═ A, T, C or G
<400>292
atgcgnggtc gcggccgang accanctctg gctcatactt gactctaaag ncntcaccag 60
nanttacggn cattgccaat ctgcagaacg atgcgggcat tgtccgcant atttgcgaag 120
atctgagccc tcaggncctc gatgatcttg aagtaanggc tccagtctct gacctggggt 180
cccttcttct ccaagtgctc ccggattttg ctctccagcc tccggttctc ggtctccaag 240
ncttctcact ctgtccagga aaagaggcca ggcggncgat cagggctttt gcatggact 299
<210>293
<211>101
<212>DNA
<213> human
<400>293
agcgtggtcg cggccgaggt tgtacaagct tttttttttt tttttttttt tttttttttt 60
tttttttttt tttttttttt tttttttttt tttttttttt t 101
<210>294
<211>285
<212>DNA
<213> human
<220>
<221>misc_feature
<222>64,103,110,237,282
<223> n ═ A, T, C or G
<400>294
tcgagcggcc gcccgggcag gtctgccaac accaagattg gcccccgccg catccacaca 60
gttngtgtgc ggggaggtaa caagaaatac cgtgccctga ggntggacgn ggggaatttc 120
tcctggggct cagagtgttg tactcgtaaa acaaggatca tcgatgttgt ctacaatgca 180
tctaataacg agctggttcg taccaagacc ctggtgaaga attgcatcgt gctcatngac 240
agcacaccgt accgacagtg ggtaccgaag tcccactatg cncct 285
<210>295
<211>216
<212>DNA
<213> human
<400>295
tcgagcggcc gcccgggcag gtccaccaca cccaattcct tgctggtatc atggcagccg 60
ccacgtgcca ggattaccgg ctacatcatc aagtatgaga agcctgggtc tcctcccaga 120
gaagtggtcc ctcggccccg ccctggtgtc acagaggcta ctattactgg cctggaaccg 180
ggaaccgaat atacaattta tgtcattgcc ctgaag 216
<210>296
<211>414
<212>DNA
<213> human
<220>
<221>misc_feature
<222>7,10,33,61,62,63,88,109,122,255,298,307,340,
355,386,393
<223> n ═ A, T, C or G
<400>296
agcgtgntcn cggccgagga tggggaagct cgnctgtctt tttccttcca atcaggggct 60
nnntcttctg attattcttc agggcaanga cataaattgt atattcggnt cccggttcca 120
gnccagtaat agtagcctct gtgacaccag ggcggggccg agggaccact tctctgggag 180
gagacccagg cttctcatac ttgatgatga agccggtaat cctggcacgt gggcggctgc 240
catgatacca ccaangaatt gggtgtggtg gacctgcccg ggcgggccgc tcgaaaancc 300
gaattcntgc aagaatatcc atcacacttg ggcgggccgn tcgaaccatg catcntaaaa 360
gggccccaat ttccccccta ttaggngaag ccncatttaa caaattccac ttgg 414
<210>297
<211>376
<212>DNA
<213> human
<220>
<221>misc_feature
<222>312,326,335,361
<223> n ═ A, T, C or G
<400>297
tcgagcggcc gcccgggcag gtctcgcggt cgcactggtg atgctggtcc tgttggtccc 60
cccggccctc ctggacctcc tggtccccct ggtcctccca gcgctggttt cgacttcagc 120
ttcctgcccc agccacctca agagaaggct cacgatggtg gccgctacta ccgggctgat 180
gatgccaatg tggttcgtga ccgtgacctc gaggtggaca ccaccctcaa gagccttgag 240
ccagcagaat cgaaaacatt cggaacccaa gaagggcaag cccgcaaaga aaccccgccc 300
gcacctggcc gngaacctcc aagaangtgc ccacntcttg actgggaaaa aaagggaaaa 360
ntacttggaa ttggac 376
<210>298
<211>357
<212>DNA
<213> human
<220>
<221>misc_feature
<222>345,346
<223> n ═ A, T, C or G
<400>298
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacacgc aggtctcacc 180
agtctccatg ttgcagaaga ctttgatggc atccaggttg cagccttggt tggggtcaat 240
ccagtactct ccactcttcc agtcagaagt ggcacatctt gaggtcacgg cagggtgcgg 300
gcggggttct tgcgggctgc ccttctgggc tcccggaatg ttctnngaac ttgctgg 357
<210>299
<211>307
<212>DNA
<213> human
<220>
<221>misc_feature
<222>281,285,306
<223> n ═ A, T, C or G
<400>299
agcgtggtcg cggccgaggt ccactagagg tctgtgtgcc attgcccagg cagagtctct 60
gcgttacaaa ctcctaggag ggcttgctgt gcggagggcc tgctatggtg tgctgcggtt 120
catcatggag agtggggcca aaggctgcga ggttgtggtg tctgggaaac tccgaggaca 180
gagggctaaa tccatgaagt ttgtggatgg cctgatgatc cacagcggag accctgttaa 240
ctactacgtt gacacttgct tgtgcgccac gtgttgctca nacangggtg ggctgggcat 300
caaggng 307
<210>300
<211>351
<212>DNA
<213> human
<400>300
tcgagcggcc gcccgggcag gtctgccaag gagaccctgt tatgctgtgg ggactggctg 60
gggcatggca ggcggctctg gcttcccacc cttctgttct gagatggggg tggtgggcag 120
tatctcatct ttgggttcca caatgctcac gtggtcaggc aggggcttct tagggccaat 180
cttaccagtt gggtcccagg gcagcatgat cttcaccttg atgcccagca caccctgtct 240
gagcaacacg tggcgcacag caagtgtcaa cgtaagtaag ttaacagggt ctccgctgtg 300
gatcatcagg ccatccacaa acttcatgga tttaaccctc tgtcctcgga g 351
<210>301
<211>330
<212>DNA
<213> human
<400>301
tcgagcggcc gcccgggcag gtgtttcaga ggttccaagg tccactgtgg aggtcccagg 60
agtgctggtg gtgggcacag aggtccgatg ggtgaaacca ttgacataga gactgttcct 120
gtccagggtg taggggccca gctctttgat gccattggcc agttggctca gctcccagta 180
cagccgctct ctgttgagtc cagggctttt ggggtcaaga tgatggatgc agatggcatc 240
cactccagtg gctgctccat ccttctcgga cctgagagag gtcagtctgc agccagagta 300
cagagggcca acactggtgt tctttgaata 330
<210>302
<211>317
<212>DNA
<213> human
<220>
<221>misc_feature
<222>129,295
<223> n ═ A, T, C or G
<400>302
agcgtggtcg cggccgaggt ctgtactggg agctaagcaa actgaccaat gacattgaag 60
agctgggccc ctacaccctg gacaggaaca gtctctatgt caatggtttc acccatcaga 120
gctctgtgnc caccaccagc actcctggga cctccacagt ggatttcaga acctcaggga 180
ctccatcctc cctctccagc cccacaatta tggctgctgg ccctctcctg gtaccattca 240
ccctcaactt caccatcacc aacctgcagt atggggagga catgggtcac cctgnctcca 300
ggaagttcaa caccaca 317
<210>303
<211>283
<212>DNA
<213> human
<220>
<221>misc_feature
<222>139,146,195
<223> n ═ A, T, C or G
<400>303
tcgagcggcc gcccggacag gtctgggcgg atagcaccgg gcatattttg gaatggatga 60
ggtctggcac cctgagcagt ccagcgagga cttggtctta gttgagcaat ttggctagga 120
ggatagtatg cagcacggnt ctgagnctgt gggatagctg ccatgaagta acctgaagga 180
ggtgctggct ggtangggtt gattacaggg ttgggaacag ctcgtacact tgccattctc 240
tgcatatact ggttagtgag gtgagcctgg ccctcttctt ttg 283
<210>304
<211>72
<212>DNA
<213> human
<220>
<221>misc_feature
<222>59
<223> n ═ A, T, C or G
<400>304
agcgtggtcg cggccgaggt gagccacagg tgaccggggc tgaagctggg gctgctggnc 60
ctgctggtcc tg 72
<210>305
<211>245
<212>DNA
<213> human
<220>
<221>misc_feature
<222>5,11,22,98,102
<223> n ═ A, T, C or G
<400>305
cagcngctcc nacggggcct gngggaccaa caacaccgtt ttcaccctta ggccctttgg 60
ctcctctttc tcctttagca ccaggttgac cagcagcncc ancaggacca gcaaatccat 120
tggggccagc aggaccgacc tcaccacgtt caccagggct tccccgagga ccagcaggac 180
cagcaggacc agcagcccca gcttcgcccc ggtcacctgt ggctcacctc ggccgcgacc 240
acgct 245
<210>306
<211>246
<212>DNA
<213> human
<220>
<221>misc_feature
<222>144,159
<223> n ═ A, T, C or G
<400>306
tcgagcggtc gcccgggcag gtccaccggg atagccgggg gtctggcagg aatgggaggc 60
atccagaacg agaaggagac catgcaaagc ctgaacgacc gcctggcctc ttacctggac 120
agagtgagga gcctggagac cganaaccgg aggctggana gcaaaatccg ggagcacttg 180
gagaagaagg gaccccaggt caagagactg gagccattac ttcaagatca tcgagggacc 240
tggagg 246
<210>307
<211>333
<212>DNA
<213> human
<220>
<221>misc_feature
<222>5
<223> n ═ A, T, C or G
<400>307
agcgnggtcg cggccgaggt ccagctctgt ctcatacttg actctaaagt catcagcagc 60
aagacgggca ttgtcaatct gcagaacgat gcgggcattg tccgcagtat ttgcgaagat 120
ctgagccctc aggtcctcga tgatcttgaa gtaatggctc cagtctctga cctggggtcc 180
cttcttctcc aagtgctccc ggattttgct ctccagcctc cggttctcgg tctccaggct 240
cctcactctg tccaggtaag aaggcccagg cggtcgttca ggctttgcat ggtctccttc 300
tcgttctgga tgcctcccat tcctgccaga ccc 333
<210>308
<211>310
<212>DNA
<213> human
<400>308
tcgagcggcc gcccgggcag gtcaggaagc acattggtct tagagccact gcctcctgga 60
ttccacctgt gctgcggaca tctccaggga gtgcagaagg gaagcaggtc aaactgctca 120
gatcagtcag actggctgtt ctcagttctc acctgagcaa ggtcagtctg cagccagagt 180
acagagggcc aacactggtg ttcttgaaca agggcttgag cagaccctgc agaaccctct 240
tccgtggtgt tgaacttcct ggaaaccagg gtgttgcatg tttttcctca taatgcaagg 300
ttggtgatgg 310
<210>309
<211>429
<212>DNA
<213> human
<400>309
agcgtggtcg cggccgaggt ccacatcggc agggtcggag ccctggccgc catactcgaa 60
ctggaatcca tcggtcatgc tctcgccgaa ccagacatgc ctcttgtcct tggggttctt 120
gctgatgtac cagttcttct gggccacact gggctgagtg gggtacaccg caggtctcac 180
cagtctccat gttgcagaag actttgatgg catccaggtt gcagccttgg ttggggtcaa 240
tccagtactc tccactcttc cagtcagaag tgggcacatc ttgaggtcac cggcaggtgc 300
cgggccgggg gttcttgcgg cttgccctct gggctccgga tgttctcgat ctgcttggct 360
caggctcttg agggtgggtg tccacctcga ggtcacggtc accgaaacct gcccgggcgg 420
cccgctcga 429
<210>310
<211>430
<212>DNA
<213> human
<220>
<221>misc_feature
<222>342
<223> n ═ A, T, C or G
<400>310
tcgagcggtc gcccgggcag gtttcgtgac cgtgacctcg aggtggacac caccctcaag 60
agcctgagcc agcagatcga gaacatccgg agcccagagg gcagccgcaa gaaccccgcc 120
cgcacctgcc gtgacctcaa gatgtgccac tctgactgga agagtggaga gtactggatt 180
gaccccaacc aaggctgcaa cctggatgcc atcaaagtct tctgcaacat ggagactggt 240
gagacctgcg tgtaccccac tcagcccagt gtgggcccag aagaaactgg tacatcagca 300
aggaacccca aggacaagag gcattgtctt ggttcggcga gnagcatgac ccgatggatt 360
ccagtttcga gtattggcgg ccagggcttc ccgacccttg ccgatgtgga cctcggccgc 420
gaccaccgct 430
<210>311
<211>2996
<212>DNA
<213> human
<400>311
cagccaccgg agtggatgcc atctgcaccc accgccctga ccccacaggc cctgggctgg 60
acagagagca gctgtatttg gagctgagcc agctgaccca cagcatcact gagctgggcc 120
cctacaccct ggacagggac agtctctatg tcaatggttt cacacagcgg agctctgtgc 180
ccaccactag cattcctggg acccccacag tggacctggg aacatctggg actccagttt 240
ctaaacctgg tccctcggct gccagccctc tcctggtgct attcactctc aacttcacca 300
tcaccaacct gcggtatgag gagaacatgc agcaccctgg ctccaggaag ttcaacacca 360
cggagagggt ccttcagggc ctggtccctg ttcaagagca ccagtgttgg ccctctgtac 420
tctggctgca gactgacttt gctcaggcct gaaaaggatg ggacagccac tggagtggat 480
gccatctgca cccaccaccc tgaccccaaa agccctaggc tggacagaga gcagctgtat 540
tgggagctga gccagctgac ccacaatatc actgagctgg gcccctatgc cctggacaac 600
gacagcctct ttgtcaatgg tttcactcat cggagctctg tgtccaccac cagcactcct 660
gggaccccca cagtgtatct gggagcatct aagactccag cctcgatatt tggcccttca 720
gctgccagcc atctcctgat actattcacc ctcaacttca ccatcactaa cctgcggtat 780
gaggagaaca tgtggcctgg ctccaggaag ttcaacacta cagagagggt ccttcagggc 840
ctgctaaggc ccttgttcaa gaacaccagt gttggccctc tgtactctgg ctgcaggctg 900
accttgctca ggccagagaa agatggggaa gccaccggag tggatgccat ctgcacccac 960
cgccctgacc ccacaggccc tgggctggac agagagcagc tgtatttgga gctgagccag 1020
ctgacccaca gcatcactga gctgggcccc tacacactgg acagggacag tctctatgtc 1080
aatggtttca cccatcggag ctctgtaccc accaccagca ccggggtggt cagcgaggag 1140
ccattcacac tgaacttcac catcaacaac ctgcgctaca tggcggacat gggccaaccc 1200
ggctccctca agttcaacat cacagacaac gtcatgaagc acctgctcag tcctttgttc 1260
cagaggagca gcctgggtgc acggtacaca ggctgcaggg tcatcgcact aaggtctgtg 1320
aagaacggtg ctgagacacg ggtggacctc ctctgcacct acctgcagcc cctcagcggc 1380
ccaggtctgc ctatcaagca ggtgttccat gagctgagcc agcagaccca tggcatcacc 1440
cggctgggcc cctactctct ggacaaagac agcctctacc ttaacggtta caatgaacct 1500
ggtccagatg agcctcctac aactcccaag ccagccacca cattcctgcc tcctctgtca 1560
gaagccacaa cagccatggg gtaccacctg aagaccctca cactcaactt caccatctcc 1620
aatctccagt attcaccaga tatgggcaag ggctcagcta cattcaactc caccgagggg 1680
gtccttcagc acctgctcag acccttgttc cagaagagca gcatgggccc cttctacttg 1740
ggttgccaac tgatctccct caggcctgag aaggatgggg cagccactgg tgtggacacc 1800
acctgcacct accaccctga ccctgtgggc cccgggctgg acatacagca gctttactgg 1860
gagctgagtc agctgaccca tggtgtcacc caactgggct tctatgtcct ggacagggat 1920
agcctcttca tcaatggcta tgcaccccag aatttatcaa tccggggcga gtaccagata 1980
aatttccaca ttgtcaactg gaacctcagt aatccagacc ccacatcctc agagtacatc 2040
accctgctga gggacatcca ggacaaggtc accacactct acaaaggcag tcaactacat 2100
gacacattcc gcttctgcct ggtcaccaac ttgacgatgg actccgtgtt ggtcactgtc 2160
aaggcattgt tctcctccaa tttggacccc agcctggtgg agcaagtctt tctagataag 2220
accctgaatg cctcattcca ttggctgggc tccacctacc agttggtgga catccatgtg 2280
acagaaatgg agtcatcagt ttatcaacca acaagcagct ccagcaccca gcacttctac 2340
ctgaatttca ccatcaccaa cctaccatat tcccaggaca aagcccagcc aggcaccacc 2400
aattaccaga ggaacaaaag gaatattgag gatgcgctca accaactctt ccgaaacagc 2460
agcatcaaga gttatttttc tgactgtcaa gtttcaacat tcaggtctgt ccccaacagg 2520
caccacaccg gggtggactc cctgtgtaac ttctcgccac tggctcggag agtagacaga 2580
gttgccatct atgaggaatt tctgcggatg acccggaatg gtacccagct gcagaacttc 2640
accctggaca ggagcagtgt ccttgtggat gggtattttc ccaacagaaa tgagccctta 2700
actgggaatt ctgaccttcc cttctgggct gtcatcctca tcggcttggc aggactcctg 2760
ggactcatca catgcctgat ctgcggtgtc ctggtgacca cccgccggcg gaagaaggaa 2820
ggagaataca acgtccagca acagtgccca ggctactacc agtcacacct agacctggag 2880
gatctgcaat gactggaact tgccggtgcc tggggtgcct ttcccccagc cagggtccaa 2940
agaagcttgg ctggggcaga aataaaccat attggtcgga cacaaaaaaa aaaaaa 2996
<210>312
<211>914
<212>PRT
<213> human
<400>312
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala Phe
1 5 10 15
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu
20 25 30
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser
35 40 45
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu
50 55 60
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Trp Ser
65 70 75 80
Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu
85 90 95
Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala
100 105 110
Ile Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu
115 120 125
Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu
130 135 140
Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly Phe Thr
145 150 155 160
His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val
165 170 175
Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala
180 185 190
Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn
195 200 205
Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr
210 215 220
Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr
225 230 235 240
Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro
245 250 255
Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg
260 265 270
Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu
275 280 285
Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu
290 295 300
Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val
305 310 315 320
Pro Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn
325 330 335
Phe Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly
340 345 350
Ser Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu Leu Ser
355 360 365
Pro Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg
370 375 380
Val Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp
385 390 395 400
Leu Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile
405 410 415
Lys Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg
420 425 430
Leu Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr
435 440 445
Asn Glu Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr
450 455 460
Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His
465 470 475 480
Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser
485 490 495
Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu Gly Val
500 505 510
Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro
515 520 525
Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly
530 535 540
Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val
545 550 555 560
Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu
565 570 575
Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser
580 585 590
Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu
595 600 605
Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp
610 615 620
Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys
625 630 635 640
Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe
645 650 655
Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys
660 665 670
Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe
675 680 685
Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr
690 695 700
Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln
705 710 715 720
Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile
725 730 735
Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn
740 745 750
Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe
755 760 765
Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr
770 775 780
Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys
785 790 795 800
Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu
805 810 815
Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr
820 825 830
Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Phe Pro Asn Arg Asn
835 840 845
Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu
850 855 860
Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly
865 870 875 880
Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val
885 890 895
Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp
900 905 910
Leu Gln
<210>313
<211>656
<212>DNA
<213> human
<400>313
acagccagtc ggagctgcaa gtgttctggg tggatcgcgy atatgcactc aaaatgctct 60
ttgtaaagga aagccacaac atgtccaagg gacctgaggc gacttggagg ctgagcaaag 120
tgcagtttgt ctacgactcc tcggagaaaa cccacttcaa agacgcagtc agtgctggga 180
agcacacagc caactcgcac cacctctctg ccttggtcac ccccgctggg aagtcctatg 240
agtgtcaagc tcaacaaacc atttcactgg cctctagtga tccgcagaag acggtcacca 300
tgatcctgtc tgcggtccac atccaacctt ttgacattat ctcagatttt gtcttcagtg 360
aagagcataa atgcccagtg gatgagcggg agcaactgga agaaaccttg cccctgattt 420
tggggctcat cttgggcctc gtcatcatgg taacactcgc gatttaccac gtccaccaca 480
aaatgactgc caaccaggtg cagatccctc gggacagatc ccagtataag cacatgggct 540
agaggccgtt aggcaggcac cccctattcc tgctccccca actggatcag gtagaacaac 600
aaaagcactt ttccatcttg tacacgagat acaccaacat agctacaatc aaacag 656
<210>314
<211>519
<212>DNA
<213> human
<400>314
tgtgcgtgga ccagtcagct tccgggtgtg actggagcag ggcttgtcgt cttcttcaga 60
gtcactttgc aggggttggt gaagctgctc ccatccatgt acagctccca gtctactgat 120
gtttaaggat ggtctcggtg gttaggccca ctagaataaa ctgagtccaa tacctctaca 180
cagttatgtt taactgggct ctctgacacc gggaggaagg tggcggggtt taggtgttgc 240
aaacttcaat ggttatgcgg ggatgttcac agagcaagct ttggtatcta gctagtctag 300
cattcattag ctaatggtgt cctttggtat ttattaaaat caccacagca tagggggact 360
ttatgtttag gttttgtcta agagttagct tatctgcttc ttgtgctaac agggctattg 420
ctaccaggga ctttggacat gggggccagc gtttggaaac ctcatctagt ttttttgaga 480
gataggccac tggccttgga cctcggccgc gaccacgct 519
<210>315
<211>441
<212>DNA
<213> human
<400>315
cacagagcgt ttattgacac caccactcct gaaaattggg atttcttatt aggttcccct 60
aaaagttccc atgttgatta catgtaaata gtcacatata tacaatgaag gcagtttctt 120
cagaggcaac cagggtttat agtgctaggt aaatgtcatc tcttttgtgc tactgactca 180
ttgtcaaacg tctctgcact gttttcagcc tctccacgtt gcctctgtcc tgcttcttag 240
ttccttcttt gtgacaaacc aaaagaataa gaggatttag aacaggactg cttttcccct 300
atgatttaaa aattccaatg actttcgccc ttgggagaaa tttccaagga aatctctctc 360
gctcgctctc tccgttttcc tttgtgagct tctgggggag ggttagtggt gactttttga 420
tacgaaaaaa tgcattttgt g 441
<210>316
<211>247
<212>DNA
<213> human
<400>316
tggcgcggct gctggatttc accttcttgc acctgccggt gagcgcctgg ggtctaaagg 60
ggcgggatac tccattatgg cccctcgccc tgtagggctg gaatagttag aaaaggcaac 120
ccagtctagc ttggtaagaa gagagacatg cccccaacct cggcgccctt tttcctcacg 180
atctgctgtc cttacttcag cgactgcagg agcttcacct gcaagaaaac agcattgagc 240
tgctgac 247
<210>317
<211>409
<212>DNA
<213> human
<400>317
tgacagggct cctggagttg ttaagtcacc aagtagctgc aggggatgga cactgcccca 60
cacgatgtgg gatgaacagc agccttggtt tgtagcccag ggtgtccatg gatttgaccc 120
gaatgctccc tggaggccct gtggcgagga caggcactgg atggtccaga ccctctggct 180
ggaggagtgg tggagccagg actgggcctt cagccatgag ggctagaata acctgacctc 240
ttgcattcta acactgggtc attaatgaca cctttccagt ggatgttgca aaaaccaaca 300
ctgtcaggaa cctggccctg ggagggctca ggtgagctca caaggagagg tcaagccaag 360
ccaaagggta ggkaacacac aacaccaggg gaaaccagcc cccaaacca 409
<210>318
<211>320
<212>DNA
<213> human
<220>
<221>misc_feature
<222>6,17,24,271
<223> n ═ A, T, C or G
<400>318
caaggnagat cttaagnggg gtcntatgta agtgtgctcc tggctccagg gttcctggag 60
cctcacgagg tcaggggaac ccttgtagaa ctccaccagc agcatcatct cgtgaaggat 120
gtcattggtc aggaagctgt cctggacgta ggccatctcc acatccatgg ggatgccata 180
gtcactgggc ctttgctcgg gaggaggcat cacccagaaa ggcgagatct tggactcggg 240
gcctgggttg ccagaatagt aaggggagca nagcagggcg aggcagggct ggaagccatt 300
gctggagccc tgcagccgca 320
<210>319
<211>212
<212>DNA
<213> human
<220>
<221>misc_feature
<222>172
<223> n ═ A, T, C or G
<400>319
tgaagcaata gcgcccccat tttacaggcg gagcatggaa gccagagagg tgggtggggg 60
agggggtcct tccctggctc aggcagatgg gaagatgagg aagccgctga agacgctgtc 120
ggcctcagag ccctggtaaa tgtgaccctt tttggggtct ttttcaaccc anacctggtc 180
accctgctgc agacctcggc cgcgaccacg ct 212
<210>320
<211>769
<212>DNA
<213> human
<400>320
tggaggtgta gcagtgagag gagatytcag gcaagagtgt cacagcagag ccctaaascc 60
tccaactcac cagtgagaga tgagactgcc cagtactcag ccttcatctc ctgggccacc 120
tggagggcgt ctttctccat cagcgcatac tgagcagggg tactcagatc cttcttggaa 180
cctacaagga agagaagcac actggaaggg tcattctcct tcagggcatc ggccagccac 240
tgcctgccat gggaggtgga aagtaaggga tgagtgagtc tgcagggccc ctcccactga 300
cattcatagg cccaattacc ccctctctgg tcctacatgc attcttcttc ttcctgacca 360
cccctctgtt ctgaaccctc tcttcccgga gcctcccatt atattgcagg atgctcactt 420
acttggtatg ttccagagat gccacatcat tcaggttgaa gacaatgatg atggcttgga 480
agagtggcag aaacagcccc aggttgacag ggaagacact actgctcatt tccccaatcc 540
ttccagctcc atatgagaaa gccatgtgca ctctgagacc cacctacccc acttcaccca 600
gccccttacc ttgagctcct ctatagtagg ttgatgcaat gcatttgaac ctctcctgcc 660
cagcggtatc ccaactggaa ggaaggaaga gtgaagcaca ggtatgtatc ttggggggtg 720
tgggtgctgg ggagaaggga tagctggaag gggtgtggaa gcactcaca 769
<210>321
<211>690
<212>DNA
<213> human
<220>
<221>misc_feature
<222>633,666
<223> n ═ A, T, C or G
<400>321
tgggctgtgg gcggcacctg tgctctgcag gccagacagc gatagaagcc tttgtctgtg 60
cctactcccc cggaggcaac tgggaggtca acgggaagac aatcatcccc tataagaagg 120
gtgcctggtg ttcgctctgc acagccagtg tctcaggctg cttcaaagcc tgggaccatg 180
caggggggct ctgtgaggtc cccaggaatc cttgtcgcat gagctgccag aaccatggac 240
gtctcaacat cagcacctgc cactgccact gtccccctgg ctacacgggc agatactgcc 300
aagtgaggtg cagcctgcag tgtgtgcacg gccggttccg ggaggaggag tgctcgtgcg 360
tctgtgacat cggctacggg ggagcccagt gtgccaccaa ggtgcatttt cccttccaca 420
cctgtgacct gaggatcgac ggagactgct tcatggtgtc ttcagaggca gacacctatt 480
acagaagcca ggatgaaatg tcagaggaat ggcggggtgc tggcccagat caagagccag 540
aaagtgcagg acatcctcgc cttctatctg ggccgcctgg agaccaccaa cgaggtgact 600
gacagtgact ttgagaccag gaacttctgg atngggctca cctacaagac cgccaaggac 660
tccttncgct gggccacagg ggagcaccag 690
<210>322
<211>104
<212>DNA
<213> human
<400>322
gtcgcaagcc ggagcaccac catgtagcct ttcccgaagt accggacctt ctcctcctcc 60
acgctcacat cacggacatc atggagcagg accaccacct ggtc 104
<210>323
<211>118
<212>DNA
<213> human
<400>323
gggccctggg cgcttccaaa tgacccagga ggtggtctgc gacgaatgcc ctaatgtcaa 60
actagtgaat gaagaacgaa cactggaagt agaaatagag cctggggtga gagacgga 118
<210>324
<211>354
<212>DNA
<213> human
<400>324
tgctctccgg gagcttgaag aagaaactgg ctacaaaggg gacattgccg aatgttctcc 60
agcggtctgt atggacccag gcttgtcaaa ctgtactata cacatcgtga cagtcaccat 120
taacggagat gatgccgaaa acgcaaggcc gaagccaaag ccaggggatg gagagtttgt 180
ggaagtcatt tctttaccca agaatgacct gctgcagaga cttgatgctc tggtagctga 240
agaacatctc acagtggacg ccagggtcta ttcctacgct ctagcgctga aacatgcaaa 300
tgcaaagcca tttgaagtgc ccttcttgaa attttaagcc caaatatgac actg 354
<210>325
<211>642
<212>DNA
<213> human
<220>
<221>misc_feature
<222>1
<223> n ═ A, T, C or G
<400>325
ncatgcttga atgggctcct ggtgagagat tgccccctgg tggtgaaaca atcgtgtgtg 60
cccactgata ccaagaccaa tgaaagagac acagttaagc agcaatccat ctcatttcca 120
ggcacttcaa taggtcgctg attggtcctt gcaccagcag tggtagtcgt acctatttca 180
gagaggtctg aaattcaggt tcttagtttg ccagggacag gccctacctt atattttttt 240
ccatcttcat catccacttc tgcttacagt ttgctgctta caataactta atgatggatt 300
gagttatctg ggtggtctct agccatctgg gcagtgtggt tctgtctaac caaagggcat 360
tggcctcaaa ccctgcattt ggtttagggg ctaacagagc tcctcagata atcttcacac 420
acatgtaact gctggagatc ttattctatt atgaataaga aacgagaagt ttttccaaag 480
tgttagtcag gatctgaagg ctgtcattca gataacccag cttttccttt tggcttttag 540
cccattcaga ctttgccaga gtcaagccaa ggattgcttt tttgctacag ttttctgcca 600
aatggcctag ttcctgagta cctggaaacc agagagaaag ag 642
<210>326
<211>455
<212>DNA
<213> human
<400>326
tccgtgagga tgagcttcga gtccttcacc aggcactgca ggggcacagt cacgtcaatc 60
accttcacct tctcgctctt cctgctcttg tcattgacaa acttcccgta ccaggcattg 120
acgatgatga ggcccattct ggactcttct gcctcaatta tccttcggac agattcctgc 180
atcagccgga cagcggactc cgcctcttgc ttcttctgca gcacatcggt ggcggcgctt 240
tccctctgct tctccaattc cttctctttc tgagccctga ggtatggttt gatgatcaga 300
cggtgcatgg caaagtagac cactagaggc cccacggtgg catagaacat ggcgctgggc 360
agaagctggt ccgtcaagtg aatagggaag aagtatgtct gactggccct gttgagcttg 420
actttgagag aaacgccctg tggaactcca acgct 455
<210>327
<211>321
<212>DNA
<213> human
<400>327
ttcactgtga actcgcagtc ctcgatgaac tcgcacagat gtgacagccc tgtctccttg 60
ctctctgagt tctcttcaat gatgctgatg atgcagtcca cgatagcgcg cttatactca 120
aagccaccct cttcccgcag catggtgaac aggaagttca taaggacggc gtgtttgcga 180
ggatatttct gacacagggc actgatggcc tggacaacca ccaccttgaa ttcatccgag 240
atttctgaca tgaaggagga gatctgcttc atgaggcggt cgatgctgct ctcgctgccc 300
gtcttaagga gggtggtgat g 321
<210>328
<211>476
<212>DNA
<213> human
<220>
<221>misc_feature
<222>302,311
<223> n ═ A, T, C or G
<400>328
tgcaggaggg gccatggggg ctgtgaatgg gatgcagccc catggtgtcc ctgataaatc 60
cagtgtgcag tctgatgaag tctgggtggg tgtggtctac gggctggcag ctaccatgat 120
ccaagaggta atgcactcct tttcccatct ctccaccatc tgtatcctgg ccmagaaaaa 180
cttcccttca aaccaaccaa aatttccttt caaaggcata acccaaatgc catccttggt 240
ccggtctaat aaagcctccc ccatttttcc cctggtatgc attcccaggc tccctggcct 300
tncagggctt nctgtctgtg ggtcatagtt tatctcctcc cacttgctgg gagctccttg 360
aaggcaaaga ctctactgcc tccatctatc cagtggaagt ggctcttcag agggtgccaa 420
gttagtatgt atgactgtca tctctcccaa cagggcctga cttggsaggg cttcca 476
<210>329
<211>340
<212>DNA
<213> human
<400>329
cgagggagat tgccagcacc ctgatggaga gtgagatgat ggagatcttg tcagtgctag 60
ctaagggtga ccacagccct gtcacaaggg ctgctgcagc ctgcctggac aaagcagtgg 120
aatatgggct tatccaaccc aaccaagatg gagagtgagg gggttgtccc tgggcccaag 180
gctcatgcac acgctaccta ttgtggcacg gagagtaagg acggaagcag ctttggctgg 240
tggtggctgg catgcccaat actcttgccc atcctcgctt gctgccctag gatgtcctct 300
gttctgagtc agcggccacg ttcagtcaca cagccctgct 340
<210>330
<211>277
<212>DNA
<213> human
<400>330
tgtcaccatc acattggtgc caaataccca gaagacatcg tagatgaaga gtccgcccag 60
caggatgcag ccagtgctga cattgttgag gtgcaggagc tctactccat taagggagaa 120
ggccaggcca aaaaggttgt tggcaatcca gtgcttcctc agcaggtacc agacgccaac 180
gatgctgctc aggcccaggc acaccaggtc cttggtgtca aattcataat tgatgatctc 240
ctccttgttt tcccagaacc ctgtgtgaag agcagac 277
<210>331
<211>136
<212>DNA
<213> human
<400>331
ttgcttccca cctcctttct ctgtcctctc ctgaggttct gccttacaat ggggacactg 60
atacaaacca cacacacaat gaggatgaaa acagataaca ggtaaaatga cctcacctgc 120
ccgggcggcc gctcga 136
<210>332
<211>184
<212>DNA
<213> human
<400>332
ttgtgagata aacgcagata ctgcaatgca ttaaaacgct tgaaatactc atcagggatg 60
ttgctgatct tattgttgtc taagtagaga gttagaagag agacagggag accagaaggc 120
agtctggcta tctgattgaa gctcaagtca aggtattcga gtgatttaag acctttaaaa 180
gcag 184
<210>333
<211>384
<212>DNA
<213> human
<400>333
cggaaaactt cgaggaattg ctcaaagtgc tgggggtgaa tgtgatgctg aggaagattg 60
ctgtggctgc agcgtccaag ccagcagtgg agatcaaaca ggagggagac actttctaca 120
tcaaaacctc caccaccgtg cgcaccacag agattaactt caaggttggg gaggagtttg 180
aggagcagac tgtggatggg aggccctgta agagcctggt gaaatgggag agtgagaata 240
aaatggtctg tgagcagaag ctcctgaagg gagagggccc caagacctcg tggaccagag 300
aactgaccaa cgatggggaa ctgatcctga ccatgacggc ggatgacgtt gtgtgcacca 360
gggtctacgt ccgagagtga gcgg 384
<210>334
<211>169
<212>DNA
<213> human
<220>
<221>misc_feature
<222>2,165
<223> n ═ A, T, C or G
<400>334
cnacaaacag agcagacacc ctggatccgg tcctgctact ggccaggacg gctggaccgt 60
aaaattgaat ttccacttcc tgaccgccgc cagaagagat tgattttctc cactatcact 120
agcaagatga acctctctga ggaggttgac ttggaagact atgtngccc 169
<210>335
<211>185
<212>DNA
<213> human
<400>335
ccaggtttgc agcccaggct gcacatcagg ggactgcctc gcaatacttc atgctgttgc 60
tgctgactga tggtgctgtg acggatgtgg aagccacacg tgaggctgtg gtgcgtgcct 120
cgaacctgcc catgtcagtg atcattgtgg gtgtgggtgg tgctgacttt gaggccatgg 180
agcag 185
<210>336
<211>358
<212>DNA
<213> human
<220>
<221>misc_feature
<222>26
<223> n ═ A, T, C or G
<400>336
ctgcccctgc cttacggcgg ccaganacac acccaggatg gcattggccc caaacttgga 60
tttgttctca gtcccatcca actccagcat caggttgtcc agtttctctt gctccaccac 120
agagagacct gagctgatga gggctggcgo gatggtggag ttgatgtggt ccactgcctt 180
caggacacct ttgcctaagt aacgctgttt gtctccatcc ctcagctcca gggcctcata 240
gatgcccgta gaggctccac tgggcactgc agcccggaaa agacctttgg cagtatagag 300
atccacctcc actgtggggt tcccgcggga gtccaggatc tcccgggccc agatcttc 358
<210>337
<211>271
<212>DNA
<213> human
<220>
<221>misc_feature
<222>17
<223> n ═ A, T, C or G
<400>337
cacaaagcca ccagccnggg aaatcagaat ttacttgatg caactgactt gtaatagcca 60
gaaatcctgc ccagcatggg attcagaacc tggtctgcaa ccaaatccac cgtcaaagtt 120
catacaggat aaaacaaatt caattgcctt ttccacatta atagcatcaa gcttccccaa 180
caaagccaaa gttgccaccg cacaaaaaga gaatcttgtg tcaatttctc cctactttat 240
aaaagtagat ttttcacatc ccatgaagca g 271
<210>338
<211>326
<212>DNA
<213> human
<220>
<221>misc_feature
<222>15,17,18
<223> n ═ A, T, C or G
<400>338
ctgtgctccc gactngnnca tctcaggtac caccgactgc actgggcggg gccctctggg 60
gggaaaggct ccacggggca gggatacatc tcgaggccag tcatcctctg gaggcagccc 120
aatcaggtca aagattttgc ccaactggtc ggcttcagag tttccacaga agagaggctt 180
tcgacgaaac atctctgcaa agatacagcc aacactccac atgtccacag gtgttgcata 240
tgtggactgc agaagaactt cgggagctcg gtaccagagt gtaacaacca cgggtgtaag 300
tgccatctgg tagctgtaga ttctgg 326
<210>339
<211>260
<212>DNA
<213> human
<220>
<221>misc_feature
<222>47,54,60,69,90,91,96,113,117,119,195
<223> n ═ A, T, C or G
<400>339
ttcacctgag gactcatttc gtgccctttg ttgacttcaa gcaaagncct tcanggtctn 60
caaggacgnc acatttccac ttgcgaatgn nctcanggct catcttgaag aanaagnanc 120
ccaagtgctg gatcccagac tcgggggtaa ccttgtgggt aagagctcat ccagtttatg 180
ctttaggacg tccanctact cgggggagct ggaagcctgc gtggatgcgg ccctgctgga 240
cctcggccgc gaccacgcta 260
<210>340
<211>220
<212>DNA
<213> human
<220>
<221>misc_feature
<222>15,18
<223> n ═ A, T, C or G
<400>340
ctggaagccc ggctnggnct ggcagcggaa ggagccaggc aggttcacgc agcggtgctg 60
gcagtagcgg tagcggcact cgtctatgtc cacacactcg ggcccgatct tgcggtaacc 120
atcagggcag gtgcactgat aggagccagg caagttatgg cagtcctggc tggggcgaca 180
gtcgtgcagg gcctgggcac actcgtccac atccacacag 220
<210>341
<211>384
<212>DNA
<213> human
<400>341
ctgctaccag gggagcgaga gctgactatc ccagcctcgg ctaatgtatt ctacgccatg 60
gatggagctt cacacgattt cctcctgcgg cagcggcgaa ggtcctctac tgctacaccg 120
ggcgtcacca gtggcccgtc tgcctcagga actcctccga gtgagggagg agggggctcc 180
tttcccagga tcaaggccac agggaggaag attgcacggg cactgttctg aggaggaagc 240
cccgttggct tacagaagtc atggtgttca taccagatgt gggtagccat cctgaatggt 300
ggcaattata tcacattgag acagaaattc agaaagggag ccagccaccc tggggcagtg 360
aagtgccact ggtttaccag acag 384
<210>342
<211>245
<212>DNA
<213> human
<400>342
ctggctaagc tcatcattgt tactggtggg caccatgtcc ttgaagcttc aggcaagcaa 60
tgtaaccaac aagaatgacc ccaagtccat caactctcga gtcttcattg gaaacctcaa 120
cacagctctg gtgaagaaat cagatgtgga gaccatcttc tctaagtatg gccgtgtggc 180
cggctgttct gtgcacaagg gctatgcctt tgttcagtac tccaatgagc gccatgcccg 240
ggcag 245
<210>343
<211>611
<212>DNA
<213> human
<400>343
ccaaaaaaat caagatttaa tttttttatt tgcactgaaa aactaatcat aactgttaat 60
tctcagccat ctttgaagct tgaaagaaga gtctttggta ttttgtaaac gttagcagac 120
tttcctgcca gtgtcagaaa atcctattta tgaatcctgt cggtattcct tggtatctga 180
aaaaaatacc aaatagtacc atacatgagt tatttctaag tttgaaaaat aaaaagaaat 240
tgcatcacac taattacaaa atacaagttc tggaaaaaat atttttcttc attttaaaac 300
tttttttaac taataatggc tttgaaagaa gaggcttaat ttgggggtgg taactaaaat 360
caaaagaaat gattgacttg agggtctctg tttggtaaga atacatcatt agcttaaata 420
agcagcagaa ggttagtttt aattatgtag cttctgttaa tattaagtgt tttttgtctg 480
ttttacctca atttgaacag ataagtttgc ctgcatgctg gacatgcctc agaaccatga 540
atagcccgta ctagatcttg ggaacatgga tcttagagtc ctttggaata agttcttata 600
taaatacccc c 611
<210>344
<211>311
<212>DNA
<213> human
<220>
<221>misc_feature
<222>1,275,284,296,297,300
<223> n ═ A, T, C or G
<400>344
nctcgaaaaa gcccaagaca gcagaagcag acacctccag tgaactagca aagaaaagca 60
aagaagtatt cagaaaagag atgtcccagt tcatcgtcca gtgcctgaac ccttaccgga 120
aacctgactg caaagtggga agaattacca caactgaaga ctttaaacat ctggctcgca 180
agctgactca cggtgttatg aataaggagc tgaagtactg taagaatcct gaggacctgg 240
agtgcaatga gaatgtgaaa cacaaaacca aggantacat taanaagtac atgcannaan 300
tttggggctt g 311
<210>345
<211>201
<212>DNA
<213> human
<400>345
cacacggtca tcccgactgc caacctggag gcccaggccc tgtggaagga gccgggcagc 60
aatgtcacca tgagtgtgga tgctgagtgt gtgcccatgg tcagggacct tctcaggtac 120
ttctactccc gaaggattga catcaccctg tcgtcagtca agtgcttcca caagctggcc 180
tctgcctatg gggccaggca g 201
<210>346
<211>370
<212>DNA
<213> human
<400>346
ctgctccagg gcgtggtgtg ccttcgtggc ctctgcctcc tccgaggagc caggctgtgt 60
tctcttcaga atgttctgga gcagcagttt gaggcgggtg atgcgttgga agggcagaat 120
cagaaaggac ttgagggaaa ggcgctggca gacggggtcg ctctccagct tctccaagac 180
ctcccggaaa ttgctgttgc tattcatcag gctctggaag gtgcgttcct gataggtctg 240
gttggtgaca taaggcaggt agacccggcg gaagtctggg gcgtggttca ggactacgtc 300
acatacttgg aaggagaaga tattgttctc aaagttctct tccaggtctg aaaggaacgt 360
ggcgctgacg 370
<210>347
<211>416
<212>DNA
<213> human
<220>
<221>misc_feature
<222>416
<223> n ═ A, T, C or G
<400>347
ctgttgtgct gtgtatggac gtgggcttta ccatgagtaa ctccattcct ggtatagaat 60
ccccatttga acaagcaaag aaggtgataa ccatgtttgt acagcgacag gtgtttgctg 120
agaacaagga tgagattgct ttagtcctgt ttggtacaga tggcactgac aatccccttt 180
ctggtgggga tcagtatcag aacatcacag tgcacagaca tctgatgcta ccagattttg 240
atttgctgga ggacattgaa agcaaaatcc aaccaggttc tcaacaggct gacttcctgg 300
atgcactaat cgtgagcatg gatgtgattc aacatgaaac aataggaaag aagtttggag 360
aagaggcata ttgaaatatt cactgacctc aagcagcccg attcagcaaa agtcan 416
<210>348
<211>351
<212>DNA
<213> human
<400>348
gtacaggaga ggatggcagg tgcagagcgg gcactgagct ctgcaggtga aagggctcgg 60
cagttggatg ctctcctgga ggctctgaaa ttgaaacggg caggaaatag tctggcagcc 120
tctacagcag aagaaacggc aggcagtgcc cagggacgag caggagacag atgccttcct 180
cttgtctcaa ctgcaaagag gcgttccttc ctctttcact aatcctcctc agcacagacc 240
ctttacgggt gtcaggctgg gggacagtaa ggtctttccc ttcccacaag gccatatctc 300
aggctgtctc agtgggggga aaccttggac aatacccggg ctttcttggg c 351
<210>349
<211>207
<212>DNA
<213> human
<220>
<221>misc_feature
<222>1
<223> n ═ A, T, C or G
<400>349
nccgggacat ctccaccctc aacagtggca agaagagcct ggagactgaa cacaaggcct 60
tgaccagtga gattgcactg ctgcagtcca ggctgaagac agagggctct gatctgtgcg 120
acagagtgag cgaaatgcag aagctggatg cacaggtcaa ggagctggtg ctgaagtcgg 180
cggtggaggc tgagcgcctg gtggctg 207
<210>350
<211>323
<212>DNA
<213> human
<400>350
ccatacaggg ctgttgccca ggccctagag gtcattcctc gtaccctgat ccagaactgt 60
ggggccagca ccatccgtct acttacctcc cttcgggcca agcacaccca ggagaactgt 120
gagacctggg gtgtaaatgg tgagacgggt actttggtgg acatgaagga actgggcata 180
tgggagccat tggctgtgaa gctgcagact tataagacag cagtggagac ggcagttctg 240
ctactgcgaa ttgatgacat cgtttcaggc cacgaaaaga aaggcgatga ccagagccgg 300
caaggcgggg ctcctgatgc tgg 323
<210>351
<211>353
<212>DNA
<213> human
<220>
<221>misc_feature
<222>12,25,39,42
<223> n ═ A, T, C or G
<400>351
cgccgcatcc cntggtccct tccantccct tttcctttnt cngggaacgt gtatgcggtt 60
tgtttttgtt ttgtagggtt tttttccttc tccacctctc cctgtctctt ttgctccatg 120
ttgtccgttt ctgtggggtt aggtttatgt ttttaatcat ctgaggtcac gtctatttcc 180
tccggactcg cctgcttggt ggcgattctc caccggttaa tatggtgcgt cccttttttc 240
ttttgttgcg aatctgagcc ttcttcctcc agcttctgcc ttttgaactt tgttcttcgg 300
ttctgaaacc atacttttac ctgagtttcc gtgaggctga ggctgtgtgc caa 353
<210>352
<211>467
<212>DNA
<213> human
<400>352
ctgcccacac tgatcacttg cgagatgtcc ttagggtaca agaacaggaa ttgaagtctg 60
aatttgagca gaacctgtct gagaaactct ctgaacaaga attacaattt cgtcgtctca 120
gtcaagagca agttgacaac tttactctgg atataaatac tgcctatgcc agactcagag 180
gaatcgaaca ggctgttcag agccatgcag ttgctgaaga ggaagccaga aaagcccacc 240
aactctggct ttcagtggag gcattaaagt acagcatgaa gacctcatct gcagaaacac 300
ctactatccc gctgggtagt gcagttgagg ccatcaaagc caactgttct gataatgaat 360
tcacccaagc tttaaccgca gctatccctc cagagtccct gacccgtggg gtgtacagtg 420
aagagaccct tagagcccgt ttctatgctg ttcaaaaact ggcccga 467
<210>353
<211>350
<212>DNA
<213> human
<400>353
ctgctgcagc cacagtagtt cctcccatgg tgggtggccc tcctggtcct gctggcccag 60
gaaatctgtc cccaccagga acagcccctg gaaaacggcc ccgtcctcta ccaccttgtg 120
gaaatgctgc acgggaactg cctcctggag gaccagcttt accttcccca gacatttgtc 180
ctgattgtgt agttttcctg gactgcattt caaattgact caggaactgt ttattgcatg 240
gagttacaac aggattctga ccatgaagtt ctcttttagg taacagatcc attaactttt 300
ttgaagatgc ttcagatcca acaccaacaa gggcaaaccc ctttgactgg 350
<210>354
<211>351
<212>DNA
<213> human
<400>354
atttagatga gatctgaggc atggagacat ggagacagta tacagactcc tagatttaag 60
ttttaggttt tttgcttttc taatcaccaa ttcttatata caatgtatat tttagactcg 120
agcagatgat catcttcatc ttaagtcatt ccttttgact gagtatggca ggattagagg 180
gaatggcagt atagatcaat gtctttttct gtaaagtata ggaaaaacca gagaggaaaa 240
aaagagctga caattggaag gtagtagaaa attgacgata atttcttctt aacaaataat 300
agttgtatat acaaggaggc tagtcaacca gattttattt gttgagggcg a 351
<210>355
<211>308
<212>DNA
<213> human
<400>355
ttttggcgca agttttacag attttattaa agtcgaagct attggtcttg gaagatgaaa 60
atgcaaatgt tgatgaggtg gaattgaagc cagatacctt aataaaatta tatcttggtt 120
ataaaaataa gaaattaagg gttaacatca atgtgccaat gaaaaccgaa cagaagcagg 180
aacaagaaac cacacacaaa aacatcgagg aagaccgcaa actactgatt caggcggcca 240
tcgtgagaat catgaagatg aggaaggttc tgaaacacca gcagttactt ggcgaggtcc 300
tcactcag 308
<210>356
<211>207
<212>DNA
<213> human
<400>356
ctgtcccaag tgctcccaga aggcaggatt ctgaagacca ctccagcgat atgttcaact 60
atgaagaata ctgcaccgcc aacgcagtca ctgggccttg ccgtgcatcc ttcccacgct 120
ggtactttga cgtggagagg aactcctgca ataacttcat ctatggaggc tgccggggca 180
ataagaacag ctaccgctct gaggagg 207
<210>357
<211>188
<212>DNA
<213> human
<220>
<221>misc_feature
<222>25,29
<223> n ═ A, T, C or G
<400>357
tcgaccacgc cctcgtagcg catgngctnc aggacgatgc tcagagtgat gaacaccccg 60
gtgcggccca cgccagcact gcagtgcacc gtgataggcc catcctgtcc aaactgctcc 120
ttggtcttat gcacctgccc gatgaagtca atgaatccct cgcctgtctt gggcacgccc 180
tgctctgg 188
<210>358
<211>291
<212>DNA
<213> human
<400>358
ctgggagcat cggcaagcta ctgccttaaa atccgatctc cccgagtgca caatttctgt 60
cccttttaag ggttcacaac actaaagatt tcacatgaaa gggttgtgat tgatttgagc 120
aggcaggcgg tacgtgacag gggctgcatg caccggtggt cagagagaaa cagaacaggg 180
cagggaattt cacaatgttc ttctatacaa tggctggaat ctatgaataa catcagtttc 240
taagttatgg gttgattttt aactactggg tttaggccag gcaggcccag g 291
<210>359
<211>117
<212>DNA
<213> human
<220>
<221>misc_feature
<222>79,98,100
<223> n ═ A, T, C or G
<400>359
gccaccacac tccagcctgg gcaatacagc aagactgtct caaaaaaaaa aaaaaaaaaa 60
cccaaaaaaa ctcaaaaang taatgaatga tacccaangn gccttttcta gaaaaag 117
<210>360
<211>394
<212>DNA
<213> human
<400>360
ctgttcctct ggggtggtcc agttctagag tgggagaaag ggagtcaggc gcattgggaa 60
tcgtggttcc agtctggttg cagaatctgc acatttgcca agaaattttc cctgtttgga 120
aagtttgccc cagctttccc gggcacacca ccttttgtcc caagtgtctg ccggtcgacc 180
aatctgcctg ccacacattg accaagccag acccggttca cccagctcga ggatcccagg 240
ttgaagagtg gccccttgag gccctggaaa gaccaatcac tggacttctt cccttgagag 300
tcagaggtca cccgtgattc tgcctgcacc ttatcattga tctgcagtga tttctgcaaa 360
tcaagagaaa ctctgcaggg cactcccctg tttc 394
<210>361
<211>394
<212>DNA
<213> human
<220>
<221>misc_feature
<222>28,31
<223> n ═ A, T, C or G
<400>361
ctgggcggat agcaccgggc atattttntt natggatgag gtctggcacc ctgagcagtc 60
cagcgaggac ttggtcttag ttgagcaatt tggctaggag gatagtatgc agcacggttc 120
tgagtctgtg ggatagctgc catgaagtaa cctgaaggag gtgctggctg gtaggggttg 180
attacagggt tgggaacagc tcgtacactt gccattctct gcatatactg gttagtgagg 240
tgagcctggc gctcttcttt gcgctgagct aaagctacat acaatggctt tgtggacctc 300
ggccgcgacc acgctaagcc gaattccagc acactggcgg ccgttactag tggatccgag 360
ctcggtacca agcttggcg taatcatggtc atag 394
<210>362
<211>268
<212>DNA
<213> human
<400>362
ctgcgcgtgg accagtcagc ttccgggtgt gactggagca gggcttgtcg tcttcttcag 60
agtcactttg caggggttgg tgaagctgct cccatccatg tacagctccc agtctactga 120
tgtttaagga tggtctcggt ggttaggccc actagaataa actgagtcca atacctctac 180
acagttatgt ttaactgggc tctctgacac cgggaggaag gtggcggggt ttaggtgttg 240
caaacttcaa tggttatgcg gggatgtt 268
<210>363
<211>323
<212>DNA
<213> human
<400>363
ccttgacctt ttcagcaagt gggaaggtgt aatccgtctc cacagacaag gccaggactc 60
gtttgtaccc gttgatgata gaatggggta ctgatgcaac agttgggtag ccaatctgca 120
gacagacact ggcaacattg cggacaccct ccaggaagcg agaatgcaga gtttcctctg 180
tgatatcaag cacttcaggg ttgtagatgc tgccattgtc gaacacctgc tggatgacca 240
gcccaaagga gaagggggag atgttgagca tgttcagcag cgtggcttcg ctggctccca 300
ctttgtctcc agtcttgatc aga 323
<210>364
<211>393
<212>DNA
<213> human
<220>
<221>misc_feature
<222>29
<223> n ═ A, T, C or G
<400>364
ccaagctctc catcgtcccc gtgcgcagng gctactgggg gaacaagatc ggcaagcccc 60
acactgtccc ttgcaaggtg acaggccgct gcggctctgt gctggtacgc ctcatcactg 120
cacccagggg cactggcatc gtctccgcac ctgtgcctaa gaagctgctc atgatggctg 180
gcatcgatga ctgctacacc tcagcccggg gctgcactgc caccctgggc aacttcgcca 240
aggccacctt tgatgccatt tctaagacct acagctacct gacccccgac ctctggaagg 300
agactgtatt caccaagtct ccctatcagg agttcactga ccacctcgtc aagacccaca 360
ccagagtctc cgtgcagcgg actcaggctc cag 393
<210>365
<211>371
<212>DNA
<213> human
<400>365
cctcctcaga gcggtagctg ttcttattgc cccggcagcc tccatagatg aagttattgc 60
aggagttcct ctccacgtca aagtaccagc gtgggaagga tgcacggcaa ggcccagtga 120
ctgcgttggc ggtgcagtat tcttcatagt tgaacatatc gctggagtgg tcttcagaat 180
cctgccttct gggagcactt gggacagagg aatccgctgc attcctgctg gtggacctcg 240
gccgcgacca cgctaagccg aattccagca cactggcggc cgttactagt ggatccgagc 300
tcggtaccaa gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg 360
ctcacaattc c 371
<210>366
<211>393
<212>DNA
<213> human
<400>366
atttcttgcc agatgggagc tctttggtga agactccttt cgggaaaagt tttttggctt 60
cttcttcagg gatggttgga aggaccatca cactatcccc atccttccaa tcaactgggg 120
tggcaaccct tttttctgct gtcagctgga gagagatgac taccctgaga atctcatcaa 180
agttcctgcc agtggtagct gggtagagga tagacagctt cagcttctta tcaggaccaa 240
aaacaaacac cacacgagct gccacaggca tgcccttttc atccttctct gctggatcca 300
gcatgcccaa caggatggca agctcccgat tcctatcatc gatgatggga aaaggtaact 360
tttctgtggg ctcttcacaa ttgtaagcat tga 393
<210>367
<211>327
<212>DNA
<213> human
<220>
<221>misc_feature
<222>34,54,55
<223> n ═ A, T, C or G
<400>367
ccagctctgt ctcatacttg actctaaagt cttnagcagc aagacgggca ttgnnaatct 60
gcagaacgat gcgggcattg tccacagtat ttgcgaagat ctgagccctc aggtcctcga 120
tgatcttgaa gtaatggctc cagtctctga cctggggtcc cttcttctcc aagtgctccc 180
ggattttgct ctccagcctc cggttctcgg tctccaggct cctcactctg tccaggtaag 240
aggccaggcg gtcgttcagg ctttgcatgg tctccttctc gttctggatg cctcccattc 300
ctgccagacc cccggctatc ccggtgg 327
<210>368
<211>306
<212>DNA
<213> human
<220>
<221>misc_feature
<222>24
<223> n ═ A, T, C or G
<400>368
ctggagaagg acttcagcag tttnaagaag tactgccaag tcatccgtgt cattgcccac 60
acccagatgc gcctgcttcc tctgcgccag aagaaggccc acctgatgga gatccaggtg 120
aacggaggca ctgtggccga gaagctggac tgggcccgcg agaggcttga gcagcaggta 180
cctgtgaacc aagtgtttgg gcaggatgag atgatcgacg tcatcggggt gaccaagggc 240
aaaggctaca aaggggtcac cagtcgttgg cacaccaaga agctgccccg caagacccac 300
cgagga 306
<210>369
<211>394
<212>DNA
<213> human
<400>369
tcgacccaca ccggaacacg gagagctggg ccagcattgg cacttgatag gatttcccgt 60
cggctgccac gaaagtgcgt ttctttgtgt tctcgggttg gaaccgtgat ttccacagac 120
ccttgaaata cactgcgttg acgaggacca gtctggtgag cacaccatca ataagatctg 180
gggacagcag attgtcaatc atatccctgg tttcattttt aacccatgca ttgatggaat 240
cacaggcaga ggctggatcc tcaaagttca cattccggac ctcacactgg aacacatctt 300
tgttccttgt aacaaaaggc acttcaattt cagaggcatt cttaacaaac acggcgttag 360
ccactgtcac aatgtcttta ttcttcttgg agac 394
<210>370
<211>653
<212>DNA
<213> human
<400>370
ccaccacacc caattccttg ctggtatcat ggcagccgcc acgtgccagg attaccggct 60
acatcatcaa gtatgagaag cctgggtctc ctcccagaga agtggtccct cggccccgcc 120
ctggtgtcac agaggctact attactggcc tggaaccggg aaccgaatat acaatttatg 180
tcattgccct gaagaataat cagaagagcg agcccctgat tggaaggaaa aagacagacg 240
agcttcccca actggtaacc cttccacacc ccaatcttca tggaccagag atcttggatg 300
ttccttccac agttcaaaag acccctttcg tcacccaccc tgggtatgac actggaaatg 360
gtattcagct tcctggcact tctggtcagc aacccagtgt tgggcaacaa atgatctttg 420
aggaacatgg ttttaggcgg accacaccgc ccacaacggc cacccccata aggcataggc 480
caagaccata cccgccgaat gtaggacaag aagctctctc tcagacaacc atctcatggg 540
ccccattcca ggacacttct gagtacatca tttcatgtca tcctgttggc actgatgaag 600
aacccttaca gttcagggtt cctggaactt ctaccagtgc cactctgaca gga 653
<210>371
<211>268
<212>DNA
<213> human
<400>371
ctgcccagcc cccattggcg agtttgagaa ggtgtgcagc aatgacaaca agaccttcga 60
ctcttcctgc cacttctttg ccacaaagtg caccctggag ggcaccaaga agggccacaa 120
gctccacctg gactacatcg ggccttgcaa atacatcccc ccttgcctgg actctgagct 180
gaccgaattc cccctgcgca tgcgggactg gctcaagaac gtcctggtca ccctgtatga 240
gagggatgag gacaacaacc ttctgact 268
<210>372
<211>392
<212>DNA
<213> human
<400>372
gctggtgccc ctggtgaacg tggacctcct ggattggcag gggccccagg acttagaggt 60
ggaactggtc cccctggtcc cgaaggagga aagggtgctg ctggtcctcc tgggccacct 120
ggtgctgctg gtactcctgg tctgcaagga atgcctggag aaagaggagg tcttggaagt 180
cctggtccaa agggtgacaa gggtgaacca ggcggtccag gtgctgatgg tgtcccaggg 240
aaagatggcc caaggggtcc tactggtcct attggtcctc ctggcccagc tggccagcct 300
ggagataagg gtgaaggtgg tgcccccgga cttccaggta tagctggacc tcgtggtagc 360
cctggtgaga gaggtgaaac ctcggccgcg ac 392
<210>373
<211>388
<212>DNA
<213> human
<220>
<221>misc_feature
<222>30
<223> n ═ A, T, C or G
<400>373
ccaagcgctc agatcggcaa ggggcaccan ttttgatctg cccagtgcac agccccacaa 60
ccaggtcagc gatgaaggta tcttcagtct cccccgaacg atgagacacc atgacgcccc 120
aaccattggc ctgggccagc ttgcacgcct gaagagactc ggtcacggag ccaatctggt 180
tgactttgag caggaggcag ttgcaggact tctcgttcac ggccttggcg atcctctttg 240
ggttggtcac tgtgagatca tcccccacta cctggattcc tgcactggct gtgaacttct 300
gccaagctcc ccagtcatcc tggtcaaagg gatcttcgat agacaccact gggtagtcct 360
tgatgaagga cttgtacagg tcagccag 388
<210>374
<211>393
<212>DNA
<213> human
<400>374
ctgacgaccg cgtgaacccc tgcattgggg gtgtcatcct cttccatgag acactctacc 60
agaaggcgga tgatgggcgt cccttccccc aagttatcaa atccaagggc ggtgttgtgg 120
gcatcaaggt agacaagggc gtggtccccc tggcagggac aaatggcgag actaccaccc 180
aagggttgga tgggctgtct gagcgctgtg cccagtacaa gaaggacgga gctgacttcg 240
ccaagtggcg ttgtgtgctg aagattgggg aacacacccc ctcagccctc gccatcatgg 300
aaaatgccaa tgttctggcc cgttatgcca gtatctgcca gcagaatggc attgtgccca 360
tcgtggagcc tgagatcctc cctgatgggg acc 393
<210>375
<211>394
<212>DNA
<213> human
<220>
<221>misc_feature
<222>30,33
<223> n ═ A, T, C or G
<400>375
ccacaaatgg cgtggtccat gtcatcaccn ttnttctgca gcctccagcc aacagacctc 60
aggaaagagg ggatgaactt gcagactctg cgcttgagat cttcaaacaa gcatcagcgt 120
tttccagggc ttcccagagg tctgtgcgac tagcccctgt ctatcaaaag ttattagaga 180
ggatgaagca ttagcttgaa gcactacagg aggaatgcac cacggcagct ctccgccaat 240
ttctctcaga tttccacaga gactgtttga atgttttcaa aaccaagtat cacactttaa 300
tgtacatggg ccgcaccata atgagatgtg agccttgtgc atgtggggga ggagggagag 360
agatgtactt tttaaatcat gttcccccta aaca 394
<210>376
<211>392
<212>DNA
<213> human
<220>
<221>misc_feature
<222>30
<223> n ═ A, T, C or G
<400>376
ctgcccagcc cccattggcg agtttgattn ggtgtgcagc aatgacaaca agaccttcga 60
ctcttcctgc cacttctttg ccacaaagtg caccctggag ggcaccaaga agggccacaa 120
gctccacctg gactacatcg ggccttgcaa atacatcccc ccttgcctgg actctgagct 180
gaccgaattc cccctgcgca tgcgggactg gctcaagaac gtcctggtca ccctgtatga 240
gagggatgag gacaacaacc ttctgactga gaagcagaag ctgcgggtga agaagatcca 300
tgagaatgag aagcgcctgg aggcaggaga ccaccccgtg gagctgctgg cccgggactt 360
cgagaagaac tataacatgt acatcttccc tg 392
<210>377
<211>292
<212>DNA
<213> human
<400>377
caatgtttga tgcttaaccc ccccaatttc tgtgagatgg atggccagtg caagcgtgac 60
ttgaagtgtt gcatgggcat gtgtgggaaa tcctgcgttt cccctgtgaa agcttgattc 120
ctgccatatg gaggaggctc tggagtcctg ctctgtgtgg tccaggtcct ttccaccctg 180
agacttggct ccaccactga tatcctcctt tggggaaagg cttggcacac agcaggcttt 240
caagaagtgc cagttgatca atgaataaat aaacgagcct atttctcttt gc 292
<210>378
<211>395
<212>DNA
<213> human
<400>378
ctgctgcttc agcgaagggt ttctggcata tccaatgata aggctgccaa agactgttcc 60
aataccagca ccagaaccag ccactcctac tgttgcagca cctgcaccaa taaatttggc 120
agcagtatca atgtctctgc tgattgcact ggtctgaaac tccctttgga ttagctgaga 180
cacaccattc tgggccctga ttttcctaag atagaactcc aactctttgc cctctagcac 240
atagccatct gctcggccac actgtcccgg ccttgaagcg atgcacgcaa gaagcttgcc 300
ctgctggaac tgctcctcca ggagactgct gattttggca ttctttttcc tttcatcata 360
tttcttctga attttttaga tcgttttttg tttaa 395
<210>379
<211>223
<212>DNA
<213> human
<400>379
ccagatgaaa tgctgccgca atggctgtgg gaaggtgtcc tgtgtcactc ccaatttctg 60
agctccagcc accaccaggc tgagcagtga ggagagaaag tttctgcctg gccctgcatc 120
tggttccagc ccacctgccc tccccttttt cgggactctg tattccctct tgggctgacc 180
acagcttctc cctttcccaa ccaataaagt aaccactttc agc 223
<210>380
<211>317
<212>DNA
<213> human
<220>
<221>misc_feature
<222>30,32
<223> n ═ A, T, C or G
<400>380
tcgaccacag tattccaacc ctcctgtgcn tngagaagtg atggagggtg ctgacaacca 60
gggtgcagga gaacaaggta gaccagtgag gcagaatatg tatcggggat atagaccacg 120
attccgcagg ggccctcctc gccaaagaca gcctagagag gacggcaatg aagaagataa 180
agaaaatcaa ggagatgaga cccaaggtca gcagccacct caacgtcggt accgccgcaa 240
cttcaattac cgacgcagac gcccagaaaa ccctaaacca caagatggca aagagacaaa 300
agcagccgat ccaccag 317
<210>381
<211>392
<212>DNA
<213> human
<220>
<221>misc_feature
<222>29,30,31
<223> n ═ A, T, C or G
<400>381
cctgaaggaa gagctggcct acctgaatnn naaccatgag gaggaaatca gtacgctgag 60
gggccaagtg ggaggccagg tcagtgtgga ggtggattcc gctccgggca ccgatctcgc 120
caagatcctg agtgacatgc gaagccaata tgaggtcatg gccgagcaga accggaagga 180
tgctgaagcc tggttcacca gccggactga agaattgaac cgggaggtcg ctggccacac 240
ggagcagctc cagatgagca ggtccgaggt tactgacctg cggcgcaccc ttcagggtct 300
tgagattgag ctgcagtcac agacctcggc cgcgaccacg ctaagccgaa ttccagcaca 360
ctggcggccg ttactagtgg atccgagctc gg 392
<210>382
<211>234
<212>DNA
<213> human
<400>382
cctcgatgtc taaatgagcg tggtaaagga tggtgcctgc tggggtctcg tagatacctc 60
gggacttcat tccaatgaag cggttctcca cgatgtcaat acggcccacg ccatgcttgc 120
ccgcgacttc gttcaggtac atgaagagct ccaaggaggt ctggtgggtg gtgccatcct 180
tgacgttggt caccttcaca gggacccctt ttttgaactc catctccaga atgt 234
<210>383
<211>396
<212>DNA
<213> human
<220>
<221>misc_feature
<222>66
<223> n ═ A, T, C or G
<400>383
ccttgacctt ttcagcaagt gggaaggtgt tttccgtctc cacagacaag gccaggactc 60
gtttgnaccc gttgatgata gaatggggta ctgatgcaac agttgggtag ccaatctgca 120
gacagacact ggcaacattg cggacaccca ggatttcaat ggtgcccctg gagattttag 180
tggtgatacc taaagcctgg aaaaaggagg tcttctcggg cccgagacca gtgttctggg 240
ctggcacagt gacttcacat ggggcaatgg caccagcacg ggcagcagac ctgcccgggc 300
ggccgctcga aagccgaatt ccagcacact ggcggccgtt actagtggat ccgagctcgg 360
taccaagctt ggcgtaatca tggtcatagc tgtttc 396
<210>384
<211>396
<212>DNA
<213> human
<400>384
gctgaatagg cacagagggc acctgtacac cttcagacca gtctgcaacc tcaggctgag 60
tagcagtgaa ctcaggagcg ggagcagtcc attcaccctg aaattcctcc ttggtcactg 120
ccttctcagc agcagcctgc tcttcttttt caatctcttc aggatctctg tagaagtaca 180
gatcaggcat gacctcccat gggtgttcac gggaaatggt gccacgcatg cgcagaactt 240
cccgagccag catccaccac atcaaaccca ctgagtgagc tcccttgttg ttgcatggga 300
tggcaatgtc cacatagcgc agaggagaat ctgtgttaca cagcgcaatg gtaggtaggt 360
taacataaga tgcctccgtg agaggctggt ggtcag 396
<210>385
<211>2943
<212>DNA
<213> human
<400>385
cagccaccgg agtggatgcc atctgcaccc accgccctga ccccacaggc cctgggctgg 60
acagagagca gctgtatttg gagctgagcc agctgaccca cagcatcact gagctgggcc 120
cctacaccct ggacagggac agtctctatg tcaatggttt cacacagcgg agctctgtgc 180
ccaccactag cattcctggg acccccacag tggacctggg aacatctggg actccagttt 240
ctaaacctgg tccctcggct gccagccctc tcctggtgct attcactctc aacttcacca 300
tcaccaacct gcggtatgag gagaacatgc agcaccctgg ctccaggaag ttcaacacca 360
cggagagggt ccttcagggc ctggtccctg ttcaagagca ccagtgttgg ccctctgtac 420
tctggctgca gactgacttt gctcaggcct gaaaaggatg ggacagccac tggagtggat 480
gccatctgca cccaccaccc tgaccccaaa agccctaggc tggacagaga gcagctgtat 540
tgggagctga gccagctgac ccacaatatc actgagctgg gcccctatgc cctggacaac 600
gacagcctct ttgtcaatgg tttcactcat cggagctctg tgtccaccac cagcactcct 660
gggaccccca cagtgtatct gggagcatct aagactccag cctcgatatt tggcccttca 720
gctgccagcc atctcctgat actattcacc ctcaacttca ccatcactaa cctgcggtat 780
gaggagaaca tgtggcctgg ctccaggaag ttcaacacta cagagagggt ccttcagggc 840
ctgctaaggc ccttgttcaa gaacaccagt gttggccctc tgtactctgg ctgcaggctg 900
accttgctca ggccagagaa agatggggaa gccaccggag tggatgccat ctgcacccac 960
cgccctgacc ccacaggccc tgggctggac agagagcagc tgtatttgga gctgagccag 1020
ctgacccaca gcatcactga gctgggcccc tacacactgg acagggacag tctctatgtc 1080
aatggtttca cccatcggag ctctgtaccc accaccagca ccggggtggt cagcgaggag 1140
ccattcacac tgaacttcac catcaacaac ctgcgctaca tggcggacat gggccaaccc 1200
ggctccctca agttcaacat cacagacaac gtcatgaagc acctgctcag tcctttgttc 1260
cagaggagca gcctgggtgc acggtacaca ggctgcaggg tcatcgcact aaggtctgtg 1320
aagaacggtg ctgagacacg ggtggacctc ctctgcacct acctgcagcc cctcagcggc 1380
ccaggtctgc ctatcaagca ggtgttccat gagctgagcc agcagaccca tggcatcacc 1440
cggctgggcc cctactctct ggacaaagac agcctctacc ttaacggtta caatgaacct 1500
ggtccagatg agcctcctac aactcccaag ccagccacca cattcctgcc tcctctgtca 1560
gaagccacaa cagccatggg gtaccacctg aagaccctca cactcaactt caccatctcc 1620
aatctccagt attcaccaga tatgggcaag ggctcagcta cattcaactc caccgagggg 1680
gtccttcagc acctgctcag acccttgttc cagaagagca gcatgggccc cttctacttg 1740
ggttgccaac tgatctccct caggcctgag aaggatgggg cagccactgg tgtggacacc 1800
acctgcacct accaccctga ccctgtgggc cccgggctgg acatacagca gctttactgg 1860
gagctgagtc agctgaccca tggtgtcacc caactgggct tctatgtcct ggacagggat 1920
agcctcttca tcaatggcta tgcaccccag aatttatcaa tccggggcga gtaccagata 1980
aatttccaca ttgtcaactg gaacctcagt aatccagacc ccacatcctc agagtacatc 2040
accctgctga gggacatcca ggacaaggtc accacactct acaaaggcag tcaactacat 2100
gacacattcc gcttctgcct ggtcaccaac ttgacgatgg actccgtgtt ggtcactgtc 2160
aaggcattgt tctcctccaa tttggacccc agcctggtgg agcaagtctt tctagataag 2220
accctgaatg cctcattcca ttggctgggc tccacctacc agttggtgga catccatgtg 2280
acagaaatgg agtcatcagt ttatcaacca acaagcagct ccagcaccca gcacttctac 2340
ctgaatttca ccatcaccaa cctaccatat tcccaggaca aagcccagcc aggcaccacc 2400
aattaccaga ggaacaaaag gaatattgag gatgcggcac cacaccgggg tggactccct 2460
gtgtaacttc tcgccactgg ctcggagagt agacagagtt gccatctatg aggaatttct 2520
gcggatgacc cggaatggta cccagctgca gaacttcacc ctggacagga gcagtgtcct 2580
tgtggatggg tattttccca acagaaatga gcccttaact gggaattctg accttccctt 2640
ctgggctgtc atcctcatcg gcttggcagg actcctggga ctcatcacat gcctgatctg 2700
cggtgtcctg gtgaccaccc gccggcggaa gaaggaagga gaatacaacg tccagcaaca 2760
gtgcccaggc tactaccagt cacacctaga cctggaggat ctgcaatgac tggaacttgc 2820
cggtgcctgg ggtgcctttc ccccagccag ggtccaaaga agcttggctg gggcagaaat 2880
aaaccatatt ggtcggaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2940
aaa 2943
<210>386
<211>2608
<212>DNA
<213> human
<400>386
gttcaagagc accagtgttg gccctctgta ctctggctgc agactgactt tgctcaggcc 60
tgaaaaggat gggacagcca ctggagtgga tgccatctgc acccaccacc ctgaccccaa 120
aagccctagg ctggacagag agcagctgta ttgggagctg agccagctga cccacaatat 180
cactgagctg ggcccctatg ccctggacaa cgacagcctc tttgtcaatg gtttcactca 240
tcggagctct gtgtccacca ccagcactcc tgggaccccc acagtgtatc tgggagcatc 300
taagactcca gcctcgatat ttggcccttc agctgccagc catctcctga tactattcac 360
cctcaacttc accatcacta acctgcggta tgaggagaac atgtggcctg gctccaggaa 420
gttcaacact acagagaggg tccttcaggg cctgctaagg cccttgttca agaacaccag 480
tgttggccct ctgtactctg gctgcaggct gaccttgctc aggccagaga aagatgggga 540
agccaccgga gtggatgcca tctgcaccca ccgccctgac cccacaggcc ctgggctgga 600
cagagagcag ctgtatttgg agctgagcca gctgacccac agcatcactg agctgggccc 660
ctacacactg gacagggaca gtctctatgt caatggtttc acccatcgga gctctgtacc 720
caccaccagc accggggtgg tcagcgagga gccattcaca ctgaacttca ccatcaacaa 780
cctgcgctac atggcggaca tgggccaacc cggctccctc aagttcaaca tcacagacaa 840
cgtcatgaag cacctgctca gtcctttgtt ccagaggagc agcctgggtg cacggtacac 900
aggctgcagg gtcatcgcac taaggtctgt gaagaacggt gctgagacac gggtggacct 960
cctctgcacc tacctgcagc ccctcagcgg cccaggtctg cctatcaagc aggtgttcca 1020
tgagctgagc cagcagaccc atggcatcac ccggctgggc ccctactctc tggacaaaga 1080
cagcctctac cttaacggtt acaatgaacc tggtccagat gagcctccta caactcccaa 1140
gccagccacc acattcctgc ctcctctgtc agaagccaca acagccatgg ggtaccacct 1200
gaagaccctc acactcaact tcaccatctc caatctccag tattcaccag atatgggcaa 1260
gggctcagct acattcaact ccaccgaggg ggtccttcag cacctgctca gacccttgtt 1320
ccagaagagc agcatgggcc ccttctactt gggttgccaa ctgatctccc tcaggcctga 1380
gaaggatggg gcagccactg gtgtggacac cacctgcacc taccaccctg accctgtggg 1440
ccccgggctg gacatacagc agctttactg ggagctgagt cagctgaccc atggtgtcac 1500
ccaactgggc ttctatgtcc tggacaggga tagcctcttc atcaatggct atgcacccca 1560
gaatttatca atccggggcg agtaccagat aaatttccac attgtcaact ggaacctcag 1620
taatccagac cccacatcct cagagtacat caccctgctg agggacatcc aggacaaggt 1680
caccacactc tacaaaggca gtcaactaca tgacacattc cgcttctgcc tggtcaccaa 1740
cttgacgatg gactccgtgt tggtcactgt caaggcattg ttctcctcca atttggaccc 1800
cagcctggtg gagcaagtct ttctagataa gaccctgaat gcctcattcc attggctggg 1860
ctccacctac cagttggtgg acatccatgt gacagaaatg gagtcatcag tttatcaacc 1920
aacaagcagc tccagcaccc agcacttcta cctgaatttc accatcacca acctaccata 1980
ttcccaggac aaagcccagc caggcaccac caattaccag aggaacaaaa ggaatattga 2040
ggatgcgctc aaccaactct tccgaaacag cagcatcaag agttattttt ctgactgtca 2100
agtttcaaca ttcaggtctg tccccaacag gcaccacacc ggggtggact ccctgtgtaa 2160
cttctcgcca ctggctcgga gagtagacag agttgccatc tatgaggaat ttctgcggat 2220
gacccggaat ggtacccagc tgcagaactt caccctggac aggagcagtg tccttgtgga 2280
tgggtatttt cccaacagaa atgagccctt aactgggaat tctgaccttc ccttctgggc 2340
tgtcatcctc atcggcttgg caggactcct gggactcatc acatgcctga tctgcggtgt 2400
cctggtgacc acccgccggc ggaagaagga aggagaatac aacgtccagc aacagtgccc 2460
aggctactac cagtcacacc tagacctgga ggatctgcaa tgactggaac ttgccggtgc 2520
ctggggtgcc tttcccccag ccagggtcca aagaagcttg gctggggcag aaataaacca 2580
tattggtcgg acacaaaaaa aaaaaaaa 2608
<210>387
<211>1761
<212>DNA
<213> human
<400>387
ctgaacttca ccatcaacaa cctgcgctac atggcggaca tgggccaacc cggctccctc 60
aagttcaaca tcacagacaa cgtcatgaag cacctgctca gtcctttgtt ccagaggagc 120
agcctgggtg cacggtacac aggctgcagg gtcatcgcac taaggtctgt gaagaacggt 180
gctgagacac gggtggacct cctctgcagg taggtgcaga ggaggtccac ggcatcaccc 240
ggctgggccc ctactctctg gacaaagaca gcctctacct taacgctccc aagccagcca 300
ccacattcct gcctcctctg tcagaagcca caacagccat ggggtaccac ctgaagaccc 360
tcacactcaa cttcaccatc tccaatctcc agtattcacc agatatgggc aagggctcag 420
ctacattcaa ctccaccgag ggggtccttc agcacctgct cagacccttg ttccagaaga 480
gcagcatggg ccccttctac ttgggttgcc aactgatctc cctcaggcct gagaaggatg 540
gggcagccac tggtgtggac accacctgca cctaccaccc tgaccctgtg ggccccgggc 600
tggacataca gcagctttac tgggagctga gtcagctgac ccatggtgtc acccaactgg 660
gcttctatgt cctggacagg gatagcctct tcatcaatgg ctatgcaccc cagaatttat 720
caatccgggg cgagtaccag ataaatttcc acattgtcaa ctggaacctc agtaatccag 780
accccacatc ctcagagtac atcaccctgc tgagggacat ccaggacaag gtcaccacac 840
tctacaaagg cagtcaacta catgacacat tccgcttctg cctggtcacc aacttgacga 900
tggactccgt gttggtcact gtcaaggcat tgttctcctc caatttggac cccagcctgg 960
tggagcaagt ctttctagat aagaccctga atgcctcatt ccattggctg ggctccacct 1020
accagttggt ggacatccat gtgacagaaa tggagtcatc agtttatcaa ccaacaagca 1080
gctccagcac ccagcacttc tacctgaatt tcaccatcac caacctacca tattcccagg 1140
acaaagccca gccaggcacc accaattacc agaggaacaa aaggaatatt gaggatgcgc 1200
tcaaccaact cttccgaaac agcagcatca agagttattt ttctgactgt caagtttcaa 1260
cattcaggtc tgtccccaac aggcaccaca ccggggtgga ctccctgtgt aacttctcgc 1320
cactggctcg gagagtagac agagttgcca tctatgagga atttctgcgg atgacccgga 1380
atggtaccca gctgcagaac ttcaccctgg acaggagcag tgtccttgtg gatgggtatt 1440
ttcccaacag aaatgagccc ttaactggga attctgacct tcccttctgg gctgtcatcc 1500
tcatcggctt ggcaggactc ctgggactca tcacatgcct gatctgcggt gtcctggtga 1560
ccacccgccg gcggaagaag gaaggagaat acaacgtcca gcaacagtgc ccaggctact 1620
accagtcaca cctagacctg gaggatctgc aatgactgga acttgccggt gcctggggtg 1680
cctttccccc agccagggtc caaagaagct tggctggggc agaaataaac catattggtc 1740
ggacacaaaa aaaaaaaaaa a 1761
<210>388
<211>772
<212>PRT
<213> human
<400>388
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala Phe
1 5 10 15
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu
20 25 30
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser
35 40 45
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu
50 55 60
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Trp Ser
65 70 75 80
Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu
85 90 95
Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala
100 105 110
Ile Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu
115 120 125
Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu
130 135 140
Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly Phe Thr
145 150 155 160
His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val
165 170 175
Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala
180 185 190
Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn
195 200 205
Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr
210 215 220
Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr
225 230 235 240
Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro
245 250 255
Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg
260 265 270
Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu
275 280 285
Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu
290 295 300
Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val
305 310 315 320
Pro Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn
325 330 335
Phe Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly
340 345 350
Ser Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu Leu Ser
355 360 365
Pro Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg
370 375 380
Val Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp
385 390 395 400
Leu Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile
405 410 415
Lys Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg
420 425 430
Leu Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr
435 440 445
Asn Glu Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr
450 455 460
Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His
465 470 475 480
Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser
485 490 495
Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu Gly Val
500 505 510
Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro
515 520 525
Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly
530 535 540
Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val
545 550 555 560
Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu
565 570 575
Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser
580 585 590
Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu
595 600 605
Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp
610 615 620
Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys
625 630 635 640
Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe
645 650 655
Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys
660 665 670
Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe
675 680 685
Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr
690 695 700
Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln
705 710 715 720
Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile
725 730 735
Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn
740 745 750
Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Ala Pro His Arg Gly
755 760 765
Gly Leu Pro Val
770
<210>389
<211>833
<212>PRT
<213> human
<400>389
Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
1 5 10 15
Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala Ile
20 25 30
Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln
35 40 45
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly
50 55 60
Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His
65 70 75 80
Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr
85 90 95
Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala
100 105 110
Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu
115 120 125
Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr
130 135 140
Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser
145 150 155 160
Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
165 170 175
Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg Pro
180 185 190
Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu
195 200 205
Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp
210 215 220
Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val Pro
225 230 235 240
Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn Phe
245 250 255
Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser
260 265 270
Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu Leu Ser Pro
275 280 285
Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val
290 295 300
Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu
305 310 315 320
Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys
325 330 335
Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu
340 345 350
Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn
355 360 365
Glu Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr
370 375 380
Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu
385 390 395 400
Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro
405 410 415
Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu Gly Val Leu
420 425 430
Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe
435 440 445
Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala
450 455 460
Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly
465 470 475 480
Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr
485 490 495
His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu
500 505 510
Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr
515 520 525
Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro
530 535 540
Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val
545 550 555 560
Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys
565 570 575
Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys Ala
580 585 590
Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu
595 600 605
Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln
610 615 620
Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro
625 630 635 640
Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile Thr
645 650 655
Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr
660 665 670
Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg
675 680 685
Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe
690 695 700
Arg Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys Asn
705 710 715 720
Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu
725 730 735
Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu
740 745 750
Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Phe Pro Asn Arg Asn Glu
755 760 765
Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu Ile
770 775 780
Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val
785 790 795 800
Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln
805 810 815
Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu
820 825 830
Gln
<210>390
<211>438
<212>PRT
<213> human
<400>390
Met Gly Tyr His Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn
1 5 10 15
Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser
20 25 30
Thr Glu Gly Val Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser
35 40 45
Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro
50 55 60
Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His
65 70 75 80
Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu
85 90 95
Leu Ser Gln Leu Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu
100 105 110
Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser
115 120 125
Ile Arg Gly Glu Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu
130 135 140
Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp
145 150 155 160
Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp
165 170 175
Thr Phe Arg Phe Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu
180 185 190
Val Thr Val Lys Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val
195 200 205
Glu Gln Val Phe Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu
210 215 220
Gly Ser Thr Tyr Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser
225 230 235 240
Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu
245 250 255
Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro
260 265 270
Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu
275 280 285
Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys
290 295 300
Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val
305 310 315 320
Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val
325 330 335
Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu
340 345 350
Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Phe
355 360 365
Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp
370 375 380
Ala Val Ile Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys
385 390 395 400
Leu Ile Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly
405 410 415
Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu
420 425 430
Asp Leu Glu Asp Leu Gln
435
<210>391
<211>2627
<212>DNA
<213> human
<400>391
ccacgcgtcc gcccacgcgt ccggaaggca gcggcagctc cactcagcca gtacccagat 60
acgctgggaa ccttccccag ccatggcttc cctggggcag atcctcttct ggagcataat 120
tagcatcatc attattctgg ctggagcaat tgcactcatc attggctttg gtatttcagg 180
gagacactcc atcacagtca ctactgtcgc ctcagctggg aacattgggg aggatggaat 240
cctgagctgc acttttgaac ctgacatcaa actttctgat atcgtgatac aatggctgaa 300
ggaaggtgtt ttaggcttgg tccatgagtt caaagaaggc aaagatgagc tgtcggagca 360
ggatgaaatg ttcagaggcc ggacagcagt gtttgctgat caagtgatag ttggcaatgc 420
ctctttgcgg ctgaaaaacg tgcaactcac agatgctggc acctacaaat gttatatcat 480
cacttctaaa ggcaagggga atgctaacct tgagtataaa actggagcct tcagcatgcc 540
ggaagtgaat gtggactata atgccagctc agagaccttg cggtgtgagg ctccccgatg 600
gttcccccag cccacagtgg tctgggcatc ccaagttgac cagggagcca acttctcgga 660
agtctccaat accagctttg agctgaactc tgagaatgtg accatgaagg ttgtgtctgt 720
gctctacaat gttacgatca acaacacata ctcctgtatg attgaaaatg acattgccaa 780
agcaacaggg gatatcaaag tgacagaatc ggagatcaaa aggcggagtc acctacagct 840
gctaaactca aaggcttctc tgtgtgtctc ttctttcttt gccatcagct gggcacttct 900
gcctctcagc ccttacctga tgctaaaata atgtgccttg gccacaaaaa agcatgcaaa 960
gtcattgtta caacagggat ctacagaact atttcaccac cagatatgac ctagttttat 1020
atttctggga ggaaatgaat tcatatctag aagtctggag tgagcaaaca agagcaagaa 1080
acaaaaagaa gccaaaagca gaaggctcca atatgaacaa gataaatcta tcttcaaaga 1140
catattagaa gttgggaaaa taattcatgt gaactagaca agtgtgttaa gagtgataag 1200
taaaatgcac gtggagacaa gtgcatcccc agatctcagg gacctccccc tgcctgtcac 1260
ctggggagtg agaggacagg atagtgcatg ttctttgtct ctgaattttt agttatatgt 1320
gctgtaatgt tgctctgagg aagcccctgg aaagtctatc ccaacatatc cacatcttat 1380
attccacaaa ttaagctgta gtatgtaccc taagacgctg ctaattgact gccacttcgc 1440
aactcagggg cggctgcatt ttagtaatgg gtcaaatgat tcacttttta tgatgcttcc 1500
aaaggtgcct tggcttctct tcccaactga caaatgccaa agttgagaaa aatgatcata 1560
attttagcat aaacagagca gtcggcgaca ccgattttat aaataaactg agcaccttct 1620
ttttaaacaa acaaatgcgg gtttatttct cagatgatgt tcatccgtga atggtccagg 1680
gaaggacctt tcaccttgac tatatggcat tatgtcatca caagctctga ggcttctcct 1740
ttccatcctg cgtggacagc taagacctca gttttcaata gcatctagag cagtgggact 1800
cagctggggt gatttcgccc cccatctccg ggggaatgtc tgaagacaat tttggttacc 1860
tcaatgaggg agtggaggag gatacagtgc tactaccaac tagtggataa aggccaggga 1920
tgctgctcaa cctcctacca tgtacaggac gtctccccat tacaactacc caatccgaag 1980
tgtcaactgt gtcaggacta agaaaccctg gttttgagta gaaaagggcc tggaaagagg 2040
ggagccaaca aatctgtctg cttcctcaca ttagtcattg gcaaataagc attctgtctc 2100
tttggctgct gcctcagcac agagagccag aactctatcg ggcaccagga taacatctct 2160
cagtgaacag agttgacaag gcctatggga aatgcctgat gggattatct tcagcttgtt 2220
gagcttctaa gtttctttcc cttcattcta ccctgcaagc caagttctgt aagagaaatg 2280
cctgagttct agctcaggtt ttcttactct gaatttagat ctccagaccc ttcctggcca 2340
caattcaaat taaggcaaca aacatatacc ttccatgaag cacacacaga cttttgaaag 2400
caaggacaat gactgcttga attgaggcct tgaggaatga agctttgaag gaaaagaata 2460
ctttgtttcc agcccccttc ccacactctt catgtgttaa ccactgcctt cctggacctt 2520
ggagccacgg tgactgtatt acatgttgtt atagaaaact gattttagag ttctgatcgt 2580
tcaagagaat gattaaatat acatttccta caccaaaaaa aaaaaaa 2627
<210>392
<211>309
<212>PRT
<213> human
<400>392
His Ala Ser Ala His Ala Ser Gly Arg Gln Arg Gln Leu His Ser Ala
1 5 10 15
Ser Thr Gln Ile Arg Trp Glu Pro Ser Pro Ala Met Ala Ser Leu Gly
20 25 30
Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile Ile Ile Leu Ala Gly
35 40 45
Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser Gly Arg His Ser Ile
50 55 60
Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile Gly Glu Asp Gly Ile
65 70 75 80
Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu Ser Asp Ile Val Ile
85 90 95
Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val His Glu Phe Lys Glu
100 105 110
Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met Phe Arg Gly Arg Thr
115 120 125
Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn Ala Ser Leu Arg Leu
130 135 140
Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys Tyr Ile Ile
145 150 155 160
Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly Ala
165 170 175
Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr
180 185 190
Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp
195 200 205
Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn Thr
210 215 220
Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met Lys Val Val Ser Val
225 230 235 240
Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser Cys Met Ile Glu Asn
245 250 255
Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val Thr Glu Ser Glu Ile
260 265 270
Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser Lys Ala Ser Leu Cys
275 280 285
Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro Leu Ser Pro
290 295 300
Tyr Leu Met Leu Lys
305
<210>393
<211>282
<212>PRT
<213> human
<400>393
Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
1 5 10 15
Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
20 25 30
Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile
35 40 45
Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
50 55 60
Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val
65 70 75 80
His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met
85 90 95
Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn
100 105 110
Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
115 120 125
Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
130 135 140
Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn
145 150 155 160
Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
165 170 175
Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
180 185 190
Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
195 200 205
Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
210 215 220
Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
225 230 235 240
Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
245 250 255
Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu
260 265 270
Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
275 280
<210>394
<211>20
<212>PRT
<213> human
<400>394
Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
1 5 10 15
Ile Ile Leu Ala
20
<210>395
<211>20
<212>PRT
<213> human
<400>395
Ile Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile
1 5 10 15
Ser Gly Arg His
20
<210>396
<211>20
<212>PRT
<213> human
<400>396
Ile Ser Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly
1 5 10 15
Asn Ile Gly Glu
20
<210>397
<211>20
<212>PRT
<213> human
<400>397
Gly Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp
1 5 10 15
Ile Lys Leu Ser
20
<210>398
<211>20
<212>PRT
<213> human
<400>398
Asp Ile Lys Leu Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val
1 5 10 15
Leu Gly Leu Val
20
<210>399
<211>20
<212>PRT
<213> human
<400>399
Val Leu Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser
1 5 10 15
Glu Gln Asp Glu
20
<210>400
<211>20
<212>PRT
<213> human
<400>400
Ser Glu Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp
1 5 10 15
Gln Val Ile Val
20
<210>401
<211>20
<212>PRT
<213> human
<400>401
Asp Gln Val Ile Val Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln
1 5 10 15
Leu Thr Asp Ala
20
<210>402
<211>21
<212>PRT
<213> human
<400>402
Val Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys Tyr Ile Ile Thr Ser
1 5 10 15
Lys Gly Lys Gly Asn
20
<210>403
<211>20
<212>PRT
<213> human
<400>403
Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser
1 5 10 15
Met Pro Glu Val
20
<210>404
<211>20
<212>PRT
<213> human
<400>404
Ser Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu
1 5 10 15
Arg Cys Glu Ala
20
<210>405
<211>20
<212>PRT
<213> human
<400>405
Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp
1 5 10 15
Ala Ser Gln Val
20
<210>406
<211>20
<212>PRT
<213> human
<400>406
Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn
1 5 10 15
Thr Ser Phe Glu
20
<210>407
<211>20
<212>PRT
<213> human
<400>407
Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met Lys Val Val
1 5 10 15
Ser Val Leu Tyr
20
<210>408
<211>20
<212>PRT
<213> human
<400>408
Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser Cys Met
1 5 10 15
Ile Glu Asn Asp
20
<210>409
<211>20
<212>PRT
<213> human
<400>409
Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val Thr
1 5 10 15
Glu Ser Glu Ile
20
<210>410
<211>20
<212>PRT
<213> human
<400>410
Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
1 5 10 15
Lys Ala Ser Leu
20
<210>411
<211>20
<212>PRT
<213> human
<400>411
Ser Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala
1 5 10 15
Leu Leu Pro Leu
20
<210>412
<211>20
<212>PRT
<213> human
<400>412
Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu Leu Pro Leu Ser Pro Tyr
1 5 10 15
Leu Met Leu Lys
20
<210>413
<211>35
<212>PRT
<213> human
<400>413
Ile Ser Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly
1 5 10 15
Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile
20 25 30
Lys Leu Ser
35
<210>414
<211>35
<212>PRT
<213> human
<400>414
Val Leu Gly Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser
1 5 10 15
Glu Gln Asp Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln
20 25 30
Val Ile Val
35
<210>415
<211>65
<212>PRT
<213> human
<400>415
Lys Gly Lys Gly Asn Ala Asn Leu Glu Tyr Lys Thr Gly Ala Phe Ser
1 5 10 15
Met Pro Glu Val Asn Val Asp Tyr Asn Ala Ser Ser Glu Thr Leu Arg
20 25 30
Cys Glu Ala Pro Arg Trp Phe Pro Gln Pro Thr Val Val Trp Ala Ser
35 40 45
Gln Val Asp Gln Gly Ala Asn Phe Ser Glu Val Ser Asn Thr Ser Phe
50 55 60
Glu
65
<210>416
<211>10
<212>PRT
<213> human
<400>416
Lys Leu Ser Asp Ile Val Ile Gln Trp Leu
1 5 10
<210>417
<211>10
<212>PRT
<213> human
<400>417
Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile
1 5 10
<210>418
<211>10
<212>PRT
<213> human
<400>418
Leu Leu Asn Ser Lys Ala Ser Leu Cys Val
1 5 10
<210>419
<211>10
<212>PRT
<213> human
<400>419
Ser Leu Cys Val Ser Ser Phe Phe Ala Ile
1 5 10
<210>420
<211>10
<212>PRT
<213> human
<400>420
Val Leu Tyr Asn Val Thr Ile Asn Asn Thr
1 5 10
<210>421
<211>10
<212>PRT
<213> human
<400>421
Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
1 5 10
<210>422
<211>10
<212>PRT
<213> human
<400>422
Leu Leu Pro Leu Ser Pro Tyr Leu Met Leu
1 5 10
<210>423
<211>10
<212>PRT
<213> human
<400>423
Cys Met Ile Glu Asn Asp Ile Ala Lys Ala
1 5 10
<210>424
<211>10
<212>PRT
<213> human
<400>424
Lys Thr Gly Ala Phe Ser Met Pro Glu Val
1 5 10
<210>425
<211>10
<212>PRT
<213> human
<400>425
Trp Ala Leu Leu Pro Leu Ser Pro Tyr Leu
1 5 10
<210>426
<211>10
<212>PRT
<213> human
<400>426
Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile
1 5 10
<210>427
<211>10
<212>PRT
<213> human
<400>427
Gln Leu Thr Asp Ala Gly Thr Tyr Lys Cys
1 5 10
<210>428
<211>10
<212>PRT
<213> human
<400>428
Ala Leu Leu Pro Leu Ser Pro Tyr Leu Met
1 5 10
<210>429
<211>10
<212>PRT
<213> human
<400>429
Gln Leu Leu Asn Ser Lys Ala Ser Leu Cys
1 5 10
<210>430
<211>10
<212>PRT
<213> human
<400>430
Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile
1 5 10
<210>431
<211>10
<212>PRT
<213> human
<400>431
Trp Leu Lys Glu Gly Val Leu Gly Leu Val
1 5 10
<210>432
<211>10
<212>PRT
<213> human
<400>432
Leu Gln Leu Leu Asn Ser Lys Ala Ser Leu
1 5 10
<210>433
<21l>10
<212>PRT
<213> human
<400>433
Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile
1 5 10
<210>434
<211>10
<212>PRT
<213> human
<400>434
Gly Ile Ser Gly Arg His Ser Ile Thr Val
1 5 10
<210>435
<211>10
<212>PRT
<213> human
<400>435
Phe Glu Pro Asp Ile Lys Leu Ser Asp Ile
1 5 10
<210>436
<211>9
<212>PRT
<213> human
<400>436
Ala Leu Leu Pro Leu Ser Pro Tyr Leu
1 5
<210>437
<211>9
<212>PRT
<213> human
<400>437
Ser Leu Cys Val Ser Ser Phe Phe Ala
1 5
<210>438
<211>9
<212>PRT
<213> human
<400>438
Ile Leu Phe Trp Ser Ile Ile Ser Ile
1 5
<210>439
<211>9
<212>PRT
<213> human
<400>439
Gln Leu Leu Asn Ser Lys Ala Ser Leu
1 5
<210>440
<211>9
<212>PRT
<213> human
<400>440
Lys Val Val Ser Val Leu Tyr Asn Val
1 5
<210>441
<211>9
<212>PRT
<213> human
<400>441
Ile Leu Ala Gly Ala Ile Ala Leu Ile
1 5
<210>442
<211>9
<212>PRT
<213> human
<400>442
Trp Leu Lys Glu Gly Val Leu Gly Leu
1 5
<210>443
<211>9
<212>PRT
<213> human
<400>443
Ile Ile Leu Ala Gly Ala Ile Ala Leu
1 5
<210>444
<211>9
<212>PRT
<213> human
<400>444
Asn Val Thr Met Lys Val Val Ser Val
1 5
<210>445
<211>9
<212>PRT
<213> human
<400>445
Glu Met Phe Arg Gly Arg Thr Ala Val
1 5
<210>446
<211>9
<212>PRT
<213> human
<400>446
Ala Val Phe Ala Asp Gln Val Ile Val
1 5
<210>447
<211>9
<212>PRT
<213> human
<400>447
Leu Leu Pro Leu Ser Pro Tyr Leu Met
1 5
<210>448
<211>9
<212>PRT
<213> human
<400>448
Leu Leu Asn Ser Lys Ala Ser Leu Cys
1 5
<210>449
<211>9
<212>PRT
<213> human
<400>449
Val Ile Gln Trp Leu Lys Glu Gly Val
1 5
<210>450
<211>9
<212>PRT
<213> human
<400>450
Ala Ile Ser Trp Ala Leu Leu Pro Leu
1 5
<210>451
<211>9
<212>PRT
<213> human
<400>451
Ser Leu Gly Gln Ile Leu Phe Trp Ser
1 5
<210>452
<211>9
<212>PRT
<213> human
<400>452
Ile Ala Leu Ile Ile Gly Phe Gly Ile
1 5
<210>453
<211>9
<212>PRT
<213> human
<400>453
Cys Thr Phe Glu Pro Asp Ile Lys Leu
1 5
<210>454
<211>9
<212>PRT
<213> human
<400>454
Ile Val Gly Asn Ala Ser Leu Arg Leu
1 5
<210>455
<211>9
<212>PRT
<213> human
<400>455
Gly Gln Ile Leu Phe Trp Ser Ile Ile
1 5
<210>456
<211>3447
<212>DNA
<213> human
<400>456
atgcccttgt tcaagaacac cagtgtcagc tctctgtact ctggttgcag actgaccttg 60
ctcaggcctg agaaggatgg ggcagccacc agagtggatg ctgtctgcac ccatcgtcct 120
gaccccaaaa gccctggact ggacagagag cggctgtact ggaagctgag ccagctgacc 180
cacggcatca ctgagctggg cccctacacc ctggacaggc acagtctcta tgtcaatggt 240
ttcacccatc agagctctat gacgaccacc agaactcctg atacctccac aatgcacctg 300
gcaacctcga gaactccagc ctccctgtct ggacctacga ccgccagccc tctcctggtg 360
ctattcacaa ttaacttcac catcactaac ctgcggtatg aggagaacat gcatcaccct 420
ggctctagaa agtttaacac cacggagaga gtccttcagg gtctgctcag gcctgtgttc 480
aagaacacca gtgttggccc tctgtactct ggctgcagac tgaccttgct caggcccaag 540
aaggatgggg cagccaccaa agtggatgcc atctgcacct accgccctga tcccaaaagc 600
cctggactgg acagagagca gctatactgg gagctgagcc agctaaccca cagcatcact 660
gagctgggcc cctacaccct ggacagggac agtctctatg tcaatggttt cacacagcgg 720
agctctgtgc ccaccactag cattcctggg acccccacag tggacctggg aacatctggg 780
actccagttt ctaaacctgg tccctcggct gccagccctc tcctggtgct attcactctc 840
aacttcacca tcaccaacct gcggtatgag gagaacatgc agcaccctgg ctccaggaag 900
ttcaacacca cggagagggt ccttcagggc ctgctcaggt ccctgttcaa gagcaccagt 960
gttggccctc tgtactctgg ctgcagactg actttgctca ggcctgaaaa ggatgggaca 1020
gccactggag tggatgccat ctgcacccac caccctgacc ccaaaagccc taggctggac 1080
agagagcagc tgtattggga gctgagccag ctgacccaca atatcactga gctgggccac 1140
tatgccctgg acaacgacag cctctttgtc aatggtttca ctcatcggag ctctgtgtcc 1200
accaccagca ctcctgggac ccccacagtg tatctgggag catctaagac tccagcctcg 1260
atatttggcc cttcagctgc cagccatctc ctgatactat tcaccctcaa cttcaccatc 1320
actaacctgc ggtatgagga gaacatgtgg cctggctcca ggaagttcaa cactacagag 1380
agggtccttc agggcctgct aaggcccttg ttcaagaaca ccagtgttgg ccctctgtac 1440
tctggctcca ggctgacctt gctcaggcca gagaaagatg gggaagccac cggagtggat 1500
gccatctgca cccaccgccc tgaccccaca ggccctgggc tggacagaga gcagctgtat 1560
ttggagctga gccagctgac ccacagcatc actgagctgg gcccctacac actggacagg 1620
gacagtctct atgtcaatgg tttcacccat cggagctctg tacccaccac cagcaccggg 1680
gtggtcagcg aggagccatt cacactgaac ttcaccatca acaacctgcg ctacatggcg 1740
gacatgggcc aacccggctc cctcaagttc aacatcacag acaacgtcat gaagcacctg 1800
ctcagtcctt tgttccagag gagcagcctg ggtgcacggt acacaggctg cagggtcatc 1860
gcactaaggt ctgtgaagaa cggtgctgag acacgggtgg acctcctctg cacctacctg 1920
cagcccctca gcggcccagg tctgcctatc aagcaggtgt tccatgagct gagccagcag 1980
acccatggca tcacccggct gggcccctac tctctggaca aagacagcct ctaccttaac 2040
ggttacaatg aacctggtct agatgagcct cctacaactc ccaagccagc caccacattc 2100
ctgcctcctc tgtcagaagc cacaacagcc atggggtacc acctgaagac cctcacactc 2160
aacttcacca tctccaatct ccagtattca ccagatatgg gcaagggctc agctacattc 2220
aactccaccg agggggtcct tcagcacctg ctcagaccct tgttccagaa gagcagcatg 2280
ggccccttct acttgggttg ccaactgatc tccctcaggc ctgagaagga tggggcagcc 2340
actggtgtgg acaccacctg cacctaccac cctgaccctg tgggccccgg gctggacata 2400
cagcagcttt actgggagct gagtcagctg acccatggtg tcacccaact gggcttctat 2460
gtcctggaca gggatagcct cttcatcaat ggctatgcac cccagaattt atcaatccgg 2520
ggcgagtacc agataaattt ccacattgtc aactggaacc tcagtaatcc agaccccaca 2580
tcctcagagt acatcaccct gctgagggac atccaggaca aggtcaccac actctacaaa 2640
ggcagtcaac tacatgacac attccgcttc tgcctggtca ccaacttgac gatggactcc 2700
gtgttggtca ctgtcaaggc attgttctcc tccaatttgg accccagcct ggtggagcaa 2760
gtctttctag ataagaccct gaatgcctca ttccattggc tgggctccac ctaccagttg 2820
gtggacatcc atgtgacaga aatggagtca tcagtttatc aaccaacaag cagctccagc 2880
acccagcact tctacccgaa tttcaccatc accaacctac catattccca ggacaaagcc 2940
cagccaggca ccaccaatta ccagaggaac aaaaggaata ttgaggatgc gctcaaccaa 3000
ctcttccgaa acagcagcat caagagttat ttttctgact gtcaagtttc aacattcagg 3060
tctgtcccca acaggcacca caccggggtg gactccctgt gtaacttctc gccactggct 3120
cggagagtag acagagttgc catctatgag gaatttctgc ggatgacccg gaatggtacc 3180
cagctgcaga acttcaccct ggacaggagc agtgtccttg tggatgggta ttctcccaac 3240
agaaatgagc ccttaactgg gaattctgac cttcccttct gggctgtcat cttcatcggc 3300
ttggcaggac tcctgggact catcacatgc ctgatctgcg gtgtcctggt gaccacccgc 3360
cggcggaaga aggaaggaga atacaacgtc cagcaacagt gcccaggcta ctaccagtca 3420
cacctagacc tggaggatct gcaatga 3447
<210>457
<211>3557
<212>DNA
<213> human
<400>457
gagagggtcc ttcagggtct gcttatgccc ttgttcaaga acaccagtgt cagctctctg 60
tactctggtt gcagactgac cttgctcagg cctgagaagg atggggcagc caccagagtg 120
gatgctgtct gcacccatcg tcctgacccc aaaagccctg gactggacag agagcggctg 180
tactggaagc tgagccagct gacccacggc atcactgagc tgggccccta caccctggac 240
aggcacagtc tctatgtcaa tggtttcacc catcagagct ctatgacgac caccagaact 300
cctgatacct ccacaatgca cctggcaacc tcgagaactc cagcctccct gtctggacct 360
acgaccgcca gccctctcct ggtgctattc acaattaact tcaccatcac taacctgcgg 420
tatgaggaga acatgcatca ccctggctct agaaagttta acaccacgga gagagtcctt 480
cagggtctgc tcaggcctgt gttcaagaac accagtgttg gccctctgta ctctggctgc 540
agactgacct tgctcaggcc caagaaggat ggggcagcca ccaaagtgga tgccatctgc 600
acctaccgcc ctgatcccaa aagccctgga ctggacagag agcagctata ctgggagctg 660
agccagctaa cccacagcat cactgagctg ggcccctaca ccctggacag ggacagtctc 720
tatgtcaatg gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc 780
acagtggacc tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc 840
cctctcctgg tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac 900
atgcagcacc ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc 960
aggtccctgt tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg 1020
ctcaggcctg aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct 1080
gaccccaaaa gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc 1140
cacaatatca ctgagctggg ccactatgcc ctggacaacg acagcctctt tgtcaatggt 1200
ttcactcatc ggagctctgt gtccaccacc agcactcctg ggacccccac agtgtatctg 1260
ggagcatcta agactccagc ctcgatattt ggcccttcag ctgccagcca tctcctgata 1320
ctattcaccc tcaacttcac catcactaac ctgcggtatg aggagaacat gtggcctggc 1380
tccaggaagt tcaacactac agagagggtc cttcagggcc tgctaaggcc cttgttcaag 1440
aacaccagtg ttggccctct gtactctggc tccaggctga ccttgctcag gccagagaaa 1500
gatggggaag ccaccggagt ggatgccatc tgcacccacc gccctgaccc cacaggccct 1560
gggctggaca gagagcagct gtatttggag ctgagccagc tgacccacag catcactgag 1620
ctgggcccct acacactgga cagggacagt ctctatgtca atggtttcac ccatcggagc 1680
tctgtaccca ccaccagcac cggggtggtc agcgaggagc cattcacact gaacttcacc 1740
atcaacaacc tgcgctacat ggcggacatg ggccaacccg gctccctcaa gttcaacatc 1800
acagacaacg tcatgaagca cctgctcagt cctttgttcc agaggagcag cctgggtgca 1860
cggtacacag gctgcagggt catcgcacta aggtctgtga agaacggtgc tgagacacgg 1920
gtggacctcc tctgcaccta cctgcagccc ctcagcggcc caggtctgcc tatcaagcag 1980
gtgttccatg agctgagcca gcagacccat ggcatcaccc ggctgggccc ctactctctg 2040
gacaaagaca gcctctacct taacggttac aatgaacctg gtctagatga gcctcctaca 2100
actcccaagc cagccaccac attcctgcct cctctgtcag aagccacaac agccatgggg 2160
taccacctga agaccctcac actcaacttc accatctcca atctccagta ttcaccagat 2220
atgggcaagg gctcagctac attcaactcc accgaggggg tccttcagca cctgctcaga 2280
cccttgttcc agaagagcag catgggcccc ttctacttgg gttgccaact gatctccctc 2340
aggcctgaga aggatggggc agccactggt gtggacacca cctgcaccta ccaccctgac 2400
cctgtgggcc ccgggctgga catacagcag ctttactggg agctgagtca gctgacccat 2460
ggtgtcaccc aactgggctt ctatgtcctg gacagggata gcctcttcat caatggctat 2520
gcaccccaga atttatcaat ccggggcgag taccagataa atttccacat tgtcaactgg 2580
aacctcagta atccagaccc cacatcctca gagtacatca ccctgctgag ggacatccag 2640
gacaaggtca ccacactcta caaaggcagt caactacatg acacattccg cttctgcctg 2700
gtcaccaact tgacgatgga ctccgtgttg gtcactgtca aggcattgtt ctcctccaat 2760
ttggacccca gcctggtgga gcaagtcttt ctagataaga ccctgaatgc ctcattccat 2820
tggctgggct ccacctacca gttggtggac atccatgtga cagaaatgga gtcatcagtt 2880
tatcaaccaa caagcagctc cagcacccag cacttctacc cgaatttcac catcaccaac 2940
ctaccatatt cccaggacaa agcccagcca ggcaccacca attaccagag gaacaaaagg 3000
aatattgagg atgcgctcaa ccaactcttc cgaaacagca gcatcaagag ttatttttct 3060
gactgtcaag tttcaacatt caggtctgtc cccaacaggc accacaccgg ggtggactcc 3120
ctgtgtaact tctcgccact ggctcggaga gtagacagag ttgccatcta tgaggaattt 3180
ctgcggatga cccggaatgg tacccagctg cagaacttca ccctggacag gagcagtgtc 3240
cttgtggatg ggtattctcc caacagaaat gagcccttaa ctgggaattc tgaccttccc 3300
ttctgggctg tcatcttcat cggcttggca ggactcctgg gactcatcac atgcctgatc 3360
tgcggtgtcc tggtgaccac ccgccggcgg aagaaggaag gagaatacaa cgtccagcaa 3420
cagtgcccag gctactacca gtcacaccta gacctggagg atctgcaatg actggaactt 3480
gccggtgcct ggggtgcctt tcccccagcc agggtccaaa gaagcttggc tggggcagaa 3540
ataaaccata ttggtcg 3557
<210>458
<211>1148
<212>PRT
<213> human
<400>458
Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys
1 5 10 15
Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val
20 25 30
Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp
35 40 45
Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr
50 55 60
Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly
65 70 75 80
Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser
85 90 95
Thr Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro
100 105 110
Thr Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile
115 120 125
Thr Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys
130 135 140
Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Phe
145 150 155 160
Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu
165 170 175
Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile Cys
180 185 190
Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln Leu
195 200 205
Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro
210 215 220
Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg
225 230 235 240
Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Pro Thr Val Asp Leu
245 250 255
Gly Thr Ser Gly Thr Pro Val Ser Lys Pro Gly Pro Ser Ala Ala Ser
260 265 270
Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg
275 280 285
Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr
290 295 300
Glu Arg Val Leu Gln Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser
305 310 315 320
Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
325 330 335
Lys Asp Gly Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro
340 345 350
Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu
355 360 365
Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly His Tyr Ala Leu Asp
370 375 380
Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser Val Ser
385 390 395 400
Thr Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala Ser Lys
405 410 415
Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala Ser His Leu Leu Ile
420 425 430
Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn
435 440 445
Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln
450 455 460
Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr
465 470 475 480
Ser Gly Ser Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu Ala
485 490 495
Thr Gly Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Thr Gly Pro
500 505 510
Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu Ser Gln Leu Thr His
515 520 525
Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr
530 535 540
Val Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly
545 550 555 560
Val Val Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu
565 570 575
Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile
580 585 590
Thr Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser
595 600 605
Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser
610 615 620
Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu
625 630 635 640
Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu
645 650 655
Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu
660 665 670
Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Leu Asp
675 680 685
Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro Leu
690 695 700
Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr Leu
705 710 715 720
Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly
725 730 735
Ser Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg
740 745 750
Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln
755 760 765
Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp
770 775 780
Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile
785 790 795 800
Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln
805 810 815
Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr
820 825 830
Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His
835 840 845
Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr
850 855 860
Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys
865 870 875 880
Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr Asn Leu
885 890 895
Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser Ser Asn
900 905 910
Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn
915 920 925
Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His
930 935 940
Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser
945 950 955 960
Thr Gln His Phe Tyr Pro Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser
965 970 975
Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg
980 985 990
Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys
995 1000 1005
Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn
1010 1015 1020
Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala
1025 1030 1035 1040
Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr
1045 1050 1055
Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val
1060 1065 1070
Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn
1075 1080 1085
Ser Asp Leu Pro Phe Trp Ala Val Ile Phe Ile Gly Leu Ala Gly Leu
1090 1095 1100
Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg
1105 1110 1115 1120
Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly
1125 1130 1135
Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
1140 1145
<210>459
<211>1156
<212>PRT
<213> human
<400>459
Glu Arg Val Leu Gln Gly Leu Leu Met Pro Leu Phe Lys Asn Thr Ser
1 5 10 15
Val Ser Ser Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
20 25 30
Lys Asp Gly Ala Ala Thr Arg Val Asp Ala Val Cys Thr His Arg Pro
35 40 45
Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Arg Leu Tyr Trp Lys Leu
50 55 60
Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp
65 70 75 80
Arg His Ser Leu Tyr Val Asn Gly Phe Thr His Gln Ser Ser Met Thr
85 90 95
Thr Thr Arg Thr Pro Asp Thr Ser Thr Met His Leu Ala Thr Ser Arg
100 105 110
Thr Pro Ala Ser Leu Ser Gly Pro Thr Thr Ala Ser Pro Leu Leu Val
115 120 125
Leu Phe Thr Ile Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn
130 135 140
Met His His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
145 150 155 160
Gln Gly Leu Leu Arg Pro Val Phe Lys Asn Thr Ser Val Gly Pro Leu
165 170 175
Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Lys Lys Asp Gly Ala
180 185 190
Ala Thr Lys Val Asp Ala Ile Cys Thr Tyr Arg Pro Asp Pro Lys Ser
195 200 205
Pro Gly Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr
210 215 220
His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu
225 230 235 240
Tyr Val Asn Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr Ser Ile
245 250 255
Pro Gly Thr Pro Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Val Ser
260 265 270
Lys Pro Gly Pro Ser Ala Ala Ser Pro Leu Leu Val Leu Phe Thr Leu
275 280 285
Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Gln His Pro
290 295 300
Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu
305 310 315 320
Arg Ser Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys
325 330 335
Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val
340 345 350
Asp Ala Ile Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp
355 360 365
Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr
370 375 380
Glu Leu Gly His Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly
385 390 395 400
Phe Thr His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro
405 410 415
Thr Val Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro
420 425 430
Ser Ala Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile
435 440 445
Thr Asn Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe
450 455 460
Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys
465 470 475 480
Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Ser Arg Leu Thr Leu Leu
485 490 495
Arg Pro Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr
500 505 510
His Arg Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr
515 520 525
Leu Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr
530 535 540
Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser
545 550 555 560
Ser Val Pro Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr
565 570 575
Leu Asn Phe Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln
580 585 590
Pro Gly Ser Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu
595 600 605
Leu Ser Pro Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly
610 615 620
Cys Arg Val Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg
625 630 635 640
Val Asp Leu Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu
645 650 655
Pro Ile Lys Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile
660 665 670
Thr Arg Leu Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn
675 680 685
Gly Tyr Asn Glu Pro Gly Leu Asp Glu Pro Pro Thr Thr Pro Lys Pro
690 695 700
Ala Thr Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly
705 710 715 720
Tyr His Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln
725 730 735
Tyr Ser Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu
740 745 750
Gly Val Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met
755 760 765
Gly Pro Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys
770 775 780
Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp
785 790 795 800
Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser
805 810 815
Gln Leu Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg
820 825 830
Asp Ser Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg
835 840 845
Gly Glu Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu Ser Asn
850 855 860
Pro Asp Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln
865 870 875 880
Asp Lys Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe
885 890 895
Arg Phe Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr
900 905 910
Val Lys Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln
915 920 925
Val Phe Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser
930 935 940
Thr Tyr Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val
945 950 955 960
Tyr Gln Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Pro Asn Phe
965 970 975
Thr Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr
980 985 990
Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln
995 1000 1005
Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val
1010 1015 1020
Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser
1025 1030 1035 1040
Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile
1045 1050 1055
Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn
1060 1065 1070
Phe Thr Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Ser Pro Asn
1075 1080 1085
Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val
1090 1095 1100
Ile Phe Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile
1105 1110 1115 1120
Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr
1125 1130 1135
Asn Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu
1140 1145 1150
Glu Asp Leu Gln
1155
<210>460
<211>79
<212>PRT
<213> human
<400>460
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala phe
1 5 10 15
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu
20 25 30
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser
35 40 45
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu
50 55 60
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Trp
65 70 75
<210>461
<211>313
<212>PRT
<213> human
<400>461
Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys
1 5 10 15
Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val
20 25 30
Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp
35 40 45
Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr
50 55 60
Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly
65 70 75 80
Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser
85 90 95
Thr Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro
100 105 110
Thr Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile
115 120 125
Thr Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys
130 135 140
Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Phe
145 150 155 160
Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu
165 170 175
Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile Cys
180 185 190
Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln Leu
195 200 205
Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro
210 215 220
Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg
225 230 235 240
Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Pro Thr Val Asp Leu
245 250 255
Gly Thr Ser Gly Thr Pro Val Ser Lys Pro Gly Pro Ser Ala Ala Ser
260 265 270
Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg
275 280 285
Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr
290 295 300
Glu Arg Val Leu Gln Gly Leu Leu Arg
305 310
<210>462
<211>2996
<212>DNA
<213> human
<400>462
cagccaccgg agtggatgcc atctgcaccc accgccctga ccccacaggc cctgggctgg 60
acagagagca gctgtatttg gagctgagcc agctgaccca cagcatcact gagctgggcc 120
cctacaccct ggacagggac agtctctatg tcaatggttt cacacagcgg agctctgtgc 180
ccaccactag cattcctggg acccccacag tggacctggg aacatctggg actccagttt 240
ctaaacctgg tccctcggct gccagccctc tcctggtgct attcactctc aacttcacca 300
tcaccaacct gcggtatgag gagaacatgc agcaccctgg ctccaggaag ttcaacacca 360
cggagagggt ccttcagggc ctggtccctg ttcaagagca ccagtgttgg ccctctgtac 420
tctggctgca gactgacttt gctcaggcct gaaaaggatg ggacagccac tggagtggat 480
gccatctgca cccaccaccc tgaccccaaa agccctaggc tggacagaga gcagctgtat 540
tgggagctga gccagctgac ccacaatatc actgagctgg gcccctatgc cctggacaac 600
gacagcctct ttgtcaatgg tttcactcat cggagctctg tgtccaccac cagcactcct 660
gggaccccca cagtgtatct gggagcatct aagactccag cctcgatatt tggcccttca 720
gctgccagcc atctcctgat actattcacc ctcaacttca ccatcactaa cctgcggtat 780
gaggagaaca tgtggcctgg ctccaggaag ttcaacacta cagagagggt ccttcagggc 840
ctgctaaggc ccttgttcaa gaacaccagt gttggccctc tgtactctgg ctgcaggctg 900
accttgctca ggccagagaa agatggggaa gccaccggag tggatgccat ctgcacccac 960
cgccctgacc ccacaggccc tgggctggac agagagcagc tgtatttgga gctgagccag 1020
ctgacccaca gcatcactga gctgggcccc tacacactgg acagggacag tctctatgtc 1080
aatggtttca cccatcggag ctctgtaccc accaccagca ccggggtggt cagcgaggag 1140
ccattcacac tgaacttcac catcaacaac ctgcgctaca tggcggacat gggccaaccc 1200
ggctccctca agttcaacat cacagacaac gtcatgaagc acctgctcag tcctttgttc 1260
cagaggagca gcctgggtgc acggtacaca ggctgcaggg tcatcgcact aaggtctgtg 1320
aagaacggtg ctgagacacg ggtggacctc ctctgcacct acctgcagcc cctcagcggc 1380
ccaggtctgc ctatcaagca ggtgttccat gagctgagcc agcagaccca tggcatcacc 1440
cggctgggcc cctactctct ggacaaagac agcctctacc ttaacggtta caatgaacct 1500
ggtccagatg agcctcctac aactcccaag ccagccacca cattcctgcc tcctctgtca 1560
gaagccacaa cagccatggg gtaccacctg aagaccctca cactcaactt caccatctcc 1620
aatctccagt attcaccaga tatgggcaag ggctcagcta cattcaactc caccgagggg 1680
gtccttcagc acctgctcag acccttgttc cagaagagca gcatgggccc cttctacttg 1740
ggttgccaac tgatctccct caggcctgag aaggatgggg cagccactgg tgtggacacc 1800
acctgcacct accaccctga ccctgtgggc cccgggctgg acatacagca gctttactgg 1860
gagctgagtc agctgaccca tggtgtcacc caactgggct tctatgtcct ggacagggat 1920
agcctcttca tcaatggcta tgcaccccag aatttatcaa tccggggcga gtaccagata 1980
aatttccaca ttgtcaactg gaacctcagt aatccagacc ccacatcctc agagtacatc 2040
accctgctga gggacatcca ggacaaggtc accacactct acaaaggcag tcaactacat 2100
gacacattcc gcttctgcct ggtcaccaac ttgacgatgg actccgtgtt ggtcactgtc 2160
aaggcattgt tctcctccaa tttggacccc agcctggtgg agcaagtctt tctagataag 2220
accctgaatg cctcattcca ttggctgggc tccacctacc agttggtgga catccatgtg 2280
acagaaatgg agtcatcagt ttatcaacca acaagcagct ccagcaccca gcacttctac 2340
ctgaatttca ccatcaccaa cctaccatat tcccaggaca aagcccagcc aggcaccacc 2400
aattaccaga ggaacaaaag gaatattgag gatgcgctca accaactctt ccgaaacagc 2460
agcatcaaga gttatttttc tgactgtcaa gtttcaacat tcaggtctgt ccccaacagg 2520
caccacaccg gggtggactc cctgtgtaac ttctcgccac tggctcggag agtagacaga 2580
gttgccatct atgaggaatt tctgcggatg acccggaatg gtacccagct gcagaacttc 2640
accctggaca ggagcagtgt ccttgtggat gggtattttc ccaacagaaa tgagccctta 2700
actgggaatt ctgaccttcc cttctgggct gtcatcctca tcggcttggc aggactcctg 2760
ggactcatca catgcctgat ctgcggtgtc ctggtgacca cccgccggcg gaagaaggaa 2820
ggagaataca acgtccagca acagtgccca ggctactacc agtcacacct agacctggag 2880
gatctgcaat gactggaact tgccggtgcc tggggtgcct ttcccccagc cagggtccaa 2940
agaagcttgg ctggggcaga aataaaccat attggtcgga cacaaaaaaa aaaaaa 2996
<210>463
<211>3557
<212>DNA
<213> human
<400>463
gagagggtcc ttcagggtct gcttatgccc ttgttcaaga acaccagtgt cagctctctg 60
tactctggtt gcagactgac cttgctcagg cctgagaagg atggggcagc caccagagtg 120
gatgctgtct gcacccatcg tcctgacccc aaaagccctg gactggacag agagcggctg 180
tactggaagc tgagccagct gacccacggc atcactgagc tgggccccta caccctggac 240
aggcacagtc tctatgtcaa tggtttcacc catcagagct ctatgacgac caccagaact 300
cctgatacct ccacaatgca cctggcaacc tcgagaactc cagcctccct gtctggacct 360
acgaccgcca gccctctcct ggtgctattc acaattaact tcaccatcac taacctgcgg 420
tatgaggaga acatgcatca ccctggctct agaaagttta acaccacgga gagagtcctt 480
cagggtctgc tcaggcctgt gttcaagaac accagtgttg gccctctgta ctctggctgc 540
agactgacct tgctcaggcc caagaaggat ggggcagcca ccaaagtgga tgccatctgc 600
acctaccgcc ctgatcccaa aagccctgga ctggacagag agcagctata ctgggagctg 660
agccagctaa cccacagcat cactgagctg ggcccctaca ccctggacag ggacagtctc 720
tatgtcaatg gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc 780
acagtggacc tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc 840
cctctcctgg tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac 900
atgcagcacc ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc 960
aggtccctgt tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg 1020
ctcaggcctg aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct 1080
gaccccaaaa gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc 1140
cacaatatca ctgagctggg ccactatgcc ctggacaacg acagcctctt tgtcaatggt 1200
ttcactcatc ggagctctgt gtccaccacc agcactcctg ggacccccac agtgtatctg 1260
ggagcatcta agactccagc ctcgatattt ggcccttcag ctgccagcca tctcctgata 1320
ctattcaccc tcaacttcac catcactaac ctgcggtatg aggagaacat gtggcctggc 1380
tccaggaagt tcaacactac agagagggtc cttcagggcc tgctaaggcc cttgttcaag 1440
aacaccagtg ttggccctct gtactctggc tccaggctga ccttgctcag gccagagaaa 1500
gatggggaag ccaccggagt ggatgccatc tgcacccacc gccctgaccc cacaggccct 1560
gggctggaca gagagcagct gtatttggag ctgagccagc tgacccacag catcactgag 1620
ctgggcccct acacactgga cagggacagt ctctatgtca atggtttcac ccatcggagc 1680
tctgtaccca ccaccagcac cggggtggtc agcgaggagc cattcacact gaacttcacc 1740
atcaacaacc tgcgctacat ggcggacatg ggccaacccg gctccctcaa gttcaacatc 1800
acagacaacg tcatgaagca cctgctcagt cctttgttcc agaggagcag cctgggtgca 1860
cggtacacag gctgcagggt catcgcacta aggtctgtga agaacggtgc tgagacacgg 1920
gtggacctcc tctgcaccta cctgcagccc ctcagcggcc caggtctgcc tatcaagcag 1980
gtgttccatg agctgagcca gcagacccat ggcatcaccc ggctgggccc ctactctctg 2040
gacaaagaca gcctctacct taacggttac aatgaacctg gtctagatga gcctcctaca 2100
actcccaagc cagccaccac attcctgcct cctctgtcag aagccacaac agccatgggg 2160
taccacctga agaccctcac actcaacttc accatctcca atctccagta ttcaccagat 2220
atgggcaagg gctcagctac attcaactcc accgaggggg tccttcagca cctgctcaga 2280
cccttgttcc agaagagcag catgggcccc ttctacttgg gttgccaact gatctccctc 2340
aggcctgaga aggatggggc agccactggt gtggacacca cctgcaccta ccaccctgac 2400
cctgtgggcc ccgggctgga catacagcag ctttactggg agctgagtca gctgacccat 2460
ggtgtcaccc aactgggctt ctatgtcctg gacagggata gcctcttcat caatggctat 2520
gcaccccaga atttatcaat ccggggcgag taccagataa atttccacat tgtcaactgg 2580
aacctcagta atccagaccc cacatcctca gagtacatca ccctgctgag ggacatccag 2640
gacaaggtca ccacactcta caaaggcagt caactacatg acacattccg cttctgcctg 2700
gtcaccaact tgacgatgga ctccgtgttg gtcactgtca aggcattgtt ctcctccaat 2760
ttggacccca gcctggtgga gcaagtcttt ctagataaga ccctgaatgc ctcattccat 2820
tggctgggct ccacctacca gttggtggac atccatgtga cagaaatgga gtcatcagtt 2880
tatcaaccaa caagcagctc cagcacccag cacttctacc cgaatttcac catcaccaac 2940
ctaccatatt cccaggacaa agcccagcca ggcaccacca attaccagag gaacaaaagg 3000
aatattgagg atgcgctcaa ccaactcttc cgaaacagca gcatcaagag ttatttttct 3060
gactgtcaag tttcaacatt caggtctgtc cccaacaggc accacaccgg ggtggactcc 3120
ctgtgtaact tctcgccact ggctcggaga gtagacagag ttgccatcta tgaggaattt 3180
ctgcggatga cccggaatgg tacccagctg cagaacttca ccctggacag gagcagtgtc 3240
cttgtggatg ggtattctcc caacagaaat gagcccttaa ctgggaattc tgaccttccc 3300
ttctgggctg tcatcttcat cggcttggca ggactcctgg gactcatcac atgcctgatc 3360
tgcggtgtcc tggtgaccac ccgccggcgg aagaaggaag gagaatacaa cgtccagcaa 3420
cagtgcccag gctactacca gtcacaccta gacctggagg atctgcaatg actggaactt 3480
gccggtgcct ggggtgcctt tcccccagcc agggtccaaa gaagcttggc tggggcagaa 3540
ataaaccata ttggtcg 3557
<210>464
<211>2712
<212>DNA
<213> human
<400>464
aggacatgcg tcaccctggc tccaggaagt tcaacaccac agagagggtc ctgcagggtc 60
tgcttggtcc cttgttcaag aactccagtg tcggccctct gtactctggc tgcagactga 120
tctctctcag gtctgagaag gatggggcag ccactggagt ggatgccatc tgcacccacc 180
accttaaccc tcaaagcctg gactggacag ggagcagctg tactggcagc tgagccagat 240
gaccaatggc atcaaagagc tgggccccta caccctggac cggaacagtc tctacgtcaa 300
tggtttcacc catcggagct ctgggctcac caccagcact ccttggactt ccacagttga 360
ccttggaacc tcagggactc catcccccgt ccccagcccc acaactgctg gccctctcct 420
ggtgccattc accctaaact tcaccatcac caacctgcag tatgaggagg acatgcatcg 480
ccctggatct aggaagttca acgccacaga gagggtcctg cagggtctgc ttagtcccat 540
attcaagaac tccagtgttg gccctctgta ctctggctgc agactgacct ctctcaggcc 600
cgagaaggat ggggcagcaa ctggaatgga tgctgtctgc ctctaccacc ctaatcccaa 660
aagacctggg ctggacagag agcagctgta ctgggagcta agccagctga cccacaacat 720
cactgagctg ggcccctaca gcctggacag ggacagtctc tatgtcaatg gtttcaccca 780
tcagaactct gtgcccacca ccagtactcc tgggacctcc acagtgtact gggcaaccac 840
tgggactcca tcctccttcc ccggccacac agagcctggc cctctcctga taccattcac 900
attcaacttt accatcacca acctgcatta tgaggaaaac atgcaacacc ctggttccag 960
gaagttcaac gccacagaga gggtcctgca gggtctgctt agtcccatat tcaagaactc 1020
cagtgttggc cctctgtact ctggctgcag actgacctct ctcaggcccg agaaggatgg 1080
ggcagcaact ggaatggatg ctgtctgtct ctaccgaccc taatcccatc ggacctgggc 1140
tggacagaga gcagctgtac tgggagctga gccagctgac ccacgacatc actgagctgg 1200
gcccctacag ccctggacag ggacagtctc tatgtcaatg gtttcaccca tcagaactct 1260
gtgcccacca ccagtactcc tgggacctcc acagtgtact gggcaaccac tgggactcca 1320
tcctccttcc ccggccacac agagcctggc cctctcctga taccattcac tttcaacttt 1380
accatcacca acctgcatta tgaggaaaac atgcaacacc tggttccagg aagttcaaca 1440
ccacggagag ggttctgcag ggtctgctca cgcccttgtt caagaacacc agtgttggcc 1500
ctctgtactc tggctgcaga ctgaccttgc tcagacctga gaagcaggag gcagccactg 1560
gagtggacac catctgcact caccgccttg accctctaaa ccctggactg gacagagagc 1620
agctatactg ggagctgagc aaactgaccc gtggcatcat cgagctgggc ccctacctcc 1680
tggacagagg cagtctctat gtcaatggtt tcacccatcg gaactttgtg cccatcacca 1740
gcactcctgg gacctccaca gtacacctag gaacctctga aactccatcc tccctaccta 1800
gacccatagt gcctggccct ctcctggtgc cattcaccct caacttcacc atcaccaact 1860
tgcagtatga ggaggccatg cgacaccctg gctccaggaa gttcaatacc acggagaggg 1920
tcctacaggg tctgctcagg cccttgttca agaataccag tatcggccct ctgtactcca 1980
gctgcagact gaccttgctc aggccagaga aggacaaggc agccaccaga gtggatgcca 2040
tctgtaccca ccaccctgac cctcaaagcc ctggactgaa cagagagcag ctgtactggg 2100
agctgagcca gctgacccac ggcatcactg agctgggccc ctacaccctg gacaggcaca 2160
gtctctatgt caatggtttc acccatcaga gccccatacc aaccaccagc actcctgata 2220
cctccacaat gcacctggga acctcgagaa ctccagcctc cctgtctgga cctacgaccg 2280
ccagccctct cctggtgcta ttcacaatta acttcaccat cactaacctg cggtatgagg 2340
agaacatgca tcaccgctgg ctctagaaag tttaacacca cggagagagt ccttcagggt 2400
ctgctcaggc ctgtgttcaa agaacaccag tgttggccct ctgtactctg gctgcagact 2460
gaccttgctc aggcccgaga aggatggggc agccacgcaa agtggatgcc atctgcacct 2520
accgccctga tcccaaaagc cctggactgg acagagagca gctatactgg gagctgagcc 2580
agggtgatgc atgttctcct catatcgcag gttagtgatg gtgaagttaa ttgtgaatag 2640
caccaggaga gggctggcgg tcatgggtcc agacagggag cctggagttc tcgaggttgc 2700
caggtgcatg tc 2712
<210>465
<211>1175
<212>DNA
<213> human
<400>465
gaggtatgct aactactact attatttagt aggctttgtt agaaacttct gttgttatag 60
tcaagggacg catggaaact ttttatatta ttctctcttt aaatcctgtt gcatatgttt 120
agaagtaggc cttttggaaa tatataaagt tctccacttt tgaacatgtt gtttctttcc 180
cacctccacg acagctgcca gccctctcct ggtgctattc actctcaact tcaccatcac 240
caacctgcgg tatgaggaga acatgcagca ccctggctcc aggaagttca acactacaga 300
gagggtcctt cagggcctgc taaggccctt gttcaagaac accagtgttg gccctctgta 360
ctctggctgc aggctgacct tgctcaggcc agagaaagat ggggaagcca ccggagtgga 420
tgccatctgc acccaccgcc ctgaccccac aggccctggg ctggacagag agcagctgta 480
tttggagctg agccagctga cccacagcat cactgagctg ggcccctaca cactggacag 540
ggacagtctc tatgtcaatg gtttcaccca tcggagctct gtacccacca ccagcaccgg 600
ggtggtcagc gaggagccat tcacactgaa cttcaccatc aacaacctgc gctacatggc 660
ggacatgggc caacccggct ccctcaagtt caacatcaca gacaacgtca tgaagcacct 720
gctcagtcct ttgttccaga ggagcagcct gggtgcacgg tacacaggct gcagggtcat 780
cgcactaagg tctgtgaaga acggtgctga gacacgggtg gacctcctct gcacctacct 840
gcagcccctc agcggcccag gtctgcctat caagcaggtg ttccatgagc tgagccagca 900
gacccatggc atcacccggc tgggccccta ctctctggac aaagacagcc tctaccttaa 960
cggttacaat gaacctggtc cagatgagcc tcctacaact cccaagccag ccaccacatt 1020
cctgcctcct ctgtcagaag ccacaacagc catggggtac cacctgaaga ccctcacact 1080
caattcacat ctccaatctc cagtattcac cagatatggg caagggctca aggtacattc 1140
aatccaccga ggggggtcct tcagcaactg gtcag 1175
<210>466
<211>1959
<212>DNA
<213> human
<400>466
catccccagc tcgaacagca gccacagtcc cattcatggt gccattcacc ctcaacttca 60
actcatcacc aacctgcagt acgaggagga catgcggcac ctggttccag gaagttcaac 120
gcgcacagag agagaactgc agggtcgtgc tcaaacccta gatcaggaat agcagtctgg 180
aatacctcta ttcaggctgc agactagcct cactcaggcc agagaaggat agctcagcca 240
cggcagtgga tgccatctgc acacatcgcc ctgaccctga agacctcgga ctggacagag 300
agcgactgta ctgggagctg agcaatctga caaatggcat ccaggagctg ggcccctaca 360
ccctggaccg gaacagtctc tatgtcaatg gtttcaccca tcgaagctct atgcccacca 420
ccagcactcc tgggacctcc acagtggatg tgggaacctc agggactcca tcctccagcc 480
ccagccccac gactgctggc cctctcctga tgccgttcac cctcaacttc accatcacca 540
acctgcagta cgaggaggac atgcgtcgca ctggctccag gaagttcaac accatggaga 600
gtgtcctgca gggtctgctc aagcccttgt tcaagaacac cagtgttggc cctctgtact 660
ctggctgcag attgaccttg ctcaggccca agaaagatgg ggcagccact ggagtggatg 720
ccatctgcac ccaccgcctt gaccccaaaa gccctggact caacagggag cagctgtact 780
gggagctaag caaactgacc aatgacattg aagagctggg cccctacacc ctggacagga 840
acagtctcta tgtcaatggt ttcacccatc agagctctgt gtccaccacc agcactcctg 900
ggacctccac agtggatctc agaacctcag tggactccat cctccctctc cagccccaca 960
attatggctg ctggccctct cctggtacca ttcaccctca acttcaccat caccaacctg 1020
cagtatgggg aggacatggg tcaccctggc tccaggaagt tcaacaccac agagagggtc 1080
ctgcagggtc tgcttggtcc catattcaag aacaccagtg ttggccctct gtactctggc 1140
tgcagactga cctctctcag gtccaagaag gatggagcag ccactggagt ggatgccatc 1200
tgcatccatc atcttgaccc caaaagccct ggactcaaca gagagcggct gtactgggag 1260
ctgagccaac tgaccaatgg catcaaagag ctgggcccct acaccctgga caggaacagt 1320
ctctatgtca atggtttcac ccatcggacc tctgtgccca ccaccagtac tcctgggacc 1380
tccacagtgt actgggcaac cactgggact ccatcctccc tccccgccac acagagcctg 1440
gccctctcct gataccattc acattcaact ttaccatcac ctacctgcat tatagaggaa 1500
aacatgcaac acccgtggtt ccaggaacga tgtcaacacc acaggagagg gttctgcagg 1560
gtcttcgctc acgcccattg ttacaagaac accagtagtt ggccctctgt actctggctg 1620
cagaatgacc ttgctcagac ctgagaagca ggaggcaaca cactggaatg gacaccatct 1680
gtatccacca gcgttagatc ccatcaggac ctggactgga cagagagcag gctatactgg 1740
gagctagagc cagctgaccc acagcatcac agagctggga ccctacagcc ctggataggg 1800
acagtctcta tgtcaatggc ttcaaccctt ggagctctgt gccaaccacc agcactcctg 1860
ggacctccac agtgcacctg gcaacctctg ggactccatc ctccctgcct ggccacacag 1920
cccctgtccc tctcttgata ccattcaccc tcaacttac 1959
<210>467
<211>1636
<212>DNA
<213> human
<400>467
gacctcctct gcacctacct gcagcccctc agcggcccag gtctgcctat caagcaggtg 60
ttccatgagc tgagccagca gacccatggc atcacccggc tgggccccta ctctctggac 120
aaagacagcc tctaccttaa cggttacaat gaacctggtc cagatgagcc tcctacaact 180
cccaagccag ccaccacatt cctgcctcct ctgtcagaag ccacaacagc catggggtac 240
cacctgaaga ccctcacact caacttcacc atctccaatc tccagtattc accagatatg 300
ggcaagggct cagctacatt caactccacc gagggggtcc ttcagcacct gctcagaccc 360
ttgttccaga agagcagcat gggccccttc tacttgggtt gccaactgat ctccctcagg 420
cctgagaagg atggggcagc cactggtgtg gacaccacct gcacctacca ccctgaccct 480
gtgggccccg ggctggacat acagcagctt tactgggagc tgagtcagct gacccatggt 540
gtcacccaac tgggcttcta tgtcctggac agggatagcc tcttcatcaa tggctatgca 600
ccccagaatt tatcaatccg gggcgagtac cagataaatt tccacattgt caactggaac 660
ctcagtaatc cagaccccac atcctcagag tacatcaccc tgctgaggga catccaggac 720
aaggtcacca cactctacaa aggcagtcaa ctacatgaca cattccgctt ctgcctggtc 780
accaacttga cgatggactc cgtgttggtc actgtcaagg cattgttctc ctccaatttg 840
gaccccagcc tggtggagca agtctttcta gataagaccc tgaatgcctc attccattgg 900
ctgggctcca cctaccagtt ggtggacatc catgtgacag aaatggagtc atcagtttat 960
caaccaacaa gcagctccag cacccagcac ttctacctga atttcaccat caccaaccta 1020
ccatattccc aggacaaagc ccagccaggc accaccaatt accagaggaa caaaaggaat 1080
attgaggatg cgctcaacca actcttccga aacagcagca tcaagagtta tttttctgac 1140
tgtcaagttt caacattcag gtctgtcccc aacaggcacc acaccggggt ggactccctg 1200
tgtaacttct cgccactggc tcggagagta gacagagttg ccatctatga ggaatttctg 1260
cggatgaccc ggaatggtac ccagctgcag aacttcaccc tggacaggag cagtgtcctt 1320
gtggatgggt attctcccaa cagaaatgag cccttaactg ggaattctga ccttcccttc 1380
tgggctgtca tcctcatcgg cttggcagga ctcctgggac tcatcacatg cctgatctgc 1440
ggtgtcctgg tgaccacccg ccggcggaag aaggaaggag aatacaacgt ccagcaacag 1500
tgcccaggct actaccagtc acacctagac ctggaggatc tgcaatgact ggaacttgcc 1560
ggtgcctggg gtgcctttcc cccagccagg gtccaaagaa gcttggctgg ggcagaaata 1620
aaccatattg gtcgga 1636
<210>468
<211>231
<212>DNA
<213> human
<400>468
actacatgac acattccgct tctgcctggt caccaacttg acaaatggag tcatcagttt 60
atcaaccaac aagcagctcc agcacccagc acttctacct gaatttcacc atcaccaacc 120
taccatattc ccaggacaaa gcccagccag gcaccaccaa ttaccagagg aacaaaagga 180
atattgagga tgcgctcaac caactcttcc gaaacagcag catcgagagt t 231
<210>469
<211>607
<212>DNA
<213> human
<400>469
atgaagagct atcgctgtcc aggacataga agcccagttg ggtgacacca tgggtcagct 60
gactcagctc ccagtaaagc tgctgtatgt ccagcccggg gcccacaggg tcagggtggt 120
aggtgcaggt ggtgtccaca ccagtggctg ccccatcctt ctcaggccag gtgctgaagg 180
accccctcgg tggagttgaa tgtagctgag cccttgccca tatctggtga atactggaga 240
ttggagatgg tgaagttgag tgtgagggtc ttcaggtggt accccatggc tgttgtggct 300
tctgacagag gaggcaggaa tgtggtggct ggcttgggag ttgtaggagg ctcatctgga 360
ccaggttcat tgtaaccgtt aaggtagagg ctgtctttgt ccagagagta ggggcccagc 420
cgggtgatgc catgggtctg ctggctcagc tcatggaaca cctgcttgat aggcagacct 480
gggccgctga ggggctgcag gtaggtgcag aggaggtcca cccgtgtctc agcaccgttc 540
ttcacagacc ttagtgcgat gaccctgcag cctgtgtacc gtgcacccag gctgctcctc 600
tggaaca 607
<210>470
<211>981
<212>DNA
<213> human
<400>470
ggtaaccaca gctgacccat ggcatcaaag agctgggccc ctacaccctg gacaggaaca 60
gtctctatgt caatggtttc acccatcgga gctctgtggc ccccaccagc actcctggga 120
cctccacagt ggaccttggg acctcaggga ctccatcctc cctccccagc cccacaacag 180
ctgttcctct cctggtgccg ttcaccctca actttaccat caccaatctg cagtatgggg 240
aggacatgcg tcaccctggc tccaggaagt tcaacaccac agagagggtc ctgcagggtc 300
tgcttggtcc cttgttcaag aactccagtg tcggccctct gtactctggc tgcagactga 360
tctctctcag gtctgagaag gatggggcag ccactggagt ggatgccatc tgcacccacc 420
accttaaccc tcaaagccct ggactggaca gggagcagct gtactggcag ctgagccaga 480
gaccacaacc tcatttatca cctattctga gacacacaca agttcagcca ttccaactct 540
ccctgtctcc ccctggtgca tcaaagatgc tgacctcact ggtcatcagt tctgggacag 600
acagcactac aactttccca acactgacgg agaccccata tgaaccagag acaacagcca 660
tacagctcat tcatcctgca gagaccaaca caatggttcc caggacaact cccaagtttt 720
cccatagtaa gtcagacacc acactcccag tagccatcac cagtcctggg ccagaagcca 780
gttcagctgt ttcaacgaca actatctcac ctgatatgtc agatctggtg acctcactgg 840
tccctagttc tgggacagac accagtacaa ccttcccaac attgagtgag accccatatg 900
aaccagagac tacagccacg tggctcactc atcctgcaga aaccagaaca acggtttctg 960
ggacaattcc caacttttcc c 981
<210>471
<211>959
<212>DNA
<213> human
<400>471
cagatggcat ccactccggt ggcttcccca tctttctctg gcctgagcaa ggtcagcctg 60
cagccagagt acagagggcc aacactggtg ttcttgaaca agggccttag caggccctga 120
aggaccctct ctgtagtgtt gaacttcctg gagccaggcc acatgttctc ctcataccgc 180
aggttagtga tggtgaagtt gagggtgaat agtatcagga gatggctggc agctgaaggg 240
ccaaatatcg aggctggagt cttagatgct cccagataca ctgtgggggt cccaggagtg 300
ctggtggtgg acacagagct ccgatgagtg aaaccattga caaagaggct gtcgttgtcc 360
agggcatagg ggcccagctc agtgatattg tgggtcagct ggctcagctc ccaatacagc 420
tgctctctgt ccagcctagg gcttttgggg tcagggtggt gggtgcagat ggcatccact 480
ccagtggctg tcccatcctt ttcaggcctg agcaaagtca gtctgcagcc agagtacaga 540
gggccaacac tggtgctctt gaacagggac ctgagcaggc cctgaaggac cctctccgtg 600
gtgttgaact tcctggagcc agggtgctgc atgttctcct cataccgcag gttggtgatg 660
gtgaagttga gagtgaatag caccaggaga gggctggcag ccgagggacc aggtttagaa 720
actggagtcc cagatgttcc caggtccact gtgggggtcc caggaatgct agtggtgggc 780
acagagctcc gctgtgtgaa accattgaca tagagactgt ccctgtccag ggtgtagggg 840
cccagctcag tgatgctgtg ggttagctgg ctcagctccc agtatagctg ctctctgtcc 900
agtccagggc ttttgggatc agggcggtag gtgcagatgg catccacttt ggtggctgc 959
<210>472
<211>1315
<212>DNA
<213> human
<400>472
ccaccgtctt gaccccaaaa gccctggagt ggacagggag cagctatact gggagctgag 60
ccagctgacc aatggcatca aagagctggg cccctacacc tggacaggaa cagtctctat 120
gtcaatggtt tcacccatcg gacctctgtg cccaccacca gcactcctgg gacctccaca 180
gtggaccttg gaacctcagg gactccattc tccctcccaa gccccgcaac tgctggccct 240
ctcctggtgc tgttcaccct caacttcacc atcaccaacc tgaagtatga ggaggacatg 300
catcgccctg gctccaggaa gttcaacacc actgagaggg tcctgcagac tctgcttggt 360
cctatgttca agaacaccag tgttggcctt ctgtactctg gctgcagact gaccttgctc 420
aggtccgaga aggatggagc agccactgga gtggatgcca tctgcaccca ccgtcttgac 480
cccaaaagcc ctggagtgga cagggagcag ctatactggg agctgagcca gctgaccaat 540
ggcatcaaag agctgggccc ctacaccctg gacaggaaca gtctctatgt caatggtttc 600
acccattgga tccctgtgcc caccagcagc actcctggga cctccacagt ggaccttggg 660
tcagggactc catcctccct ccccagcccc acaactgctg gccctctcct ggtgccgttc 720
accctcaact tcaccatcac caacctgaag tacgaggagg acatgcattg ccctggctcc 780
aggaagttca acaccacaga gagagtcctg cagagtctgc ttggtcccat gttcaagaac 840
accagtgttg gccctctgta ctctggctgc agactgacct tgctcaggtc cgagaaggat 900
ggagcagcca ctggagtgga tgccatctgc acccaccgtc ttgaccccaa aagcctggag 960
tggacaggga gcagctatac tgggagctga gccagctgac caatgccatc aaagagctgg 1020
gtccctacac cctggacagc aacagtcttc tatgtcaatg gtttcaccca tcagacctct 1080
gcgcccaaca ccagcactcc tgggacctcc acagtggacc ttgggacctc agggactcca 1140
tcctccctcc ccagccctac atctgctggc cctctcctgg tgccattcac cctcaacttc 1200
accatcacca acctgcagta cgaggaggac atgcatcacc caggctccag gaagttcaac 1260
accacggagc gggtcctgca gggtctgctt ggtcccatgt tcaagaacac tacga 1315
<210>473
<211>689
<212>DNA
<213> human
<400>473
acggcatcag gagagggcca gcagtcgtgg ggctggggct ggaggatgga gtccctgagg 60
ttcccacatc cactgtggag gtcccaggag tgctggtggt gggcatagag cttcgatggg 120
tgaaaccatt gacatagaga ctgttccggt ccagggtgta ggggcccagc tcagtgatgc 180
cgtgggtcag ctggctcagc tcccagtaca gctgctctct gttcagtcca gggctttgag 240
ggtcagggtg gtgggtacag atggcatcca ctctggtggc tgccttgtcc ttctctggcc 300
ttgagcaagg tcagtctgca gcctgagagc taacagaggt ccgataactg gtattcttga 360
acaagggcct agagcagaac cctgtaggac catcgccgtg gtatatgaac ttcctagagc 420
caggatttcg cacggccatc actcatactg caacttgctg atggcaaagt tgaggataaa 480
cggcaccagg agagggccag ccacttatgg gtctaggtag ggaggatgga gtttcagagg 540
ttctcgagat ccactgtgga ggtcccagga gtgctggtgg tggacacaga gctctgatgg 600
gtgaaaccat tgacatagag actgttcctg tccagggtgt aggggcccag ctcttcaatg 660
tcattggtca gtttgcttag ctcccagta 689
<210>474
<211>495
<212>DNA
<213> human
<400>474
gtggatatga gttgaatact cactgctggt ggtggacaca gagctctgat gggtgaaacc 60
tgcatagaga aggagggagg agagtgggta agagacaagg agaggtgggg gaccaaatgg 120
aggtcaatgc taccctggtg caatgaaccg agtttcatgg tacagggaca attgaagatt 180
ttctatcagc atcctcacat caggaaagaa tgccctgagg gaacacagtc catgatggta 240
aggaaaccat gaagtccaga ccttagtcat cccatgtaga gcacatgaca gaattttcaa 300
aggccaggca gggagtgtga cctctagtta gagattagag gctgcccagc aagggggaag 360
agatttcaac cacatcacag ccactcacca ttgacataga gactgttcct gtccagggtg 420
taggggccca gctcttcaat gtcattggtc agtttgctta gctcccagta cagctgctcc 480
ctgttgagtc caggg 495
<210>475
<211>192
<212>DNA
<213> human
<400>475
agtgcccagg ctactaccag tcacacctag acctggagga tctgcaatga ctggaacttg 60
ccggtgcctg gggatagcct cttcatcaat ggctatgcac cccagaattt atcaatccgg 120
ggcgagtacc agataaattt ccacattgtc aactggaacc tcagtaatcc agaccccaca 180
tcctcagagt ac 192
<210>476
<211>500
<212>DNA
<213> human
<400>476
ccggtggctg ccccacgttt ttcaggcctg agcaaggtca gtctgcagcc agagtacaga 60
gggccaacac tggtgctctt gaacaagggc ttgagcagac cctgcaggac tctctccgtg 120
gtgttgaact tcctggaacc agggtgacgc atgtcctcct catactgcag gttggtgata 180
gtgaagttga gggtgaatgg caccaggaga gggccagggc tgtgtggcca gggagggagg 240
ctggagtccc agaggtttcc aggtgcactg cagaggtccc aggaatactg gtggttggca 300
cagagctccg atgggtgaag ccattgacat agagactgtc cctgtccagg tgtaggggcc 360
cagctctgta acgctgttgg tcagctggct cagctcccag tatagccgct ctctgtccag 420
tccaggacca gtgggatcaa ggcggagggt gcagatggcg tccactccag tggctgcccc 480
atgtttctca ggtctgagca 500
<210>477
<211>191
<212>DNA
<213> human
<400>477
gaggtatgct aactactact attatttagt aggctttgtt agaaacttct gttgttatag 60
tcaagggacg catggaaact ttttatatta ttctctcttt aaatcctgtt gcatatgttt 120
agaagtaggc cttttggaaa tatataaagt tctccacttt tgaacatgtt gtttctttcc 180
cacctccacg a 191
<210>478
<211>914
<212>PRT
<213> human
<400>478
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala Phe
1 5 10 15
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu
20 25 30
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser
35 40 45
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu
50 55 60
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Trp Ser
65 70 75 80
Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu
85 90 95
Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala
100 105 110
Ile Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu
115 120 125
Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu
130 135 140
Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly Phe Thr
145 150 155 160
His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val
165 170 175
Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala
180 185 190
Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn
195 200 205
Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr
210 215 220
Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr
225 230 235 240
Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro
245 250 255
Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg
260 265 270
Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu
275 280 285
Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu
290 295 300
Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val
305 310 315 320
Pro Thr Thr Ser Thr Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn
325 330 335
Phe Thr Ile Asn Asn Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly
340 345 350
Ser Leu Lys Phe Asn Ile Thr Asp Asn Val Met Lys His Leu Leu Ser
355 360 365
Pro Leu Phe Gln Arg Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg
370 375 380
Val Ile Ala Leu Arg Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp
385 390 395 400
Leu Leu Cys Thr Tyr Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile
405 410 415
Lys Gln Val Phe His Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg
420 425 430
Leu Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr
435 440 445
Asn Glu Pro Gly Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr
450 455 460
Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His
465 470 475 480
Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser
485 490 495
Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu Gly Val
500 505 510
Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met Gly Pro
515 520 525
Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly
530 535 540
Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp Pro Val
545 550 555 560
Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu
565 570 575
Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser
580 585 590
Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu
595 600 605
Tyr Gln Ile Asn Phe His Ile Val Asr Trp Asn Leu Ser Asn Pro Asp
610 615 620
Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys
625 630 635 640
Val Thr Thr Lau Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe
645 650 655
Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys
660 665 670
Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe
675 680 685
Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr
690 695 700
Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln
705 710 715 720
Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe Thr Ile
725 730 735
Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn
740 745 750
Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe
755 760 765
Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr
770 775 780
Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys
785 790 795 800
Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu
805 810 815
Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr
820 825 830
Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Phe Pro Asn Arg Asn
835 840 845
Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu
850 855 860
Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly
865 870 875 880
Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val
885 890 895
Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp
900 905 910
Leu Gln
<210>479
<211>1148
<212>PRT
<213> human
<400>479
Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys
1 5 10 15
Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val
20 25 30
Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp
35 40 45
Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr
50 55 60
Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly
65 70 75 80
Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser
85 90 95
Thr Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro
100 105 110
Thr Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile
115 120 125
Thr Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys
130 135 140
Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Phe
145 150 155 160
Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu
165 170 175
Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile Cys
180 185 190
Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln Leu
195 200 205
Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro
210 215 220
Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg
225 230 235 240
Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Pro Thr Val Asp Leu
245 250 255
Gly Thr Ser Gly Thr Pro Val Ser Lys Pro Gly Pro Ser Ala Ala Ser
260 265 270
Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg
275 280 285
Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr
290 295 300
Glu Arg Val Leu Gln Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser
305 310 315 320
Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
325 330 335
Lys Asp Gly Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro
340 345 350
Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu
355 360 365
Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly His Tyr Ala Leu Asp
370 375 380
Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser Val Ser
385 390 395 400
Thr Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala Ser Lys
405 410 415
Thr Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala Ser His Leu Leu Ile
420 425 430
Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn
435 440 445
Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln
450 455 460
Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr
465 470 475 480
Ser Gly Ser Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu Ala
485 490 495
Thr Gly Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Thr Gly Pro
500 505 510
Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu Ser Gln Leu Thr His
515 520 525
Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr
530 535 540
Val Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly
545 550 555 560
Val Val Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu
565 570 575
Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile
580 585 590
Thr Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser
595 600 605
Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser
610 615 620
Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu
625 630 635 640
Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu
645 650 655
Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu
660 665 670
Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Leu Asp
675 680 685
Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro Leu
690 695 700
Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr Leu
705 710 715 720
Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly
725 730 735
Ser Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg
740 745 750
Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln
755 760 765
Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp
770 775 780
Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile
785 790 795 800
Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln
805 810 815
Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr
820 825 830
Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His
835 840 845
Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr
850 855 860
Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys
865 870 875 880
Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr Asn Leu
885 890 895
Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser Ser Asn
900 905 910
Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn
915 920 925
Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His
930 935 940
Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser
945 950 955 960
Thr Gln His Phe Tyr Pro Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser
965 970 975
Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg
980 985 990
Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys
995 1000 1005
Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn
1010 1015 1020
Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala
1025 1030 1035 1040
Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr
1045 1050 1055
Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val
1060 1065 1070
Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn
1075 1080 1085
Ser Asp Leu Pro Phe Trp Ala Val Ile Phe Ile Gly Leu Ala Gly Leu
1090 1095 1100
Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg
1105 1110 1115 1120
Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly
1125 1130 1135
Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
1140 1145
<210>480
<211>230
<212>PRT
<213> human
<400>480
Met His Arg Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
1 5 10 15
Gln Thr Leu Leu Gly Pro Met Phe Lys Asn Thr Ser Val Gly Leu Leu
20 25 30
Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala
35 40 45
Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser
50 55 60
Pro Gly Val Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr
65 70 75 80
Asn Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu
85 90 95
Tyr Val Asn Gly Phe Thr His Trp Ile Pro Val Pro Thr Ser Ser Thr
100 105 110
Pro Gly Thr Ser Thr Val Asp Leu Gly Ser Gly Thr Pro Ser Ser Leu
115 120 125
Pro Ser Pro Thr Thr Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn
130 135 140
Phe Thr Ile Thr Asn Leu Lys Tyr Glu Glu Asp Met His Cys Pro Gly
145 150 155 160
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Ser Leu Leu Gly
165 170 175
Pro Met Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg
180 185 190
Leu Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp
195 200 205
Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser Leu Glu Trp Thr Gly
210 215 220
Ser Ser Tyr Thr Gly Ser
225 230
<210>481
<211>210
<212>PRT
<213> human
<400>481
Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
1 5 10 15
Gln Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser Val Gly Pro Leu
20 25 30
Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr
35 40 45
Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro Asp Pro Lys Ser
50 55 60
Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr
65 70 75 80
His Asn Ile Thr Glu Leu Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu
85 90 95
Phe Val Asn Gly Phe Thr His Arg Ser Ser Val Ser Thr Thr Ser Thr
100 105 110
Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser
115 120 125
Ile Phe Gly Pro Ser Ala Ala Ser His Leu Leu Ile Leu Phe Thr Leu
130 135 140
Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly
145 150 155 160
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg
165 170 175
Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg
180 185 190
Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu Ala Thr Gly Val Asp
195 200 205
Ala Ile
210
<210>482
<211>97
<212>PRT
<213> human
<400>482
Met Ser Met Val Ser His Ser Gly Ala Leu Cys Pro Pro Leu Ala Phe
1 5 10 15
Leu Gly Pro Pro Gln Trp Thr Trp Glu His Leu Gly Leu Gln Phe Leu
20 25 30
Asn Leu Val Pro Arg Leu Pro Ala Leu Ser Trp Cys Tyr Ser Leu Ser
35 40 45
Thr Ser Pro Ser Pro Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu
50 55 60
Ala Pro Gly Ser Ser Thr Pro Arg Arg Gly Ser Phe Arg Ala Cys Ser
65 70 75 80
Gly Pro Cys Ser Arg Ala Pro Val Leu Ala Leu Cys Thr Leu Ala Ala
85 90 95
Asp
<210>483
<211>438
<212>PRT
<213> human
<400>483
Met Gly Tyr His Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn
1 5 10 15
Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser
20 25 30
Thr Glu Gly Val Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser
35 40 45
Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro
50 55 60
Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His
65 70 75 80
Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu
85 90 95
Leu Ser Gln Leu Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu
100 105 110
Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr Ala Pro Gln Asn Leu Ser
115 120 125
Ile Arg Gly Glu Tyr Gln Ile Asn Phe His Ile Val Asn Trp Asn Leu
130 135 140
Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp
145 150 155 160
Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys Gly Ser Gln Leu His Asp
165 170 175
Thr Phe Arg Phe Cys Leu Val Thr Asn Leu Thr Met Asp Ser Val Leu
180 185 190
Val Thr Val Lys Ala Leu Phe Ser Ser Asn Leu Asp Pro Ser Leu Val
195 200 205
Glu Gln Val Phe Leu Asp Lys Thr Leu Asn Ala Ser Phe His Trp Leu
210 215 220
Gly Ser Thr Tyr Gln Leu Val Asp Ile His Val Thr Glu Met Glu Ser
225 230 235 240
Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu
245 250 255
Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala Gln Pro
260 265 270
Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu Asp Ala Leu
275 280 285
Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys
290 295 300
Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly Val
305 310 315 320
Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val Asp Arg Val
325 330 335
Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly Thr Gln Leu
340 345 350
Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu Val Asp Gly Tyr Ser
355 360 365
Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp
370 375 380
Ala Val Ile Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys
385 390 395 400
Leu Ile Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly
405 410 415
Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu
420 425 430
Asp Leu Glu Asp Leu Gln
435
<210>484
<211>216
<212>PRT
<213> human
<400>484
Met Thr Leu Lys Ser Trp Ala Pro Thr Pro Trp Thr Gly Thr Val Ser
1 5 10 15
Met Ser Met Val Ser Pro Ile Arg Ala Leu Cys Pro Pro Pro Ala Leu
20 25 30
Leu Gly Pro Pro Gln Trp Ile Ser Glu Pro Gln Trp Thr Pro Ser Ser
35 40 45
Leu Ser Ser Pro Thr Ile Met Ala Ala Gly Pro Leu Leu Val Pro Phe
50 55 60
Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Gly Glu Asp Met Gly
65 70 75 80
His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly
85 90 95
Leu Leu Gly Pro Ile Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser
100 105 110
Gly Cys Arg Leu Thr Ser Leu Arg Ser Lys Lys Asp Gly Ala Ala Thr
115 120 125
Gly Val Asp Ala Ile Cys Ile His His Leu Asp Pro Lys Ser Pro Gly
130 135 140
Leu Asn Arg Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly
145 150 155 160
Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val
165 170 175
Asn Gly Phe Thr His Arg Thr Ser Val Pro Thr Thr Ser Thr Pro Gly
180 185 190
Thr Ser Thr Val Tyr Trp Ala Thr Thr Gly Thr Pro Ser Ser Leu Pro
195 200 205
Ala Thr Gln Ser Leu Ala Leu Ser
210 215
<210>485
<211>268
<212>PRT
<213> human
<400>485
Met Pro Thr Thr Ser Thr Pro Gly Thr Ser Thr Val Asp Val Gly Thr
1 5 10 15
Ser Gly Thr Pro Ser Ser Ser Pro Ser Pro Thr Thr Ala Gly Pro Leu
20 25 30
Leu Met Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu
35 40 45
Glu Asp Met Arg Arg Thr Gly Ser Arg Lys Phe Asn Thr Met Glu Ser
50 55 60
Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys Asn Thr Ser Val Gly
65 70 75 80
Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Lys Lys Asp
85 90 95
Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg Leu Asp Pro
100 105 110
Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr Trp Glu Leu Ser Lys
115 120 125
Leu Thr Asn Asp Ile Glu Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn
130 135 140
Ser Leu Tyr Val Asn Gly Phe Thr His Gln Ser Ser Val Ser Thr Thr
145 150 155 160
Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Arg Thr Ser Val Asp Ser
165 170 175
Ile Leu Pro Leu Gln Pro His Asn Tyr Gly Cys Trp Pro Ser Pro Gly
180 185 190
Thr Ile His Pro Gln Leu His His His Gln Pro Ala Val Trp Gly Gly
195 200 205
His Gly Ser Pro Trp Leu Gln Glu Val Gln His His Arg Glu Gly Pro
210 215 220
Ala Gly Ser Ala Trp Ser His Ile Gln Glu His Gln Cys Trp Pro Ser
225 230 235 240
Val Leu Trp Leu Gln Thr Asp Leu Ser Gln Val Gln Glu Gly Trp Ser
245 250 255
Ser His Trp Ser Gly Cys His Leu His Pro Ser Ser
260 265
<210>486
<211>304
<212>PRT
<213> human
<400>486
Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
1 5 10 15
Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu
20 25 30
Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu
35 40 45
Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Thr Gly
50 55 60
Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu Ser Gln Leu Thr
65 70 75 80
His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu
85 90 95
Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr
100 105 110
Gly Val Val Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn
115 120 125
Leu Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn
130 135 140
Ile Thr Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg
145 150 155 160
Ser Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg
165 170 175
Ser Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr
180 185 190
Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His
195 200 205
Glu Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser
210 215 220
Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Pro
225 230 235 240
Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro
245 250 255
Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr
260 265 270
Leu Asn Ser His Leu Gln Ser Pro Val Phe Thr Arg Tyr Gly Gln Gly
275 280 285
Leu Lys Val His Ser Ile His Arg Gly Gly Ser Phe Ser Asn Trp Ser
290 295 300
<210>487
<211>294
<212>PRT
<213> human
<400>487
Met Thr Asn Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn
1 5 10 15
Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser Ser Gly Leu Thr Thr
20 25 30
Ser Thr Pro Trp Thr Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro
35 40 45
Ser Pro Val Pro Ser Pro Thr Thr Ala Gly Pro Leu Leu Val Pro Phe
50 55 60
Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His
65 70 75 80
Arg Pro Gly Ser Arg Lys Phe Asn Ala Thr Glu Arg Val Leu Gln Gly
85 90 95
Leu Leu Ser Pro Ile Phe Lys Asn Ser Ser Val Gly Pro Leu Tyr Ser
100 105 110
Gly Cys Arg Leu Thr Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr
115 120 125
Gly Met Asp Ala Val Cys Leu Tyr His Pro Asn Pro Lys Arg Pro Gly
130 135 140
Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn
145 150 155 160
Ile Thr Glu Leu Gly Pro Tyr Ser Leu Asp Arg Asp Ser Leu Tyr Val
165 170 175
Asn Gly Phe Thr His Gln Asn Ser Val Pro Thr Thr Ser Thr Pro Gly
180 185 190
Thr Ser Thr Val Tyr Trp Ala Thr Thr Gly Thr Pro Ser Ser Phe Pro
195 200 205
Gly His Thr Glu Pro Gly Pro Leu Leu Ile Pro Phe Thr Phe Asn Phe
210 215 220
Thr Ile Thr Asn Leu His Tyr Glu Glu Asn Met Gln His Pro Gly Ser
225 230 235 240
Arg Lys Phe Asn Ala Thr Glu Arg Val Leu Gln Gly Leu Leu Ser Pro
245 250 255
Ile Phe Lys Asn Ser Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu
260 265 270
Thr Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Met Asp Ala
275 280 285
Val Cys Leu Tyr Arg Pro
290
<210>488
<211>233
<212>PRT
<213> human
<400>488
Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn Ala Ser Phe
1 5 10 15
His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His Val Thr Glu
20 25 30
Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser Thr Gln His
35 40 45
Phe Tyr Leu Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys
50 55 60
Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu
65 70 75 80
Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe
85 90 95
Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His
100 105 110
Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val
115 120 125
Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly
130 135 140
Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu Val Asp
145 150 155 160
Gly Tyr Phe Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu
165 170 175
Pro Phe Trp Ala Val Ile Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu
180 185 190
Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys
195 200 205
Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln
210 215 220
Ser His Leu Asp Leu Glu Asp Leu Gln
225 230
<210>489
<211>178
<212>PRT
<213> human
<400>489
Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn Ala Ser Phe
1 5 10 15
His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His Val Thr Glu
20 25 30
Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser Thr Gln His
35 40 45
Phe Tyr Leu Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys
50 55 60
Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg Asn Ile Glu
65 70 75 80
Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser Tyr Phe
85 90 95
Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg His His
100 105 110
Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val
115 120 125
Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg Asn Gly
130 135 140
Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu Val Asp
145 150 155 160
Gly Tyr Phe Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu
165 170 175
Pro Phe
<210>490
<211>15
<212>PRT
<213> human
<400>490
Thr Cys Gly Met Arg Arg Thr Cys Ser Thr Leu Ala Pro Gly Ser
1 5 10 15
<210>491
<211>15
<212>PRT
<213> human
<400>491
Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr
1 5 10 15
<210>492
<211>15
<212>PRT
<213> human
<400>492
Asp Gly Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro
1 5 10 15
<210>493
<211>15
<212>PRT
<213> human
<400>493
Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu
1 5 10 15
<210>494
<211>15
<212>PRT
<213> human
<400>494
Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr
1 5 10 15
<210>495
<211>15
<212>PRT
<213> human
<400>495
Leu Gly Pro Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn Gly
1 5 10 15
<210>496
<211>15
<212>PRT
<213> human
<400>496
Ser Val Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Tyr Val Leu
1 5 10 15
<210>497
<211>15
<212>PRT
<213> human
<400>497
Leu Arg Pro Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile
1 5 10 15
<210>498
<211>15
<212>PRT
<213> human
<400>498
Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu Tyr Leu Glu
1 5 10 15
<210>499
<211>15
<212>PRT
<213> human
<400>499
Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser
1 5 10 15
<210>500
<211>15
<212>PRT
<213> human
<400>500
Gly Pro Tyr Ser Leu Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr
1 5 10 15
<210>501
<211>15
<212>PRT
<213> human
<400>501
Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Pro Asp Glu Pro Pro Thr
1 5 10 15
<210>502
<211>15
<212>PRT
<213> human
<400>502
Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg
1 5 10 15
<210>503
<211>15
<212>PRT
<213> human
<400>503
Gln Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly
1 5 10 15
<210>504
<211>15
<212>PRT
<213> human
<400>504
Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp
1 5 10 15
<210>505
<211>15
<212>PRT
<213> human
<400>505
Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln Gln
1 5 10 15
<210>506
<211>15
<212>PRT
<213> human
<400>506
Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His
1 5 10 15
<210>507
<211>15
<212>PRT
<213> human
<400>507
His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser
1 5 10 15
<210>508
<211>15
<212>PRT
<213> human
<400>508
Asp Pro Thr Ser Ser Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln
1 5 10 15
<210>509
<211>15
<212>PRT
<213> human
<400>509
Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys Gly Ser
1 5 10 15
<210>510
<211>15
<212>PRT
<213> human
<400>510
Leu Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu
1 5 10 15
<210>511
<211>15
<212>PRT
<213> human
<400>511
Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg
1 5 10 15
<210>512
<211>450
<212>DNA
<213> human
<400>512
gttacaatga acctggtcca gatgagcctc ctacaactcc caagccagcc accacattcc 60
tgcctcctct gtcagaagcc acaacagcca tggggtacca cctgaagacc ctcacactca 120
acttcaccat ctccaatctc cagtattcac cagatatggg caagggctca gctacattca 180
actccaccga gggggtcctt cagcacctgc tcagaccctt gttccagaag agcagcatgg 240
gccccttcta cttgggttgc caactgatct ccctcaggcc tgagaaggat ggggcagcca 300
ctggtgtgga caccacctgc acctaccacc ctgaccctgt gggccccggg ctggacatac 360
agcagcttta ctgggagctg agtcagctga cccatggtgt cacccaactg ggcttctatg 420
tcctggacag ggatagcctc ttcatcaatg 450
<210>513
<211>402
<212>DNA
<213> human
<400>513
gtttcaccca tcggagctct gtacccacca ccagcaccgg ggtggtcagc gaggagccat 60
tcacactgaa cttcaccatc aacaacctgc gctacatggc ggacatgggc caacccggct 120
ccctcaagtt caacatcaca gacaacgtca tgaagcacct gctcagtcct ttgttccaga 180
ggagcagcct gggtgcacgg tacacaggct gcagggtcat cgcactaagg tctgtgaaga 240
acggtgctga gacacgggtg gacctcctct gcacctacct gcagcccctc agcggcccag 300
gtctgcctat caagcaggtg ttccatgagc tgagccagca gacccatggc atcacccggc 360
tgggccccta ctctctggac aaagacagcc tctaccttaa cg 402
<210>514
<211>465
<212>DNA
<213> human
<400>514
gtttcactca tcggagctct gtgtccacca ccagcactcc tgggaccccc acagtgtatc 60
tgggagcatc taagactcca gcctcgatat ttggcccttc agctgccagc catctcctga 120
tactattcac cctcaacttc accatcacta acctgcggta tgaggagaac atgtggcctg 180
gctccaggaa gttcaacact acagagaggg tccttcaggg cctgctaagg cccttgttca 240
agaacaccag tgttggccct ctgtactctg gctgcaggct gaccttgctc aggccagaga 300
aagatgggga agccaccgga gtggatgcca tctgcaccca ccgccctgac cccacaggcc 360
ctgggctgga cagagagcag ctgtatttgg agctgagcca gctgacccac agcatcactg 420
agctgggccc ctacacactg gacagggaca gtctctatgt caatg 465
<210>515
<211>463
<212>DNA
<213> human
<400>515
gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc acagtggacc 60
tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc cctctcctgg 120
tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac atgcagcacc 180
ctggctccag gaagttcaac accacggaga gggtccttca gggcctggtc cctgttcaag 240
agcaccagtg ttggccctct gtactctggc tgcagactga ctttgctcag gcctgaaaag 300
gatgggacag ccactggagt ggatgccatc tgcacccacc accctgaccc caaaagccct 360
aggctggaca gagagcagct gtattgggag ctgagccagc tgacccacaa tatcactgag 420
ctgggcccct atgccctgga caacgacagc ctctttgtca atg 463
<210>516
<211>156
<212>DNA
<213> human
<400>516
cagccaccgg agtggatgcc atctgcaccc accgccctga ccccacaggc cctgggctgg 60
acagagagca gctgtatttg gagctgagcc agctgaccca cagcatcact gagctgggcc 120
cctacaccct ggacagggac agtctctatg tcaatg 156
<210>517
<211>450
<212>DNA
<213> human
<400>517
gttacaatga acctggtcta gatgagcctc ctacaactcc caagccagcc accacattcc 60
tgcctcctct gtcagaagcc acaacagcca tggggtacca cctgaagacc ctcacactca 120
acttcaccat ctccaatctc cagtattcac cagatatggg caagggctca gctacattca 180
actccaccga gggggtcctt cagcacctgc tcagaccctt gttccagaag agcagcatgg 240
gccccttcta cttgggttgc caactgatct ccctcaggcc tgagaaggat ggggcagcca 300
ctggtgtgga caccacctgc acctaccacc ctgaccctgt gggccccggg ctggacatac 360
agcagcttta ctgggagctg agtcagctga cccatggtgt cacccaactg ggcttctatg 420
tcctggacag ggatagcctc ttcatcaatg 450
<210>518
<211>402
<212>DNA
<213> human
<400>518
gtttcaccca tcggagctct gtacccacca ccagcaccgg ggtggtcagc gaggagccat 60
tcacactgaa cttcaccatc aacaacctgc gctacatggc ggacatgggc caacccggct 120
ccctcaagtt caacatcaca gacaacgtca tgaagcacct gctcagtcct ttgttccaga 180
ggagcagcct gggtgcacgg tacacaggct gcagggtcat cgcactaagg tctgtgaaga 240
acggtgctga gacacgggtg gacctcctct gcacctacct gcagcccctc agcggcccag 300
gtctgcctat caagcaggtg ttccatgagc tgagccagca gacccatggc atcacccggc 360
tgggccccta ctctctggac aaagacagcc tctaccttaa cg 402
<210>519
<211>465
<212>DNA
<213> human
<400>519
gtttcactca tcggagctct gtgtccacca ccagcactcc tgggaccccc acagtgtatc 60
tgggagcatc taagactcca gcctcgatat ttggcccttc agctgccagc catctcctga 120
tactattcac cctcaacttc accatcacta acctgcggta tgaggagaac atgtggcctg 180
gctccaggaa gttcaacact acagagaggg tccttcaggg cctgctaagg cccttgttca 240
agaacaccag tgttggccct ctgtactctg gctccaggct gaccttgctc aggccagaga 300
aagatgggga agccaccgga gtggatgcca tctgcaccca ccgccctgac cccacaggcc 360
ctgggctgga cagagagcag ctgtatttgg agctgagcca gctgacccac agcatcactg 420
agctgggccc ctacacactg gacagggaca gtctctatgt caatg 465
<210>520
<211>468
<212>DNA
<213> human
<400>520
gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc acagtggacc 60
tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc cctctcctgg 120
tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac atgcagcacc 180
ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc aggtccctgt 240
tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg ctcaggcctg 300
aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct gaccccaaaa 360
gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc cacaatatca 420
ctgagctggg ccactatgcc ctggacaacg acagcctctt tgtcaatg 468
<210>521
<211>468
<212>DNA
<213> human
<400>521
gtttcaccca tcagagctct atgacgacca ccagaactcc tgatacctcc acaatgcacc 60
tggcaacctc gagaactcca gcctccctgt ctggacctac gaccgccagc cctctcctgg 120
tgctattcac aattaacttc accatcacta acctgcggta tgaggagaac atgcatcacc 180
ctggctctag aaagtttaac accacggaga gagtccttca gggtctgctc aggcctgtgt 240
tcaagaacac cagtgttggc cctctgtact ctggctgcag actgaccttg ctcaggccca 300
agaaggatgg ggcagccacc aaagtggatg ccatctgcac ctaccgccct gatcccaaaa 360
gccctggact ggacagagag cagctatact gggagctgag ccagctaacc cacagcatca 420
ctgagctggg cccctacacc ctggacaggg acagtctcta tgtcaatg 468
<210>522
<211>262
<212>DNA
<213> human
<400>522
gagagggtcc ttcagggtct gcttatgccc ttgttcaaga acaccagtgt cagctctctg 60
tactctggtt gcagactgac cttgctcagg cctgagaagg atggggcagc caccagagtg 120
gatgctgtct gcacccatcg tcctgacccc aaaagccctg gactggacag agagcggctg 180
tactggaagc tgagccagct gacccacggc atcactgagc tgggccccta caccctggac 240
aggcacagtc tctatgtcaa tg 262
<210>523
<211>302
<212>DNA
<213> human
<400>523
aggacatgcg tcaccctggc tccaggaagt tcaacaccac agagagggtc ctgcagggtc 60
tgcttggtcc cttgttcaag aactccagtg tcggccctct gtactctggc tgcagactga 120
tctctctcag gtctgagaag gatggggcag ccactggagt ggatgccatc tgcacccacc 180
accttaaccc tcaaagcctg gactggacag ggagcagctg tactggcagc tgagccagat 240
gaccaatggc atcaaagagc tgggccccta caccctggac cggaacagtc tctacgtcaa 300
tg 302
<210>524
<211>468
<212>DNA
<213> human
<400>524
gtttcaccca tcggagctct gggctcacca ccagcactcc ttggacttcc acagttgacc 60
ttggaacctc agggactcca tcccccgtcc ccagccccac aactgctggc cctctcctgg 120
tgccattcac cctaaacttc accatcacca acctgcagta tgaggaggac atgcatcgcc 180
ctggatctag gaagttcaac gccacagaga gggtcctgca gggtctgctt agtcccatat 240
tcaagaactc cagtgttggc cctctgtact ctggctgcag actgacctct ctcaggcccg 300
agaaggatgg ggcagcaact ggaatggatg ctgtctgcct ctaccaccct aatcccaaaa 360
gacctgggct ggacagagag cagctgtact gggagctaag ccagctgacc cacaacatca 420
ctgagctggg cccctacagc ctggacaggg acagtctcta tgtcaatg 468
<210>525
<211>470
<212>DNA
<213> human
<400>525
gtttcaccca tcagaactct gtgcccacca ccagtactcc tgggacctcc acagtgtact 60
gggcaaccac tgggactcca tcctccttcc ccggccacac agagcctggc cctctcctga 120
taccattcac attcaacttt accatcacca acctgcatta tgaggaaaac atgcaacacc 180
ctggttccag gaagttcaac gccacagaga gggtcctgca gggtctgctt agtcccatat 240
tcaagaactc cagtgttggc cctctgtact ctggctgcag actgacctct ctcaggcccg 300
agaaggatgg ggcagcaact ggaatggatg ctgtctgtct ctaccgaccc taatcccatc 360
ggacctgggc tggacagaga gcagctgtac tgggagctga gccagctgac ccacgacatc 420
actgagctgg gcccctacag ccctggacag ggacagtctc tatgtcaatg 470
<210>526
<211>467
<212>DNA
<213> human
<400>526
gtttcaccca tcagaactct gtgcccacca ccagtactcc tgggacctcc acagtgtact 60
gggcaaccac tgggactcca tcctccttcc ccggccacac agagcctggc cctctcctga 120
taccattcac tttcaacttt accatcacca acctgcatta tgaggaaaac atgcaacacc 180
tggttccagg aagttcaaca ccacggagag ggttctgcag ggtctgctca cgcccttgtt 240
caagaacacc agtgttggcc ctctgtactc tggctgcaga ctgaccttgc tcagacctga 300
gaagcaggag gcagccactg gagtggacac catctgcact caccgccttg accctctaaa 360
ccctggactg gacagagagc agctatactg ggagctgagc aaactgaccc gtggcatcat 420
cgagctgggc ccctacctcc tggacagagg cagtctctat gtcaatg 467
<210>527
<211>468
<212>DNA
<213> human
<400>527
gtttcaccca tcggaacttt gtgcccatca ccagcactcc tgggacctcc acagtacacc 60
taggaacctc tgaaactcca tcctccctac ctagacccat agtgcctggc cctctcctgg 120
tgccattcac cctcaacttc accatcacca acttgcagta tgaggaggcc atgcgacacc 180
ctggctccag gaagttcaat accacggaga gggtcctaca gggtctgctc aggcccttgt 240
tcaagaatac cagtatcggc cctctgtact ccagctgcag actgaccttg ctcaggccag 300
agaaggacaa ggcagccacc agagtggatg ccatctgtac ccaccaccct gaccctcaaa 360
gccctggact gaacagagag cagctgtact gggagctgag ccagctgacc cacggcatca 420
ctgagctggg cccctacacc ctggacaggc acagtctcta tgtcaatg 468
<210>528
<211>537
<212>DNA
<213> human
<400>528
gtttcaccca tcagagcccc ataccaacca ccagcactcc tgatacctcc acaatgcacc 60
tgggaacctc gagaactcca gcctccctgt ctggacctac gaccgccagc cctctcctgg 120
tgctattcac aattaacttc accatcacta acctgcggta tgaggagaac atgcatcacc 180
gctggctcta gaaagtttaa caccacggag agagtccttc agggtctgct caggcctgtg 240
ttcaaagaac accagtgttg gccctctgta ctctggctgc agactgacct tgctcaggcc 300
cgagaaggat ggggcagcca cgcaaagtgg atgccatctg cacctaccgc cctgatccca 360
aaagccctgg actggacaga gagcagctat actgggagct gagccagggt gatgcatgtt 420
ctcctcatat cgcaggttag tgatggtgaa gttaattgtg aatagcacca ggagagggct 480
ggcggtcatg ggtccagaca gggagcctgg agttctcgag gttgccaggt gcatgtc 537
<210>529
<211>231
<212>DNA
<213> human
<400>529
tgttccagag gagcagcctg ggtgcacggt acacaggctg cagggtcatc gcactaaggt 60
ctgtgaagaa cggtgctgag acacgggtgg acctcctctg cacctacctg cagcccctca 120
gcggcccagg tctgcctatc aagcaggtgt tccatgagct gagccagcag acccatggca 180
tcacccggct gggcccctac tctctggaca aagacagcct ctaccttaac g 231
<210>530
<211>376
<212>DNA
<213> human
<400>530
gttacaatga agctggtcca gatgagcctc ctacaactcc caagccagcc accacattcc 60
tgcctcctct gtcagaagcc acaacagcca tggggtacca cctgaagacc ctcacactca 120
acttcaccat ctccaatctc cagtattcac cagatatggg caagggctca gctacattca 180
actccaccga gggggtcctt cagcacctgg cctgagaagg atggggcagc cactggtgtg 240
gacaccacct gcacctacca ccctgaccct gtgggccccg ggctggacat acagcagctt 300
tactgggagc tgagtcagct gacccatggt gtcacccaac tgggcttcta tgtcctggac 360
agcgatagct cttcat 376
<210>531
<211>75
<212>DNA
<213> human
<400>531
ggtaaccaca gctgacccat ggcatcaaag agctgggccc ctacaccctg gacaggaaca 60
gtctctatgt caatg 75
<210>532
<211>906
<212>DNA
<213> human
<400>532
gtttcaccca tcggagctct gtggccccca ccagcactcc tgggacctcc acagtggacc 60
ttgggacctc agggactcca tcctccctcc ccagccccac aacagctgtt cctctcctgg 120
tgccgttcac cctcaacttt accatcacca atctgcagta tggggaggac atgcgtcacc 180
ctggctccag gaagttcaac accacagaga gggtcctgca gggtctgctt ggtcccttgt 240
tcaagaactc cagtgtcggc cctctgtact ctggctgcag actgatctct ctcaggtctg 300
agaaggatgg ggcagccact ggagtggatg ccatctgcac ccaccacctt aaccctcaaa 360
gccctggact ggacagggag cagctgtact ggcagctgag ccagagacca caacctcatt 420
tatcacctat tctgagacac acacaagttc agccattcca actctccctg tctccccctg 480
gtgcatcaaa gatgctgacc tcactggtca tcagttctgg gacagacagc actacaactt 540
tcccaacact gacggagacc ccatatgaac cagagacaac agccatacag ctcattcatc 600
ctgcagagac caacacaatg gttcccagga caactcccaa gttttcccat agtaagtcag 660
acaccacact cccagtagcc atcaccagtc ctgggccaga agccagttca gctgtttcaa 720
cgacaactat ctcacctgat atgtcagatc tggtgacctc actggtccct agttctggga 780
cagacaccag tacaaccttc ccaacattga gtgagacccc atatgaacca gagactacag 840
ccacgtggct cactcatcct gcagaaacca gaacaacggt ttctgggaca attcccaact 900
tttccc 906
<210>533
<211>404
<212>DNA
<213> human
<400>533
gtttcaccca tcggagctct gtggccccca ccagcactcc tgggacctcc acagtggacc 60
ttgggacctc agggactcca tcctccctcc ccagccccac aacagctgtt cctctcctgg 120
tgccgttcac cctcaacttt accatcacca atctgcagta tggggaggac atgcgtcacc 180
ctggctccag gaagttcaac accacagaga gggtcctgca gggtctgctt ggtcccttgt 240
tcaagaactc cagtgtcggc cctctgtact ctggctgcag actgatctct ctcaggtctg 300
agaaggatgg ggcagccact ggagtggatg ccatctgcac ccaccacctt aaccctcaaa 360
gccctggact ggacagggag cagctgtact ggcagctgag ccag 404
<210>534
<211>157
<212>DNA
<213> human
<400>534
gcagccacca aagtggatgc catctgcacc taccgccctg atcccaaaag ccctggactg 60
gacagagagc agctatactg ggagctgagc cagctaaccc acagcatcac tgagctgggc 120
ccctacaccc tggacaggga cagtctctat gtcaatg 157
<210>535
<211>468
<212>DNA
<213> human
<400>535
gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc acagtggacc 60
tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc cctctcctgg 120
tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac atgcagcacc 180
ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc aggtccctgt 240
tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg ctcaggcctg 300
aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct gaccccaaaa 360
gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc cacaatatca 420
ctgagctggg cccctatgcc ctggacaacg acagcctctt tgtcaatg 468
<210>536
<211>334
<212>DNA
<213> human
<400>536
gtttcactca tcggagctct gtgtccacca ccagcactcc tgggaccccc acagtgtatc 60
tgggagcatc taagactcca gcctcgatat ttggcccttc agctgccagc catctcctga 120
tactattcac cctcaacttc accatcacta acctgcggta tgaggagaac atgtggcctg 180
gctccaggaa gttcaacact acagagaggg tccttcaggg cctgctaagg cccttgttca 240
agaacaccag tgttggccct ctgtactctg gctgcaggct gaccttgctc aggccagaga 300
aagatgggga agccaccgga gtggatgcca tctg 334
<210>537
<211>127
<212>DNA
<213> human
<400>537
ccaccgtctt gaccccaaaa gccctggagt ggacagggag cagctatact gggagctgag 60
ccagctgacc aatggcatca aagagctggg cccctacacc tggacaggaa cagtctctat 120
gtcaatg 127
<210>538
<211>468
<212>DNA
<213> human
<400>538
gtttcaccca tcggacctct gtgcccacca ccagcactcc tgggacctcc acagtggacc 60
ttggaacctc agggactcca ttctccctcc caagccccgc aactgctggc cctctcctgg 120
tgctgttcac cctcaacttc accatcacca acctgaagta tgaggaggac atgcatcgcc 180
ctggctccag gaagttcaac accactgaga gggtcctgca gactctgctt ggtcctatgt 240
tcaagaacac cagtgttggc cttctgtact ctggctgcag actgaccttg ctcaggtccg 300
agaaggatgg agcagccact ggagtggatg ccatctgcac ccaccgtctt gaccccaaaa 360
gccctggagt ggacagggag cagctatact gggagctgag ccagctgacc aatggcatca 420
aagagctggg cccctacacc ctggacagga acagtctcta tgtcaatg 468
<210>539
<211>465
<212>DNA
<213> human
<400>539
gtttcaccca ttggatccct gtgcccacca gcagcactcc tgggacctcc acagtggacc 60
ttgggtcagg gactccatcc tccctcccca gccccacaac tgctggccct ctcctggtgc 120
cgttcaccct caacttcacc atcaccaacc tgaagtacga ggaggacatg cattgccctg 180
gctccaggaa gttcaacacc acagagagag tcctgcagag tctgcttggt cccatgttca 240
agaacaccag tgttggccct ctgtactctg gctgcagact gaccttgctc aggtccgaga 300
aggatggagc agccactgga gtggatgcca tctgcaccca ccgtcttgac cccaaaagcc 360
tggagtggac agggagcagc tatactggga gctgagccag ctgaccaatg ccatcaaaga 420
gctgggtccc tacaccctgg acagcaacag tcttctatgt caatg 465
<210>540
<211>255
<212>DNA
<213> human
<400>540
gtttcaccca tcagacctct gcgcccaaca ccagcactcc tgggacctcc acagtggacc 60
ttgggacctc agggactcca tcctccctcc ccagccctac atctgctggc cctctcctgg 120
tgccattcac cctcaacttc accatcacca acctgcagta cgaggaggac atgcatcacc 180
caggctccag gaagttcaac accacggagc gggtcctgca gggtctgctt ggtcccatgt 240
tcaagaacac tacga 255
<210>541
<211>390
<212>DNA
<213> human
<400>541
catccccagc tcgaacagca gccacagtcc cattcatggt gccattcacc ctcaacttca 60
actcatcacc aacctgcagt acgaggagga catgcggcac ctggttccag gaagttcaac 120
gcgcacagag agagaactgc agggtcgtgc tcaaacccta gatcaggaat agcagtctgg 180
aatacctcta ttcaggctgc agactagcct cactcaggcc agagaaggat agctcagcca 240
cggcagtgga tgccatctgc acacatcgcc ctgaccctga agacctcgga ctggacagag 300
agcgactgta ctgggagctg agcaatctga caaatggcat ccaggagctg ggcccctaca 360
ccctggaccg gaacagtctc tatgtcaatg 390
<210>542
<211>468
<212>DNA
<213> human
<400>542
gtttcaccca tcgaagctct atgcccacca ccagcactcc tgggacctcc acagtggatg 60
tgggaacctc agggactcca tcctccagcc ccagccccac gactgctggc cctctcctga 120
tgccgttcac cctcaacttc accatcacca acctgcagta cgaggaggac atgcgtcgca 180
ctggctccag gaagttcaac accatggaga gtgtcctgca gggtctgctc aagcccttgt 240
tcaagaacac cagtgttggc cctctgtact ctggctgcag attgaccttg ctcaggccca 300
agaaagatgg ggcagccact ggagtggatg ccatctgcac ccaccgcctt gaccccaaaa 360
gccctggact caacagggag cagctgtact gggagctaag caaactgacc aatgacattg 420
aagagctggg cccctacacc ctggacagga acagtctcta tgtcaatg 468
<210>543
<211>475
<212>DNA
<213> human
<400>543
gtttcaccca tcagagctct gtgtccacca ccagcactcc tgggacctcc acagtggatc 60
tcagaacctc agtggactcc atcctccctc tccagcccca caattatggc tgctggccct 120
ctcctggtac cattcaccct caacttcacc atcaccaacc tgcagtatgg ggaggacatg 180
ggtcaccctg gctccaggaa gttcaacacc acagagaggg tcctgcaggg tctgcttggt 240
cccatattca agaacaccag tgttggccct ctgtactctg gctgcagact gacctctctc 300
aggtccaaga aggatggagc agccactgga gtggatgcca tctgcatcca tcatcttgac 360
cccaaaagcc ctggactcaa cagagagcgg ctgtactggg agctgagcca actgaccaat 420
ggcatcaaag agctgggccc ctacaccctg gacaggaaca gtctctatgt caatg 475
<210>544
<211>485
<212>DNA
<213> human
<400>544
gtttcaccca tcggacctct gtgcccacca ccagtactcc tgggacctcc acagtgtact 60
gggcaaccac tgggactcca tcctccctcc ccgccacaca gagcctggcc ctctcctgat 120
accattcaca ttcaacttta ccatcaccta cctgcattat agaggaaaac atgcaacacc 180
cgtggttcca ggaacgatgt caacaccaca ggagagggtt ctgcagggtc ttcgctcacg 240
cccattgtta caagaacacc agtagttggc cctctgtact ctggctgcag aatgaccttg 300
ctcagacctg agaagcagga ggcaacacac tggaatggac accatctgta tccaccagcg 360
ttagatccca tcaggacctg gactggacag agagcaggct atactgggag ctagagccag 420
ctgacccaca gcatcacaga gctgggaccc tacagccctg gatagggaca gtctctatgt 480
caatg 485
<210>545
<211>141
<212>DNA
<213> human
<400>545
gcttcaaccc ttggagctct gtgccaacca ccagcactcc tgggacctcc acagtgcacc 60
tggcaacctc tgggactcca tcctccctgc ctggccacac agcccctgtc cctctcttga 120
taccattcac cctcaactta c 141
<210>546
<211>142
<212>DNA
<213> human
<400>546
gacctcctct gcacctacct gcagcccctc agcggcccag gtctgcctat caagcaggtg 60
ttccatgagc tgagccagca gacccatggc atcacccggc tgggccccta ctctctggac 120
aaagacagcc tctaccttaa cg 142
<210>547
<211>185
<212>DNA
<213> human
<400>547
gttcttaccc aggccagaga aggatagctc agccacggca gtggatgcca tctgcacaca 60
tcgccctgac cctgaagacc tcggactgga cagagagcga ctgtactggg agctgagcaa 120
tctgacaaat ggcatccagg agctgggccc ctacaccctg gaccggaaca gtctctatgt 180
caatg 185
<210>548
<211>462
<212>DNA
<213> human
<400>548
gtttcaccca tcgaagctct atgcccacca ccagcactcc tgggacctcc acagtggatg 60
tgggaacctc agggactcca tcctccagcc ccagccccac gactgctggc cctctcctga 120
tgccgttcac cctcaacttc accatcacca acctgcagta cgaggaggac atgcgtcgca 180
ctggctccag gaagttcaac accatggaga gtgtcctgca gggtctgccc ttgttcaaga 240
acaccagtgt tggccctctg tactctggct gcagattgac cttgctcagg cccgagaaag 300
atggggcagc cactggagtg gatgccatct gcacccaccg ccttgacccc aaaagccctg 360
gactcaacag ggagcagctg tactgggagc taagcaaact gaccaatgac attgaagagc 420
tgggccccta caccctggac aggaacagtc tctatgtcaa tg 462
<210>549
<211>400
<212>DNA
<213> human
<400>549
actccatcct ccctctccag ccccacaatt atggctgctg gccctctcct ggtaccattc 60
accctcaact tcaccatcac caacctgcag tatggggagg acatgggtca ccctggctcc 120
aggaagttca acaccacaga gagggtcctg cagggtctgc ttggtcccat attcaagaac 180
accagtgttg gccctctgta ctctggctgc agactgacct ctctcaggtc tgagaaggat 240
ggagcagcca ctggagtgga tgccatctgc atccatcatc ttgaccccaa aagccctgga 300
ctcaacagag agcggctgta ctgggagctg agccaactga ccaatggcat caaagagctg 360
ggcccctaca ccctggacag gaacagtctc tatgtcaatg 400
<210>550
<211>468
<212>DNA
<213> human
<400>550
gtttcaccca tcggacctct gtgcccacca gcagcactcc tgggacctcc acagtggacc 60
ttggaacctc agggactcca ttctccctcc caagccccgc aactgctggc cctctcctgg 120
tgctgttcac cctcaacttc accatcacca acctgaagta tgaggaggac atgcatcgcc 180
ctggctccag gaagttcaac accactgaga gggtcctgca gactctgctt ggtcctatgt 240
tcaagaacac cagtgttggc cttctgtact ctggctgcag actgaccttg ctcaggtccg 300
agaaggatgg agcagtcact ggagtggatg ccatctgcac ccaccgtctt gaccccaaaa 360
gccctggagt ggacagggag cagctatact gggagctgag ccagctgacc aatggcatca 420
aagagctggg cccctacacc ctggacaggc acagtctcta tgtcaatg 468
<210>551
<211>366
<212>DNA
<213> human
<400>551
ctgctggccc tctcctggtg ctgttcaccc tcaacttcac catcaccaac ctgaagtatg 60
aggaggacat gcatcgccct ggctccagga agttcaacac cactgagagg gtcctgcaga 120
ctctgcgtgg tcctatgttc aagaacacca gtggtggcct tctgtactct ggctgcagac 180
tgaccttgct caggtccgag aaggatggag cagccactgg agtggatgcc atctgcaccc 240
accgtcttga ccccaaaagc cctggagtgg acagggagca gctatactgg gagctgagcc 300
agctgaccaa tggcatcaaa gagctgggcc cctacaccct ggacaggaac agtctctatg 360
tcaatg 366
<210>552
<211>465
<212>DNA
<213> human
<400>552
gtttcaccca ttggatccct gtgcccacca gcagcactcc tgggacctcc acagtggacc 60
ttgggtcagg gactccatcc tccctcccca gccccacaac tgctggccct ctcctggtgc 120
cattcaccct caacttcacc atcaccaacc tgcagtacga ggaggacatg catcacccag 180
gctccaggaa gttcaacacc acggagcggg tcctgcaggg tctgcttggt cccatgttca 240
agaacaccag tgtcggcctt ctgtactctg gctgcagact gaccttgctc aggcctgaga 300
agaatggggc agccactgga atggatgcca tctgcagcca ccgtcttgac cccaaaagcc 360
ctggactcaa cagagagcag ctgtactggg agctgagcca gctgacccat ggcatcaaag 420
agctgggccc ctacaccctg gacaggcaca gtctctatgt caatg 465
<210>553
<211>401
<212>DNA
<213> human
<400>553
aacgattcga ccttctcctg ggacctccac agtggacctt gggtcaggga ctccatcctc 60
cctccccagc cccacaactg ctggccctct cctggtgccg ttcaccctca acttcaccat 120
caccaacctg gagtacgagg aggacatgca ttgccctggc tccaggaagt tcaacaccac 180
agagagagtc ctgcagagtc tgcttggtcc catgttcaag aacaccagtg ttggccctct 240
gtactctggc tgcagactga ccttgctcag gtccgagaag gatggagcag ccactggagt 300
ggatgccatc tgcacccacc gtcttgaccc caaaagccct ggagtggaca gggagcagct 360
atactgggag ctgagccagc tgaccaatgg catcaaagaa a 401
<210>554
<211>385
<212>DNA
<213> human
<400>554
tcctgggacc tccacagtgg accttgggtc ctcagggact ccatcctccc tccccagccc 60
tacatctgct ggccctctcc tggtgccatt caccctcaac ttcaccatca ccaacctgca 120
gtacgaggag gacatgcatc acccaggctc caggaagttc aacaccacgg agcgggtcct 180
gcagggtctg cttggtccca tgttcaagaa caccagtgtc ggccttctgt actctggctg 240
cagactgacc ttgctcaggc ctgagaagaa tggggcagcc actggaatgg atgccatctg 300
cagccaccgt cttgacccca aaagccctgg actcaacaga gagcagctgt actgggagct 360
gagccagctg acccatggca tcaaa 385
<210>555
<211>173
<212>DNA
<213> human
<400>555
gtctgagaag gatggggcag ccactggagt ggatgccatc tgcacccacc accttaaccc 60
tcaaagccct ggactggaca gggagcagct gtactggcag ctgagccaga tgaccaatgg 120
catcaaagag ctgggcccct acaccctgga ccggaacagt ctctacgtca atg 173
<210>556
<211>468
<212>DNA
<213> human
<400>556
gtttcaccca tcggagctct gggctcacca ccagcactcc ttggacttcc acagttgacc 60
ttggaacctc agggactcca tcccccgtcc ccagccccac aactgctggc cctctcctgg 120
tgccattcac cctaaacttc accatcacca acctgcagta tgaggaggac atgcatcgcc 180
ctggatctag gaagttcaac gccacagaga gggtcctgca gggtctgctt agtcccatat 240
tcaagaactc cagtgttggc cctctgtact ctggctgcag actgacctct ctcaggcccg 300
agaaggatgg ggcagcaact ggaatggatg ctgtctgcct ctaccaccct aatcccaaaa 360
gacctgggct ggacagagag cagctgtact gggagctaag ccagctgacc cacaacatca 420
ctgagctggg cccctacagc ctggacaggc acagtctcta tgtcaatg 468
<210>557
<211>468
<212>DNA
<213> human
<400>557
gtttcaccca tcagaactct gtgcccacca ccagtactcc tgggacctcc acagtgtact 60
gggcaaccac tgggactcca tcctccttcc ccggccacac agagcctggc cctctcctga 120
taccattcac tttcaacttt accatcacca acctgcatta tgaggaaaac atgcaacacc 180
ctggttccag gaagttcaac accacggaga gggttctgca gggtctgctc acgcccttgt 240
tcaagaacac cagtgttggc cctctgtact ctggctgcag actgaccttg ctcagacctg 300
agaagcagga ggcagccact ggagtggaca ccatctgtac ccaccgcgtt gatcccatcg 360
gacctggact ggacagagag cggctatact gggagctgag ccagctgacc aacagcatca 420
cagagctggg accctacacc ctggataggg acagtctcta tgtcaatg 468
<210>558
<211>468
<212>DNA
<213> human
<400>558
gcttcaaccc ttggagctct gtgccaacca ccagcactcc tgggacctcc acagtgcacc 60
tggcaacctc tgggactcca tcctccctgc ctggccacac agcccctgtc cctctcttga 120
taccattcac cctcaacttt accatcacca acctgcatta tgaagaaaac atgcaacacc 180
ctggttccag gaagttcaac accacggaga gggttctgca gggtctgctc aagcccttgt 240
tcaagagcac cagcgttggc cctctgtact ctggctgcag actgaccttg ctcagacctg 300
agaaacatgg ggcagccact ggagtggacg ccatctgcac cctccgcctt gatcccactg 360
gtcctggact ggacagagag cggctatact gggagctgag ccagctgacc aacagcgtta 420
cagagctggg cccctacacc ctggacaggg acagtctcta tgtcaatg 468
<210>559
<211>468
<212>DNA
<213> human
<400>559
gcttcaccca tcggagctct gtgccaacca ccagtattcc tgggacctct gcagtgcacc 60
tggaaacctc tgggactcca gcctccctcc ctggccacac agcccctggc cctctcctgg 120
tgccattcac cctcaacttc actatcacca acctgcagta tgaggaggac atgcgtcacc 180
ctggttccag gaagttcaac accacggaga gagtcctgca gggtctgctc aagcccttgt 240
tcaagagcac cagtgttggc cctctgtact ctggctgcag actgaccttg ctcaggcctg 300
aaaaacgtgg ggcagccacc ggcgtggaca ccatctgcac tcaccgcctt gaccctctaa 360
accctggact ggacagagag cagctatact gggagctgag caaactgacc tgtggcatca 420
tcgagctggg cccctacctc ctggacagag gcagtctcta tgtcaatg 468
<210>560
<211>468
<212>DNA
<213> human
<400>560
gtttcaccca tcggaacttt gtgcccatca ccagcactcc tgggacctcc acagtacacc 60
taggaacctc tgaaactcca tcctccctac ctagacccat agtgcctggc cctctcctgg 120
tgccattcac cctcaacttc accatcacca acttgcagta tgaggaggcc atgcgacacc 180
ctggctccag gaagttcaat accacggaga gggtcctaca gggtctgctc aggcccttgt 240
tcaagaatac cagtatcggc cctctgtact ccagctgcag actgaccttg ctcaggccag 300
agaaggacaa ggcagccacc agagtggatg ccatctgtac ccaccaccct gaccctcaaa 360
gccctggact gaacagagag cagctgtact gggagctgag ccagctgacc cacggcatca 420
ctgagctggg cccctacacc ctggacaggg acagtctcta tgtcgatg 468
<210>561
<211>468
<212>DNA
<213> human
<400>561
gtttcactca ttggagcccc ataccaacca ccagcactcc tgggacctcc atagtgaacc 60
tgggaacctc tgggatccca ccttccctcc ctgaaactac agccaccggc cctctcctgg 120
tgccattcac actcaacttc accatcacta acctacagta tgaggagaac atgggtcacc 180
ctggctccag gaagttcaac atcacggaga gtgttctgca gggtctgctc aagcccttgt 240
tcaagagcac cagtgttggc cctctgtatt ctggctgcag actgaccttg ctcaggcctg 300
agaaggacgg agtagccacc agagtggacg ccatctgcac ccaccgccct gaccccaaaa 360
tccctgggct agacagacag cagctatact gggagctgag ccagctgacc cacagcatca 420
ctgagctggg accctacacc ctggataggg acagtctcta tgtcaatg 468
<210>562
<211>407
<212>DNA
<213> human
<400>562
gtttcaccca gcggagctct gtgcccacca ccagcaccac tggccctgtc ctgctgccat 60
tcaccctcaa ttttaccatc attaacctgc agtatgagga ggacatgcat cgccctggct 120
ccaggaagtt caacaccacg gagagggtcc ttcagggtct gcttatgccc ttgttcaaga 180
acaccagtgt cagctctctg tactctggtt gcagactgac cttgctcagg cctgagaagg 240
atggggcagc caccagagtg gatgctgtct gcacccatcg tcctgacccc aaaagccctg 300
gactggacag agagcggctg tactggaagc tgagccagct gacccacggc atcactgagc 360
tgggccccta caccctggac aggcacagtc tctatgtcaa tggtttc 407
<210>563
<211>468
<212>DNA
<213> human
<400>563
gtttcaccca tcagagctct atgacgacca ccagaactcc tgatacctcc acaatgcacc 60
tggcaacctc gagaactcca gcctccctgt ctggacctac gaccgccagc cctctcctgg 120
tgctattcac aattaacttc accatcacta acctgcggta tgaggagaac atgcatcacc 180
ctggctctag aaagtttaac accacggaga gagtccttca gggtctgctc aggcctgtgt 240
tcaagaacac cagtgttggc cctctgtact ctggctgcag actgaccttg ctcaggccca 300
agaaggatgg ggcagccacc aaagtggatg ccatctgcac ctaccgccct gatcccaaaa 360
gccctggact ggacagagag cagctatact gggagctgag ccagctaacc cacagcatca 420
ctgagctggg cccctacacc ctggacaggg acagtctcta tgtcaatg 468
<210>564
<211>468
<212>DNA
<213> human
<400>564
gtttcacaca gcggagctct gtgcccacca ctagcattcc tgggaccccc acagtggacc 60
tgggaacatc tgggactcca gtttctaaac ctggtccctc ggctgccagc cctctcctgg 120
tgctattcac tctcaacttc accatcacca acctgcggta tgaggagaac atgcagcacc 180
ctggctccag gaagttcaac accacggaga gggtccttca gggcctgctc aggtccctgt 240
tcaagagcac cagtgttggc cctctgtact ctggctgcag actgactttg ctcaggcctg 300
aaaaggatgg gacagccact ggagtggatg ccatctgcac ccaccaccct gaccccaaaa 360
gccctaggct ggacagagag cagctgtatt gggagctgag ccagctgacc cacaatatca 420
ctgagctggg ccactatgcc ctggacaacg acagcctctt tgtcaatg 468
<210>565
<211>465
<212>DNA
<213> human
<400>565
gtttcactca tcggagctct gtgtccacca ccagcactcc tgggaccccc acagtgtatc 60
tgggagcatc taagactcca gcctcgatat ttggcccttc agctgccagc catctcctga 120
tactattcac cctcaacttc accatcacta acctgcggta tgaggagaac atgtggcctg 180
gctccaggaa gttcaacact acagagaggg tccttcaggg cctgctaagg cccttgttca 240
agaacaccag tgttggccct ctgtactctg gctgcaggct gaccttgctc aggccagaga 300
aagatgggga agccaccgga gtggatgcca tctgcaccca ccgccctgac cccacaggcc 360
ctgggctgga cagagagcag ctgtatttgg agctgagcca gctgacccac agcatcactg 420
agctgggccc ctacacactg gacagggaca gtctctatgt caatg 465
<210>566
<211>402
<212>DNA
<213> human
<400>566
gtttcaccca tcggagctct gtacccacca ccagcaccgg ggtggtcagc gaggagccat 60
tcacactgaa cttcaccatc aacaacctgc gctacatggc ggacatgggc caacccggct 120
ccctcaagtt caacatcaca gacaacgtca tgaagcacct gctcagtcct ttgttccaga 180
ggagcagcct gggtgcacgg tacacaggct gcagggtcat cgcactaagg tctgtgaaga 240
acggtgctga gacacgggtg gacctcctct gcacctacct gcagcccctc agcggcccag 300
gtctgcctat caagcaggtg ttccatgagc tgagccagca gacccatggc atcacccggc 360
tgggccccta ctctctggac aaagacagcc tctaccttaa cg 402
<210>567
<211>450
<212>DNA
<213> human
<400>567
gttacaatga acctggtcta gatgagcctc ctacaactcc caagccagcc accacattcc 60
tgcctcctct gtcagaagcc acaacagcca tggggtacca cctgaagacc ctcacactca 120
acttcaccat ctccaatctc cagtattcac cagatatggg caagggctca gctacattca 180
actccaccga gggggtcctt cagcacctgc tcagaccctt gttccagaag agcagcatgg 240
gccccttcta cttgggttgc caactgatct ccctcaggcc tgagaaggat ggggcagcca 300
ctggtgtgga caccacctgc acctaccacc ctgaccctgt gggccccggg ctggacatac 360
agcagcttta ctgggagctg agtcagctga cccatggtgt cacccaactg ggcttctatg 420
tcctggacag ggatagcctc ttcatcaatg 450
<210>568
<211>1060
<212>DNA
<213> human
<220>
<221>misc_feature
<222>406,742,801
<223> n ═ A, T, C or G
<400>568
gctatgcacc ccagaattta tcaatccggg gcgagtacca gataaatttc cacattgtca 60
actggaacct cagtaatcca gaccccacat cctcagagta catcaccctg ctgagggaca 120
tccaggacaa ggtcaccaca ctctacaaag gcagtcaact acatgacaca ttccgcttct 180
gcctggtcac caacttgacg atggactccg tgttggtcac tgtcaaggca ttgttctcct 240
ccaatttgga ccccagcctg gtggagcaag tctttctaga taagaccctg aatgcctcat 300
tccattggct gggctccacc taccagttgg tggacatcca tgtgacagaa atggagtcat 360
cagtttatca accaacaagc agctccagca cccagcactt ctaccygaat ttcaccatca 420
ccaacctacc atattcccag gacaaagccc agccaggcac caccaattac cagaggaaca 480
aaaggaatat tgaggatgcg ctcaaccaac tcttccgaaa cagcagcatc aagagttatt 540
tttctgactg tcaagtttca acattcaggt ctgtccccaa caggcaccac accggggtgg 600
actccctgtg taacttctcg ccactggctc ggagagtaga cagagttgcc atctatgagg 660
aatttctgcg gatgacccgg aatggtaccc agctgcagaa cttcaccctg gacaggagca 720
gtgtccttgt ggatgggtat tytcccaaca gaaatgagcc cttaactggg aattctgacc 780
ttcccttctg ggctgtcatc ytcatcggct tggcaggact cctgggactc atcacatgcc 840
tgatctgcgg tgtcctggtg accacccgcc ggcggaagaa ggaaggagaa tacaacgtcc 900
agcaacagtg cccaggctac taccagtcac acctagacct ggaggatctg caatgactgg 960
aacttgccgg tgcctggggt gcctttcccc cagccagggt ccaaagaagc ttggctgggg 1020
cagaaataaa ccatattggt cggacacaaa aaaaaaaaaa 1060
<210>569
<211>10622
<212>DNA
<213> human
<220>
<221>misc_feature
<222>1,691,1164,1165,1730,2015,2149,2785,3044,3163,
4483,4632,4825,4841,4849,4883,4915,4932,4947,6355,
6370,7716,8210,9131,9968,10304,10363
<223> n ═ A, T, C or G
<400>569
ncatccccag ctcgaacagc agccacagtc ccattcatgg tgccattcac cctcaacttc 60
aactcatcac caacctgcag tacgaggagg acatgcggca cctggttcca ggaagttcaa 120
cgcgcacaga gagagaactg cagggtcgtg ctcaaaccct agatcaggaa tagcagtctg 180
gaatacctct attcaggctg cagactagcc tcactcaggc cagagaagga tagctcagcc 240
acggcagtgg atgccatctg cacacatcgc cctgaccctg aagacctcgg actggacaga 300
gagcgactgt actgggagct gagcaatctg acaaatggca tccaggagct gggcccctac 360
accctggacc ggaacagtct ctatgtcaat ggtttcaccc atcgaagctc tatgcccacc 420
accagcactc ctgggacctc cacagtggat gtgggaacct cagggactcc atcctccagc 480
cccagcccca cgactgctgg ccctctcctg atgccgttca ccctcaactt caccatcacc 540
aacctgcagt acgaggagga catgcgtcgc actggctcca ggaagttcaa caccatggag 600
agtgtcctgc agggtctgct caagcccttg ttcaagaaca ccagtgttgg ccctctgtac 660
tctggctgca gattgacctt gctcaggccc ragaaagatg gggcagccac tggagtggat 720
gccatctgca cccaccgcct tgaccccaaa agccctggac tcaacaggga gcagctgtac 780
tgggagctaa gcaaactgac caatgacatt gaagagctgg gcccctacac cctggacagg 840
aacagtctct atgtcaatgg tttcacccat cagagctctg tgtccaccac cagcactcct 900
gggacctcca cagtggatct cagaacctca gtgactccat cctccctctc cagccccaca 960
attatggctg ctggccctct cctggtacca ttcaccctca acttcaccat caccaacctg 1020
cagtatgggg aggacatggg tcaccctggc tccaggaagt tcaacaccac agagagggtc 1080
ctgcagggtc tgcttggtcc catattcaag aacaccagtg ttggccctct gtactctggc 1140
tgcagactga cctctctcag gtcyragaag gatggagcag ccactggagt ggatgccatc 1200
tgcatccatc atcttgaccc caaaagccct ggactcaaca gagagcggct gtactgggag 1260
ctgagccaac tgaccaatgg catcaaagag ctgggcccct acaccctgga caggaacagt 1320
ctctatgtca atgctgctgg ccctctcctg gtgctgttca ccctcaactt caccatcacc 1380
aacctgaagt atgaggagga catgcatcgc cctggctcca ggaagttcaa caccactgag 1440
agggtcctgc agactctgcg tggtcctatg ttcaagaaca ccagtggtgg ccttctgtac 1500
tctggctgca gactgacctt gctcaggtcc gagaaggatg gagcagccac tggagtggat 1560
gccatctgca cccaccgtct tgaccccaaa agccctggag tggacaggga gcagctatac 1620
tgggagctga gccagctgac caatggcatc aaagagctgg gcccctacac cctggacagg 1680
aacagtctct atgtcaatgg tttcacccat cggacctctg tgcccaccas cagcactcct 1740
gggacctcca cagtggacct tggaacctca gggactccat tctccctccc aagccccgca 1800
actgctggcc ctctcctggt gctgttcacc ctcaacttca ccatcaccaa cctgaagtat 1860
gaggaggaca tgcatcgccc tggctccagg aagttcaaca ccactgagag ggtcctgcag 1920
actctgcttg gtcctatgtt caagaacacc agtgttggcc ttctgtactc tggctgcaga 1980
ctgaccttgc tcaggtccga gaaggatgga gcagycactg gagtggatgc catctgcacc 2040
caccgtcttg accccaaaag ccctggagtg gacagggagc agctatactg ggagctgagc 2100
cagctgacca atggcatcaa agagctgggc ccctacaccc tggacaggma cagtctctat 2160
gtcaatggtt tcacccattg gatccctgtg cccaccagca gcactcctgg gacctccaca 2220
gtggaccttg ggtcagggac tccatcctcc ctccccagcc ccacaactgc tggccctctc 2280
ctggtgccat tcaccctcaa cttcaccatc accaacctgc agtacgagga ggacatgcat 2340
cacccaggct ccaggaagtt caacaccacg gagcgggtcc tgcagggtct gcttggtccc 2400
atgttcaaga acaccagtgt cggccttctg tactctggct gcagactgac cttgctcagg 2460
cctgagaaga atggggcagc cactggaatg gatgccatct gcagccaccg tcttgacccc 2520
aaaagccctg gactcaacag agagcagctg tactgggagc tgagccagct gacccatggc 2580
atcaaagagc tgggccccta caccctggac aggcacagtc tctatgtcaa tggtttcacc 2640
cattggatcc ctgtgcccac cagcagcact cctgggacct ccacagtgga ccttgggtca 2700
gggactccat cctccctccc cagccccaca actgctggcc ctctcctggt gccgttcacc 2760
ctcaacttca ccatcaccaa cctgragtac gaggaggaca tgcattgccc tggctccagg 2820
aagttcaaca ccacagagag agtcctgcag agtctgcttg gtcccatgtt caagaacacc 2880
agtgttggcc ctctgtactc tggctgcaga ctgaccttgc tcaggtccga gaaggatgga 2940
gcagccactg gagtggatgc catctgcacc caccgtcttg accccaaaag ccctggagtg 3000
gacagggagc agctatactg ggagctgagc cagctgacca atgscatcaa agagctgggt 3060
ccctacaccc tggacagcaa cagtctctat gtcaatggtt tcacccatca gacctctgcg 3120
cccaacacca gcactcctgg gacctccaca gtggaccttg ggwcctcagg gactccatcc 3180
tccctcccca gccctacatc tgctggccct ctcctggtgc cattcaccct caacttcacc 3240
atcaccaacc tgcagtacga ggaggacatg catcacccag gctccaggaa gttcaacacc 3300
acggagcggg tcctgcaggg tctgcttggt cccatgttca agaacaccag tgtcggcctt 3360
ctgtactctg gctgcagact gaccttgctc aggcctgaga agaatggggc agccactgga 3420
atggatgcca tctgcagcca ccgtcttgac cccaaaagcc ctggactcaa cagagagcag 3480
ctgtactggg agctgagcca gctgacccat ggcatcaaag agctgggccc ctacaccctg 3540
gacaggaaca gtctctatgt caatggtttc acccatcgga gctctgtggc ccccaccagc 3600
actcctggga cctccacagt ggaccttggg acctcaggga ctccatcctc cctccccagc 3660
cccacaacag ctgttcctct cctggtgccg ttcaccctca actttaccat caccaatctg 3720
cagtatgggg aggacatgcg tcaccctggc tccaggaagt tcaacaccac agagagggtc 3780
ctgcagggtc tgcttggtcc cttgttcaag aactccagtg tcggccctct gtactctggc 3840
tgcagactga tctctctcag gtctgagaag gatggggcag ccactggagt ggatgccatc 3900
tgcacccacc accttaaccc tcaaagccct ggactggaca gggagcagct gtactggcag 3960
ctgagccaga tgaccaatgg catcaaagag ctgggcccct acaccctgga ccggaacagt 4020
ctctacgtca atggtttcac ccatcggagc tctgggctca ccaccagcac tccttggact 4080
tccacagttg accttggaac ctcagggact ccatcccccg tccccagccc cacaactgct 4140
ggccctctcc tggtgccatt caccctaaac ttcaccatca ccaacctgca gtatgaggag 4200
gacatgcatc gccctggatc taggaagttc aacgccacag agagggtcct gcagggtctg 4260
cttagtccca tattcaagaa ctccagtgtt ggccctctgt actctggctg cagactgacc 4320
tctctcaggc ccgagaagga tggggcagca actggaatgg atgctgtctg cctctaccac 4380
cctaatccca aaagacctgg gctggacaga gagcagctgt actgggagct aagccagctg 4440
acccacaaca tcactgagct gggcccctac agcctggaca ggsacagtct ctatgtcaat 4500
ggtttcaccc atcagaactc tgtgcccacc accagtactc ctgggacctc cacagtgtac 4560
tgggcaacca ctgggactcc atcctccttc cccggccaca cagagcctgg ccctctcctg 4620
ataccattca cwttcaactt taccatcacc aacctgcatt atgaggaaaa catgcaacac 4680
cctggttcca ggaagttcaa caccacggag agggttctgc agggtctgct cacgcccttg 4740
ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcagacct 4800
gagaagcagg aggcagccac tggartggac accatctgta yccaccgcst tgatcccatc 4860
ggacctggac tggacagaga gcrgctatac tgggagctga gccagctgac ccacrgcatc 4920
acagagctgg gmccctacac cctggayagg gacagtctct atgtcaatgg cttcaaccct 4980
tggagctctg tgccaaccac cagcactcct gggacctcca cagtgcacct ggcaacctct 5040
gggactccat cctccctgcc tggccacaca gcccctgtcc ctctcttgat accattcacc 5100
ctcaacttta ccatcaccaa cctgcattat gaagaaaaca tgcaacaccc tggttccagg 5160
aagttcaaca ccacggagag ggttctgcag ggtctgctca agcccttgtt caagagcacc 5220
agcgttggcc ctctgtactc tggctgcaga ctgaccttgc tcagacctga gaaacatggg 5280
gcagccactg gagtggacgc catctgcacc ctccgccttg atcccactgg tcctggactg 5340
gacagagagc ggctatactg ggagctgagc cagctgacca acagcgttac agagctgggc 5400
ccctacaccc tggacaggga cagtctctat gtcaatggct tcacccatcg gagctctgtg 5460
ccaaccacca gtattcctgg gacctctgca gtgcacctgg aaacctctgg gactccagcc 5520
tccctccctg gccacacagc ccctggccct ctcctggtgc cattcaccct caacttcact 5580
atcaccaacc tgcagtatga ggaggacatg cgtcaccctg gttccaggaa gttcaacacc 5640
acggagagag tcctgcaggg tctgctcaag cccttgttca agagcaccag tgttggccct 5700
ctgtactctg gctgcagact gaccttgctc aggcctgaaa aacgtggggc agccaccggc 5760
gtggacacca tctgcactca ccgccttgac cctctaaacc ctggactgga cagagagcag 5820
ctatactggg agctgagcaa actgacctgt ggcatcatcg agctgggccc ctacctcctg 5880
gacagaggca gtctctatgt caatggtttc acccatcgga actttgtgcc catcaccagc 5940
actcctggga cctccacagt acacctagga acctctgaaa ctccatcctc cctacctaga 6000
cccatagtgc ctggccctct cctggtgcca ttcaccctca acttcaccat caccaacttg 6060
cagtatgagg aggccatgcg acaccctggc tccaggaagt tcaataccac ggagagggtc 6120
ctacagggtc tgctcaggcc cttgttcaag aataccagta tcggccctct gtactccagc 6180
tgcagactga ccttgctcag gccagagaag gacaaggcag ccaccagagt ggatgccatc 6240
tgtacccacc accctgaccc tcaaagccct ggactgaaca gagagcagct gtactgggag 6300
ctgagccagc tgacccacgg catcactgag ctgggcccct acaccctgga caggsacagt 6360
ctctatgtcr atggtttcac tcattggagc cccataccaa ccaccagcac tcctgggacc 6420
tccatagtga acctgggaac ctctgggatc ccaccttccc tccctgaaac tacagccacc 6480
ggccctctcc tggtgccatt cacactcaac ttcaccatca ctaacctaca gtatgaggag 6540
aacatgggtc accctggctc caggaagttc aacatcacgg agagtgttct gcagggtctg 6600
ctcaagccct tgttcaagag caccagtgtt ggccctctgt attctggctg cagactgacc 6660
ttgctcaggc ctgagaagga cggagtagcc accagagtgg acgccatctg cacccaccgc 6720
cctgacccca aaatccctgg gctagacaga cagcagctat actgggagct gagccagctg 6780
acccacagca tcactgagct gggaccctac accctggata gggacagtct ctatgtcaat 6840
ggtttcaccc agcggagctc tgtgcccacc accagcactc ctgggacttt cacagtacag 6900
ccggaaacct ctgagactcc atcatccctc cctggcccca cagccactgg ccctgtcctg 6960
ctgccattca ccctcaattt taccatcatt aacctgcagt atgaggagga catgcatcgc 7020
cctggctcca ggaagttcaa caccacggag agggtccttc agggtctgct tatgcccttg 7080
ttcaagaaca ccagtgtcag ctctctgtac tctggttgca gactgacctt gctcaggcct 7140
gagaaggatg gggcagccac cagagtggat gctgtctgca cccatcgtcc tgaccccaaa 7200
agccctggac tggacagaga gcggctgtac tggaagctga gccagctgac ccacggcatc 7260
actgagctgg gcccctacac cctggacagg cacagtctct atgtcaatgg tttcacccat 7320
cagagctcta tgacgaccac cagaactcct gatacctcca caatgcacct ggcaacctcg 7380
agaactccag cctccctgtc tggacctacg accgccagcc ctctcctggt gctattcaca 7440
attaacttca ccatcactaa cctgcggtat gaggagaaca tgcatcaccc tggctctaga 7500
aagtttaaca ccacggagag agtccttcag ggtctgctca ggcctgtgtt caagaacacc 7560
agtgttggcc ctctgtactc tggctgcaga ctgaccttgc tcaggcccaa gaaggatggg 7620
gcagccacca aagtggatgc catctgcacc taccgccctg atcccaaaag ccctggactg 7680
gacagagagc agctatactg ggagctgagc cagctraccc acagcatcac tgagctgggc 7740
ccctacaccc tggacaggga cagtctctat gtcaatggtt tcacacagcg gagctctgtg 7800
cccaccacta gcattcctgg gacccccaca gtggacctgg gaacatctgg gactccagtt 7860
tctaaacctg gtccctcggc tgccagccct ctcctggtgc tattcactct caacttcacc 7920
atcaccaacc tgcggtatga ggagaacatg cagcaccctg gctccaggaa gttcaacacc 7980
acggagaggg tccttcaggg cctgctcagg tccctgttca agagcaccag tgttggccct 8040
ctgtactctg gctgcagact gactttgctc aggcctgaaa aggatgggac agccactgga 8100
gtggatgcca tctgcaccca ccaccctgac cccaaaagcc ctaggctgga cagagagcag 8160
ctgtattggg agctgagcca gctgacccac aatatcactg agctgggccm ctatgccctg 8220
gacaacgaca gcctctttgt caatggtttc actcatcgga gctctgtgtc caccaccagc 8280
actcctggga cccccacagt gtatctggga gcatctaaga ctccagcctc gatatttggc 8340
ccttcagctg ccagccatct cctgatacta ttcaccctca acttcaccat cactaacctg 8400
cggtatgagg agaacatgtg gcctggctcc aggaagttca acactacaga gagggtcctt 8460
cagggcctgc taaggccctt gttcaagaac accagtgttg gccctctgta ctctggctgc 8520
aggctgacct tgctcaggcc agagaaagat ggggaagcca ccggagtgga tgccatctgc 8580
acccaccgcc ctgaccccac aggccctggg ctggacagag agcagctgta tttggagctg 8640
agccagctga cccacagcat cactgagctg ggcccctaca cactggacag ggacagtctc 8700
tatgtcaatg gtttcaccca tcggagctct gtacccacca ccagcaccgg ggtggtcagc 8760
gaggagccat tcacactgaa cttcaccatc aacaacctgc gctacatggc ggacatgggc 8820
caacccggct ccctcaagtt caacatcaca gacaacgtca tgaagcacct gctcagtcct 8880
ttgttccaga ggagcagcct gggtgcacgg tacacaggct gcagggtcat cgcactaagg 8940
tctgtgaaga acggtgctga gacacgggtg gacctcctct gcacctacct gcagcccctc 9000
agcggcccag gtctgcctat caagcaggtg ttccatgagc tgagccagca gacccatggc 9060
atcacccggc tgggccccta ctctctggac aaagacagcc tctaccttaa cggttacaat 9120
gaacctggtc yagatgagcc tcctacaact cccaagccag ccaccacatt cctgcctcct 9180
ctgtcagaag ccacaacagc catggggtac cacctgaaga ccctcacact caacttcacc 9240
atctccaatc tccagtattc accagatatg ggcaagggct cagctacatt caactccacc 9300
gagggggtcc ttcagcacct gctcagaccc ttgttccaga agagcagcat gggccccttc 9360
tacttgggtt gccaactgat ctccctcagg cctgagaagg atggggcagc cactggtgtg 9420
gacaccacct gcacctacca ccctgaccct gtgggccccg ggctggacat acagcagctt 9480
tactgggagc tgagtcagct gacccatggt gtcacccaac tgggcttcta tgtcctggac 9540
agggatagcc tcttcatcaa tggctatgca ccccagaatt tatcaatccg gggcgagtac 9600
cagataaatt tccacattgt caactggaac ctcagtaatc cagaccccac atcctcagag 9660
tacatcaccc tgctgaggga catccaggac aaggtcacca cactctacaa aggcagtcaa 9720
ctacatgaca cattccgctt ctgcctggtc accaacttga cgatggactc cgtgttggtc 9780
actgtcaagg cattgttctc ctccaatttg gaccccagcc tggtggagca agtctttcta 9840
gataagaccc tgaatgcctc attccattgg ctgggctcca cctaccagtt ggtggacatc 9900
catgtgacag aaatggagtc atcagtttat caaccaacaa gcagctccag cacccagcac 9960
ttctaccyga atttcaccat caccaaccta ccatattccc aggacaaagc ccagccaggc 10020
accaccaatt accagaggaa caaaaggaat attgaggatg cgctcaacca actcttccga 10080
aacagcagca tcaagagtta tttttctgac tgtcaagttt caacattcag gtctgtcccc 10140
aacaggcacc acaccggggt ggactccctg tgtaacttct cgccactggc tcggagagta 10200
gacagagttg ccatctatga ggaatttctg cggatgaccc ggaatggtac ccagctgcag 10260
aacttcaccc tggacaggag cagtgtcctt gtggatgggt attytcccaa cagaaatgag 10320
cccttaactg ggaattctga ccttcccttc tgggctgtca tcytcatcgg cttggcagga 10380
ctcctgggac tcatcacatg cctgatctgc ggtgtcctgg tgaccacccg ccggcggaag 10440
aaggaaggag aatacaacgt ccagcaacag tgcccaggct actaccagtc acacctagac 10500
ctggaggatc tgcaatgact ggaacttgcc ggtgcctggg gtgcctttcc cccagccagg 10560
gtccaaagaa gcttggctgg ggcagaaata aaccatattg gtcggacaca aaaaaaaaaa 10620
aa 10622
<210>570
<211>469
<212>DNA
<213> human
<220>
<221>misc_feature
<222>71,92,93,120,124,168,178,218,230,300,
321,350,387,412,414,415,422,423,451
<223> n ═ A, T, C or G
<400>570
gtttcaccca tcggagctct gtgcccacca ccagcactcc tgggacctcc acagtggacc 60
tgggaacctc wgggactcca tcctccctcc cyrgccccac agctgctggc cctctcctgr 120
tgcyattcac cctcaacttc accatcacca acctgcagta tgaggagrac atgcatcrcc 180
ctggctccag gaagttcaac accacggaga gggtcctkca gggtctgcty aggtcccttg 240
ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcaggccy 300
gagaaggatg gggcagccac yggagtggat gccatctgca cccaccgccy tgaccccaaa 360
agccctggac tggacagaga gcagctrtac tgggagctga gccagctgac cmayrgcatc 420
amwgagctgg gcccctacac cctggacagg racagtctct atgtcaatg 469
<210>571
<211>130
<212>PRT
<213> human
<220>
<221>variant
<222>69,107,110
<223> Xaa ═ any amino acid
<400>571
His Pro Gln Leu Glu Gln Gln Pro Gln Ser His Ser Trp Cys His Ser
5 10 15
Pro Ser Thr Ser Thr His His Gln Pro Ala Val Arg Gly Gly His Ala
20 25 30
Ala Pro Gly Ser Arg Lys Phe Asn Ala His Arg Glu Arg Thr Ala Gly
35 40 45
Ser Cys Ser Asn Pro Arg Ser Gly Ile Ala Val Trp Asn Thr Ser Ile
50 55 60
Gln Ala Ala Asp Xaa Pro His Ser Gly Gln Arg Arg Ile Ala Gln Pro
65 70 75 80
Arg Gln Trp Met Pro Ser Ala His Ile Ala Leu Thr Leu Lys Thr Ser
85 90 95
Asp Trp Thr Glu Ser Asp Cys Thr Gly Ser Xaa Ala Ile Xaa Gln Met
100 105 110
Ala Ser Arg Ser Trp Ala Pro Thr Pro Trp Thr Gly Thr Val Ser Met
115 120 125
Ser Met
130
<210>572
<211>130
<212>PRT
<213> human
<220>
<221>variant
<222>1,58,78,92,94
<223> Xaa ═ any amino acid
<400>572
Xaa Ile Pro Ser Ser Asn Ser Ser His Ser Pro Ile His Gly Ala Ile
5 10 15
His Pro Gln Leu Gln Leu Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met
20 25 30
Arg His Leu Val Pro Gly Ser Ser Thr Arg Thr Glu Arg Glu Leu Gln
35 40 45
Gly Arg Ala Gln Thr Leu Asp Gln Glu Xaa Gln Ser Gly Ile Pro Leu
50 55 60
Phe Arg Leu Gln Thr Ser Leu Thr Gln Ala Arg Glu Gly Xaa Leu Ser
65 70 75 80
His Gly Ser Gly Cys His Leu His Thr Ser Pro Xaa Pro Xaa Arg Pro
85 90 95
Arg Thr Gly Gln Arg Ala Thr Val Leu Gly Ala Glu Gln Ser Asp Lys
100 105 110
Trp His Pro Gly Ala Gly Pro Leu His Pro Gly Pro Glu Gln Ser Leu
115 120 125
Cys Gln
130
<210>573
<211>130
<212>PRT
<213> human
<220>
<221>variant
<222>1,54
<223> Xaa ═ any amino acid
<400>573
Xaa Ser Pro Ala Arg Thr Ala Ala Thr Val Pro Phe Met Val Pro Phe
5 10 15
Thr Leu Asn Phe Asn Ser Ser Pro Thr Cys Ser Thr Arg Arg Thr Cys
20 25 30
Gly Thr Trp Phe Gln Glu Val Gln Arg Ala Gln Arg Glu Asn Cys Arg
35 40 45
Val Val Leu Lys Pro Xaa Ile Arg Asn Ser Ser Leu Glu Tyr Leu Tyr
50 55 60
Ser Gly Cys Arg Leu Ala Ser Leu Arg Pro Glu Lys Asp Ser Ser Ala
65 70 75 80
Thr Ala Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Glu Asp Leu
85 90 95
Gly Leu Asp Arg Glu Arg Leu Tyr Trp Glu Leu Ser Asn Leu Thr Asn
100 105 110
Gly Ile Gln Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr
115 120 125
Val Asn
130
<210>574
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>101
<223> Xaa ═ any amino acid
<400>574
Gly Phe Thr His Arg Ser Ser Met Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Val Gly Thr Ser Gly Thr Pro Ser Ser Ser Pro Ser
20 25 30
Pro Thr Thr Ala Gly Pro Leu Leu Met Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met Arg Arg Thr Gly Ser Arg
50 55 60
Lys Phe Asn Thr Met Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Xaa Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Lys Leu Thr Asn Asp Ile Glu Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
145 150 155
<210>575
<211>158
<212>PRT
<213> human
<220>
<221>variant
<222>103
<223> Xaa ═ any amino acid
<400>575
Gly Phe Thr His Gln Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Arg Thr Ser Val Thr Pro Ser Ser Leu Ser Ser
20 25 30
Pro Thr Ile Met Ala Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn
35 40 45
Phe Thr Ile Thr Asn Leu Gln Tyr Gly Glu Asp Met Gly His Pro Gly
50 55 60
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly
65 70 75 80
Pro Ile Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg
85 90 95
Leu Thr Ser Leu Arg Ser Xaa Lys Asp Gly Ala Ala Thr Gly Val Asp
100 105 110
Ala Ile Cys Ile His His Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg
115 120 125
Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile Lys Glu
130 135 140
Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
145 150 155
<210>576
<211>122
<212>PRT
<213> human
<400>576
Ala Ala Gly Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr
5 10 15
Asn Leu Lys Tyr Glu Glu Asp Met His Arg Pro Gly Ser Arg Lys Phe
20 25 30
Asn Thr Thr Glu Arg Val Leu Gln Thr Leu Arg Gly Pro Met Phe Lys
35 40 45
Asn Thr Ser Gly Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu
50 55 60
Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr
65 70 75 80
His Arg Leu Asp Pro Lys Ser Pro Gly Val Asp Arg Glu Gln Leu Tyr
85 90 95
Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile Lys Glu Leu Gly Pro Tyr
100 105 110
Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
115 120
<210>577
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>11,106,151
<223> Xaa ═ any amino acid
<400>577
Gly Phe Thr His Arg Thr Ser Val Pro Thr Xaa Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Phe Ser Leu Pro Ser
20 25 30
Pro Ala Thr Ala Gly Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Lys Tyr Glu Glu Asp Met His Arg Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Thr Leu Leu Gly Pro Met
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Ser Glu Lys Asp Gly Ala Xaa Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Val Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile Lys Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Xaa Ser Leu Tyr Val Asn
145 150 155
<210>578
<211>155
<212>PRT
<213> human
<400>578
Gly Phe Thr His Trp Ile Pro Val Pro Thr Ser Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro
20 25 30
Thr Thr Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile
35 40 45
Thr Asn Leu Gln Tyr Glu Glu Asp Met His His Pro Gly Ser Arg Lys
50 55 60
Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Met Phe
65 70 75 80
Lys Asn Thr Ser Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr Leu
85 90 95
Leu Arg Pro Glu Lys Asn Gly Ala Ala Thr Gly Met Asp Ala Ile Cys
100 105 110
Ser His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu
115 120 125
Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Lys Glu Leu Gly Pro
130 135 140
Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn
145 150 155
<210>579
<211>155
<212>PRT
<213> human
<220>
<221>variant
<222>52,138
<223> Xaa ═ any amino acid
<400>579
Gly Phe Thr His Trp Ile Pro Val Pro Thr Ser Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro
20 25 30
Thr Thr Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile
35 40 45
Thr Asn Leu Xaa Tyr Glu Glu Asp Met His Cys Pro Gly Ser Arg Lys
50 55 60
Phe Asn Thr Thr Glu Arg Val Leu Gln Ser Leu Leu Gly Pro Met Phe
65 70 75 80
Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu
85 90 95
Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys
100 105 110
Thr His Arg Leu Asp Pro Lys Ser Pro Gly Val Asp Arg Glu Gln Leu
115 120 125
Tyr Trp Glu Leu Ser Gln Leu Thr Asn Xaa Ile Lys Glu Leu Gly Pro
130 135 140
Tyr Thr Leu Asp Ser Asn Ser Leu Tyr Val Asn
145 150 155
<210>580
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>23
<223> Xaa ═ any amino acid
<400>580
Gly Phe Thr His Gln Thr Ser Ala Pro Asn Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Xaa Ser Gly Thr Pro Ser Ser Leu Pro Ser
20 25 30
Pro Thr Ser Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Met
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asn Gly Ala Ala Thr Gly Met Asp Ala Ile
100 105 110
Cys Ser His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Lys Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
145 150 155
<210>581
<211>156
<212>PRT
<213> human
<400>581
Gly Phe Thr His Arg Ser Ser Val Ala Pro Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Ser Leu Pro Ser
20 25 30
Pro Thr Thr Ala Val Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Gly Glu Asp Met Arg His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Leu
65 70 75 80
Phe Lys Asn Ser Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Ile
85 90 95
Ser Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr His His Leu Asn Pro Gln Ser Pro Gly Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Gln Leu Ser Gln Met Thr Asn Gly Ile Lys Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
145 150 155
<210>582
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>151
<223> Xaa ═ any amino acid
<400>582
Gly Phe Thr His Arg Ser Ser Gly Leu Thr Thr Ser Thr Pro Trp Thr
5 10 15
Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Pro Val Pro Ser
20 25 30
Pro Thr Thr Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His Arg Pro Gly Ser Arg
50 55 60
Lys Phe Asn Ala Thr Glu Arg Val Leu Gln Gly Leu Leu Ser Pro Ile
65 70 75 80
Phe Lys Asn Ser Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Met Asp Ala Val
100 105 110
Cys Leu Tyr His Pro Asn Pro Lys Arg Pro Gly Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Ser Leu Asp Arg Xaa Ser Leu Tyr Val Asn
145 150 155
<210>583
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>109,114,117,128,139
<223> Xaa ═ any amino acid
<400>583
Gly Phe Thr His Gln Asn Ser Val Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Tyr Trp Ala Thr Thr Gly Thr Pro Ser Ser Phe Pro Gly
20 25 30
His Thr Glu Pro Gly Pro Leu Leu Ile Pro Phe Thr Phe Asn Phe Thr
35 40 45
Ile Thr Asn Leu His Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Thr Pro Leu
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Gln Glu Ala Ala Thr Gly Xaa Asp Thr Ile
100 105 110
Cys Xaa His Arg Xaa Asp Pro Ile Gly Pro Gly Leu Asp Arg Glu Xaa
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Xaa Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
<210>584
<211>156
<212>PRT
<213> human
<400>584
Gly Phe Asn Pro Trp Ser Ser Val Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val His Leu Ala Thr Ser Gly Thr Pro Ser Ser Leu Pro Gly
20 25 30
His Thr Ala Pro Val Pro Leu Leu Ile Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu His Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Lys Pro Leu
65 70 75 80
Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys His Gly Ala Ala Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr Leu Arg Leu Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Arg
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Ser Val Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
<210>585
<211>156
<212>PRT
<213> human
<400>585
Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr
5 10 15
Ser Ala Val His Leu Glu Thr Ser Gly Thr Pro Ala Ser Leu Pro Gly
20 25 30
His Thr Ala Pro Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met Arg His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Lys Pro Leu
65 70 75 80
Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Arg Gly Ala Ala Thr Gly Val Asp Thr Ile
100 105 110
Cys Thr His Arg Leu Asp Pro Leu Asn Pro Gly Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Lys Leu Thr Cys Gly Ile Ile Glu Leu Gly
130 135 140
Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn
145 150 155
<210>586
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>151,156
<223> Xaa ═ any amino acid
<400>586
Gly Phe Thr His Arg Asn Phe Val Pro Ile Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val His Leu Gly Thr Ser Glu Thr Pro Ser Ser Leu Pro Arg
20 25 30
Pro Ile Val Pro Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Ala Met Arg His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu
65 70 75 80
Phe Lys Asn Thr Ser Ile Gly Pro Leu Tyr Ser Ser Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asp Lys Ala Ala Thr Arg Val Asp Ala Ile
100 105 110
Cys Thr His His Pro Asp Pro Gln Ser Pro Gly Leu Asn Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Xaa Ser Leu Tyr Val Xaa
145 150 155
<210>587
<211>156
<212>PRT
<213> human
<400>587
Gly Phe Thr His Trp Ser Pro Ile Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Ile Val Asn Leu Gly Thr Ser Gly Ile Pro Pro Ser Leu Pro Glu
20 25 30
Thr Thr Ala Thr Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asn Met Gly His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Ile Thr Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu
65 70 75 80
Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asp Gly Val Ala Thr Arg Val Asp Ala Ile
100 105 110
Cys Thr His Arg Pro Asp Pro Lys Ile Pro Gly Leu Asp Arg Gln Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
<210>588
<211>156
<212>PRT
<213> human
<400>588
Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Phe Thr Val Gln Pro Glu Thr Ser Glu Thr Pro Ser Ser Leu Pro Gly
20 25 30
Pro Thr Ala Thr Gly Pro Val Leu Leu Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Ile Asn Leu Gln Tyr Glu Glu Asp Met His Arg Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Met Pro Leu
65 70 75 80
Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val Asp Ala Val
100 105 110
Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Arg
115 120 125
Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn
145 150 155
<210>589
<211>156
<212>PRT
<213> human
<400>589
Gly Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr
5 10 15
Ser Thr Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly
20 25 30
Pro Thr Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr
35 40 45
Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile
100 105 110
Cys Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
<210>590
<211>156
<212>PRT
<213> human
<220>
<221>variant
<222>145
<223> Xaa ═ any amino acid
<400>590
Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr
5 10 15
Pro Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Val Ser Lys Pro Gly
20 25 30
Pro Ser Ala Ala Ser Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Gln His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Ser Leu
65 70 75 80
Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asp Gly Thr Ala Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr His His Pro Asp Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Asn Ile Thr Glu Leu Gly
130 135 140
Xaa Tyr Ala Leu Asp Asn Asp Ser Leu Phe Val Asn
145 150 155
<210>591
<211>155
<212>PRT
<213> human
<400>591
Gly Phe Thr His Arg Ser Ser Val Ser Thr Thr Ser Thr Pro Gly Thr
5 10 15
Pro Thr Val Tyr Leu Gly Ala Ser Lys Thr Pro Ala Ser Ile Phe Gly
20 25 30
Pro Ser Ala Ala Ser His Leu Leu Ile Leu Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Trp Pro Gly Ser Arg Lys
50 55 60
Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe
65 70 75 80
Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu
85 90 95
Leu Arg Pro Glu Lys Asp Gly Glu Ala Thr Gly Val Asp Ala Ile Cys
100 105 110
Thr His Arg Pro Asp Pro Thr Gly Pro Gly Leu Asp Arg Glu Gln Leu
115 120 125
Tyr Leu Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro
130 135 140
Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
<210>592
<211>134
<212>PRT
<213> human
<400>592
Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly Val Val
5 10 15
Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu Arg Tyr
20 25 30
Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile Thr Asp
35 40 45
Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser Ser Leu
50 55 60
Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser Val Lys
65 70 75 80
Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu Gln Pro
85 90 95
Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu Leu Ser
100 105 110
Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu Asp Lys
115 120 125
Asp Ser Leu Tyr Leu Asn
130
<210>593
<211>150
<212>PRT
<213> human
<220>
<221>variant
<222>7
<223> Xaa ═ any amino acid
<400>593
Gly Tyr Asn Glu Pro Gly Xaa Asp Glu Pro Pro Thr Thr Pro Lys Pro
5 10 15
Ala Thr Thr Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly
20 25 30
Tyr His Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn Leu Gln
35 40 45
Tyr Ser Pro Asp Met Gly Lys Gly Ser Ala Thr Phe Asn Ser Thr Glu
50 55 60
Gly Val Leu Gln His Leu Leu Arg Pro Leu Phe Gln Lys Ser Ser Met
65 70 75 80
Gly Pro Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro Glu Lys
85 90 95
Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr His Pro Asp
100 105 110
Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu Tyr Trp Glu Leu Ser
115 120 125
Gln Leu Thr His Gly Val Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg
130 135 140
Asp Ser Leu Phe Ile Asn
145 150
<210>594
<211>318
<212>PRT
<213> human
<220>
<221>variant
<222>136,248,268
<223> Xaa ═ any amino acid
<400>594
Gly Tyr Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn
5 10 15
Phe His Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser
20 25 30
Glu Tyr Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu
35 40 45
Tyr Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr
50 55 60
Asn Leu Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser
65 70 75 80
Ser Asn Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr
85 90 95
Leu Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp
100 105 110
Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser
115 120 125
Ser Ser Thr Gln His Phe Tyr Xaa Asn Phe Thr Ile Thr Asn Leu Pro
130 135 140
Tyr Ser Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn
145 150 155 160
Lys Arg Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser
165 170 175
Ile Lys Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val
180 185 190
Pro Asn Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro
195 200 205
Leu Ala Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg
210 215 220
Met Thr Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser
225 230 235 240
Ser Val Leu Val Asp Gly Tyr Xaa Pro Asn Arg Asn Glu Pro Leu Thr
245 250 255
Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Xaa Ile Gly Leu Ala
260 265 270
Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr
275 280 285
Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys
290 295 300
Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
305 310 315
<210>595
<211>3451
<212>PRT
<213> human
<220>
<221>VARIANT
<222>177,335,523,618,663,875,961,1001,1441,1555,1560,
1563,1574,1585,2065,2070,2683,2990,3269,3381,3401
<223> Xaa ═ any amino acid
<400>595
Ile Arg Asn Ser Ser Leu Glu Tyr Leu Tyr Ser Gly Cys Arg Leu Ala
1 5 10 15
Ser Leu Arg Pro Glu Lys Asp Ser Ser Ala Thr Ala Val Asp Ala Ile
20 25 30
Cys Thr His Arg Pro Asp Pro Glu Asp Leu Gly Leu Asp Arg Glu Arg
35 40 45
Leu Tyr Trp Glu Leu Ser Asn Leu Thr Asn Gly Ile Gln Glu Leu Gly
50 55 60
Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His
65 70 75 80
Arg Ser Ser Met Pro Thr Thr Ser Thr Pro Gly Thr Ser Thr Val Asp
85 90 95
Val Gly Thr Ser Gly Thr Pro Ser Ser Ser Pro Ser Pro Thr Thr Ala
100 105 110
Gly Pro Leu Leu Met Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu
115 120 125
Gln Tyr Glu Glu Asp Met Arg Arg Thr Gly Ser Arg Lys Phe Asn Thr
130 135 140
Met Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys Asn Thr
145 150 155 160
Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro
165 170 175
Xaa Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr His Arg
180 185 190
Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr Trp Glu
195 200 205
Leu Ser Lys Leu Thr Asn Asp Ile Glu Glu Leu Gly Pro Tyr Thr Leu
210 215 220
Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His Gln Ser Ser Val
225 230 235 240
Ser Thr Thr Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Arg Thr Ser
245 250 255
Val Thr Pro Ser Ser Leu Ser Ser Pro Thr Ile Met Ala Ala Gly Pro
260 265 270
Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr
275 280 285
Gly Glu Asp Met Gly His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu
290 295 300
Arg Val Leu Gln Gly Leu Leu Gly Pro Ile Phe Lys Asn Thr Ser Val
305 310 315 320
Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Ser Leu Arg Ser Xaa Lys
325 330 335
Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Ile His His Leu Asp
340 345 350
Pro Lys Ser Pro Gly Leu Asn Arg Glu Arg Leu Tyr Trp Glu Leu Ser
355 360 365
Gln Leu Thr Asn Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg
370 375 380
Asn Ser Leu Tyr Val Asn Ala Ala Gly Pro Leu Leu Val Leu Phe Thr
385 390 395 400
Leu Asn Phe Thr Ile Thr Asn Leu Lys Tyr Glu Glu Asp Met His Arg
405 410 415
Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Thr Leu
420 425 430
Arg Gly Pro Met Phe Lys Asn Thr Ser Gly Gly Leu Leu Tyr Ser Gly
435 440 445
Cys Arg Leu Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly
450 455 460
Val Asp Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Val
465 470 475 480
Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile
485 490 495
Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn
500 505 510
Gly Phe Thr His Arg Thr Ser Val Pro Thr Xaa Ser Thr Pro Gly Thr
515 520 525
Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Phe Ser Leu Pro Ser
530 535 540
Pro Ala Thr Ala Gly Pro Leu Leu Val Leu Phe Thr Leu Asn Phe Thr
545 550 555 560
Ile Thr Asn Leu Lys Tyr Glu Glu Asp Met His Arg Pro Gly Ser Arg
565 570 575
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Thr Leu Leu Gly Pro Met
580 585 590
Phe Lys Asn Thr Ser Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr
595 600 605
Leu Leu Arg Ser Glu Lys Asp Gly Ala Xaa Thr Gly Val Asp Ala Ile
610 615 620
Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Val Asp Arg Glu Gln
625 630 635 640
Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Gly Ile Lys Glu Leu Gly
645 650 655
Pro Tyr Thr Leu Asp Arg Xaa Ser Leu Tyr Val Asn Gly Phe Thr His
660 665 670
Trp Ile Pro Val Pro Thr Ser Ser Thr Pro Gly Thr Ser Thr Val Asp
675 680 685
Leu Gly Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro Thr Thr Ala Gly
690 695 700
Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln
705 710 715 720
Tyr Glu Glu Asp Met His His Pro Gly Ser Arg Lys Phe Asn Thr Thr
725 730 735
Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Met Phe Lys Asn Thr Ser
740 745 750
Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
755 760 765
Lys Asn Gly Ala Ala Thr Gly Met Asp Ala Ile Cys Ser His Arg Leu
770 775 780
Asp Pro Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr Trp Glu Leu
785 790 795 800
Ser Gln Leu Thr His Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp
805 810 815
Arg His Ser Leu Tyr Val Asn Gly Phe Thr His Trp Ile Pro Val Pro
820 825 830
Thr Ser Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Gly Ser Gly Thr
835 840 845
Pro Ser Ser Leu Pro Ser Pro Thr Thr Ala Gly Pro Leu Leu Val Pro
850 855 860
Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Xaa Tyr Glu Glu Asp Met
865 870 875 880
His Cys Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln
885 890 895
Ser Leu Leu Gly Pro Met Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr
900 905 910
Ser Gly Cys Arg Leu Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala Ala
915 920 925
Thr Gly Val Asp Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser Pro
930 935 940
Gly Val Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn
945 950 955 960
Xaa Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Ser Asn Ser Leu Tyr
965 970 975
Val Asn Gly Phe Thr His Gln Thr Ser Ala Pro Asn Thr Ser Thr Pro
980 985 990
Gly Thr Ser Thr Val Asp Leu Gly Xaa Ser Gly Thr Pro Ser Ser Leu
995 1000 1005
Pro Ser Pro Thr Ser Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn
1010 1015 1020
Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His His Pro Gly
1025 1030 1035 1040
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly
1045 1050 1055
Pro Met Phe Lys Asn Thr Ser Val Gly Leu Leu Tyr Ser Gly Cys Arg
1060 1065 1070
Leu Thr Leu Leu Arg Pro Glu Lys Asn Gly Ala Ala Thr Gly Met Asp
1075 1080 1085
Ala Ile Cys Ser His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asn Arg
1090 1095 1100
Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Lys Glu
1105 1110 1115 1120
Leu Gly Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe
1125 1130 1135
Thr His Arg Ser Ser Val Ala Pro Thr Ser Thr Pro Gly Thr Ser Thr
1140 1145 1150
Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro Thr
1155 1160 1165
Thr Ala Val Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr
1170 1175 1180
Asn Leu Gln Tyr Gly Glu Asp Met Arg His Pro Gly Ser Arg Lys Phe
1185 1190 1195 1200
Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Leu Phe Lys
1205 1210 1215
Asn Ser Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Ile Ser Leu
1220 1225 1230
Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys Thr
1235 1240 1245
His His Leu Asn Pro Gln Ser Pro Gly Leu Asp Arg Glu Gln Leu Tyr
1250 1255 1260
Trp Gln Leu Ser Gln Met Thr Asn Gly Ile Lys Glu Leu Gly Pro Tyr
1265 1270 1275 1280
Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser
1285 1290 1295
Ser Gly Leu Thr Thr Ser Thr Pro Trp Thr Ser Thr Val Asp Leu Gly
1300 1305 1310
Thr Ser Gly Thr Pro Ser Pro Val Pro Ser Pro Thr Thr Ala Gly Pro
1315 1320 1325
Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr
1330 1335 1340
Glu Glu Asp Met His Arg Pro Gly Ser Arg Lys Phe Asn Ala Thr Glu
1345 1350 1355 1360
Arg Val Leu Gln Gly Leu Leu Ser Pro Ile Phe Lys Asn Ser Ser Val
1365 1370 1375
Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Ser Leu Arg Pro Glu Lys
1380 1385 1390
Asp Gly Ala Ala Thr Gly Met Asp Ala Val Cys Leu Tyr His Pro Asn
1395 1400 1405
Pro Lys Arg Pro Gly Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser
1410 1415 1420
Gln Leu Thr His Asn Ile Thr Glu Leu Gly Pro Tyr Ser Leu Asp Arg
1425 1430 1435 1440
Xaa Ser Leu Tyr Val Asn Gly Phe Thr His Gln Asn Ser Val Pro Thr
1445 1450 1455
Thr Ser Thr Pro Gly Thr Ser Thr Val Tyr Trp Ala Thr Thr Gly Thr
1460 1465 1470
Pro Ser Ser Phe Pro Gly His Thr Glu Pro Gly Pro Leu Leu Ile Pro
1475 1480 1485
Phe Thr Phe Asn Phe Thr Ile Thr Asn Leu His Tyr Glu Glu Asn Met
1490 1495 1500
Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln
1505 1510 1515 1520
Gly Leu Leu Thr Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr
1525 1530 1535
Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Gln Glu Ala Ala
1540 1545 1550
Thr Gly Xaa Asp Thr Ile Cys Xaa His Arg Xaa Asp Pro Ile Gly Pro
1555 1560 1565
Gly Leu Asp Arg Glu Xaa Leu Tyr Trp Glu Leu Ser Gln Leu Thr His
1570 1575 1580
Xaa Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr
1585 1590 1595 1600
Val Asn Gly Phe Asn Pro Trp Ser Ser Val Pro Thr Thr Ser Thr Pro
1605 1610 1615
Gly Thr Ser Thr Val His Leu Ala Thr Ser Gly Thr Pro Ser Ser Leu
1620 1625 1630
Pro Gly His Thr Ala Pro Val Pro Leu Leu Ile Pro Phe Thr Leu Asn
1635 1640 1645
Phe Thr Ile Thr Asn Leu His Tyr Glu Glu Asn Met Gln His Pro Gly
1650 1655 1660
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Lys
1665 1670 1675 1680
Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg
1685 1690 1695
Leu Thr Leu Leu Arg Pro Glu Lys His Gly Ala Ala Thr Gly Val Asp
1700 1705 1710
Ala Ile Cys Thr Leu Arg Leu Asp Pro Thr Gly Pro Gly Leu Asp Arg
1715 1720 1725
Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu Thr Asn Ser Val Thr Glu
1730 1735 1740
Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe
1745 1750 1755 1760
Thr His Arg Ser Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Ser Ala
1765 1770 1775
Val His Leu Glu Thr Ser Gly Thr Pro Ala Ser Leu Pro Gly His Thr
1780 1785 1790
Ala Pro Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr
1795 1800 1805
Asn Leu Gln Tyr Glu Glu Asp Met Arg His Pro Gly Ser Arg Lys Phe
1810 1815 1820
Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys
1825 1830 1835 1840
Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu
1845 1850 1855
Arg Pro Glu Lys Arg Gly Ala Ala Thr Gly Val Asp Thr Ile Cys Thr
1860 1865 1870
His Arg Leu Asp Pro Leu Asn Pro Gly Leu Asp Arg Glu Gln Leu Tyr
1875 1880 1885
Trp Glu Leu Ser Lys Leu Thr Cys Gly Ile Ile Glu Leu Gly Pro Tyr
1890 1895 1900
Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn Gly Phe Thr His Arg Asn
1905 1910 1915 1920
Phe Val Pro Ile Thr Ser Thr Pro Gly Thr Ser Thr Val His Leu Gly
1925 1930 1935
Thr Ser Glu Thr Pro Ser Ser Leu Pro Arg Pro Ile Val Pro Gly Pro
1940 1945 1950
Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr
1955 1960 1965
Glu Glu Ala Met Arg His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu
1970 1975 1980
Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Ile
1985 1990 1995 2000
Gly Pro Leu Tyr Ser Ser Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys
2005 2010 2015
Asp Lys Ala Ala Thr Arg Val Asp Ala Ile Cys Thr His His Pro Asp
2020 2025 2030
Pro Gln Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr Trp Glu Leu Ser
2035 2040 2045
Gln Leu Thr His Gly Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg
2050 2055 2060
Xaa Ser Leu Tyr Val Xaa Gly Phe Thr His Trp Ser Pro Ile Pro Thr
2065 2070 2075 2080
Thr Ser Thr Pro Gly Thr Ser Ile Val Asn Leu Gly Thr Ser Gly Ile
2085 2090 2095
Pro Pro Ser Leu Pro Glu Thr Thr Ala Thr Gly Pro Leu Leu Val Pro
2100 2105 2110
Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asn Met
2115 2120 2125
Gly His Pro Gly Ser Arg Lys Phe Asn Ile Thr Glu Ser Val Leu Gln
2130 2135 2140
Gly Leu Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr
2145 2150 2155 2160
Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Val Ala
2165 2170 2175
Thr Arg Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Lys Ile Pro
2180 2185 2190
Gly Leu Asp Arg Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His
2195 2200 2205
Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr
2210 2215 2220
Val Asn Gly Phe Thr Gln Arg Ser Ser Val Pro Thr Thr Ser Thr Pro
2225 2230 2235 2240
Gly Thr Phe Thr Val Gln Pro Glu Thr Ser Glu Thr Pro Ser Ser Leu
2245 2250 2255
Pro Gly Pro Thr Ala Thr Gly Pro Val Leu Leu Pro Phe Thr Leu Asn
2260 2265 2270
Phe Thr Ile Ile Asn Leu Gln Tyr Glu Glu Asp Met His Arg Pro Gly
2275 2280 2285
Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Met
2290 2295 2300
Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys Arg
2305 2310 2315 2320
Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val Asp
2325 2330 2335
Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg
2340 2345 2350
Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr Glu
2355 2360 2365
Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly Phe
2370 2375 2380
Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser Thr
2385 2390 2395 2400
Met His Leu Ala Thr Ser Arg Thr Pro Ala Ser Leu Ser Gly Pro Thr
2405 2410 2415
Thr Ala Ser Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile Thr
2420 2425 2430
Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys Phe
2435 2440 2445
Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Val Phe Lys
2450 2455 2460
Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu
2465 2470 2475 2480
Arg Pro Lys Lys Asp Gly Ala Ala Thr Lys Val Asp Ala Ile Cys Thr
2485 2490 2495
Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln Leu Tyr
2500 2505 2510
Trp Glu Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr
2515 2520 2525
Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg Ser
2530 2535 2540
Ser Val Pro Thr Thr Ser Ile Pro Gly Thr Pro Thr Val Asp Leu Gly
2545 2550 2555 2560
Thr Ser Gly Thr Pro Val Ser Lys Pro Gly Pro Ser Ala Ala Ser Pro
2565 2570 2575
Leu Leu Val Leu Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr
2580 2585 2590
Glu Glu Asn Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu
2595 2600 2605
Arg Val Leu Gln Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser Val
2610 2615 2620
Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys
2625 2630 2635 2640
Asp Gly Thr Ala Thr Gly Val Asp Ala Ile Cys Thr His His Pro Asp
2645 2650 2655
Pro Lys Ser Pro Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser
2660 2665 2670
Gln Leu Thr His Asn Ile Thr Glu Leu Gly Xaa Tyr Ala Leu Asp Asn
2675 2680 2685
Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser Val Ser Thr
2690 2695 2700
Thr Ser Thr Pro Gly Thr Pro Thr Val Tyr Leu Gly Ala Ser Lys Thr
2705 2710 2715 2720
Pro Ala Ser Ile Phe Gly Pro Ser Ala Ala Ser His Leu Leu Ile Leu
2725 2730 2735
Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met
2740 2745 2750
Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly
2755 2760 2765
Leu Leu Arg Pro Leu Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser
2770 2775 2780
Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Glu Ala Thr
2785 2790 2795 2800
Gly Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Thr Gly Pro Gly
2805 2810 2815
Leu Asp Arg Glu Gln Leu Tyr Leu Glu Leu Ser Gln Leu Thr His Ser
2820 2825 2830
Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val
2835 2840 2845
Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly Val
2850 2855 2860
Val Ser Glu Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn Leu Arg
2865 2870 2875 2880
Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile Thr
2885 2890 2895
Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser Ser
2900 2905 2910
Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser Val
2915 2920 2925
Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu Gln
2930 2935 2940
Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu Leu
2945 2950 2955 2960
Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu Asp
2965 2970 2975
Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Xaa Asp Glu
2980 2985 2990
Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro Leu Ser
2995 3000 3005
Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr Leu Asn
3010 3015 3020
Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly Ser
3025 3030 3035 3040
Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg Pro
3045 3050 3055
Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln Leu
3060 3065 3070
Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Thr
3075 3080 3085
Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln
3090 3095 3100
Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln Leu
3105 3110 3115 3120
Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr Ala
3125 3130 3135
Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His Ile
3140 3145 3150
Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr Ile
3155 3160 3165
Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys Gly
3170 3175 3180
Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr Asn Leu Thr
3185 3190 3195 3200
Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser Ser Asn Leu
3205 3210 3215
Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn Ala
3220 3225 3230
Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His Val
3235 3240 3245
Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser Thr
3250 3255 3260
Gln His Phe Tyr Xaa Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser Gln
3265 3270 3275 3280
Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg Asn
3285 3290 3295
Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys Ser
3300 3305 3310
Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn Arg
3315 3320 3325
His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg
3330 3335 3340
Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr Arg
3345 3350 3355 3360
Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val Leu
3365 3370 3375
Val Asp Gly Tyr Xaa Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser
3380 3385 3390
Asp Leu Pro Phe Trp Ala Val Ile Xaa Ile Gly Leu Ala Gly Leu Leu
3395 3400 3405
Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg Arg
3410 3415 3420
Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly Tyr
3425 3430 3435 3440
Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
3445 3450
<210>596
<211>156
<212>PRT
<213> human
<400>596
Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Thr Pro Gly Thr
5 10 15
Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Ser Leu Pro Ser
20 25 30
Pro Thr Ala Ala Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr
35 40 45
Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met His His Pro Gly Ser Arg
50 55 60
Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Gly Pro Leu
65 70 75 80
Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
85 90 95
Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile
100 105 110
Cys Thr His Arg Leu Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Gln
115 120 125
Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly
130 135 140
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn
145 150 155
Claims (35)
1. Having the structure Xn-O772P polypeptide of Y, wherein X comprises a sequence identical to SEQ ID NO: 596 to seq id no 772P; y comprises a nucleotide sequence similar to SEQ ID NO: 594 to O772P constant region sequence, which is at least 80% identical; n is an integer from 1 to 35; wherein each X present in the polypeptide is different.
2. The polypeptide of claim 1, wherein X comprises a sequence selected from SEQ ID NO: 574-593.
3. The polypeptide of claim 1, wherein Y comprises the amino acid sequence of SEQ ID NO: 594 to seq id no.
4. The polypeptide of claim 1, wherein n is an integer from 15 to 25.
5. The polypeptide of claim 1, wherein n is 20.
6. The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 595.
7. the polypeptide of claim 1, wherein the polypeptide is overexpressed in ovarian cancer cells compared to normal tissue.
8. Having the structure Xn-O772P polypeptide of Y, wherein X comprises an amino acid sequence selected from SEQ ID NOs: 574-593 and O772P repeat sequence; y comprises a sequence identical to SEQ ID NO: 594 to O772P constant region sequence, which is at least 90% identical; n is an integer from 15 to 25; wherein each X present in the polypeptide is different.
9. The polypeptide of claim 8, wherein n is 20.
10. The polypeptide of claim 8, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 595.
11. the polypeptide of claim 8, wherein the polypeptide is overexpressed in ovarian cancer cells compared to normal tissue.
12. Having the structure Xn-O772P polypeptide of Y, wherein n is 20 and X comprises the following O772P repeat sequence: SEQ ID NO: 574-SEQ ID NO: 575-SEQ ID NO: 576-SEQ ID NO: 577-SEQ ID NO: 578-SEQ ID NO: 579-SEQ ID NO: 580-SEQ ID NO: 581-SEQ ID NO: 582-SEQ ID NO: 583-SEQ ID NO: 584-SEQ ID NO: 585-SEQ ID NO: 586-SEQ ID NO: 587-SEQ ID NO: 588-SEQ ID NO: 589-SEQ ID NO: 590-SEQ ID NO: 591-SEQ ID NO: 592-SEQ ID NO: 593; y comprises SEQ ID NO: 594 to seq id no.
13. The polypeptide of claim 12, wherein the polypeptide comprises SEQ ID NO: 595.
14. the polypeptide of claim 12, wherein the polypeptide is overexpressed in ovarian cancer cells compared to normal tissue.
15. Having the structure Xn-O772P polynucleotide of Y, wherein X comprises a sequence selected from SEQ id nos: O772P repeated sequence of any one of S12-540, 542-546 and 548-567; y comprises a sequence identical to SEQ ID NO: 568O 772P constant region sequences at least 95% identical; n is an integer from 1 to 35; wherein each X present in the polypeptide is different.
16. The polynucleotide of claim 15, wherein the polynucleotide comprises the sequence of SEQ id no: 569.
17. the polynucleotide of claim 15, wherein n is 15 to 25.
18. The polynucleotide of claim 15, wherein n is 20.
19. The polynucleotide of claim 15, wherein the polynucleotide is overexpressed in ovarian cancer cells compared to normal tissue.
20. An isolated polynucleotide comprising a sequence selected from the group consisting of:
(a) SEQ ID NOs: 464-477 and 512-569;
(b) SEQ ID NOs: 464-477 and 512-569;
(c) consists of SEQ ID NOs: 464-477 and 512-569 by at least 20 consecutive residues of the sequence provided;
(d) and SEQ ID NOs: 464-477 and 512-569 under highly stringent conditions;
(e) and SEQ ID NOs: sequences having at least 75% identity to the sequences provided in 464-477 and 512-569;
(f) and SEQ ID NOs: 464-477 and 512-569, wherein the sequences have at least 90% identity; and
(g) SEQ ID NOs: degenerate variants of the sequences provided in 464-477 and 512-569.
21. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a sequence encoded by the polynucleotide of claim 20; and
(b) a sequence having at least 80% identity to a sequence encoded by the polynucleotide of claim 20; and
(c) a sequence having at least 90% identity to a sequence encoded by the polynucleotide of claim 20.
22. An expression vector comprising the polynucleotide of claim 20 operably linked to an expression control sequence.
23. A host cell transformed or transfected with the expression vector of claim 22.
24. An isolated antibody or antigen-binding portion thereof that specifically binds to the polypeptide of claim 21.
25. A method of detecting the presence of cancer in a patient comprising the steps of:
(a) obtaining a biological sample from a patient;
(b) contacting a biological sample with a binding agent that binds to the polypeptide of claim 21;
(c) detecting the amount of polypeptide bound to the binding agent in the sample; and
(d) comparing the amount of the polypeptide to a predetermined cutoff value, thereby determining the presence or absence of cancer in the patient.
26. A fusion protein comprising at least one polypeptide of claim 21.
27. A method of stimulating and/or expanding T cells specific for a tumor protein comprising contacting T cells with at least one member selected from the group consisting of:
(a) the polypeptide of claim 21;
(b) the polynucleotide of claim 20; and
(c) an antigen presenting cell expressing the polynucleotide of claim 20.
28. An isolated population of T cells comprising T cells prepared according to the method of claim 27.
29. A pharmaceutical composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:
(a) the polypeptide of claim 21;
(b) the polynucleotide of claim 20;
(c) the antibody of claim 24;
(d) a fusion protein of claim 26; and
(e) the population of T cells of claim 28; and
(f) an antigen presenting cell expressing the polypeptide of claim 21.
30. A method of stimulating an immune response in a patient comprising administering to the patient the composition of claim 29.
31. A method for treating ovarian cancer in a patient, comprising administering to the patient the composition of claim 29.
32. A method of determining the presence or absence of cancer in a patient comprising the steps of:
(a) obtaining a biological sample from a patient;
(b) contacting a biological sample with an oligonucleotide that hybridizes to the polynucleotide sequence of claim 21 under moderately stringent conditions;
(c) detecting the amount of said polynucleotide hybridized to said oligonucleotide in the sample; and
(d) comparing the amount of said polynucleotide hybridized to the oligonucleotide to a predetermined cutoff value, and thereby determining the presence or absence of cancer in the patient.
An O772P polypeptide comprising at least SEQ ID NOs: 490-511.
An O8E polypeptide comprising at least SEQ ID NOs: 394-415 of the epitope sequence of the antibody.
35. An isolated antibody or antigen-binding fragment thereof that specifically binds to the polypeptide of claim 1.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US617747 | 1984-06-06 | ||
| US636801 | 2000-08-10 | ||
| US667857 | 2000-09-20 | ||
| US827271 | 2001-04-04 | ||
| US884441 | 2001-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1068506A true HK1068506A (en) | 2005-04-22 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100439395C (en) | Compositions and methods for the treatment and diagnosis of ovarian cancer | |
| US6468546B1 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
| US20030091580A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| US20030165504A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| US20030124140A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| CN1714150A (en) | Gene products differentially expressed in tumors and their applications | |
| US20100239615A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| CN1367830A (en) | Cancer associated antigens and uses therefor | |
| US6488931B1 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
| HK1047135A1 (en) | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use | |
| US20020068288A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| US6670463B1 (en) | Compositions and methods for therapy of ovarian cancer | |
| US6699664B1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| US6528253B1 (en) | Compositions and methods for diagnosis of ovarian cancer | |
| KR100935092B1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| KR100836516B1 (en) | Pharmaceutical compositions and vaccines for inhibiting the progression of ovarian cancer | |
| EP1319069B1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| HK1068506A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| HK1121464A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| CN101230100A (en) | Compositions and methods for treating and diagnosing ovarian cancer | |
| EP1351967B1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| CN106913862A (en) | The application of albumen TIF1 β and its polypeptide in medicine of the treatment with pre- anti-cancer is prepared | |
| US20030059432A1 (en) | Lipophilin complexes for use in cancer diagnosis and therapy | |
| US20020102679A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| US20030170246A1 (en) | Lipophilin complexes for use in cancer diagnosis and therapy |